0001144204-14-048848.txt : 20140813 0001144204-14-048848.hdr.sgml : 20140812 20140812150330 ACCESSION NUMBER: 0001144204-14-048848 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140630 FILED AS OF DATE: 20140812 DATE AS OF CHANGE: 20140812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProPhase Labs, Inc. CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 141033679 BUSINESS ADDRESS: STREET 1: 621 N. SHADY RETREAT ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18901 BUSINESS PHONE: 2153450919 MAIL ADDRESS: STREET 1: 621 N. SHADY RETREAT ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18901 FORMER COMPANY: FORMER CONFORMED NAME: QUIGLEY CORP DATE OF NAME CHANGE: 19930328 10-Q 1 v385647_10q.htm 10-Q

FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2014

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission file number 0-21617

ProPhase Labs, Inc.

(Exact name of registrant as specified in its charter)

Nevada	23-2577138
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)

	621 N. Shady Retreat Road, Doylestown, Pennsylvania	18901
	(Address of principal executive office)	(Zip Code)

(215) 345-0919

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or shorter period that the registration was required to submit and post such files). Yes x No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company (See definition of “large accelerated filer”, "accelerated filer”, “non-accelerated filer" and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer ¨

Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at August 12, 2014
Common Stock, $0.0005 par value		19,299,213

ProPhase Labs, Inc. and Subsidiaries

TABLE OF CONTENTS

		PAGE
*PART I.*	*FINANCIAL INFORMATION*	3

Item 1.	Financial Statements	3

	Condensed Consolidated Balance Sheets as of June 30, 2014 (unaudited) and December 31, 2013	3

	Condensed Consolidated Statements of Operations for the Three and Six Months Ended
	June 30, 2014 and 2013 (unaudited)	4

	Condensed Consolidated Statement of Stockholders’ Equity for the Six
	Months Ended June 30 2014 (unaudited)	5

	Condensed Consolidated Statements of Cash Flows for the Six Months Ended
	June 30, 2014 and 2013 (unaudited)	6

	Notes to Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31

Item 4.	Controls and Procedures	31


PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings	32
Item 1A.	Risk Factors	32
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	32
Item 3.	Defaults Upon Senior Securities	33
Item 4.	Mine Safety Disclosures	33
Item 5.	Other Information	33
Item 6.	Exhibits	33

Signatures		34

Certifications		35

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	June 30, 2014			December 31, 2013
	(unaudited)
ASSETS
Cash and cash equivalents (Note 2)	$	7,350		$	1,638
Accounts receivable, net		2,343			5,319
Inventory (Note 2)		3,248			2,521
Prepaid expenses and other current assets		733			1,801
Total current assets		13,674			11,279

Property, plant and equipment, net of accumulated depreciation		2,509			2,564
and amortization of $4,197 and $4,064, respectively (Note 2)
Intangible asset, licensed technology (Note 6)		3,577			3,577
Total assets	$	19,760		$	17,420


LIABILITIES AND STOCKHOLDERS' EQUITY
LIABILITIES:
Accounts payable	$	1,399		$	1,011
Accrued advertising and other allowances		3,078			2,847
Other current liabilities		1,475			766
Total current liabilities		5,952			4,624

Other long term obligations (Note 3)		200			200

Commitments and contingencies (Note 3)		-			-

STOCKHOLDERS' EQUITY:
Common Stock, $.0005 par value; authorized 50,000,000;
issued: 24,635,266 and 21,437,059 shares, respectively (Note 4)		12			11
Additional paid-in-capital		48,560			43,607
Accumulated deficit		(9,327	)		(5,385	)
Treasury stock, at cost 5,336,053 and 5,336,053 shares, respectively		(25,637	)		(25,637	)
Total stockholders' equity		13,608			12,596
Total liabilities and stockholders' equity	$	19,760		$	17,420

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

(unaudited)

	Three Months Ended						Six Months Ended
	June 30, 2014			June 30, 2013			June 30, 2014			June 30, 2013

Net sales (Note 2)	$	1,797		$	1,939		$	7,968		$	9,481

Cost of sales (Note 2)		1,005			1,011			3,196			3,214

Gross profit		792			928			4,772			6,267

Operating expenses:
Sales and marketing		852			709			3,849			4,072
Administration		2,804			1,721			4,311			3,216
Research and development		273			216			551			404
		3,929			2,646			8,711			7,692

Loss from operations		(3,137	)		(1,718	)		(3,939	)		(1,425	)

Interest income		1			1			1			1
Interest expense		(2	)		(2	)		(4	)		(5	)

Loss before income tax		(3,138	)		(1,719	)		(3,942	)		(1,429	)

Income tax (Note 5)		-			-			-			-

Net loss	$	(3,138	)	$	(1,719	)	$	(3,942	)	$	(1,429	)

Basic and diluted loss per share:
Net loss	$	(0.19	)	$	(0.11	)	$	(0.24	)	$	(0.09	)

Weighted average common
shares outstanding:
Basic and diluted		16,944			15,845			16,709			15,799

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of

Stockholders’ Equity

(in thousands, except share data)

(unaudited)

	Common Stock Shares
	Outstanding, Net of				Additional
	Shares of Treasury Stock		Par Value		Paid-In Capital		Accumulated Deficit			Treasury Stock			Total

Balance at December 31, 2013		16,101,006	$	11	$	43,607	$	(5,385	)	$	(25,637	)	$	12,596

Net loss		-		-		-		(3,942	)		-			(3,942	)

Share-based compensation expense (Note 4)		-		-		128		-			-			128

Common shares issued (Note 4)		3,198,207		1		4,825		-			-			4,826

Balance at June 30, 2014		19,299,213	$	12	$	48,560	$	(9,327	)	$	(25,637	)	$	13,608

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

	Six Months Ended
	June 30, 2014			June 30, 2013

Cash flows from operating activities:
Net loss	$	(3,942	)	$	(1,429	)
Adjustments to reconcile net loss to net cash
provided by operating activities:
Depreciation and amortization		133			120
Share-based compensation expense		128			79
Changes in operating assets and liabilities:
Accounts receivable		2,976			4,281
Inventory		(727	)		(1,237	)
Accounts payable		388			(269	)
Accrued advertising and other allowances		231			(576	)
Other operating assets and liabilities, net		1,777			2,572
Net cash provided by operating activities		964			3,541

Cash flows from investing activities:
Capital expenditures		(78	)		(250	)
Net cash used in investing activities		(78	)		(250	)

Cash flows from financing activities:
Proceeds from issuance of common stock		4,826			195
Net cash provided by financing activities		4,826			195

Net increase in cash and cash equivalents		5,712			3,486

Cash and cash equivalents at beginning of period		1,638			572

Cash and cash equivalents at end of period	$	7,350		$	4,058

See accompanying notes to condensed consolidated financial statements

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 1 – Organization and Business

ProPhase Labs, Inc. (“we”, “us” or the “Company”), organized under the laws of the State of Nevada, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (“OTC”) drug, natural base health products along with supplement, personal care and cosmeceutical products.

Our primary business is the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. Our flagship brand is Cold-EEZE^ÒCold Remedy and our principal product is Cold-EEZE^Ò Cold Remedy zinc gluconate lozenges, proven in clinical studies to reduce the duration of the common cold. In addition to Cold-EEZE^® Cold Remedy lozenges, we market and distribute non-lozenge forms of our proprietary zinc gluconate formulation, (i) Cold-EEZE^® Cold Remedy QuickMelts^® and (ii) Cold-EEZE^® Cold Remedy Oral Spray. Cold-EEZE^® Cold Remedy Oral Spray is a liquid form of our zinc gluconate formulation that is sprayed in the mouth. Cold-EEZE^® Cold Remedy QuickMelts^® are fast dissolving tablets that are taken orally. Cold-EEZE^Ò Cold Remedy is an established product in the health care and cold remedy market. For the three and six months ended June 30, 2014 and 2013, we operated in one reporting segment and our revenues have come principally from our OTC cold remedy products.

We use a December 31 year-end for financial reporting purposes. References herein to the fiscal year ended December 31, 2014 shall be the term “Fiscal 2014” and references to other “Fiscal” years shall mean the year, which ended on December 31 of the year indicated. The term “we”, “us” or the “Company” as used herein also refer, where appropriate, to the Company, together with its subsidiaries unless the context otherwise requires.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2013. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the six months ended June 30, 2014 are not necessarily indicative of operating results that may be achieved over the course of the full year.

Seasonality of the Business

Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Use of Estimates

The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

Our primary product, Cold-EEZE^ÒCold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE^® Cold Remedy lozenges, we market and distribute a variety of Cold-EEZE^® Cold Remedy QuickMelts^® and a Cold-EEZE^®Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix^®”). Each of the Cold-EEZE^® Cold Remedy Oral Spray and QuickMelts^® products, and Organix^® products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.

Cash Equivalents

We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.

Inventory Valuation

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At June 30, 2014 and December 31, 2013, inventory included raw material, work in progress and packaging amounts of $1.5 million and $1.1 million, respectively, and finished goods of $1.7 million and $1.4 million, respectively.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost. We compute depreciation using the straight-line method for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures – five years.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Concentration of Risks

Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedyproducts are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.

We maintain cash and cash equivalents with certain major financial institutions. As of June 30, 2014, our cash balance was $7.3 million and our bank balance was $7.6 million. Of the total bank balance, $636,000 was covered by federal depository insurance and $6.9 million was uninsured at June 30, 2014.

Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. At June 30, 2014 and December 31, 2013, our largest accounts receivable balances are with two customers representing approximately 48% and two customers representing 46%, respectively, of our total trade receivable balance. As a consequence of an evaluation of our customer’s financial condition, payment patterns, balance due us and other factors, we did not offset our account receivable with an allowance for bad debt at June 30, 2014 and December 31, 2013.

Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately 91% and 91% of total revenues for each of the six months ended June, 2014 and 2013, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three and six months ended June 30, 2014 and 2013, our net sales were principally related to domestic markets.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Long-lived Assets

We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.

Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Fair Value of Financial Instruments

Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments.

Revenue Recognition

Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

As of June 30, 2014, accrued advertising and other allowances included (i) $1.7 million for estimated future sales returns and (ii) $1.3 million for cooperative incentive promotion costs. As of December 31, 2013, accrued advertising and other allowances included (i) $1.5 million for estimated future sales returns and (ii) $1.3 million for cooperative incentive promotion costs. Additionally, as of June 30, 2014 and December 31, 2013, we included a provision for sales allowances of $37,000 and $128,000, respectively, which are reported as a reduction to sales and account receivables.

Advertising and Incentive Promotions

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended June 30, 2014 and 2013 were $1.1 million and $527,000, respectively. Advertising and incentive promotion expenses incurred for the six months ended June 30, 2014 and 2013 were $4.5 million and $4.4 million, respectively. Included in prepaid expenses and other current assets was $180,000 and $1.3 million at June 30, 2014 and December 31, 2013, respectively, relating to prepaid advertising and promotion expenses.

Shipping and Handling

Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.

Stock Based Compensation

We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.

Stock and stock options for the purchase of our common stock, $0.0005 par value, (“Common Stock”) have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 4). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended June 30, 2014 and 2013, we charged to operations $64,000 and $40,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned. For the six months ended June 30, 2014 and 2013, we charged to operations $128,000 and $79,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.

Variable Interest Entity

On March 22, 2010, we, Phosphagenics Limited (“PSI Parent”), an Australian corporation, Phosphagenics Inc. (“PSI”), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the “Joint Venture”), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the “LLC Agreement”) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM™ technology (“TPM”). TPM facilitates the delivery and depth of penetration of active molecules in pharmaceutical, nutraceutical, and other products. Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture. The Joint Venture, of which we own a 50% membership interest, qualifies as a variable interest entity (“VIE”), we are the current primary beneficiary and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Summary of Significant Accounting Policies – continued

Research and Development

Research and development costs are charged to operations in the period incurred. Research and development costs for the three months ended June 30, 2014 and 2013 were $273,000 and $216,000, respectively. Research and development costs for the six months ended June 30, 2014 and 2013 were $551,000 and $404,000, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.

Income Taxes

We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided
(see Note 5).

We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.

As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits. The tax years 2006 and forward remain open to examination by the IRS. The tax years 2004 and forward remain open to examination by the various state taxing authorities to which we are subject.

Recently Issued Accounting Standards

In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”). ASU 2013-11 amends Accounting Standards Codification 740, “Income Taxes,” to require that in certain cases, an unrecognized tax benefit, or portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date, and retrospective application is permitted. The adoption of ASU 2013-11 did not have a material impact on our consolidated financial position, results from operations or cash flows.

In May 2014, the FASB issued new accounting guidance, namely ASU No. 2014-09, “Revenue from Contracts with Customers”, on revenue recognition. The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. There is no option for early adoption. This ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2016. We are currently evaluating the impact of the new guidance on our consolidated financial statements.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 3 – Commitments and Contingencies

Settlement Agreement

In November 2004, we commenced an action against John C. Godfrey, Nancy Jane Godfrey, and Godfrey Science and Design, Inc. (together the “Godfreys”) for injunctive relief regarding the ownership of the Cold-EEZE^® trademark. The Godfreys subsequently asserted against us counterclaims and sought monetary damages and injunctive and declaratory relief relative to the Cold-EEZE^® trademark and other intellectual property.

On December 20, 2012, we and the Godfreys, including the Estate of Nancy Jane Godfrey, entered into a Settlement Agreement and Mutual General Release (the “Settlement Agreement”), pursuant to which we resolved all disputes, including claims asserted by us and counterclaims asserted against us in the action. Pursuant to the terms of the Settlement Agreement, we paid the Godfreys $2.1 million in December 2012 and we agreed to make four additional annual payments of $100,000 due in December of each of the next four years. Each annual payment in the amount of $100,000 will accrue interest at the per annum rate of 3.25%. The first annual installment of $100,000 plus accrued interest of $13,000 was paid in December 2013. Under the Settlement Agreement, the Godfreys assigned, transferred and conveyed to us all of their right, title, and interest in U.S. Trademark Registration No. 1,838,542 for the trademark Cold-EEZE^®, among other intellectual property associated with such trademark. At each of June 30, 2014 and December 31, 2013, other current liabilities and other long term obligations include $100,000 and $200,000, respectively, for the three remaining annual installment payments.

We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2014, as follows (in thousands):

Fiscal Year	Employment Contracts		Settlement Agreement		Total
2014		541		100		641
2015		1,040		100		1,140
2016		-		100		100
2017		-		-		-
2018		-		-		-
Total	$	1,581	$	300	$	1,881

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 4 – Transactions Affecting Stockholders’ Equity

Stockholder Rights Plan

On September 8, 1998, our Board of Directors declared a dividend distribution of Common Stock Purchase Rights (each individually, a “Right” and collectively, the “Rights”) payable to the stockholders of record on September 25, 1998, thereby creating a Stockholder Rights Plan (the “Rights Agreement”). The Plan was subsequently amended effective each of (i) May 23, 2008, (ii) August 18, 2009 and (iii) June 18, 2014. The Rights Agreement, as amended, provides that each Right entitles the stockholder of record to purchase from the Company that number of common shares having a combined market value equal to two times the Rights exercise price of $45. The Rights are not exercisable until the distribution date, which will be the earlier of a public announcement that a person or group of affiliated or associated persons has acquired 15% or more of the outstanding common shares, or the announcement of an intention by a similarly constituted party to make a tender or exchange offer resulting in the ownership of 15% or more of the outstanding common shares. The Rights Agreement allows for an exemption for Ted Karkus, the Company’s Chairman and Chief Executive Officer, to acquire up to 20% of our Common Stock without our Board of Directors declaring a dividend distribution. The dividend has the effect of giving the stockholder a 50% discount on the share’s current market value for exercising such right. In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one common share of the Company. The Rights Agreement, as amended, includes a provision pursuant to which our Board of Directors may exempt from the provisions of the Rights Agreement an offer for all outstanding shares of our Common Stock that the directors determine to be fair and not inadequate and to otherwise be in the best interests of the Company and its stockholders, after receiving advice from one or more investment banking firms. The expiration date of the Rights Agreement, as amended, is June 18, 2024.

2012 Equity Line of Credit

On November 21, 2012, we entered into the equity line of credit agreement (such arrangement, the “2012 Equity Line”) with Dutchess Opportunity Fund II, LP (“Dutchess”) whereby Dutchess committed to purchase, subject to certain restrictions and conditions, up to 2,500,000 shares of our Common Stock, over a period of 36 months from the first trading day following the effectiveness of the registration statement registering the resale of shares purchased by Dutchess pursuant to the 2012 Equity Line. On November 26, 2012, we filed a registration statement with Securities and Exchange Commission (“SEC”) to register for sale for up to 2,500,000 shares of our Common Stock and the registration statement was deemed effective by the SEC on December 12, 2012. We amended this registration statement effective May 29, 2014 to withdraw and remove from registration all unissued and unsold shares. We also agreed with Dutchess to terminate the 2012 Equity Line as of May 28, 2014.

We drew on the facility from time to time, as and when we determine appropriate in accordance with the terms and conditions of the 2012 Equity Line. The maximum amount that we were entitled to put to Dutchess in any one draw down notice is the greater of (i) 500% of the average daily volume of our Common Stock traded on the NASDAQ Global Market for the one (1) trading day prior to the date of delivery of the applicable draw down notice, multiplied by the closing price for such trading day, or (ii) $250,000.

The purchase price under the 2012 Equity Line is set at ninety-five percent (95%) of the lowest daily volume weighted average price (“VWAP”) of our Common Stock during the five (5) consecutive trading day period beginning on the date of delivery of the applicable draw down notice. In the event Dutchess received more than a five percent (5%) return on the net sales for a specific put, Dutchess remitted such excess proceeds to us; however, in the event Dutchess received less than a five percent (5%) return on the net sales for a specific put Dutchess had the right to use any such excess proceeds to off-set against the aggregated deficit proceeds.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 4 – Transactions Affecting Stockholders’ Equity – continued

There were put restrictions applied on days between the draw down notice date and the closing date with respect to that particular put. During such time, we are not allowed to deliver another draw down notice. In addition, Dutchess is not obligated to purchase shares if its total number of shares beneficially held at that time would exceed 9.99% of the number of shares of our Common Stock as determined in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended. In addition, we are not permitted to draw on the facility unless there is an effective registration statement to cover the resale of the shares.

During the period January 1, 2014 through May 23, 2014, we sold an aggregate of 698,207 shares of Common Stock to Dutchess under and pursuant to the 2012 Equity Line and we derived approximately $1.2 million in net proceeds. The sales of the shares under the 2012 Equity Line were deemed to be exempt from registration under the Securities Act of 1933, as amended in reliance upon Section 4(2) (or Regulation D promulgated thereunder).

2014 Equity Line of Credit

The Company and Dutchess executed a new equity line of credit agreement (such arrangement, the “2014 Equity Line”) each dated May 28, 2014 whereby Dutchess committed to purchase, subject to certain restrictions and conditions, up to 3,000,000 shares of the Company’s Common Stock, over a period of 36 months from the effectiveness of the registration statement registering the resale of shares purchased by the Investor pursuant to the Investment Agreement. On May 29, 2014, we filed a registration statement with the SEC to register for sale up to 3,000,000 shares of our Common Stock and the registration statement was declared effective by the SEC on June 4, 2014.

We may in our discretion draw on the facility from time to time, as and when we determine appropriate in accordance with the terms and conditions of the 2014 Equity Line. The maximum number of shares that the Company is entitled to put to Dutchess in any one draw down notice shall not exceed shares with a purchase price of $500,000, calculated in accordance with the 2014 Equity Line. We may deliver a notice for a subsequent put from time to time, following the one day pricing period for the prior put.

The purchase price shall be set at ninety-five percent (95%) of the volume weighted average price (VWAP) of the Company’s Common Stock during the one trading day immediately following our put notice. The Company has the right to withdraw all or any portion of any put, except that portion of the put that has already been sold to a third party, including any portion of a put that is below the minimum acceptable price set forth on the put notice, before the closing. In the event Dutchess receives more than a five percent (5%) return on the net sales for a specific put, Dutchess must remit such excess proceeds to the Company; however, in the Dutchess receives less than a five percent (5%) return on the net sales for a specific put, Dutchess will have the right to deduct from the proceeds of the put amount on the applicable closing date so Dutchess’s return will equal five percent (5%).

There are put restrictions applied on days between the draw down notice date and the closing date with respect to that particular put. During such time, the Company shall not be entitled to deliver another draw down notice. In addition, the Investor will not be obligated to purchase shares if Dutchess’s total number of shares beneficially held at that time would exceed 4.99% of the number of shares of our Common Stock as determined in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended. In addition, we are not permitted to draw on the facility unless there is an effective registration statement to cover the resale of the shares.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 4 – Transactions Affecting Stockholders’ Equity – continued

During the period June 13, 2014 through June 30, 2014, we sold an aggregate of 2,500,000 shares of our Common Stock to Dutchess under and pursuant to the 2014 Equity Line and we derived approximately $3.6 million in net proceeds. The sales of the shares under the 2014 Equity Line were deemed to be exempt from registration under the Securities Act of 1933, as amended in reliance upon Section 4(2) (or Regulation D promulgated thereunder). At June 30, 2014, we have 500,000 shares of our Common Stock available for sale, at our discretion, under the terms of the 2014 Equity Line and covered pursuant to a registration statement.

The 1997 Option Plan

On December 2, 1997, our Board of Directors approved a Stock Option Plan (the “1997 Plan”), which was amended in 2005, and provided for the granting of up to 4.5 million shares of Common Stock. Under the 1997 Plan, we were permitted to grant options to employees, officers or directors of the Company at variable percentages of the market value of stock at the date of grant. No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998. No options were granted under this Plan for the six months ended June 30, 2014 or 2013.

We are precluded from issuing any additional options or grants in the future under the 1997 Plan pursuant to the terms of the plan document. Options previously granted continue to be available for exercise at any time prior to such options’ respective expiration dates, but in no event later than ten years from the date granted. At June 30, 2014, there are 67,000 options outstanding under the 1997 Plan with various expiration dates ranging from October 2014 through December 2015, depending upon the date of grant.

The 2010 Equity Compensation Plan

On May 5, 2010, our shareholders approved the 2010 Equity Compensation Plan which was subsequently amended, restated and approved by shareholders on April 24, 2011 and further amended and approved by shareholders on May 6, 2013 (the “2010 Plan”). The 2010 Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Plan is equal to 1.6 million shares plus up to 900,000 shares that are authorized for issuance but unissued under the 1997 Plan for an aggregate of 2.5 million shares. The 1997 Plan expired on December 2, 2007 and no additional awards may be made. As of June 30, 2014, 1,481,750 of the options issued under the 1997 Plan prior to December 2007 expired unexercised or were terminated. As a consequence, these shares are deemed and remain unissued which up to a maximum of 900,000 shares became available for issuance under the 2010 Plan and the remaining 581,750 options are deemed cancelled. No options were granted under the 2010 Plan for the six months ended June 30, 2014. We granted 15,000 options under the 2010 Plan for the three and six months ended June 30, 2013. At June 30, 2014, there are 267,159 shares of Common Stock that may be issued pursuant to the terms of the 2010 Equity Compensation Plan.

There were no stock options exercised for the six months ended June 30, 2014 or 2013.

The 2010 Directors’ Equity Compensation Plan

On May 5, 2010, our shareholders approved the 2010 Directors’ Equity Compensation Plan which was subsequently amended and approved by shareholders on May 6, 2013. A primary purpose of the 2010 Directors’ Equity Compensation Plan is to provide us with the ability to pay all or a portion of the fees of directors in restricted stock instead of cash. The 2010 Directors’ Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Directors’ Equity Compensation Plan is equal to 425,000. For the three and six months ended June 30, 2014 and 2013, no shares were granted to directors. At June 30, 2014, there are 176,135 shares of Common Stock that may be issued pursuant to the terms of the 2010 Directors’ Equity Compensation Plan.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 5 – Income Taxes

As of December 31, 2013, we have net operating loss carry-forwards of approximately $34.7 million for federal purposes that will expire beginning in Fiscal 2020 through Fiscal 2032. Additionally, there are net operating loss carry-forwards of approximately $20.4 million for state purposes that will expire beginning in Fiscal 2018 through Fiscal 2032. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock are assured, a valuation allowance equaling the total deferred tax asset is being provided. Management believes that this allowance is required due to the uncertainty of realizing these tax benefits in the future. The uncertainty arises largely due to substantial marketing and research and development costs.

Note 6 – Investment in a Joint Venture

On March 22, 2010, we, PSI Parent, PSI and the Joint Venture entered into the LLC Agreement of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM.

In connection with the LLC Agreement, PSI Parent granted to us, pursuant to the terms of a License Agreement, dated March 22, 2010 (the “Original License Agreement”), (i) an exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit OTC drugs and certain other products that embody certain of PSI Parent’s TPM-related patents and related know-how (collectively, the “PSI Technology”) and (ii) a non-exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit certain compounds that embody the PSI Technology for use in a product combining one or more of such compounds with an OTC drug or in a product that is part of a regimen that includes the application of an OTC drug.

The Joint Venture is managed by a four-person Board of Managers, with two managers appointed by each member. The LLC Agreement contains other normally found terms in such arrangements, including provisions relating to governance of the Joint Venture, indemnification obligations of the Joint Venture, allocation of profits and losses, the distribution of funds to the members and restrictions on transfer of a member’s interest.

Pursuant to the Original License Agreement, we issued 1,440,000 shares of our Common Stock having an aggregate value of approximately $2.6 million to PSI Parent (such shares, the “PSI Shares”), and made a one-time payment to PSI Parent of $1.0 million.

In accordance with a Contribution Agreement, dated March 22, 2010 (the “Contribution Agreement”), by and among us, PSI Parent, PSI, and the Joint Venture, we transferred, conveyed and assigned to the Joint Venture all of our rights, title and interest in, to and under the Original License Agreement, and the Joint Venture assumed, and undertook to pay, discharge and perform when due, all of our liabilities and obligations under and arising pursuant to the Original License Agreement (such actions, collectively, the “Assignment and Assumption”).

Pursuant to the Contribution Agreement and in order to reflect the Assignment and Assumption, we, PSI Parent and the Joint Venture entered into an Amended and Restated License Agreement, dated March 22, 2010 (the “Amended License Agreement”), which amends and restates the Original License Agreement to reflect that the Joint Venture is the licensee thereunder and which otherwise contains substantially the same terms as the Original License Agreement. The Joint Venture has the right to grant one or more sub-licenses of the rights granted under the Amended License Agreement to one or more third parties for reasonable consideration in any part of the applicable territory. The Amended License Agreement provides that PSI Parent shall not, directly or through third parties, exploit the covered intellectual property during the term thereof, subject to certain limitations. The Amended License Agreement will remain in effect until the expiration of the last to expire of the patents included within the PSI Technology or any extensions thereof. Either party may terminate the Amended License Agreement upon written notice to the other party in the event of certain events involving bankruptcy or insolvency. The Amended License Agreement also contains, among other things, provisions concerning the treatment of confidential information, the ownership of intellectual property and indemnification obligations.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 6 – Investment in a Joint Venture – continued

Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture. PSI Parent will conduct and oversee much of the product development, formulation, testing and other research and development needed by the Joint Venture, and we will oversee much of the production, distribution, sales and marketing. The LLC Agreement provides that each member may be required, from time to time and subject to certain limitations, to make capital contributions to the Joint Venture to fund its operations, in accordance with agreed upon budgets for products to be developed. Specifically, we contributed in Fiscal 2010 $500,000 in cash as initial capital and we are committed to fund up to $2.0 million, subject to agreed upon budgets (which have not been established to date), toward the initial development and marketing costs of new products for the Joint Venture. The Joint Venture has not engaged in any financial transactions, other than organizational expenses and general market and initial product evaluation and analysis. At June 30, 2014, cash and cash equivalents includes $374,000 which is expected to be used by the Joint Venture to fund future product development initiatives currently under consideration by PSI Parent, PSI and us.

Our determination is that the Joint Venture qualifies as a VIE and that we are the primary beneficiary. We have consolidated the Joint Venture financial statements beginning with the quarter ended March 31, 2010. In Fiscal 2010, we recorded the $3.6 million payment noted above representing the estimated fair value to acquire the product license as an intangible asset. We currently estimate the expected remaining useful life of the product license to be approximately 12.75 years which we will begin amortizing the cost of intangible asset once product development and commercialization begins. Thus far, the Joint Venture has not generated any revenues and its expenses, including organizational, marketing analysis and preliminary formulations have been absorbed by the respective Joint Venture members. Furthermore, the liabilities and other obligations incurred, if any, by the Joint Venture is without recourse to us and do not create a claim on our general assets.

Due to multiple factors affecting our capital position, including (i) the $2.1 million payment we made in December 2012 under the Settlement Agreement (see Note 3) and (ii) some of the product market research performed, we expect to modify the Joint Venture’s product development plans to stagger and/or defer into future periods certain product development initiatives due to the pre-commercialization investments required. As of June 30, 2014, we have not established a formal commercialization program timeline pending the results from additional clinical studies. We do not project that any such OTC products will be available for shipment within the next twelve months. We do not expect that the Joint Venture will derive any meaningful revenues until its commercialization efforts are completed which is not expected to occur until Fiscal 2015 at the earliest.

Note 7 – Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of our Common Stock outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance of Common Stock that shared in the earnings of the entity. Diluted earnings per share also utilize the treasury stock method which prescribes a theoretical buy-back of shares from the theoretical proceeds of all options and warrants outstanding during the period. Options and warrants outstanding to acquire shares of our Common Stock at June 30, 2014 and 2013 were 1,632,500 and 1,301,500, respectively.

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 7 – Earnings (Loss) Per Share – continued

For the three and six months ended June 30, 2014 and 2013 dilutive earnings per share is the same as basic earnings per share due to (i) the inclusion of Common Stock, in the form of stock options and warrants (“Common Stock Equivalents”), would have an anti-dilutive effect on the loss per share or (ii) there were no Common Stock Equivalents for the respective period. For the three months ended June 30, 2014 and 2013, there were 559,318 and 359,271 Common Stock Equivalents, respectively, which were in the money, that were excluded from the earnings per share computation. For the six months ended June 30, 2014 and 2013, there were 571,736 and 401,849 Common Stock Equivalents, respectively, which were in the money, that were excluded from the earnings per share computation.

A reconciliation of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing operations, is as follows (in thousands, except per share amounts):

	Three Months Ended								Three Months Ended								Six Months Ended								Six Months Ended
	June 30, 2014								June 30, 2013								June 30, 2014								June 30, 2013
	Loss			Shares		EPS			Loss			Shares		EPS			Loss			Shares		EPS			Loss			Shares		EPS
Basic earnings (loss) per share	($	3,138	)		16,944	($	0.19	)	($	1,719	)		15,845	($	0.11	)	($	3,942	)		16,709	($	0.24	)	($	1,429	)		15,799	($	0.09	)

Dilutives:
Options		-			-		-			-			-		-			-			-		-			-			-		-

Diluted income(loss) per share	($	3,138	)		16,944	($	0.19	)	($	1,719	)		15,845	($	0.11	)	($	3,942	)		16,709	($	0.24	)	($	1,429	)		15,799	($	0.09	)

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations.

General

ProPhase Labs, Inc. (“we”, “us”, “ProPhase” or the “Company”), organized under the laws of the State of Nevada, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (“OTC”) drug, natural base health products along with supplements, personal care and cosmeceutical products.

Our primary business is the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. Our flagship brand is Cold-EEZE^ÒCold Remedy and our principal product is Cold-EEZE^Ò Cold Remedy zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold by 42%. In addition to Cold-EEZE^® Cold Remedy lozenges, we market and distribute non-lozenge forms of our proprietary zinc gluconate formulation, (i) Cold-EEZE^® Cold Remedy QuickMelts^® and (ii) Cold-EEZE^® Cold Remedy Oral Spray. In Fiscal 2014, we expanded our Cold-EEZE^® Cold Remedy QuickMelts^®product line and began shipments to retailers in July 2014, Cold-EEZE^® Cold Remedy Plus Multi-Symptom QuickMelts^® for cold and flu. Each of our Cold-EEZE^® Cold Remedy QuickMelts^®products are based on our proprietary zinc gluconate formulation in combination with certain natural (i) immune system support, (ii) energy, (iii) sleep and relaxation, and/or (iv) cold and flu symptom relieving active ingredients. For the three and six months ended June 30, 2014 and 2013, our revenues from operations have come principally from our OTC cold remedy products.

General Developments

For the three and six months ended June 30, 2014, we incurred substantial pre-trial and trial legal costs pursuing certain cases that the Company has been involved. These litigation expenses impacted the Company’s financial statements during the second quarter of 2014 and will continue to impact us at least through the third quarter of this year.

These cases include, among others, ProPhase Labs, Inc. v. Quigley, et al., Court of Common Pleas of Bucks County, Pennsylvania, Civ. A. No. 2010-08227 (“Case 8227”) and ProPhase Labs, Inc. v. Quigley, et al., Court of Common Pleas of Bucks County, Pennsylvania, Civ. A. No. 2011-09815 (“Case 9815”). On June 9, 2014, a trial in this matter commenced and the Company began witness testimony and evidence for Case 8227. As of July 10, 2014 and prior to the completion of the presentation of the Company’s case, the case was recessed in order to explore a possible settlement between the Company and the defendants of Case 8227 as well as all other matters in dispute between the parties. Since July 10, 2014, the Company and the defendants have been engaged in preliminary settlement discussions. No assurance can be given that these preliminary settlement discussions will lead to definitive agreements executed by all of the parties or that a settlement will in fact be consummated. If the settlement is not consummated, the litigation will continue in late September 2014. At this time, no prediction as to the outcome of this action can be made.

On June 30, 2014, the Court of Common Pleas of Philadelphia County, Pennsylvania dismissed the matter Guy Quigley vs. Ted Karkus, Robert V. Cuddihy, Jr., Mark Burnett, Mark Leventhal, Mark Frank, Louis Gleckel MD, and James McCubbin and ProPhase Labs, Inc. as a nominal defendant (No. 111200409). On August 1, 2014, we received a notice of appeal by Mr. Quigley.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Our flagship Cold-EEZE^® Cold Remedy brand has generally outperformed the cough-cold category over the past several years. However, some retailers are reallocating shelf space away from the cough-cold category to other product categories. With cough-cold shelf space at a premium, opportunities in the future to introduce new Cold-EEZE^® branded products in the cough-cold category may be limited. Therefore, to continue to grow our Company, we are in the process of implementing a series of new product development and pre-commercialization initiatives in the dietary supplement category. While the dynamics in this category should be better, the risks associated with introducing new products that do not leverage the Cold-EEZE^® brand name will be higher. Therefore, no assurance can be made that our new product efforts will be successful. We currently forecast that at least one product in this new category will begin shipping in Fiscal 2015.

Seasonality of the Business

Our sales are derived principally from our OTC cold remedy products. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for our OTC cold remedy products with a corresponding increase in marketing and advertising expenditures designed to promote our products during the Cold Season. In addition, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.

Financial Condition and Results of Operations

Results from Operations for the Three Months Ended June 30, 2014

as Compared to the Three Months Ended June 30, 2013

For the three months ended June 30, 2014, net sales were $1.8 million as compared to $1.9 million for the three months ended June 30, 2013. For the three months ended June 30, 2014, net sales of OTC cold remedy products were $1.5 million as compared to net sales of $1.5 million for three months ended June 30, 2013. For the three months ended June 30, 2014 and 2013, our contract manufacturing operations generated net sales to third party customers of $316,000 and $413,000, respectively.

Cost of sales for the three months ended June 30, 2014 were $1.0 million as compared to $1.0 million for the three months ended June 30, 2013. For the three months ended June 30, 2014 and the three months ended June 30, 2013, we realized a gross margin of 44.1% and 47.9%, respectively. The decrease of 3.8% in gross margin from the prior period is principally due to (i) a reduction in the absorption of fixed production costs as a consequence of a decline in net sales, (ii) fluctuations in our product mix shipped from period to period and (iii) the initial expenses incurred as a consequence of a packaging transition to a slightly narrower package of our Cold-EEZE^® Cold Remedy lozenges at certain retail accounts to obtain additional/new distribution of our Cold-EEZE^® Cold Remedy QuickMelts^® products for Fiscal 2014. Gross margins are principally influenced by fluctuations in quarter-to-quarter production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to market write-downs, if any, retail cooperative incentive promotion and the timing of shipments to customers which are factors of the seasonality of our sales activities and products.

Sales and marketing expense for the three months ended June 30, 2014 was $852,000 as compared to $709,000 for the three months ended June 30, 2013. The increase in sales and marketing expense for the three months ended June 30, 2014 as compared to the three months ended June 30, 2013 was principally due to an increase in our marketing expenditures.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Administration expense for the three months ended June 30, 2014 was $2.8 million as compared to $1.7 million for the three months ended June 30, 2013. The increase of $1.1 million in administration expense for the three months ended June 30, 2014 as compared to the three months ended June 30, 2013 was principally due to an increase in professional and legal fees related to the litigation matters.

Research and development costs during the three months ended June 30, 2014 increased $57,000 to $273,000, as compared to $216,000 for the three months ended June 30, 2013. The increase in research and development costs for the three months ended June 30, 2014 as compared to the three months ended June 30, 2013 was due principally to an increase in the amount and timing of our product development expenditures.

Interest and other income for the three months ended June 30, 2014 was $1,000 as compared to $1,000 for the three month periods ended June 30, 2013. Interest expense for the three month periods ended June 30, 2014 and 2013 was $2,000 and $2,000 respectively.

As a consequence of the effects of the above, the net loss for the three months ended June 30, 2014, was $3.1 million, or ($0.19) per share, as compared to a net loss of $1.7 million, or ($0.11) per share, for the three months ended June 30, 2013.

Financial Condition and Results of Operations

Results from Operations for the Six Months Ended June 30, 2014

as Compared to the Six Months Ended June 30, 2013

For the six months ended June 30, 2014, net sales were $8.0 million as compared to $9.5 million for the six months ended June 30, 2013. For the six months ended June 30, 2014, net sales of OTC cold remedy products were $7.2 million as compared to net sales of $8.6 million for six months ended June 30, 2013. The decline in net sales for the six months ended June 30, 2014 as compared to the six months ended June 30, 2013 was due principally to (i) industry data suggesting during the three and six months ended June 30, 2014, there was a reduction of over 12% and 7.5%, respectively, in the incidence of upper respiratory disorders, as compared to the comparable periods in Fiscal 2013, and as a consequence, (ii) effecting the timing of purchases and the ultimate level of demand for our products. For the six months ended June 30, 2014 and 2013, our contract manufacturing operations generated net sales to third party customers of $720,000 and $839,000, respectively.

Cost of sales for the six months ended June 30, 2014 were $3.2 million as compared to $3.2 million for the six months ended June 30, 2013. For the six months ended June 30, 2014 and the six months ended June 30, 2013, we realized a gross margin of 59.9% and 66.1%, respectively. The decrease of 6.2% in gross margin from the prior period is principally due to (i) a reduction in the absorption of fixed production costs as a consequence of a decline in net sales, (ii) fluctuations in our product mix shipped from period to period and (iii) the initial expenses incurred as a consequence of a packaging transition to a slightly narrower package of our Cold-EEZE^® Cold Remedy lozenges at certain retail accounts to obtain additional/new distribution of our Cold-EEZE^® Cold Remedy QuickMelts^® products for Fiscal 2014. Gross margins are principally influenced by fluctuations in quarter-to-quarter production volume, fixed production costs and related overhead absorption, raw ingredient costs, inventory mark to market write-downs, if any, retail cooperative incentive promotion and the timing of shipments to customers which are factors of the seasonality of our sales activities and products.

Sales and marketing expense for the six months ended June 30, 2014 was $3.8 million as compared to $4.1 million for the six months ended June 30, 2013. The decrease in sales and marketing expense for the six months ended June 30, 2014 as compared to the six months ended June 30, 2013 was principally due to a decrease in our marketing expenditures.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Administration expense for the six months ended June 30, 2014 was $4.3 million as compared to $3.2 million for the six months ended June 30, 2013. The increase of $1.1 million in administration expense for the six months ended June 30, 2014 as compared to the six months ended June 30, 2013 was principally due to an increase in professional and legal fees related to the litigation matters.

Research and development costs during the six months ended June 30, 2014 increased $147,000 to $551,000, as compared to $404,000 for the six months ended June 30, 2013. The increase in research and development costs for the six months ended June 30, 2014 as compared to the six months ended June 30, 2013 was due principally to an increase in the amount and timing of our product development expenditures.

Interest and other income for the six months ended June 30, 2014 was $1,000 comparable to $1,000 for the six month periods ended June 30, 2013. Interest expense for the six month periods ended June 30, 2014 and 2013 was $4,000 and $5,000 respectively.

As a consequence of the effects of the above, the net loss for the six months ended June 30, 2014, was $3.9 million, or ($0.24) per share, as compared to a net loss of $1.4 million, or ($0.09) per share, for the six months ended June 30, 2013.

Liquidity and Capital Resources

Our aggregate cash and cash equivalents as of June 30, 2014 were $7.3 million compared to $1.6 million at December 31, 2013. The increase of $5.7 million in our cash balance for the six months ended June 30, 2014 was principally due to the net effect of (i) cash provided by operations of $964,000 principally as a consequence of the net effect of (a) a decrease of accounts receivable of $2.9 million, (b) a decrease of other operating assets and liabilities, comprised principally of a decrease in prepaid advertising, of $1.1 million, offset by (c) an increase to inventory of $727,000 (d) our net loss of $3.9 million, and, (ii) net proceeds of $4.8 million from the sale of our Common Stock, offset by (iii) capital expenditures of $78,000. Our working capital was $8.4 million and $6.6 million as of June 30, 2014 and December 31, 2013, respectively.

2012 Equity Line of Credit

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

2014 Equity Line of Credit

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

General

Management believes that its strategy to maintain Cold-EEZE^Ò as a recognized brand name, its broader range of products, its adequate manufacturing capacity, together with its current working capital and its available 2014 Equity Line, if exercised, should provide a source of capital to fund normal business operations. Our operations support the current research and development expenditures related to new products. In addition to the funding from operations, it is likely that we will in the short and long term raise capital through the issuance of securities or secure other financing sources to support such product development research, new product acquisitions or a venture investment or acquisition. Such funding through the issuance of equity securities would result in the dilution of current stockholders’ ownership in the Company. Should our product development initiatives progress on certain formulations, additional development expenditures may require substantial financial support and may necessitate the consideration of alternative approaches such as licensing, joint venture, or partnership arrangements that we determine will meet our long term goals and objectives. Ultimately, should internal working capital be insufficient and external funding methods or other business arrangements become unattainable, it would likely result in the deferral or abandonment of future development relative to current and prospective product development initiatives and formulations.

Management is not aware of any trends, events or uncertainties that have or are reasonably likely to have a material negative impact upon our (i) short-term or long-term liquidity, or (ii) net sales or income from continuing operations. Any challenge to our patent rights could have a material adverse effect on our future; however, we are not aware of any condition that would make such an event probable. Our business is subject to seasonal variations thereby impacting liquidity and working capital during the course of our fiscal year.

Management believes that cash generated from operations, along with our current cash balances, will be sufficient to finance working capital and capital expenditure requirements to fund normal business operations for at least the next twelve months. However, we will likely require additional capital to support, among other items, (i) new product introductions, (ii) expansion of our product marketing and promotion activities, (iii) additional research development activities, (iv) further investment in our Joint Venture, (v) venture investments or acquisitions, and/or (vi) support current operations.

To the extent that we do not generate sufficient cash from operations, we may need to incur indebtedness to finance plans for growth. Volatility in the credit markets and the liquidity of major financial institutions may have an adverse effect on our ability to fund our business strategy through borrowings, under either existing or newly created instruments in the public or private markets on terms that we believe to be reasonable, if at all.

Capital Expenditures

Capital expenditures during the remainder of Fiscal 2014 are not expected to be material.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Off-Balance Sheet Arrangements

It is not our usual business practice to enter into off-balance sheet arrangements such as guarantees on loans and financial commitments and retained interests in assets transferred to an unconsolidated entity for securitization purposes. We have no off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Certain Risk Factors

Our business is regulated by various agencies of the states and localities where our products are sold. Governmental regulations in foreign countries where we plan to commence or expand sales may prevent or delay entry into a market or prevent or delay the introduction, or require the reformulation of certain of our products. In addition, no prediction can be made as to whether new domestic or foreign legislation regulating our activities will be enacted. Any new legislation could have a material adverse effect on our business, financial condition and operations. Non-compliance with any applicable requirements may subject us or the manufacturers of our products to agency action, including warning letters, fines, product recalls, seizures and injunctions.

The manufacturing, processing, formulation, packaging, labeling and advertising of our cold remedy products are subject to regulation by several federal agencies, including (i) the Food and Drug Administration (“FDA”), (ii) the Federal Trade Commission (“FTC”), (iii) the Consumer Product Safety Commission, (iv) the United States Department of Agriculture, (v) the United States Postal Service, (vi) the United States Environmental Protection Agency and (vii) the United States Occupational Safety and Health Administration.

In addition to OTC and prescription drug products, the FDA regulates the safety, manufacturing, labeling and distribution of dietary supplements, including vitamins, minerals and herbs, food additives, food supplements and cosmetics. The FTC also has overlapping jurisdiction with the FDA to regulate the promotion and advertising of vitamins, OTC drugs, cosmetics and foods. In addition, certain of our OTC cold remedy products are homeopathic remedies which are subject to standards established by the Homeopathic Pharmacopoeia of the United States (“HPUS”). HPUS sets the standards for source, composition and preparation of homeopathic remedies which are officially recognized under the Federal Food, Drug and Cosmetics Act, as amended.

Preclinical development, clinical trials, product manufacturing, labeling, distribution and marketing of potential new products are also subject to federal and state regulation in the United States and other countries. Clinical trials and product marketing and manufacturing are subject to the rigorous review and approval processes of the FDA and foreign regulatory authorities. To obtain approval of a new drug product, a company must demonstrate through adequate and well-controlled clinical trials that the drug product is safe and effective for its intended use. Obtaining FDA and other required regulatory approvals is lengthy and expensive. Typically, obtaining regulatory approval for pharmaceutical products requires substantial resources and takes several years. The length of this process depends on the type, complexity and novelty of the product and the nature of the disease or other indication to be treated. Preclinical studies must comply with FDA regulations. Clinical trials must also comply with FDA regulations to ensure safety of the human subjects in the trial and may require large numbers of test subjects, complex protocols and possibly lengthy follow-up periods. Consequently, satisfaction of government

regulations may take several years, may cause delays in introducing potential new products for considerable periods of time and may require imposing costly procedures upon our activities. If regulatory approval of new products is not obtained in a timely manner or not at all, we could be materially adversely affected. Even if regulatory approval of new products is obtained, such approval may impose limitations on the indicated uses for which the products may be marketed which could also materially adversely affect our business, financial condition and future operations.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

The Joint Venture is at its early stage of development where product and market research has been initiated and new product initiatives are being evaluated and prioritized for future development and commercialization. Prior to any new product being available for sale, substantial resources will have to be committed to commercialize a product which may include research, development, preclinical testing, clinical trials, manufacturing scale-up and regulatory approval. The Joint Venture may disrupt our ongoing operations, divert management from day-to-day responsibilities and increase our expenses.

We face significant technological risks inherent in developing these products. The Joint Venture may be subject to delays and/or ultimately unable to successfully implement its business plan and strategy to develop and commercialize one or more non-prescription remedies using certain patented and proprietary TPM^TM that exploit certain compounds that embody the TPM^TM for use in a product combining one or more of such compounds with an OTC drug. The commercialization and ultimate product market acceptance is subject to, among other influences, consumer purchasing trends, demand for our OTC drug, health and wellness trends, regulatory factors, retail acceptance and overall economic and market conditions. As a consequence, we may suspend or abandon some or all of our proposed new products before they become commercially viable. Even if we develop and obtain approval of a new product, if we cannot successfully commercialize it in a timely manner, our business and financial condition may be materially adversely affected. Any of these developments could also result in a full or partial impairment of our intangible asset, licensed technology.

We have aligned our operations to focus principally in the research, development, manufacture, marketing and sale of OTC cold remedy and consumer products, natural based health products and other supplement and cosmeceutical products. In addition, we may seek to acquire from third parties or enter into other arrangements with respect to new formulations, ingredients, applications and other products developed by third parties who may be seeking our commercialization, marketing and distribution expertise. There can be no assurance that we will be able to effectuate our business plan successfully or that our revenue growth will continue. In addition, we may not be successful in acquiring or otherwise entering into any new lines of business and, if we are successful in doing so, there can be no assurance that such new business will achieve profitability.

Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capability and the requirements associated with the development of potential OTC drug and other medicinal products in order to continue to compete on a national and international level. Our business development is dependent on continued conformity with government regulations, a reliable information technology system capable of supporting continued growth and continued reliable sources for product and materials to satisfy consumer demand. Many of our competitors have substantially greater capital resources, technical staffs, facilities, marketing resources, product development, distribution and experience than we do. As a consequence, our competitors may have certain advantages, including the ability to allocate greater resources for new product development, marketing and other purposes.

Readers should carefully review the risk factors described in other sections of this filing, our Annual Report on Form 10-K for the year ended December 31, 2013 as well as in other documents we file from time to time with the Securities and Exchange Commission.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Our significant accounting policies are described in Note 2 of Notes to Condensed Consolidated Financial Statements included under Item 1 of this Part I. However, certain accounting policies are deemed “critical”, as they require management’s highest degree of judgment, estimates and assumptions. These accounting estimates and disclosures have been discussed with Audit Committee of our Board of Directors. A discussion of our critical accounting policies, the judgments and uncertainties affecting their application and the likelihood that materially different amounts would be reported under different conditions or using different assumptions are as follows:

Revenue Recognition – Sales Allowances

When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

Our primary product, Cold-EEZE^ÒCold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE^® Cold Remedy lozenges we market and distribute two additional forms of our proprietary zinc formulation, Cold-EEZE^® Cold Remedy QuickMelts^® and Cold-EEZE^® Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix^®”). Each of the Cold-EEZE^® Cold Remedy Oral Spray and QuickMelts^® products, and Organix^® products carry shelf-life expiration dates for which we aggregate such product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.

Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity fall within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such item that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

We classify product returns into principally three categories, (i) non-routine returns, (ii) obsolete product and (iii) product mix realignment by certain of our customers. “Non-routine” returns are defined as product returned to us as a consequence of unanticipated circumstances principally due to (i) retail store closings or (ii) unexpected poor retail sell through to consumers causing us to discontinue the product. “Obsolete” returns are defined as product returned to us as a consequence of product shelf-life “use by” expiration date. “Product mix realignment” returns are defined as product returned to us due to initiatives by the trade to discontinue purchasing certain of our products. Product mix realignment returns are generally nominal and are frequently related to discontinued or soon to be discontinued products.

Income Taxes

Recently Issued Accounting Standards

ProPhase Labs, Inc. and Subsidiaries

Management’s Discussion and Analysis of

Financial Condition and Results of Operations

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward looking statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. Many of these factors are beyond our ability to predict. Given the risks and uncertainties surrounding forward-looking statements, you should not place undue reliance on these statements. Forward-looking statements typically are identified by use of terms such as “anticipate”, “believe”, “plan”, “expect”, “intend”, “may”, “will”, “should”, “estimate”, “predict”, “potential”, “continue” and similar words although some forward-looking statements are expressed differently. This Report may contain forward-looking statements attributed to third parties relating to their estimates regarding the growth of our markets. You are cautioned that such forward looking statements are not guarantees of future performance and that all forward-looking statements address matters that involve risk and uncertainties, and there are many important risks, uncertainties and other factors that could cause our actual results, levels of activity, performance, achievements and prospects, as well as those of the markets we serve, to differ materially from the forward-looking statements contained in this Report.

Such risks and uncertainties include, but are not limited to:

The ability of our management to successfully implement our business plan and strategy;

Our ability to fund our operations including the cost and availability of capital and credit;

Our ability to compete effectively, including our ability to maintain and increase our markets and/or market share in the markets in which we do business;

Our dependence on sales from our principal product, Cold-EEZE^Ò Cold Remedy, and our ability to successfully develop and commercialize our new products;

Changes in our retail and distribution customers strategic business plans including, but not limited to, (i) expansions, mergers, and/or consolidations, (ii) retail shelf space allocations for products within each outlet and in particular the cough/cold category in which we compete, (iii) changes in their private label assortment and (iv) product selections, distribution allocation, merchandising programs and retail pricing of our products as well as competitive products;

The uncertain length and severity of the general financial and economic downturn, the timing and strength of an economic recovery, if any, and their impacts on our business including demand for our products;

Our ability to protect our proprietary rights;

Our continued ability to comply with regulations relating to our current products and any new products we develop, including our ability to effectively respond to changes in laws and regulations or the interpretation thereof including changing market rules and evolving federal, state and regional laws and regulations;

Potential disruptions in our ability to manufacture our products or our access to raw materials;

Seasonal fluctuations in demand for our products;

Our ability to attract, retain and motivate our key employees;

The ability of Phusion Laboratories, LLC, a 50% owned joint venture, to successfully implement its business plan and strategy to develop and commercialize one or more non-prescription remedies using certain patented and proprietary technology; and

Other risks identified in this Report.

You should also consider carefully the statements under other sections of this Report and our Annual Report on Form 10-K for the year ended December 31, 2013, which address additional risks that could cause our actual results to differ from those set forth in any forward-looking statements. Our forward-looking statements speak only as the date of this Report. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Like virtually all commercial enterprises, we can be exposed to the risk (“market risk”) that the cash flows to be received or paid relating to certain financial instruments could change as a result of changes in interest rate, exchange rates, commodity prices, equity prices and other market changes.

Our operations are not subject to risks of material foreign currency fluctuations, nor do we use derivative financial instruments in our investment practices. We place our marketable investments in instruments that meet high credit quality standards. We do not expect material losses with respect to our investment portfolio or exposure to market risks associated with interest rates. The impact on our results of one percentage point change in short-term interest rates would not have a material impact on our future earnings, fair value, or cash flows related to investments in cash equivalents or interest-earning marketable securities.

Current economic conditions may cause a decline in business and consumer spending which could adversely affect our business and financial performance including the collection of accounts receivables, realization of inventory and recoverability of assets. In addition, our business and financial performance may be adversely affected by current and future economic conditions, including due to a reduction in the availability of credit, financial market volatility and recession.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to provide reasonable assurance that material information required to be disclosed by us in the reports filed or submitted under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that the information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. We performed an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the disclosure controls and procedures as of the end of the period covered by this report. Based on our review, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that the Company’s disclosure controls and procedures were effective at the reasonable assurance level as of the end of the period covered by this Report.

Management's Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining an adequate system of internal control over financial reporting. Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

Our internal control over financial reporting includes those policies and procedures that:

pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;

provide reasonable assurance that our transactions are recorded as necessary to permit preparation of our financial statements in accordance with accounting principles generally accepted in the United States of America, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our directors; and

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable assurance and may not prevent or detect misstatements. Further, because of changes in conditions, effectiveness of internal controls over financial reporting may vary over time. Our system contains self-monitoring mechanisms, and actions are taken to correct deficiencies as they are identified.

Our management conducted an evaluation of our effectiveness of the system of internal control over financial reporting based on the framework in Internal Control-Integrated Framework issued in 1992 by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon our review, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that the Company’s internal controls over financial reporting were effective as of June 30, 2014.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the six months ended June 30, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II. Other Information

Item 1. Legal Proceedings.

PROPHASE LABS, INC.(formerly THE QUIGLEY CORPORATION) vs. Guy Quigley, Gary Quigley, Scanda Systems Limited, Scanda Systems LTD, Chilesha Holdings LTD, Kevin Brogan, Innerlight Holdings, Inc., George Longo, Graham Brandon AND Pacific Rim Pharmaceuticals LTD

On August 23, 2010, we initiated an action in the Court of Common Pleas of Bucks County, Pennsylvania Civil Action No. 2010-08227. This action is against certain former officers and directors of the Company, including a shareholder that beneficially owns approximately 15.5% of our Common Stock, and against certain third parties. The Company has asserted claims arising from, among other things, a variety of transactions and payments previously made or entered into by the Company. All of the transactions and events that are the subject of this litigation occurred prior to June 2009 and the installation of the current board of directors. We are seeking recovery of monetary damages and other relief. On June 9, 2014, a trial in this matter commenced and the Company began presenting witness testimony and evidence. As of July 10, 2014 and prior to the completion of the presentation of the Company’s case, the case was recessed from the trial in order to explore a possible settlement between the Company and the defendants of this litigation as well as all other matters in dispute between the parties. Since July 10, 2014, the Company and the defendants have been engaged in preliminary settlement discussions. No assurance can be given that these preliminary settlement discussions will lead to definitive agreements executed by all of the parties or that a settlement will be in fact be consummated. If the settlement is not consummated, the litigation will continue in late September 2014. At this time, no prediction as to the outcome of this action can be made.

GUY QUIGLEY VS. TED KARKUS, ROBERT V. CUDDIHY, JR., MARK BURNETT, MARK LEVENTHAL, MARK FRANK, LOUIS GLECKEL, MD, JAMES McCUBBIN AND PROPHASE LABS, INC. AS A NOMINAL DEFENDANT

We were named as a nominal defendant in a purported derivative complaint filed on February 2, 2012 by stockholder and former director and Chief Executive Officer Guy Quigley in the Court of Common Pleas of Philadelphia County, Pennsylvania (No. 111200409). The complaint also names as a defendant each of our directors and executive officers. Among other things, the suit alleges various breaches of fiduciary and other duties, and seeks recovery of unspecified damages and other relief. Prior to filing this complaint, the plaintiff applied to the same court for permission to take pre-complaint discovery on the basis that the plaintiff required such discovery in order to assert claims. The court denied the plaintiff's request. We believe the lawsuit is without merit and intend to vigorously defend against it. On April 5, 2013, the court entered an order allowing limited pre-trial discovery limited to demand futility and plaintiff adequacy issues, which was completed by July 12, 2013. We filed a motion to dismiss on July 26, 2013 on demand futility and plaintiff adequacy issues. On August 26, 2013 the court heard oral arguments regarding the Company’s motion for summary judgment and dismissal with prejudice. The court stayed any additional discovery until the court rules on our motion to dismiss with and our motion is currently pending with the court. On June 30, 2014, the Court of Common Pleas of Philadelphia County, Pennsylvania dismissed this matter. On August 1, 2014, we received a notice of appeal by Mr. Quigley.

Item 1A. Risk Factors.

Not applicable

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the period January 1, 2014 through May 23, 2014, we sold an aggregate of 698,207 shares of our Common Stock to Dutchess Opportunity Fund II, LP (“Dutchess”) under and pursuant to the 2012 Equity Line with Dutchess dated November 21, 2012, and we derived approximately $1.2 million in net proceeds. The sales of the shares under the 2012 Equity Line were deemed to be exempt from registration under the Securities Act of 1933, as amended in reliance upon Section 4(2) (or Regulation D promulgated thereunder).

Item 3.

Defaults Upon Senior Securities.

None

Item 4.

Mine Safety Disclosures.

Not applicable

Item 5. Other Information.

None

Item 6. Exhibits

(1)	Exhibit 31.1	Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(2)	Exhibit 31.2	Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
(3)	Exhibit 32.1	Certification by the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(4)	Exhibit 32.2	Certification by the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		ProPhase Labs, Inc.


	By:	/s/ Ted Karkus
		Ted Karkus
		Chairman of the Board and Chief Executive Officer
		(Principal Executive Officer)

Date: August 12, 2014
	By:	/s/ Robert V. Cuddihy, Jr.
		Robert V. Cuddihy, Jr.
		Chief Operating Officer and Chief Financial Officer
		(Principal Accounting and Financial Officer)
Date: August 12, 2014

EX-31.1 2 v385647_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

OFFICER’S CERTIFICATION PURSUANT TO

RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Ted Karkus, certify that:

I have reviewed this Quarterly Report on Form 10-Q of ProPhase Labs, Inc.;

Based on my knowledge, this Quarterly Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Quarterly Report;

Based on my knowledge, the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Quarterly Report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Quarterly Report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this Quarterly Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 12, 2014
	By:	/s/ Ted Karkus
		Ted Karkus
		Chairman of the Board and Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 v385647_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

OFFICER’S CERTIFICATION PURSUANT TO

RULE 13a-14(a)/15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Robert V. Cuddihy, Jr., certify that:

I have reviewed this Quarterly Report on Form 10-Q of ProPhase Labs, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 12, 2014
	By:	/s/ Robert V. Cuddihy, Jr.
		Robert V. Cuddihy, Jr.
		Chief Operating Officer and Chief Financial Officer (Principal Accounting and Financial Officer)

EX-32.1 4 v385647_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

PROPHASE LABS, INC.

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Ted Karkus, Chief Executive Officer of ProPhase Labs, Inc., a Nevada corporation (the “Registrant”), in connection with the Registrant’s Quarterly Report on Form 10-Q for the period ended June 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

	/s/ Ted Karkus
	Ted Karkus
	Chairman of the Board and Chief Executive Officer
	(Principal Executive Officer)
	August 12, 2014

EX-32.2 5 v385647_ex32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

PROPHASE LABS, INC.

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Robert V. Cuddihy, Jr., Chief Financial Officer of ProPhase Labs, Inc., a Nevada corporation (the “Registrant”), in connection with the Registrant’s Quarterly Report on Form 10-Q for the period ended June 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), do hereby represent, warrant and certify, in compliance with Rule 13a-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

	/s/ Robert V. Cuddihy, Jr.
	Robert V. Cuddihy, Jr.
	Chief Operating Officer and Chief Financial Officer
	(Principal Accounting and Financial Officer)
	August 12, 2014

EX-101.INS 6 prph-20140630.xml XBRL INSTANCE DOCUMENT 0000868278 2010-01-01 2010-12-31 0000868278 2012-01-01 2012-12-31 0000868278 2013-01-01 2013-06-30 0000868278 2013-01-01 2013-12-31 0000868278 2014-01-01 2014-06-30 0000868278 2013-04-01 2013-06-30 0000868278 2014-04-01 2014-06-30 0000868278 2013-06-30 0000868278 2014-06-30 0000868278 2014-08-12 0000868278 2012-12-01 2012-12-20 0000868278 2013-12-31 0000868278 2012-12-31 0000868278 us-gaap:SalesRevenueGoodsNetMember 2013-01-01 2013-06-30 0000868278 us-gaap:AccountsReceivableMember prph:TwoCustomerMember 2013-01-01 2013-12-31 0000868278 us-gaap:SalesRevenueGoodsNetMember 2014-01-01 2014-06-30 0000868278 us-gaap:AccountsReceivableMember prph:TwoCustomerMember 2014-01-01 2014-06-30 0000868278 prph:EstimatedFutureSalesReturnMember 2014-06-30 0000868278 prph:CooperativeIncentiveMember 2014-06-30 0000868278 prph:EstimatedFutureSalesReturnMember 2013-12-31 0000868278 prph:CooperativeIncentiveMember 2013-12-31 0000868278 prph:LimitedLiabilityCompanyAgreementMember 2010-01-01 2010-03-31 0000868278 us-gaap:BuildingAndBuildingImprovementsMember us-gaap:MinimumMember 2014-01-01 2014-06-30 0000868278 us-gaap:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2014-01-01 2014-06-30 0000868278 us-gaap:MachineryAndEquipmentMember us-gaap:MinimumMember 2014-01-01 2014-06-30 0000868278 us-gaap:MaximumMember us-gaap:MachineryAndEquipmentMember 2014-01-01 2014-06-30 0000868278 us-gaap:ComputerSoftwareIntangibleAssetMember 2014-01-01 2014-06-30 0000868278 us-gaap:FurnitureAndFixturesMember 2014-01-01 2014-06-30 0000868278 us-gaap:EmploymentContractsMember 2014-06-30 0000868278 prph:SettlementAgreementMember 2014-06-30 0000868278 prph:TwoThousandTwelveEquityLineOfCreditMember 2012-11-01 2012-11-21 0000868278 prph:TwoThousandFourteenEquityLineOfCreditMember 2014-01-01 2014-06-30 0000868278 prph:DutchessMember us-gaap:CommonStockMember prph:TwoThousandTwelveEquityLineOfCreditMember 2014-01-01 2014-06-30 0000868278 prph:Plan1997Member 2014-06-30 0000868278 prph:Plan2010Member 2014-06-30 0000868278 prph:DirectorsPlan2010Member 2014-06-30 0000868278 prph:Plan2010Member 2013-01-01 2013-06-30 0000868278 prph:AmendedOptionPlan1997Member 2014-01-01 2014-06-30 0000868278 prph:Plan2010Member 2013-04-01 2013-06-30 0000868278 us-gaap:DomesticCountryMember 2013-12-31 0000868278 us-gaap:DomesticCountryMember 2013-01-01 2013-12-31 0000868278 us-gaap:StateAndLocalJurisdictionMember 2013-01-01 2013-12-31 0000868278 us-gaap:StateAndLocalJurisdictionMember 2013-12-31 0000868278 prph:PsiParentMember 2010-01-01 2010-12-31 0000868278 prph:PsiParentMember 2014-06-30 0000868278 prph:CommonStockEquivalentsMember 2013-01-01 2013-06-30 0000868278 prph:CommonStockEquivalentsMember 2014-01-01 2014-06-30 0000868278 prph:CommonStockEquivalentsMember 2013-04-01 2013-06-30 0000868278 prph:CommonStockEquivalentsMember 2014-04-01 2014-06-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000868278 us-gaap:RetainedEarningsMember 2013-12-31 0000868278 us-gaap:TreasuryStockMember 2013-12-31 0000868278 us-gaap:CommonStockMember 2013-12-31 0000868278 us-gaap:CommonStockMember 2014-01-01 2014-06-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-06-30 0000868278 us-gaap:RetainedEarningsMember 2014-01-01 2014-06-30 0000868278 us-gaap:TreasuryStockMember 2014-01-01 2014-06-30 0000868278 us-gaap:CommonStockMember 2014-06-30 0000868278 us-gaap:AdditionalPaidInCapitalMember 2014-06-30 0000868278 us-gaap:RetainedEarningsMember 2014-06-30 0000868278 us-gaap:TreasuryStockMember 2014-06-30 0000868278 prph:TwoThousandFourteenEquityLineOfCreditMember 2014-05-28 0000868278 prph:TwoThousandFourteenEquityLineOfCreditMember 2014-06-30 0000868278 prph:TwoThousandFourteenEquityLineOfCreditMember 2014-05-01 2014-05-28 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"><b>Note 7  Earnings (Loss) Per Share</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; TEXT-INDENT: 0.25in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left">Basic earnings (loss) per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of our Common Stock outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance of Common Stock that shared in the earnings of the entity. Diluted earnings per share also utilize the treasury stock method which prescribes a theoretical buy-back of shares from the theoretical proceeds of all options and warrants outstanding during the period. Options and warrants outstanding to acquire shares of our Common Stock at June 30, 2014 and 2013 were 1,632,500 and 1,301,500, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; TEXT-INDENT: 0.25in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left">For the three and six months ended June 30, 2014 and 2013 dilutive earnings per share is the same as basic earnings per share due to (i) the inclusion of Common Stock, in the form of stock options and warrants (“Common Stock Equivalents”), would have an anti-dilutive effect on the loss per share or (ii) there were no Common Stock Equivalents for the respective period. For the three months ended June 30, 2014 and 2013, there were 559,318 and 359,271 Common Stock Equivalents, respectively, which were in the money, that were excluded from the earnings per share computation. For the six months ended June 30, 2014 and 2013, there were 571,736 and 401,849 Common Stock Equivalents, respectively, which were in the money, that were excluded from the earnings per share computation.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; TEXT-INDENT: 0.25in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left">A reconciliation of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing operations, is as follows (in thousands, except per share amounts):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>Three Months Ended</div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>Three Months Ended</div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>Six Months Ended</div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>Six Months Ended</div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>June 30, 2014</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>June 30, 2013</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>June 30, 2014</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>June 30, 2013</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Loss</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Shares</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>EPS</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Loss</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Shares</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>EPS</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Loss</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Shares</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>EPS</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Loss</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Shares</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>EPS</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>Basic earnings<br/> (loss) per share</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>3,138</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>16,944</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>1,719</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>15,845</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>0.11</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>3,942</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>16,709</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>0.24</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>1,429</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>15,799</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>0.09</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"> <div>Dilutives:</div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>Options</div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap; TEXT-ALIGN: center; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.125in; FONT-SIZE: 10pt"> <div style="CLEAR:both;MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" align="left">Diluted income(loss) per share</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>3,138</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>16,944</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>1,719</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>15,845</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>0.11</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>3,942</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>16,709</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>0.24</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>1,429</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>15,799</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>0.09</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Basis of Presentation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2013. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the six months ended June 30, 2014 are not necessarily indicative of operating results that may be achieved over the course of the full year.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold italic 10pt Times New Roman, Times, Serif"> Cash Equivalents</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Long-lived Assets</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><i>Fair Value of Financial Instruments</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Revenue Recognition</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">As of June 30, 2014, accrued advertising and other allowances included (i) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.7</font> million for estimated future sales returns and (ii) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million for cooperative incentive promotion costs. As of December 31, 2013, accrued advertising and other allowances included (i) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million for estimated future sales returns and (ii) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million for cooperative incentive promotion costs. Additionally, as of June 30, 2014 and December 31, 2013, we included a provision for sales allowances of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">37,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">128,000</font>, respectively, which are reported as a reduction to sales and account receivables.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Advertising and Incentive Promotions</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended June 30, 2014 and 2013 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.1</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">527,000</font>, respectively. Advertising and incentive promotion expenses incurred for the six months ended June 30, 2014 and 2013 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.5</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.4</font> million, respectively. Included in prepaid expenses and other current assets was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">180,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million at June 30, 2014 and December 31, 2013, respectively, relating to prepaid advertising and promotion expenses.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Stock Based Compensation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Stock and stock options for the purchase of our common stock, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0005</font> par value, (“Common Stock”) have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 4). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended June 30, 2014 and 2013, we charged to operations $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">64,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,000</font>, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned. For the six months ended June 30, 2014 and 2013, we charged to operations $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">128,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">79,000</font>, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif"> <i>Research and Development</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Research and development costs are charged to operations in the period incurred. Research and development costs for the three months ended June 30, 2014 and 2013 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">273,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">216,000</font>, respectively. Research and development costs for the six months ended June 30, 2014 and 2013 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">551,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">404,000</font>, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b><i>Income Taxes</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits. The tax years 2006 and forward remain open to examination by the IRS. The tax years 2004 and forward remain open to examination by the various state taxing authorities to which we are subject.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recently Issued Accounting Standards</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”). ASU 2013-11 amends Accounting Standards Codification 740, “Income Taxes,” to require that in certain cases, an unrecognized tax benefit, or portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date, and retrospective application is permitted. The adoption of ASU 2013-11 did not have a material impact on our consolidated financial position, results from operations or cash flows.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="left"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="left"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; TEXT-INDENT: 0.25in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left">In May 2014, the FASB issued new accounting guidance, namely ASU No. 2014-09, “Revenue from Contracts with Customers”, on revenue recognition.  The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts.  Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard.  There is no option for early adoption.  This ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2016.  We are currently evaluating the impact of the new guidance on our consolidated financial statements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2014, as follows (in thousands):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><strong> </strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.25in; WIDTH: 55%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>Fiscal Year</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Employment Contracts</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%" colspan="2"> <div>Settlement Agreement</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>Total</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="16%"> <div>2014</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>541</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>641</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,040</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,140</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="16%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,581</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,881</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; TEXT-INDENT: 0.25in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left">A reconciliation of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing operations, is as follows (in thousands, except per share amounts):</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>Three Months Ended</div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>Three Months Ended</div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>Six Months Ended</div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>Six Months Ended</div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>June 30, 2014</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>June 30, 2013</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>June 30, 2014</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="10"> <div>June 30, 2013</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Loss</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Shares</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>EPS</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Loss</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Shares</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>EPS</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Loss</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Shares</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>EPS</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Loss</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>Shares</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-SIZE: 10pt" colspan="2"> <div>EPS</div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>Basic earnings<br/> (loss) per share</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>3,138</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>16,944</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>1,719</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>15,845</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>0.11</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>3,942</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>16,709</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>0.24</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>1,429</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>15,799</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt"> <div>0.09</div> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt"> <div>)</div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: justify; FONT-SIZE: 10pt"> <div>Dilutives:</div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>Options</div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,238,255); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: justify; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div> </div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 10pt"> <div> </div> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="white-space:nowrap; TEXT-ALIGN: center; PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 0.125in; FONT-SIZE: 10pt"> <div style="CLEAR:both;MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px" align="left">Diluted income(loss) per share</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>3,138</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>16,944</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>0.19</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>1,719</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>15,845</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>0.11</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>3,942</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>16,709</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>0.24</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>1,429</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>15,799</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div> </div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT-SIZE: 10pt"> <div>($</div> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT-SIZE: 10pt"> <div>0.09</div> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> <div>)</div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

636000

6900000

1500000

1100000

1700000

1400000

7600000

0.91

0.46

0.91

0.48

128000

37000

1700000

1300000

1500000

1300000

0.5

4400000

4500000

527000

1100000

180000 1300000

0.0005

79000

128000

40000

64000

P10Y

P39Y

P3Y

P7Y

P3Y

P5Y

641000

541000

100000

1140000

1040000

100000

1881000

1581000

300000

7350000

1638000

2343000

5319000

3248000

2521000

733000

1801000

13674000

11279000

2509000

2564000

3577000

19760000

17420000

1399000

1011000

3078000

2847000

1475000

766000

5952000

4624000

200000

12000

11000

48560000

43607000

-9327000

-5385000

25637000

13608000

12596000

19760000

17420000

2100000

100000 0.0325 100000 100000 100000 200000

13000

2500000 5 250000 0.05 0.05 0.0499 0.0999 698207 1200000

67000

1600000

425000

581750

15000

4500000

15000

2500000 0.15

1481750

0.95 0.95

900000

267159

176135

In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one common share of the Company. No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998.

34700000

Fiscal 2020 through Fiscal 2032 Fiscal 2018 through Fiscal 2032

20400000

1440000

2600000

500000 1000000 2000000

374000

3600000

P12Y9M

0.5

-1429000

-3942000

-1719000

-3138000

15799

16709

15845

16944

-0.09

-0.24

-0.11

-0.19

0 0 0 0 0 0 0 0 0 0 0 0

-1429000

-3942000

-1719000

-3138000

15799

16709

15845

16944

-0.09

-0.24

-0.11

-0.19

401849

571736

359271

559318

4197000

4064000

0.0005

50000000

24635266

21437059

5336053

9481000

7968000

1939000

1797000

3214000

3196000

1011000

1005000

6267000

4772000

928000

792000

4072000

3849000

709000

852000

3216000

4311000

1721000

2804000

404000

551000

216000

273000

7692000

8711000

2646000

3929000

-1425000

-3939000

-1718000

-3137000

1000

5000

4000

2000

-1429000

-3942000

-1719000

-3138000

-1429000

-3942000

-1719000

-3138000

-0.09

-0.24

-0.11

-0.19

43607000

-5385000

-25637000

11000

16101006

-3942000

128000

4826000

1000

4825000

3198207

12000

48560000

-9327000

-25637000

19299213

120000

133000

79000

128000

-4281000

-2976000

1237000

727000

-269000

388000

-576000 231000

-2572000

-1777000

3541000

964000

250000

78000

-250000

-78000

195000

4826000

195000

4826000

3486000

5712000

572000

4058000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Note 2  Summary of Significant Accounting Policies</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basis of Presentation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2013. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the six months ended June 30, 2014 are not necessarily indicative of operating results that may be achieved over the course of the full year.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Seasonality of the Business</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold italic 10pt Times New Roman, Times, Serif" align="left"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Our primary product, Cold-EEZE<font style="FONT-FAMILY:Symbol"><sup style="font-style:normal">Ò</sup></font> <sup style="font-style:normal"></sup>Cold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy lozenges, we market and distribute a variety of Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy QuickMelts<sup style="font-style:normal">®</sup> and a Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix<sup style="font-style:normal">®</sup>”). Each of the Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy Oral Spray and QuickMelts<sup style="font-style:normal">®</sup> products, and Organix<sup style="font-style:normal">®</sup> products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold italic 10pt Times New Roman, Times, Serif" align="left"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Cash Equivalents</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventory Valuation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At June 30, 2014 and December 31, 2013, inventory included raw material, work in progress and packaging amounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.1</font> million, respectively, and finished goods of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.7</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.4</font> million, respectively.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property, Plant and Equipment</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Property, plant and equipment are recorded at cost. We compute depreciation using the straight-line method for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures  five years.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Concentration of Risks</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC and other personal care products in order to compete on a national level and/or international level.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy <sup style="font-style:normal"> </sup>products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">We maintain cash and cash equivalents with certain major financial institutions. As of June 30, 2014, our cash balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.3</font> million and our bank balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.6</font> million. Of the total bank balance, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">636,000</font> was covered by federal depository insurance and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.9</font> million was uninsured at June 30, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. At June 30, 2014 and December 31, 2013, our largest accounts receivable balances are with two customers representing approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 48</font>% and two customers representing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 46</font>%, respectively, of our total trade receivable balance. As a consequence of an evaluation of our customer’s financial condition, payment patterns, balance due us and other factors, we did not offset our account receivable with an allowance for bad debt at June 30, 2014 and December 31, 2013.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 91</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 91</font>% of total revenues for each of the six months ended June, 2014 and 2013, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three and six months ended June 30, 2014 and 2013, our net sales were principally related to domestic markets.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Long-lived Assets</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i> </i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Instruments</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue Recognition</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">As of June 30, 2014, accrued advertising and other allowances included (i) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.7</font> million for estimated future sales returns and (ii) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million for cooperative incentive promotion costs. As of December 31, 2013, accrued advertising and other allowances included (i) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million for estimated future sales returns and (ii) $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million for cooperative incentive promotion costs. Additionally, as of June 30, 2014 and December 31, 2013, we included a provision for sales allowances of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">37,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">128,000</font>, respectively, which are reported as a reduction to sales and account receivables.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Advertising and Incentive Promotions</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended June 30, 2014 and 2013 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.1</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">527,000</font>, respectively. Advertising and incentive promotion expenses incurred for the six months ended June 30, 2014 and 2013 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.5</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.4</font> million, respectively. Included in prepaid expenses and other current assets was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">180,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.3</font> million at June 30, 2014 and December 31, 2013, respectively, relating to prepaid advertising and promotion expenses.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Shipping and Handling</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock Based Compensation</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Stock and stock options for the purchase of our common stock, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0005</font> par value, (“Common Stock”) have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 4). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended June 30, 2014 and 2013, we charged to operations $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">64,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,000</font>, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned. For the six months ended June 30, 2014 and 2013, we charged to operations $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">128,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">79,000</font>, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Variable Interest Entity</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">On March 22, 2010, we, Phosphagenics Limited (“PSI Parent”), an Australian corporation, Phosphagenics Inc. (“PSI”), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the “Joint Venture”), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the “LLC Agreement”) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM technology (“TPM”). TPM facilitates the delivery and depth of penetration of active molecules in pharmaceutical, nutraceutical, and other products. Pursuant to the LLC Agreement, we and PSI each own a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% membership interest in the Joint Venture. The Joint Venture, of which we own a 50% membership interest, qualifies as a variable interest entity (“VIE”), we are the current primary beneficiary and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif" align="left"><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">Research and development costs are charged to operations in the period incurred. Research and development costs for the three months ended June 30, 2014 and 2013 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">273,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">216,000</font>, respectively. Research and development costs for the six months ended June 30, 2014 and 2013 were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">551,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">404,000</font>, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income Taxes</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 5).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left">As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits. The tax years 2006 and forward remain open to examination by the IRS. The tax years 2004 and forward remain open to examination by the various state taxing authorities to which we are subject.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"><b><i><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recently Issued Accounting Standards</i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="left"> In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”). ASU 2013-11 amends Accounting Standards Codification 740, “Income Taxes,” to require that in certain cases, an unrecognized tax benefit, or portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date, and retrospective application is permitted. The adoption of ASU 2013-11 did not have a material impact on our consolidated financial position, results from operations or cash flows.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="left"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="left"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; TEXT-INDENT: 0.25in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="left">In May 2014, the FASB issued new accounting guidance, namely ASU No. 2014-09, “Revenue from Contracts with Customers”, on revenue recognition.  The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts.  Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard.  There is no option for early adoption.  This ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2016.  We are currently evaluating the impact of the new guidance on our consolidated financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

10-Q false 2014-06-30 2014 Q2 ProPhase Labs, Inc. 0000868278 --12-31 Smaller Reporting Company PRPH 19299213

3000000

2500000

P36M 500000

3600000

500000

15799

16709

15845

16944

0.5

1301500

1632500

EX-101.SCH 7 prph-20140630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Organization and Business link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Transactions Affecting Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Investment in a Joint Venture link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Earnings (Loss) Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Transactions Affecting Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Investment in a Joint Venture (Details Textual) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Earnings (Loss) Per Share (Details) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Earnings (Loss) Per Share (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 prph-20140630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 prph-20140630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 prph-20140630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Stockholders Equity Note [Abstract] Stockholders Equity Note Disclosure [Text Block] Transactions Affecting Stock Holders Equity [Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Tax Disclosure [Text Block] Investments in and Advances to Affiliates, Schedule of Investments [Abstract] Investments In and Advances To Affiliates, Schedule Of Investments [Text Block] Investments in and Advances to Affiliates, Schedule of Investments [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Text Block] Earnings Per Share [Text Block] Accounting Policies [Abstract] Organization, Consolidation, Basis Of Presentation, Business Description and Accounting Policies [Text Block] Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Policy Text Block] Nature Of Operations [Policy Text Block] Nature Of Operations [Policy Text Block] Disclosure of accounting policy for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Use Of Estimates, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Inventory, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration Risk Disclosure [Policy Text Block] Impairment Or Disposal Of Long-Lived Assets, Policy [Policy Text Block] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Fair Value Of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Advertising Costs, Policy [Policy Text Block] Advertising and Incentive Promotions [Policy Text Block] Shipping and Handling Cost, Policy [Policy Text Block] Shipping and Handling Cost, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Consolidation, Variable Interest Entity, Policy [Policy Text Block] Consolidation, Variable Interest Entity, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Commitments and Contingencies Disclosure [Abstract] Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule Of Future Contingency Obligation [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block] Accounting Policies [Table] Other Operating Cost And Expense General Component [Axis] Information by component of other operating costs and expenses not included in the cost of sales. Other Operating Cost And Expense General Component [Domain] Name of each detailed component of other operating costs and expenses that are applicable to general sales and revenues, but not included in the cost of sales in the Income Statement. Advertising and Incentive Promotion Costs [Member] Advertising And Incentive Promotion Costs. Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Building and Building Improvements [Member] Machinery and Equipment [Member] Computer Software, Intangible Asset [Member] Furniture and Fixtures [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Accounts Receivable [Member] Sales Revenue, Goods, Net [Member] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 3 [Member] Accrued Advertising and Other Allowances [Axis] Accrued Advertising And Other Allowances. Accrued Advertising and Other Allowances [Domain] Accrued Advertising And Other Allowances. Estimated Future Sales Return [Member] Estimated Future Sales Return. Cooperative Incentive [Member] Cooperative Incentive. Other Advertising and Marketing Promotions [Member] Other Advertising And Marketing Promotions. Award Type [Axis] Equity Award [Domain] Employee Stock Option [Member] Customer [Axis] Customer [Domain] Five Customer [Member] Two Customer [Member] Three Customer [Member] Three Customer [Member] Four Customer [Member] Legal Entity [Axis] Entity [Domain] Limited Liability Company Agreement [Member] Range [Axis] Range [Domain] Maximum [Member] Minimum [Member] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Prepaid Expenses and Other Current Assets [Member] Accounting Policies [Line Items] Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, At Carrying Value Cash and cash equivalents (Note 2) Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, FDIC Insured Amount Cash, FDIC Insured Amount Cash, Uninsured Amount Cash, Uninsured Amount Inventory, Work in Process and Raw Materials, Total Inventory, Work in Process and Raw Materials Inventory, Finished Goods, Gross Inventory, Finished Goods Due From Banks Due from Banks Concentration Risk, Percentage Concentration Risk, Percentage Sales Allowances, Goods Provision of Sales Allowance Accrued Liabilities Accrued Liabilities Variable Interest Entity, Qualitative Or Quantitative Information, Ownership Percentage Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Marketing and Advertising Expense, Total Marketing and Advertising Expense Prepaid Advertising And Incentive Promotions Amount of consideration paid in advance and included in prepaid expenses and other current assets for advertising and incentive promotions that provides economic benefits within a future period of one year or the normal operating cycle, if longer. Research and Development Expense, Total Research and development Research and development Common Stock, Par or Stated Value Per Share Common Stock, par value (in dollars per share) Share-based Compensation, Total Share-based compensation expense Property, Plant and Equipment, Useful Life Commitments And Contingencies [Table] Estimated Future Obligation [Axis] Estimated Future Obligation. Estimated Future Obligation [Domain] Estimated Future Obligation Domain. Employment Contracts [Member] Settlement Agreement [Member] Commitments And Contingencies [Line Items] Contractual Obligation, Due In Next Twelve Months 2014 Contractual Obligation, Due In Second Year 2015 Contractual Obligation, Due In Third Year 2016 Contractual Obligation, Due In Fourth Year 2017 Contractual Obligation, Due In Fifth Year 2018 Contractual Obligation, Total Total Statement Of Financial Position [Abstract] Statement [Table] Statement [Line Items] Statement [Line Items] Assets [Abstract] ASSETS Accounts Receivable, Net, Current, Total Accounts receivable, net Inventory, Net, Total Inventory (Note 2) Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current, Total Total current assets Property, Plant and Equipment, Net, Total Property, plant and equipment, net of accumulated depreciation and amortization of $4,197 and $4,064, respectively (Note 2) Finite-Lived Intangible Assets, Net, Total Intangible asset, licensed technology (Note 6) Assets, Total Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Accounts Payable, Current Accounts payable Accrued Marketing Costs, Current Accrued advertising and other allowances Other Liabilities, Current Other current liabilities Liabilities, Current, Total Total current liabilities Liabilities, Other than Long-term Debt, Noncurrent, Total Other long term obligations (Note 3) Commitments and Contingencies Commitments and contingencies (Note 3) Liabilities [Abstract] LIABILITIES: Common Stock, Value, Issued Common Stock, $.0005 par value; authorized 50,000,000; issued: 24,635,266 and 21,437,059 shares, respectively (Note 4) Additional Paid In Capital, Common Stock Additional paid-in-capital Retained Earnings (Accumulated Deficit), Total Accumulated deficit Treasury Stock, Value Treasury stock, at cost 5,336,053 and 5,336,053 shares, respectively Stockholders Equity Attributable to Parent, Total Total stockholders' equity Balance Balance Liabilities and Equity, Total Total liabilities and stockholders' equity Related Party [Axis] Related Party [Domain] Mr Karkus [Member] Mr karkus. Mr Cuddihy [Member] Mr Cuddihy. Employee Agreements [Axis] Employee Agreements [Domain] Employment Agreements Dated November 8, 2011 [Member] Reprensents employee agreemens plan Employment Agreements Dated August 19, 2009 [Member] reprents empoloyee agreements plan. Employment Agreements Dated August 19, 2009 Amendment 1 April 2011 [Member] Reprents employee agreements plan Title of Individual [Axis] Relationship to Entity [Domain] Chief Operating Officer [Member] Chief Executive Officer [Member] Chief Operating Officer and Chief Financial Officer [Member] Payments For Legal Settlements Payments for Legal Settlements Settlement Benefit Settlement benefit (Note 3) Represents the amount of realized benefit as a consequence of a reduction of the previously recorded accrued royalties and commission obligation. Additional Royalties And Commissions Accrual Interest Percentage Additional Royalties and Commissions, Accrual Interest Percentage Represents the interest rate percentage computed on royalty installment amount due. Additional Royalties And Commissions Payable Installment Amount Additional Royalties and Commissions Payable, Installment Amount Represents additional royalties and commissions installment amount. Additional Annual Installment Includes In Other Current Liability Additional Annual Installment Includes In Other Current Liability It defines the portion of additional annual installment includes in other current Liability. Additional Annual Installment Includes In Other Long Term Obligation Additional Annual Installment Includes In Other Long Term Obligation It defines the portion of additional annual installment includes In other long term obligation. Litigation Settlement Interest Stockholders' Equity [Table] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Plan Name [Axis] Plan Name [Domain] Plan 1997 [Member] Plan 2010 [Member] Directors Plan 2010 [Member] Directors Plan 2010 Fiscal 2010 Bonus [Member] fiscal year director plan Directors Plan 2010 Fiscal 2011 Bonus [Member] 2011 fiscal year director plan Directors Plan 2010 Deferred and Unpaid Cash Compensation [Member] Unpaid cash compensation Amended Option Plan 1997 [Member] Amended option Plan 1997. Equity Compensation Plan 2010 [Member] 2010 Equity Compensation Plan [member] Restricted Stock [Member] Dutchess [Member] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Option Indexed to Issuers Equity [Axis] Option Indexed to Issuers Equity, Type [Domain] Short-term Debt, Type [Axis] Maximum Number Of Common Stock Authorized For Issuance Over 36 Months Maximum Number Of Common Stock Authorized For Issuance Over 36 Months Maximum number of common stock authorized for issuance over thirty six months. Maximum Amount Entitled To Put To Investor In One Draw Down Notice, Percentage Of Average Daily Volume On Trading Day Maximum Amount Entitled To Put To Investor In One Draw Down Notice, Percentage Of Average Daily Volume On Trading Day Maximum amount entitled to put to investor in one draw down notice, percentage of average daily volume on trading day. Maximum Amount Entitled To Put To Investor In One Draw Down Notice Maximum Amount Entitled To Put To Investor In One Draw Down Notice Maximum amount entitled to put to investor in one draw down notice. Investor Right To Use Excess Proceeds Maximum Percentage Investory Right To Use Excess Proceeds, Maximum Percentage The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations before deduction of valuation allowance. Share Purchase Put Restrictions Maximum Percentage Of Ownership Held By Investor To Purchase Shares In Equity Line Of Credit Share Purchase Put Restrictions Maximum Percentage Of Ownership Held By Investor To Purchase Shares In Equity Line Of Credit Share purchase put restrictions maximum percentage of ownership held by investor to purchase shares in equity line of credit. Stock Issued During Period Shares Under Specific Agreement Stock Issued During Period Shares Under Specific Agreement Definition :Stock issued during period shares under specific agreements. Stock Issued During Period Value Specific Agreement Stock Issued During Period Value Specific Agreement It defines the aggregate value of stock issued during a period . Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance Options outstanding - Shares Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share Based Compensation Arrangement By Share Based Payment Award, Options, Deemed Cancelled Share Based Compensation Arrangement By Share Based Payment Award, Options, Deemed Cancelled Share-based compensation arrangement by share-based payment award, options, deemed cancelled. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Common Stock Shares Unissued Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Common Stock Shares Unissued Share based compensation arrangement by share based payment award options grants in period common stock shares unissued. Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement Equity method investment ownership percentage required for rights exercisable under right agreement. Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Equity Line, Purchase Price Percentage Equity Line, Purchase Price Percentage It represents the lowest daily volume weighted average price of our Common Stock during the five consecutive trading day period. Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Cash Less Exercise Of Right Terms Description of cash less exercise of rights terms. Share Based Compensation Arrangement By Share Based Payment Option Expiration Terms Description of stock option plan expiration terms. Income Taxes [Table] Income Tax Authority [Axis] Income Tax Authority [Domain] State and Local Jurisdiction [Member] Domestic Tax Authority [Member] Income Taxes [Line Items] EX-101.PRE 11 prph-20140630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#ZP-;3N@$``-<0```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/@S`4AN]-_`^DMP9* M4>#T;*N M@@486RJ9$A;%)`"9*5'*:4H^)B]AGP36<2EXI22D9`66C(:7%X/)2H,-?+6T M*2FFYL[?FBG5/)OQ*=`DCGLT4]*!=*%K>I#AX`ER M/J]<\+STC]2KA1B'QEN\86I;97'H/0 M3H5FYG>!3=V;WQI3"@C&W+A77GL,NJSHES*S3Z5FT>$F'90JS\L,A,KFM=^! MR&H#7-@"P-55U(Y1S4NYY3Z@WRZVM!W8F4&:]VL;G\B1(.&X1L)Q@X3C%@E' M#PG''1*./A*.>R0<+,8"@L51&19+95@\E6$Q58;%51D66V58?)5A,5:&Q5D3 M+,Z:8''6!(NS)EB<-?DO9W4^-@)MKW__.MHV1W*+=:L*[)G_-=9-CRD7W(!X M=\8'[+,#_.Q]B,/'S[%1VOH@;N#T7=@F[:8ZU+X1&%?"+FMW9=:=H@_QIPON MA69HC@D$B`YMVAY+#+\!``#__P,`4$L#!!0`!@`(````(0"U53`C]0```$P" M```+``@"7W)E;',O+G)E;',@H@0"**```@`````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````````````````C)+/ M3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?/ M/UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBD ME)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&74"T\ MU<%J"`=[!ZH^^CSYLK$SO+=N5#9@NIS]NHFD++28,5 M\YS3$$ MX4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A`$ MM^X'F$1-0E,[V-Y'__U,UZ4M=-HEZ!*P0^271Z\4>;'ZVC?)!SI?6Y,)&*0B M09/;HC9E)MXVSP\SD?B@3:$;:S`3!_1BM;R_6[Q@HT/\R%=UZY,8Q?A,5"&T MCU+ZO,*]]@/;HHEOMM;M=8A+5\I6YSM=HE1I.I'N,H987L5,UD4FW+J(YV\. M;3SY_]AVNZUS?++Y^QY-N'&$_+1NYRO$$(-J5V+(1+?EY?'-;!`5"WE;#`R9 MU<"0E,,-!T@Z:M(G'1\.331;EZB?-86#.SED;A3T":-SZ9E'MW4RK@**S919 MS902`XI9#2A2#C<<(.FH<9]T0FS%>';-<2F/3](OW!FB$]1K8^D*YTREVSK5 M$DPHOZCXDV3])ZF4DL/=:$C?<&>*3!2PHR'9J!&W;T:4;WIM,UT%_5U48TH, M<*L!4H[BGB44.4P`=\?D-``#__P,`4$L#!!0`!@`(````(0`R MK]'$UP(``'X(```/````>&PO=V]R:V)O;VLN>&ULE%9=;]HP%'V?M/\0Y7W- M%_V@*E3]FL8T;95@[:/E)@ZQZEPCVRFP7[^;,,(-65%YBAV'XW///?/UTMM7E] MT?K50P"P([]P;G$9!#8M1,GMB5X(P)5B\\)4B]M**EP=)F'B!^.VR$?C92+GE7(S+&^+CGK% M@S@^J[^LI7B28FEW/ZJGWNI90J:7]:P`GW9I-8*.^U-C"6O4)5A;YGKF4.#"3 M+*J)4Y0[#9D`*S*&(ZN5S#B*Q6ZYXI`*@A(CTQ8F/@X&&;1L4+L=3J/X!^A, M';(J*9T!01E\D,T_E`Z;AQ.3*JB137FH$7],G,.\D_C6(:Y8K>5E2"L M)0`QAJZ5]WR?R+0J2V[63.=L*N<@,1$<'+M)4UV!HS!#`G.Q#W.GRU*Z.D:V MX8$M=YAZ3+_$C.]ZE*!O6S+#?929X6!YVN2/W>2YP"',V=3I]+6@QDLZS@OW M<29XZ)2"S?BJNSGJVFX>]0P[@3>,<%T#D\`X^ZXE#I]P7AEJD"2A,#W#/G`# MR-JR']I:]B@,FQ:\"T`M%O6<>K@EU&-U[G<%_<>L!YK":%>HR:*>6=^I"/5] M45V!J>>CGEL/%T9-GU#/1CW3'G0;ZRA$71L=9UM&&44=H".=2QD-:`+P&-\[ M-:EUV;UP7"K+9F+E*HZ7SNZLHP&(C[,R[7Q,(X&3/3;O=7Y#C/*AF8A[ECZ, M0^6):39P4E]73=5X1Z5NZP]RRVGPGRZR=U`=9 M`;*IFS+KX&NSM=I#([-U/ZC<6XYM^U:9%96)$>;-/3'JS:;(95+G+Z6L.@S2 MR'W6P?S;77%HS]'*_)YP9=8\OQP>\KH\0(BG8E]T[WU0TRCS^8]M53?9TQYT MOPDOR\^Q^R]7X. M;5JK1;]`_Q;RV&J?C797'W]KBO7/HI*PVN"3WJ\C\DB5,H#.*<@L"( M4Q`!C\8'6SB17E>2==EJT=1'`Y(%7M4>,I5Z8@X!SX+P]1>)GRD$:2K(=Q6E MCP63;\&6U]4T7%BOL)+YB1(A)3"-"\6W*24^4]2ZJ;#)^<$P1M`AZ9FA3`-% M%UFP(%R6"VY_[--9A1K$5+CT?=$UQ:&,^)KALTDGUQ06)+UF:$&(4)<*'1>H MR$L3@@\>L#='2)GU'HH@#)@Z`HB4P([P+C"1!#M+3\=QEQ2921K"]I.* MD.+UDH*0>1CK:.@P$Q)$<3F$&"#4QWV'7](`"+(_XH@189*IZ<=,R%""BSF M)3,9([[)2&XRTC$&D0=EZGZ_%)GYQ;(D0@KZ-9NR)8]U-+#YGD(4_7)G'H-3 M'?9LS4XB2!U`M#(_GH"*S`0-:8`)B!2$QPQ_>&=491!)\%5S81//"U,D2%J1Y]=^X)[.AZCPK8 M.2$Z<5#8@RMFS7)93@AAY;E902(/6&"-0MU:GO%X=] MG8AC:QJI7S*7U&.;+AX#DS$P_02D8E1KOE\,-G(B9D@![%`".7B2_=`I0OC( M*4+XR"E"&'%*]>C[Q6%'UX]+`2O-D4#.V'GI-B6Y34E'*=1!U;7O%XD]GCC( MJG@DD!/VI]P'>\*W4GQ%8.4RX02'97S*"=KABXI3+5P3IWXFW_X]*;#Q$R=9 MO8A.G%$GS^>'3P_'R>THZ2B%B(4+%")V_+#8L^E))!@J%N[%$P<;MO!#C_D0 M4$TYK'=G%""?W5*5K<^JG:=7C$-PF$.*`[O=/#NHY3-5L9ROV^-O'Y1]S4. M)-GE*=XE16(.-Q)PL<">)W#'U#^W+@!<\1RRK?PC:[9%U1I[N8&0]B2`>MK@ M)1%^Z>I#?[_P5'=PN=-_W,%EGH2[#GL"Y$U==^&ULG)A=CZ,V%(;O*_4_(.XW8`B0B9*L)GRT*[525?7CFA`G00,X M`C*9^?<]QH;%)FN3WL!`'K_XO#ZVSWCS]:,LC'=<-SFIMB9:V*:!JXP<\^J\ M-?_^*_FR,HVF3:MC6I`*;\U/W)A?=S__M+F3^JVY8-P:H%`U6_/2MM>U9379 M!9=ILR!77,$O)U*7:0N/]=EJKC5.CUVCLK`5,E)`!^!J ME#E-#7`D_>CN]_S87K:FZR^\P'81X,8!-VV24TG3R&Y-2\I_&82X%!-QN`C< MN0CR%DO'"U;/J+AZ]BK-P5A[R_"?ZLN0J<.]5@N?[`K%WML"]5_D???&Y M"MP'%9VI%AN@;KRCM$UWFYK<#9A$,`3--:53$JU!L!]H-BS#T/]HY&'(J<@K M5=F:@6G`H#:0KN\[UU]NK'=(L8PS>\;`=6"02(13%<=?B4S4,S3GZ*?C7K9_ MD8Q>6!#D$"FDT3C2QZGOAIHZT)-@]1NGX@.<&859?MRY7CV[8M$B$CX#JH2%Y%6B+6 M$HF*$)R`5>=Y)V@CV0DI'?>,4<09:HF($7[GI@=6RF;&6HE$10A&P#KWO!&T MD6R$-+WWC%$9H24B1C`CH.IYX(16(U$1@A.P8H^=4$\*"DL.!%+*[QG#>A^X MW4!*DV),>`&-4`0B!BA,C,<2R'=7$XUD3"QM3R`$`VC!.MK^U`906#;@^[K; M;4=[QBAZ'VJ)B!',1)>N*[)'L58C41&"`R^B`_/61]I(=D+:#_>,43FA):(I MX0:NF"_QE)%6V41%"%X@V!CFIT-'RRY,JAXJN355-G`=!1)QQ%]VZZ.]D"*, M]1*)$A%=H!74[$F!6+TE[)6!U+\]AQ0AAASA"Q]ZD/617B76(XD2$8V@==9\ M(UA5)AHAET^(04HCM$BD5XGU2*)$1"-HM37?"%:;P76H>Z9U)%(5<-U2&NJ1 M2(_$>B11(J(1,'!C(^:MEHBVDA<*N9SDD#(SF(X"B;@*FT5HN7RP=^@_E"@1 MT1!:=(TR8Z8AK%03ILJDOJ;G#;J54XM$7(4O*P\W4_V'$B4B&D)KK^<-816; M:(A<9B-56<>GC!:)N`K/D&Z9E2JP6/^A1(F(AM!:;&2(NL2"0ZWI5)'ZM^<0 M^]?+#6B2BS5!R`GE3&%?4B"Q7H4>POTX29D/[)"-';J4N#[C$!=%8V3D1@_0 M'-C1A[?#X=ZK0T\>I/O^O,#I*H8#%"@F3.-$2-L_T`\,Y[6[_P```/__`P!0 M2P,$%``&``@````A`!YT](FY`@``+0@``!D```!X;"]W;W)K&ULG%5=;YLP%'V?M/]@^;U\!O*AD*I5U:W2)E73/IX=8X(5P,AV MFO;?[]I.*)"U8^,!<'+NN>?<>['7U\]UA9Z85%PT&0Z]`"/64)'S9I?A']_O MKQ88*4V:G%2B81E^80I?;SY^6!^%W*N2,8V`H5$9+K5N5[ZO:,EJHCS1L@;^ M*82LB8:EW/FJE8SD-JBN_"@(4K\FO,&.826G<(BBX)3="7JH6:,=B605T:!? ME;Q59[::3J&KB=P?VBLJZA8HMKSB^L628E33U<.N$9)L*_#]',X(/7/;Q05] MS:D42A3:`SK?";WTO/27/C!MUCD'!Z;L2+(BPS?AZC8,L+]9VP+]Y.RH>N]( ME>+X2?+\"V\85!OZ9#JP%6)OH`^Y^0F"_8OH>]N!1XER5I!#I;^)XV?&=Z6& M=B?@R!A;Y2]W3%&H*-!X46*8J*A``-Q1S>:[+#,>IE\R#.`0X MVC*E[[FAQ(@>E!;U+P<*3U2.)#J1P/-$$BV\693,%Q-8?*?(&KPCFFS64AP1 M3`WD5"TQ,QBN@/G/CL"*P=X8L`T!L0K:\+2)D]G:?X+2T1/F]A(3I8L.XT/: M+C?DFY[;@,>YDX[7ZKN]Q$1OI([_);4!9QC(>[;346J'F?4PK^(&I@$RW;0! MP[#T6.-D/LKL,!,RPZCU,YLACN%3>+_E)FCL_;6FKNP.TU<0)\M.YB)D/Q;Q?"`,>BP@[7B?"8?J%>&,(S,$P M^:LSX+\-@<-,R+P<9IXV!"9H[#T:>7<8UX!XYLV#_A5WX$$#8,\>U&&:&ALU MDI.,9_($ZE\4:AB!7P<@3>'R99NNW<++5J[!VV% MAFW:OI9P+#/8'`,/P(40^KPP!TIWT&]^`P``__\#`%!+`P04``8`"````"$` M^QK3T^@)``!]10``&0```'AL+W=O:V.^_6)_?7X-JX_CN7ZI5EHOQN;D\ETO%]O#T-187F\I4;U^KK= ME%ZU^=R7AY,H%@OUG&;X?JN'[>L?W^9=CK35N[^4NG_'Z[.59U]7H:L7)CL:'=?5Z,%V-6 MZ>GA9U._55WC6#IHS\(_CX*5\77_N3O^LOJ)R^_9^8J?;87O$ M=VSY\MLKZPT[HJS,R'1XI4VU8QO`?A_LMSP:[(BL?ST.3;;B[R_H4;'G)X6#S69^J_7\%:O;H7,221=B?LHC!ZMVXL"T79G^>%QZ9 M<\=PIG=L`MO89C]FYRJ6=?=^L!=%4\1@N]MNRV)DV)-[MH3ONJAR.:;F;#1W M''LZG]U^4(WVJ/(?Y-98SL@VG=G\GI-CM`>8_]#6N?G8C$5>FOAYZ]/ZZ>%8 M?0W8:YH=HOICS6<(8\DKM\$3,3E'\?\ED4605_G.RSP.V5EC(:O9R^?GDV5, M'\8_6>0WTJRZQE"%VPJ>;U[6$P,BI7S`;\75>B8SM4K0FK9*V%:Y+$16'+6B M721N!RZ+3"?J:I(N(553(6;-RY5O?48'\G;@LAI2HV@%V[(Q.V7G\\9"J9RW M_HFB/3U<\]/3[M^J';BLV%1WS^V**=DVKTO,N5K%%X3MQ%4NZ/D29NHTL;&- MV9R`L%N$;&P$1=P5='<23-(N(5N209%#4>B$$@(VH]P1`JZ5$-`!EPYX=,`7 M`^KY).<\Z#,+-1?A#2;J,29Y$<9]AL0TN<&D-YBLSY#3G_<92]WWHFOF%Z*< M7S8?WW%^N5;.+QUPZ8!'!WPQ<)EP`SH0TH&(#L1T(*$#*1W(Z$!.!XIVX&HB M,>WS@56.&KLVWW'4N%:.&AUPZ8!'!WPQ<'74Z$!(!R(Z$-.!A`ZD=""C`SD= M*-J!JZ-F7%ZNRE&;WG74N&;WF-?SNNF<3T=S\5X)PT[<>>XGPH7"@\*'(H`B MA"*"(H8B@2*%(H,BAZ+0"242['9.>2'Q>T.;14I_K\&7:AY$SJ?=,NFMH#"Z M:$#A0>$+,6WN*TQGPG^I$0U@C1"*"(H8B@2*%(H,BAR*0B>4:/"^`WULF+*G M7GTT^%(T&N1F;R6,+AI0>%#X0DSM)AMD6@K@XB$4$10Q%`D4*109%#D4A4XH MJ5CTI,*"J>!+T51<+E+B6B*,+A50>%#X0LRO)@PR7\`2(101%#$4"10I%!D4 M.12%3BC),%@*.A,&CD:S&,T&>9982:0+!R8>)KXDP%KR1%_VS#WSSI7(0N?3UQ&RN1=BH1=33$PU5\ M3`),0DPB2>0+;W9]-)M=CG&-!),4DPR3')-"2]1\\.8:G4EP>X2_J]O)R:63 M*7,BD"8$KJRC(1XF/B8!)B$F$28Q)@DFJ23R!3Y57^#-T20)XZ5H6OF-7OK8N)AXF,28!)B$F$28Y)@DDHB@N+, MC9ESN1#(G,"#F^/U%%JB!H6WWVA0<%?-$%T[-2BTXRJ19KIP,?$P\3$),`DQ MB3"))9%S0?=UGB"0XI5DF.3*:NR^3G2AK:*FA+?C_B`EHHNGIH0V7PU=JT]. M)Y!XN(J/28!)B$F$28Q)@DDJB+B*CTF`28A))(F81\1[!.=& M5'.K%>,B"2:ILAYS.C,<,D=GBC!F4\,BKXPJWV<9E` MV1JK:8"3>^Y0(;W-B@BO*,8DP23%),,DQZ30$C4CM!$+,M+3@+5IP\042'/^ M74P\3'Q,@AYBV>2N,.Q!9$Z+,(DQ23!),3=R-SD;W.J#X^N>4V,1??-#T\*S8SD8Q)@$BJ;8O6])1OA*C$F"28I M)ADF.2:%EBA!X9GH/./@H#2+D4</^^/+Z5;KG;U8-- M],?ORBX_U6YFOCV_;0SW8E:]L M%R(OI^JC^9*#Y^K$OO:B^?&=?&PO M=V]R:W-H965TL:,$UJM M;-_Q;`M7*B'KANCS=XQ)QA]:X@D]RRDHDX)+M7%XSC+)F4%FX@>>%;HE(92N%!;M% M@^8Y27%,TT.)*Z%$&"Z0@/KYGM2\52O36^1*Q)X.]5U*RQHDMJ0@XK41M:TR M77S9592A;0&^7_PQ2EOMYN)"OB0IHYSFP@$Y5Q5ZZ7GNSEU06B\S`@YD[!;# M^)[]GN>MD$])O@(S][;_$]/7YB)/M**@QIPSS)&=A2^B31+YF\!8/= MB]&/S0Q\9U:&VI;$"2')?*\'GGATGV& M:4U/3*08.)XQ4YW97.H$X4QGXI:1,RT?GK3">ZH^0*TQ&:(U@_YX[D9(W@^V1V)@TCKY=PI!B3OT$B5L2L M6=V![\F7GE%BTM#\P1?M=G\2[OGS>T^.%&/RIXBPJ?Y:\?&@1&(B-'NA;N^V M92H']6WZ>L"18DPV%1&.U1X$/PC-/+4'/[D+=,EX4#(Q$9IMV/[.9_4VVW)0 MWW:OQD@Q;\_=9@B(%6`(+C$1FDO95O5^,(;W(#FH[[*_!RG&4.-FD(@'B401 M5[/4;,[_QZ8[\4T0DR.3PA:B_U1Y<.AS5DRRG#OOX8Y5&UE*K=*3';X0TN"FZE]"#;Q0#V MB.YNU\H^!+(%Z-W?^`MH.V1_T7T`'6:-=O@;8CM2<:O`.4AZSA0V2:9Z5'4A M:-TT65LJH+=LWN[AOP2&QL5S`,XI%>V%?$#W[V3]%P``__\#`%!+`P04``8` M"````"$`PI,&*.4#``"4#@``&0```'AL+W=OV`ZM*B]I4"K/V$0VZV109B6FVKTC-E4A+RI3# M_-FN:-A)KD:O2]FW?/&6T:D!B790%_Y2BIE%EL]=M3=MT78+O#\=/LY.V MO.C)5T764D8W?`1REIIHW_/4FEJ@M)SG!3@0RVZT9+,PGYU9XGBFM9S+!?I1 MD`/K_#;8CA[^;(O\[Z(FL-J0)Y&!-:5O`GW-Q2T8;/5&O\@,_-L:.=FD^Y+_ M1P]_D6*[XY#N,3@2QF;Y9TQ8!BL*,B-W+)0R6L($X*]1%:(T8$72#_G_4.1\ MMS"]8#0.;<\!W%@3QE\*(6D:V9YQ6OU4D'.44B+N401&'$44L/!A0+/(HUJ2@]9P:")T/J\6>+MQR"-2'R+%2D%DR>05K>EUXXF5OO ML)39D8D4$YK&F0ELC*Q.B%@XH1N?;ES&.'A(LB.[+@W1?3]3) MAAB$;8P]_+RHC[B86/6)0)MTW$1P_X$O#!A\^X&7K^A(OWOT"%8-T?UIQ18H)I#\GF/J^ECT4 M'T]\+;LQB@>A?9F_?"<3%!^'TTL<^0M^QY\8I/O3UC=2S%3ESQ[I^5GI<6U] M8BWN:NN3:/&.?^0/&EDW?\-U*6#\WKEZW42*@>HYUZZ6F=5=(KY+)$,$\B>V M+)T/P[`_`>.\N;[>.17CR[QI[^1J(!8/Q)+K,>1C^BL^!(Q]>!/=AV*N^QB( MQ0.QY'H,^7#@Z_5X0B2M.]$J/3I"JA7J*1D*QD/!Y$80NQ'?[8?+RU%?>=S7 MM;-AH_XY+]>7'N0QUEPJZW>3ELQ?F!="[O`[TVKP.]/J\.@2HS7)% MVBU9D;)D1D;W8H/O0A\[WU6'C\B9P0X6-J+:_5@<2N2QXAR`,T&3;LD_:;LM M:F:49`.2]BB$;VNK3A7J@M-&[D?7E,-I0/[

F/P-[8'@&\H92?+L0.^'R> M7/X/``#__P,`4$L#!!0`!@`(````(0`%>[@%&P,``)4)```9````>&PO=V]R M:W-H965TD-TUP'[\^[SD'GRSO7HH'@I;*B`B:$P7QRXQ5LE$KXFOD"B*>#M5-S(L*)'8L9^JU%L6HB!>/^Y(+ MLLO!]XMS2^)&NWX8R1O\_&'T*#O?DZ`#\$ M2FA*#KGZR8]?*=MG"JKM@2'M:Y&\1E3&D%"0F4P]K13S'`*`OZA@NC,@(>2E M_CRR1&4A=OV)%]BN`SC:4:D>F);$*#Y(Q8N_!G).4D9D>A*!'2<1!Y;.;[9, M(+6OB"BR6@I^1-`K<)2LB.X\9P&"C2%S?&OQ?P[!FA:YURHA#C""X"54Y7GE MSF9+ZQE2&9^8]9CQ[3ZR:1"=.*T;-0MONDY_R[8A=-7`4NL+,M+U]7Z!FO`U MK,-OSEV;!=!N_4S[YV[&A#\(+1HC`Y'MF.B(].RX'[&C8>BL3O1N,._'OS;, M;8?Q^L3F(A%=)+;GB)X_".3ZO[\C_C3 M\*7^-,PY?Q>)Z"*Q/4?T_,'5UJV?OB9=F![GKQ6]:5C'P26Q-HSI4\^;N\[@ MVMQT`=>;3X.!0M0%O,`)7+__(L,\U&&8(VYM9W;[]JX8CV;9"^]0N]I.V?NIOBT'ZVMG`7?X>#V"J5RO6^T&F(H5V=/O1.Q9*5%. M4SC*G@30<<+,5?.@>%4/J1U7,`_KKQG\_*$P'>P)P"GGJGG0,Z#]0;7Z!P`` M__\#`%!+`P04``8`"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H M96UE,2YX;6SL64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B M0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$ M(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S: MWIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53& M`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4& M.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y& MK9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#% M-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\ M]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V M">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!# M\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G M^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U M."O3>H<],9&R;,UM`?H6G'X#0[TJ=?L>FT1.[P:3?$45*&'=`X M+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXG MW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@= M/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5G MY*8TO;>$#6C\S21 M0*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09 MHW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3] M$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76 M&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA M_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005W MU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X M,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"? M[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4 MX9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F M!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q M\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q M)4TPP:&PO=V]R:W-H965T&ULE%C;CJ,X$'U? M:?\!\=X!FUL2)1D-M'IWI!UIM=K+,R%.@AIP!'2G^^^W['(#-KF0ER2DCLO' MI\I5V*MO'V5AO;.ZR7FUMLG,M2U697R75X>U_<_?+T]SVVK:M-JE!:_8VOYD MC?UM\^LOJS.O7YLC8ZT%'JIF;1_;]K1TG"8[LC)M9OS$*K#L>5VF+3S6!ZV56;+'X>*U^FV@'5_$#_-OGS+AY'[,L]J MWO!].P-W#A(=KWGA+!SPM%GM[/_**@=H0)Q&!+>>O`OIC)_Z"PU[87SH+( M]0C`K2UKVI=?D?@H@@U3FAR@E\*R<$?DX<[*G!\-T-GM%Y0(+P M/@4'ER/5>4[;=+.J^=F"E`/"S2D5"4R6X%G(XH&XEV6!I8@QW\4@.130#<3R M?4/#E?,.\F<*$B,DLJT>HB.2"XAY!W&`7L<1-'J8%A3H9F$GI7`@8[8CHI`39($8,40D+,-,_W=',R-`<>Z=76E`H? M(27`!BFJSQHC!$EYU.^ED,F5#,TTH/V2-%*P089*3=M^8I!!SI`D1HBOPFA8 M$[0B=3)WKW`3K6]0&FYGO0`;G'Q#,(2H6;TP,NR)9BK5AB MD$'/V'(Q0E22!6X_.\93-X<]>2V>!)@,19L64#G*H#!4?HA1N64&YDU3L[\E9-T[O>IH2OW4#\0;V7&7O7[E2MB MPY)/_&@45;2K^A?V>TGG]5!+(..>X)L]06%0L&`1&/9$L_LAO59%C+9P9Y.. M^X'9(F,R;`AP]-!+XHQ@6 M\V'M\(T4B@EB;M:.6Q"-'KW0%NXW+3E*;PM^G\JHG,*@3CM!)&JWA]K:@XY9@ M'@!BA4%R!")G")SH`!HL^HS5J1E-8:)^X^80]&FML@\Q>(8A%UY(Q'$9.HP" M7'@AP5L$/">7K#ZPA!5%8V7\3=P04'@%Z_[%VXN8+&,JSI'&_XFXU9#W$IT! M+A5.Z8']3.M#7C56P?;@TIU%P*G&:PE\:/E)'E^WO(7K!/GS"-='#,ZI[@S` M>\[;KP=Q\=%=2&W^!P``__\#`%!+`P04``8`"````"$`9+)*I.`"```&"``` M&````'AL+W=OLV:9.F:1_/#ABP"AC93M/^^UW;E!9:=30/`=OG'LX]U[[>7=ZW#;JC M0C+>I=AW/(QHE_."=56*?_^ZN=A@)!7I"M+PCJ;X@4I\N?_X87?FXE;6E"H$ M#)U,<:U4G[BNS&O:$NGPGG:P4G+1$@5#4;FR%Y04)JAMW,#S8K\_S4TDY9$D$;HD"_K%DO']G:?`E=2\3MJ;_(>=L#Q9$U3#T84HS: M//E:=5R08P-YW_LKDC]RF\$+^I;E@DM>*@?H7"OT9P=R9J?/PM6?&,=!;.A3+H`1\YO-?1KH:<@V'T1 M?6,*\$.@@I;DU*B?_/R%LJI64.T($M)Y)<7#-94Y&`HT3A!IIIPW(`#^4]$5*R3J*$E4'K. M&LHI;".W`\5[<^"/7$$#-J\UW+<4.I;G`+CD7#T.]%4QWN#[?P```/__`P!0 M2P,$%``&``@````A`+\V3W]W9V=J^DQ63P7183BY^=^>;TV>;G]S) MJD4^&>:CZ:3XW9WKHKKS;X__ZW_YO*H6&>].JM_=N5PL9I]^]%$UN"S&>;4U MG143?CF?SL?Y@C_G%Q]5LWF1#ZO+HEB,1Q_M;F\__&B=5^?CSQ>,GTT$]+B:+[&`RS)Y.%N7B.CN:^`#, M^_./%H\__TA-O?G#[*OI9'%9T718#+N__J&>;&5[VQO9[O;.?O?'@_IB*]O9 M7?UC,XUD[.S[Y^6DR(X6Q;CZ]VYO'W8?-#V<7L^*[H\?[FQO?MU]>,"ZA[;V M9Z/\HOOKA^?YJ.IUU(QR7,S+J2@VS)[DB_7MGI75(!]E?RKR>?8,6E>]<5;1 MJADFO!Y&6]W!U[O=/L,^OBHNRFHQS]G=%_FX-\CX7@Z646$>V#SY MI#`[N1Z?34?=P3X\?G7\^^[#,`,Z'$\GV^.7F2W;W???EHDIU>3NL* M%<'VU)-14579='%9S*]*=JV:%8/RO.R+X9-B@!CNF*3M=3L].#EY>GK2?7J8 M5Y<9XV0#_:/X=@RLT'@G;RJH%.WZ]/I`IZ\N0T\/BOF MB^N-;`;)%]:WEC>3X-N$L^EYE@_0@O7(]F98H%$'9;Y`_5GS?"QN^M$?T/CN M_L;.HX_M)_ZY_7!_`QIH,Q;EFV*T?IU'$Y3]10FA,EO/1C8J!\XOMB5Q/B^='!%T?/CTZ/GIY\VB52LT^S_%J;M.+W>0U+YD-,U:*L M)!?M!B!0TRNQ:H_X+\6'#?%'97Y6CLI%V6^XO$LW-/0>L847V:*8C[/IV:B\ M,*I'+MSK447R6"ZTE\XV`ZP3*\#.,I/`)R.B]_A'8/MC?X5?__LZRL*LCY M:;:[O_%P[\'&[L.'1L[=G8W]O8\WMA\\RBK3&BN99K^WP(/A$*I.)S"ZA&2S MG&P.\ED)XZ_8R(2'S\M!V9/%4UR%JD84*]=?^0(O`6?CP<;>WD/FMF=3;?]: M-=/NL+Z]UN'E=#3$W?G0],?B>G7+A`%LM-N\>3LM^OTQVACGI%B4F-Q_OYU6 M+=X.BMG"-7F&;#0W%FTV[3+'*&QIN7_7#&7E<;M9($>=9%$6[YD+5&(5YNY MO5O[E#UC]J)89!6&*HIZWTP=BK^9QLVMOIQ/,:VS^?2\+S1A`6BE:*!ZJN+$ MIB"M.<[GK^&_OB-P,!R7$_/&),U=VK\J*AS$@9O@88$9F9J!ZK9S89-%@Z3M MC+K-GFLUY_,I.K2A?K<-UJC`;"VRDIBD[QPV/X=%=U^W(&(^79?_2*ORH%IB&$YJN4TJ54K&;U-B!TU@C2=)\U[ MXWY7E!>7ZC;'[N47!9K07+O`]M/6I^N-U)_:KQ42\R<;]?D4_X0P[%9>84]_ M=>EH+--]F*J%[/NOBO%9,>^%6(GI.7;3@^MMIF?M*Z^*!;$G1'V:SRNX-U;-6Q>^>FM!(WI[_N?NC4 M[;Z)FKH_N)/\KB%71F)2D+>B9'?,[N:6A'25V9\;-C>J"A,A?-@:8]/MN)E1 M+<3=H9KYI;RW M:KQ5+V)7Y6[+/#K95X77W1=M<:L:2H>=@>=,I%;ET`:!^T?O`7>O??#F_ MR"E;G[]+]$U`WW`5X+OO^M'B[R+X8L;V]L5X(VMC)_OJ7_\C284V`URT?3NJ" M9MF]O_[E/Z^*O_[E?VW0UW_6%?_*IO.,4$1_8R1F@%`\O+_!8R,S[%[C/'N; M48YBA5)J;S32'R^*-_F0:*0DL,6MG-3G4(L%S3>"D\G+VJ:AG,KRK`9BT6LY M#PQS%C"4@?WAV?#X$C=L.LL7E\&GNBSRT>)2'N^P'A`[+R[A+XP@;<]Q"X<9 MFE?3(9+&.R+VK`G&096^`[N@%=#H%##[`K_)Y%9-M>VK?%@-/X/0!.9T-&5R MFS3?-/2(-8AV+T\/19UL.*\O4%TYZZ2I[''6G:BP\HOLJF3R53V;C2S0`-PA M[K0@>6#3@RX$MF.0J=J"P6:A'8!S+@C\93WG]Q+7_3H["TPOLFM1">$W6E+# MZG$73.\PG.(+K92E,/0(TC.SX74SL`B*>:L`VW%+%Y?S:7UQJ:5Z;#^XQ&\2 M)'!A?V\XN,<>7;LUF0X@R%S>U4C!.[3>`G:<9^<@U]5E.+.1^#[/_KCG6W]Q1*< M@</ M_S\C*6/R:37+!TQX)EZK13T4]&;^'+J%X`\Q&B+0AJ M&19G^BE*#@V"ENMLJ-H)_#:U=J^\_WX+UNN0K^MR\/JK8A2S$?]L_?K/9D_I MU'OE>YZYR>Z\E#=S,IOGUUOO16N]:+5DDA20DUHP6YQ?Q0I$-XYLHH;6!7DANL0G2$JF")F!MPC, M@:T-:*%SC;(38_ M]](B=16(D(S@95;*W(V(I-T+MZPZX7:HQ%'AD9`*K7[>#D+O7GS1M%0CC8)R MM>[&!5LJ-UX/(3&@`C4CM@V43"23D-J.[8@2AD0(9%RVJ&IA0DKQ,\1M6PS'&( MZ=D+:S11(IR%X"(C@!79S%4LHG#;HX"V$NZD'AMBP!)/B*DIQ!FHOB246TAI M'%/NHS*$[ILKFF3K\;!W=/YN?&O7\*V_?;K*=ED4<:RH.@![W35I1^M)3NRG ME!ID#%5/@CR:JJ>6SU$',45LHG96H$UGJ@,2]@2+YT#D\Z%AM(;U!!P*(>07 M$O:T4I/:JCVBD"H/+'DJE=HLQXE<)>.)V]6EY(A)SVN]%?CTI*"8R'(5)A1/ MWP++"$"#D\88`^(C@ZM.GCI(Q-4+7`SC`6\GLV9? MXD`6`8QSDY5\<%EBS,'[0#UM0)3%'#,<)/V\ALS:IKY>)VJ+]':AM24!Q=$ MPS;)`#?H6@_L%@4JT,('H'01"!`,WJ9$?VA-(U_*%8;4AN@:@',NV;HC*69G4C%JRA!Z_S*L@K8>=?8HBS6!60Q3`GEHYI< M&W5.82Q;H9R)^!CCO=32U3F"?%60"Z%[S=^]':57J!BQ%$>K%96]Q$G0:$$O M8CGFS-CH5L\AP9_K?(Z]R2Y1V/S'J&MRE;!&F[30O*B'KF:82% MQ^R.YG-5C$9*-_(+KB3SX%FHA&*NEOCPQ:(S4;_*'E(&'J!FQ)6T1D($*58= MFAC6#$E.28EEKT)N=:T-T2Z?WB_F.8`I9)W.Q.<_FD/HJ\$?-W'J.X+?N%9Y M2D9;:-!#X2D=("]:6+5G3CC&"[M`7'4K1Z[7;N"\QQ4HY[S/+8)H93UH^,'PK%0P\)(Y")RFF1KM7U#+XUC;^B MADQ*]0"0>.T[QDBJL&SD=BT55DVE""8M'7TN49H=?T/!,ZPBJW2&$S$LSB@*=_T+T]5SB*0!,D9 MOFU14<,](.H@0,&J4---<81H0N\,'Q)XVAZKZ+/NL6!*N?FZOSR M=]LJ.]4F!XM@\TXV.PH\;`&+=6N^$4HI6".)*:9HJ)/(:IDPYJHT5#%'04ZL M,X\&'TR#9\&60':80YO#"&@L$=WUC?*_)V9`#QHBR[6TT%T>-BX_3F4IIC?B M2<&0\Q:OC0GK.(2CJ<+IVO`!%">3*BYLN%P_!QE0$W8>B6WV'G6$A/)DO9C( M$GIQ&+.^9&S*O@?HH-8XX%R%DPJ)]EJR*RYKB?(Y*T;R4$S=G(EG4:UV0,$% M!9%%2<*DJZ6$&9^R9C=7I:S;C!^%#",LDCP;"'>+5%[`9?`!B9$0[9BB94/%_/*F5'/7Y&BK MZ,9)=M.$;>I?5=?8CND8;GCF_I)4/U`*D:V%8,MREL(RR\JCHU5#;(%+&)BB MT=,$>V=@7AZ[(L"E:UI9E#?"5#OJ0.7FHI07M^$Y*86E>H+>L55SW&9H M/]$7`\ESLK_?W%?8:G:094A?4+V!&M&X8):C\\U1>8Y`F5PA>LQS8KZ7^%=J MH`SI;3-OHM\]NL0IU61"CZT'$GPH3.\X_X&Q.!0(2546HC?-O]P$",%RB+9! MC=G9A/>Y\E!6"`'TR.4WIH3^V7E=D0.,PVJ8 MWF>(.ADBQ#3_K5FMWQ+#M)EWVVK,^"SX77)`?$*Z'_U01JC4<124,%_QP(/G$&.UZ?9YX<.<7AR"\NJ.45 MV%'5B.B$6MGHV09?I`T>S;4STM*T&N0G@\0@S7!^`K@W^ITTASE)(743[Q!6*@0&WY& M\C"4M@$S:XV3"@N64N7_FP9D2\I1U!YH\JS/,1]=7``"*DB".*C%:N7]ZXT`1EM< M1CYQ&*+9Y=R^'==X"K8#[@(@TE"U0ZAR8%9`380("3P@H"BB_*SAC,$ZMS=0^-1YT@16UE1XAI,2()CM M@'X^*2B%L>51H2R<%9J2"1@Z6.+"H.#(L4(/\]X&D%'$LR15>$^0E"J`C<[Z ML>+8_&(3R'S<6:Y0F(0F'?Q@\?BH`7&_C3#7YYW[:=HFQ&@V2C<;1V;UG1\]>@D>Q!;XDA6$13B;R!#*V M7`FP]+5N`V`KFL[9?E!SD5@K7Z*(T7T&/WK9@LW6$>(T_:>>$;M8/8,8V2'` M3JU+4G/AMWZD,&6`/('\\RM1G(1&/D("I_/7VF1F@*X2:S'+&:A\SBFCN+6& M9-[=V7J04=\_$FJG5CS8B0^$/4?DU9(\_`YFY;4^%],I4#Y\RAL?QS=B%_OQ MP7(7O6T_#D#J1G;<7.$AF5MY0KIMO.*^#]LG'3.<#]DG1$F[8RZJD`(.&;-Q M"'R\_$-G03R-HFR#\O'@`*C%!'9LT;D$=&Y*=Y9.($H%D9$2>!!&,QD32I=6 M.ICX<'7`]$J#VP$>HR!,8`+&O'49BN/,GW)@I1P97JM]`406LN,:91-];1B/ M$(7%]29HAF>FJ\_@`O*CG.SQTR4M.,T[5F(%"PL.FGC9SV=QPIBEZ?GB2CP9 M6UI=$)=A:->!R^V"XOG_+YT*]^O+47#8O-6BQT MED]>\S]^Z59H]3"V@J\\@E[8?5)IVXWL[D/=C+.]G>FM@:I)X%WX*?"1#(8* M;"3#S)AC3A#;AKW[<.M1',%>)H>E!FYXEE;2(]_I.D*W!RE[6QXVM;/;5K*J M7-+F8KII.25QJ.TZ.V%U#>RVV)0?87G.=.778C'^N\!3<'O?E(XT[N:;Z0A. M9%-T3TTYFTE:0KZ=IVWQ57#A\1MA"2HK5?(:9@J;:FNBEX_+3[4*QV*IC("` M&=FPD,J,.03=ZXDGG`@<_G%Q0HF;N&[J`RX!>?WCRUI./J75,1 MDQ+")!=$(G&=RL+P(/Q,,Z0++TJ&R>-1'%>@**W4RW(=[,M$\:=E/J327&,L M$SS42E7L/`N"HYH4"`SNI8]F1%3E,1V7`_EIC<5B!#<^#?V#5DHFW_*5[PW$ M)@J+UA3ZQEJ#$!W4\,EM_5LMQ;9!_G5?)45IA]OQ&]R,7D&VR)`L9::4FQ>0 M6I+;`QC(L/_)!S;?Q?H7]A]^L.RUHHW\B(HK$5>5K8:,TS%-UI._'KNG^[2. MW7NBBNF**D[TQ!)(ZRYEH2WN'G*H1K5U'/66(ZFQ`@$3E>XD8V(-G&`6.Q9) MR'E>TF$V5B\,Z6FVEPP6G3C;F=3NN*":H@?!/JV&`8*M+ MTZIXC!_>;BAEY(T")#(3+YM2;SRS=9[6KSJ/(6YKP18B7!ROLA,3D.1+FA$8(G6AHL$#=(E7FA$XNK@O&R MRD1B^U#.H\HVI<>Q2N9^L5.)?AR4\T$]QJ$T`"J6Q;K&E0HT[%`C![A$?,CC M,)[TI<21($6AJ70]%>483-7CA,YTE15O)45"Q5N\-A?G"&3H*(39`77>AHO` M-J$L!T*13C8QH,6YAU3F0/G-/8Q@:&68&(&J04[XFE9Y215@9R6HZZ-S:R38 M+YV>W=5%!UH1AR,$BY@-8M567H9)0OM/``(Q-2[#:RB5SDB77>D2%YHRF58, M'6^R?65*IRPN`C`F2UJQ(5*^\TS+70W$],^U:@`"BXD3!2$R4TRO0M;`>CY; MCP1US2G;S\84Q/,4HF)^T#AYB0P16;LD64>RP%0ZN3A_II=03(J6&+!/_&23 MT*TY/HC!$?@F#E)!)UR/6`Z/Z,,O!'7X:O(Z:=LX78W.D7/@Y`C M52+>3,9'*Q:PA>:9<$>`D3@\DP07;?@;BM)KO\@NW"?@)A`4G2,\%CBI MAV%-'*7BBE`<,ITX?A'\Q"RZ.V;2&F*V;@Z\#C!*D35L2.63U\'T+-TSU>GW M&4Y<'MC,8KBK]A"#HBE(SM:*%!(H$T1C'-V/RP^X%9/JG%%S%%/TH\2NRIP2 M?J/@K8G8E[T^*Q97*OT)N..,HA).),TH,X,P"U-"G.524&(NOY(/5F+2H`;L MN=]AQ.J]Z&[@/K6(EZ.H=.>K(I]4OI(N<4ERA@'')O@P8C5$H3Y_KL)N52.5 M%-1QPRZB)_*4$Z"X<."+-8?NDA&,IT'2U&7CF7^:/45)=Z$/WWG3BT&!K.N&!4F:L7+!1Q_"B8,%^^0Z MI/FKF:?SHJ]E;VGP>M)?C1P85Y]LQ$)7T&!>!6@99,^&Y@@/EH*-$+?Z\2,/ M?ES6.+='F&TH6*RV%H0VO3+NBS64J[G[6T/V$?$6HSAJ,8HN-'^H3,0J'``> M6>&_JV7S/-Q=;(1D$8HBD!383OQR2`#HURCSKZHY;=9.ZD10CXF_8;[+?H!3 M+W$:B2U;T3U#$>*>19OYCM1%@\_TZ/7*@7/B?F@XE5X)!H-(.4 M6N3.GL#ONNP'"Q8U@?`$*0;H$&.;+48QF%3M^)U+6`+<9K`"*M,+<.&)UDMP MNQ7RC<"KVJQH$M)`H@D'S$QJV(JKY6.V#'!!CZ(7YYW&)0ET-QR@4Y4.`S5( M5C2,3-)JZ]($J$M=,H$X#.L?A/);C(&NY0\VQT;#:"HODQ;NMLM+F.(`>R>M!#\B?LPAMHRD&[,3\GB`.2GVU%S8]#JV+39- M?K&V[NX(>S3[3OY2MH[)*.Z(G46ZSHM/C8;`0I8R@-"Z"SHV:U1W0">&^1CW MJZ$RY$$Z$;%ZLBE&-R,C!C(+XYW$1;D_*3U[#O]ZC,$49>)M3'O74*>P=6NF ME)!&DL;X:S=O_;:EG+!FG*!9+=KQ<6B8L)KV.4@H__5K.6TZ8OJHAYRH-D$] MGMN!5K8MD&8ZP0H:K3R'ZN0$>`PI;=66!UMI4:_`H>_"3BE>6MJM2&B[\5>I M'%DWTPM!@H5E^P$@SAN\),CB^4!'!L#NQ?0\?04TX-LNEHS[ MA-BF04LD;'PAF(;KGBX^L&4LX5SFK'0/SYA]Z)FG$##I?J3[RPEPT:XUO2$6 M7++`UJ/=JT3FO,UGZ,5;':LQG!&R]!"Y7S'_M@;@'S+_YL,'MMO]G3`2K5@? MFJJAO*FIY(Q7<$B:@T;BG+OZ+`,)'K'?W9W=3^Q3#NB3M*@A.(GFF\VH7H%W M+8]BWI6%6O!QZ)QNT!A*D=%)S)#UT:N#SO= M=V#II5-5\KE"U+QTW4'PCQ`S7Q)J"`>#Q@X$F"WN3&S5()U:!H`&2?.Y<3HE MX^0VD].KNB<0K:,!,K=C4%H9(PB@TYMQ MT?BV[9Z%[6!X4UKM%!H@TCT_=X[.57455$3L!2N_MA.K$GK0>YN3SZ+7>6! MMMEP+[\(-5]N2Y;4CW&I4&@*Z-BUM!#'&?C!KG'SOVTGS&F_ M6RVTO[6NU">#ZW4%ABE^N.1VWP&R=.K=G4_LBRM!;A,EB5?4I]D*1;$LXEX- MZ%Y#G$G"Q#9,*V41D>J9C).8#15C_Y[_$:;5E>/C8-E=8\32TI!&U8LJRC,P M#(M&IA%?ST.\Z!MQZPYBZ91+1$I.!8[.5.><8&'^DS#P8`2<9-^+DA0V$=(1 M/JC*9;"X"(UAXJ3^1A\:DKZ89#@6WA5OUN M.YRZ)N*UN53)=?PA'6T4*#C".[TN((=HY-ZA'?9R6LCE0P<$A]_\.SO(3=R& M?'O559Q#U!-:A:C6II.M+L3!@@8EI@6X50L+X(FV$Y9IJ713*%&!)K%(]1V MG$$#)6#"%R.\Q,V3`=]]8$DZ\JH?IQQ6$7=""78=/( MBFO,C[-CC+;#(BK>'RY7MLP4NOZT?6)>K@[5!O&1GVW;%8M.TL$8@K$R!6,*>)`50L? M+HL^S[Y_O0HA3%T>[5\JB$M<&.U_W.2VW+T5$K/QQAQ!*,/G,<0JXBGV<)EC MN(V%6RW:A=[2ZMRTS.#.N8WX^-$JU^Z?MLZN&OQ6J5^QT9&NKX)`X7.1?8MLR0=T1LMGO%MLQ[B1TL@ MRK&4"\7KW&S0K/QYDQ]!F:AE=A"%O1E3XS=/3<^@I#2?I. MB?*(Z`(E4=7*(FV=^FQ(EV*/A%>I6V(K?XB\BF3(% M48)T8"C\VM0C2;W-X`V[M5U-E;FQ^[:]5KDENU6-X*_@!?B=S]1SN0M^>OS5 M7__[_T;?M)\,S+!RX$^`HM&O;^CPRA*OS02VOUXKS5INSM6M-F-@FXY M]"T-3PAW'CS8:0?>WS;#^@L'%A$1U*8`-VH8%%IZ9O^Y<8?=<@!,;#GIC6N*U"-@A>M50N2*'"TA5( M\.^CJB"C6EC8JP_#A6J3M#,)5^2#@(ZII20B5*V:%V<^E`:(.+@YB$TL84&E M*+#2N9=[2I\!M[2T=X#DI++7C&KZIZTGU81T]X5%+?*)TMJ.,#O7;^;B%1-T MI(<6Z$L\,WU%(48@F@RF55@T.E6W9'V#'N&BJ_I$$CYI M!S*T>:R? M[*FTL[;+W3?3^S"C&!$^9CLQX"J%M^H'-P_$%GY3D#X-BOJ$PC:F5>/UN4%9 M%;_U`[O@V876#W]POZ?+$NZDW.!JNHEWR<'Q&6^+(5EP9(IHCKVH0'_5$,CO M#-(.>`DMV^I6PHZ"L4YZ8TKT$ZJ279.G+QB_IFR.QQ_]?PU#N9-6?&5?'93U MS-_8P1+\/:[L(7]-?!8KQP)+`YPS*!\?5A7::]U@8EPT(?=A+*_^XGP]UW*F M!!D!;'.JK09]CU"!9C$O,"E64Z\I1#4#H0K@=+$>5C]\GF,O84FAF7&MS,]9@,RD M+KX)E>%-*3JY&NH=)$V@6WAWC?EE%7@F?#I''!F7R-:MV>B&IH^*XN/9!K0`],5Y3VP-?2M-H&DW6^9BD?.)K[=GB4#X",2H>Z MPI-?L+7,BA,\%.[VY48X'SN.H"J8;_L6RR3]MSI;2K:>!+:ULXO(0-B_(`*: MJYW<(M;8?FARSUO"#NC2$JTH$\)79(,[UJC*-R4/]XL=CEZ=.-[)=9O#&>Y,."H=A>GKB%7C\1,4W1R@I..K`<7IU1XW(9,BB M>B?/?O[I:`*>R$M>_*MEM:4EJWK(OIB*.O+_GAV?'L!(S=]I*>4RP#LFVG;))7P2QL[K1G,\S+>*W=UG> MHL+1/^D;W*&G0B+F9TMCJG&*FC*L MUSZ@0`X?M%I)7Z!`+!/WIQF??`SXH`6FOL>&AF!+XQD-4W9XDU%/!Z@2&JQC M75L(UM"&<'*M;TI-3[A'>.94MEC2V'>EXV!>/^1Q2ZF)\LVUGD/CJ0:3TV!L MV06KBC6X-]F%0A M3H3JGB3LL*-@!D\`!)5C+/7S3U9IK;%1S*8\Y3/(F7'O/2?ISL44`M??%.Z2 M&:JM/<53B?LM`6*'XQ#03QA!G$JL-\">,CFKBY55!]I&6+'-T=RM9?2:D@W*0>31BGVP8#BPL$TH5`_NM'YN7`C<%9@C3ED_ MM5O'XQ'*C7V@[SA]L84O:PNZ.2(E_R34)T3T7[.A\B'4BLJ#Z+"M.[1B%?_P MO,35^1U:Q*_I+GF^G!EP-\D6%W=*LSA50:A<3.#HP/&2?%`!6"8/0N`-:20> MXC^M<'6UA!GU=RL)MCY^Q72UCGBH(?'HI9,"5L)\XG%`D95-BJ?CW*L6#T:F M%[O>((<0(-2"]D2,74$-N'[4EDHHV$9<#5]VN'T7[_J$ MZ1XF]#_$5;>?_TGC/K<(Z/(:[;Y.U,X+,DIV%3?^'[H'?W4@+!/],I0?HO`/ MDD?7]`_32R[IXMKOZ9!$.C[H"S31=?:'G,L'FF>B;O@C.U%L2_"C9T_L9NL- M$/`!P'-SP%X;CH\0WI!2NF\VJ@S7_2,#R%Q92"(O<+U,]GBG+9A%6-7)X6_K MHM%_V)5MCW_^">6CNM7Y:[=QD99RE1U3D5LL*,:+6T*@42MK6@O8)'M/I%7MZ"S8B6PL#LLB5JNE%Q*9R+Y,/L&SBW>-RT"B"+'5AHC@<>]3 M8$#/GYINE&%;);.$'YB+)LVR2G_8"%]QK(Q9?DDT0H8I>\6]QBKFBVF>5>]) MH"D2JEO@OXGF,/)\@DN:!A,*T6FJ'<6.#J*AH94XP M=`DNJ*=L*EI,Y2,8C]T5H,[ MVL]ELA)O)MRNU50_L"EW=[:]X$7ER&FW_.:ID&@,^8"1]><7KF1/A8$M=]@L MW7P<;7G3>ZR$IL:15MIS`0[N6<-WUM'83Z?QVM[6[H,/7*4X5A;&$4S!ELF8 M+O4^&VEWPO7C3?-K0#6N"293$Q M^W2KRBX?*R;:(MQE"#6*P7^U3W)(Q+,I7Z;350F@ONRR556UXB".N8OGLZYT MP';9[DQR-$R^QPH9B((X^Q:'`";A2N>0OH!.*TB M#Y6U%RNE2E&3\NE(8J#:,X_F/7I$PL[M@BFJ6^!J`OBZ8IG5_4^7'<#%8W_M MYY_^1$S0_>VI%6.9@#?18[?-9O?!W>X#I(FJ,%/`A!B.0$!!J[.A+HKI5Q]F M3XGV%M?=5],VH8D7ZJS_EMI-HW%/CPT7N_K^74[WOCG=-W49%D`J_MU+R%Y) M]51VQ5EWI5CT]H,XGVQD.X\>\;^R&(XTLL%/[*B$CHF[RR5=A[VTS()*Y9+J M`EHK4L!G-PHJX4XJ"A,=9G#/1$VY"-[&E%OYM?QO^UW8G&M1$R2]5<[A=LF8R*\NN+IRKNM,VGHT:1M7Z!K7LR7?:AM)6AW]07]28 M@1W^YNDC(X(7#)M*\N<[^SYF=S8H0#ZERZ("2&+)IX]H+&=92EL?S)@G) M$HI!3QPEWS"#;D1Z]G.F"A?K;U);M`:1%:=!8:OB,JC!E),>GUF&*)P25:8! M%$&).?/)N?5$1[=\%F$EHC]`;2I00@?#A3GH2MS\KK*M8%5G%!8>7, MVI,D1<^KJ(S'B3W!9:&M5B^_PV"C8;;SX`,UL]0:@VELKGLT;$0D6J*;P;%J ML30335&W,ZBF1N$OS"JX*UZD,V!(MA)G56>!=#X].GKD)\5X+-(.VED.F`7@ MGR`32A=I`J:5._'K+YGSTL8T(B%7!VC1G!,FST;Y=X#LP2DS_2/A88UWK=4& MEK(RHD.N-Z*,QPN3#CFX?4XN@"(?.WGP4NGI@H)D5A@(#*JLOW:WH;+GONBM M53B"&'6[YHT*S%EUI0;SU34_:6>->\QZ:,0+-!=4U,-4B'(K$X(3+3*0[K$6 M*C:V949_84DL#!'S&D_UZ6?[I*JM8L#&U<$RXT$#`>W*C$9<`G>Y>$MOZHU` M)CX9EC*EO0B'3VR:GH13O=@J&".4OL%RB5K4J/V=9LJL]-#->6MYH:5#=6S*'I!&63<*Q`>,F& M%J$0,!73H-=6L9@I"O78%(EC%^7LZ0Y,6!.%8X6JVA$I+=*6=G*7>EO;)`!1 MWI[;%V!I&^3QS.,`^N$?S:0##>U%^[9LNR7(DF.'KY1*;:#_TPF MJJ'VKCTN)YG8MXP(J/2AE5.606U)>O`V;E^77IT=J]Q;=M.TN]\#/"T>=>R[*0$I/_*WP0%H8D)2DWK3H%]9O40$17,@\ZHX2#^LN9+`LVC45?L\DR(I( M_,N>KFYP'KJS,9C/TA%/Z@5GDTE@OIS-2.IQD1XC/`.VSXZ.*"(]MGQD;.2O M!02$AP/NZ<1;I_G&ERNVC0X<1!(F4]6-X;;8V9%.N*-(0+LGGE47XUW8E_&"T(+R-G&G0V> MC?G08U)20?6Q$&I(M:=AEG'9=G]A0YE4A+6!W6W@7KP4`WZ8;#XF%ZNA+,7* M"=G>_<)/ZB*;<1TF\[8$"?_M*>\2S$K630NE.U35?^K\8;^U>+[L*[O0(#;B MA$NQCJ`6&,Y6OE&.HQ>B_KFV8HJ6DKU0F[*,SQ9E02EUE9LI3N"8PH_%`V'0B+3\8QJ!^'DAN$Y&Z@#1J@I-E1! M>\LYE@TT^@]5X(O6EQYF([7O@'%,U3Q/N?^(]P=1Q_(E^#E5]0BGOD$;KDB# MAC)T2VZ-I)@)!+*].#AY1-9RFLB;0%%[S;[UH.5/_XG1W*=R%+.]Q9@>M`SN'JQ\PV&9SZ+]!5L*PYMWZ M.>/=!P9R]/CAE'&CZ@@]H7HAEB;4W2D1M*+R!,!0]TUS[;0A%'CA5MMU[]&# M#^Y'RN*,RJ`N$=;KXZ15`ME]ZE9+_9U_ZK(.+"/B%JY&4P;YL^P2VD)!@4*V M3U:,FO81+IMJG)$8*K1Y13C(HM]'+U%&0:FC@0V9V'\51, M!23[CF3Q1L0"O:]&+H.)IU!3+JC?'7-J9`D_%9.Z2,Y:AZVM2Z7T4F MAJ+S1UN/'C4ZL-?3*A$TLQH,@-)$A#G+6O\5IT*RG;WAYLZ]'QHED/@'3\/] M#92-63RU\VB/?+-")`=..H1)J(M0!9E`?QH]N\:KG@1.QUN5CB+*:BWUD@%N M'2KZLNL8G9T;;TJ\$ZQQUW0&%E`+IB0E0]Z[5DVV^\S[=.5'05N`2?4\+,6, M/+-J.%]J[B$XW^[VQ]&!X\FRQ4F,G*MDF=-W.72L??CS3PR)#D5C@_K5U) MV*+EAKV4&\1AROK;A=MV!0#O&!:S?V_W?G8/8_?*;RL6/O-$:\!`ZI,\0\US M7MA@_5IRYK\?,>";@Z)3MCD-_AH-S?HP.Z*L'=_X52'1TEPLMC&\4&IIN.3' MR0LST+29Q@#0Y>\6\UAVSLZY!&42]C\0P'&B!.6Y7?S3R.#?/;X1;QZ1Z`,@ M";?=)&?*_`>+1QNL`1?_9:BQ"TZ[R>5M8AR-I<@![G95@G.DF,6"%P]<5I&O MY\1(>M77>D#+M!]QO*"7J,$X#1#8Q&I8B->Z;R.]UH:MP:H`7BB`*+3_]88`(8FZ))M#;8O<+A9?0'1`6YW M5Q2^OQO"?UV3-Y('(%E<8?"T+5UU8A&<-J%Q`V(H8A"7$(E0CR.O8E70M8P0 M6%1#=YJQ\?^BQPLB;V=I3@@4]&T]^!`-K7/:O_WNX/C_L7=N M.W5=61I^E7U14AP)7`;L.)9*)1%C=R'9AC8DN8CZ`@RXZ6!OQ(:XJ*?I9^DG MZ^__QSRMT]Z;)*5.2W51*;S76O,PYICC?"B,?HI0Y*QYK5:;N6TD]4OBS"@F M0_!+:Q@1[@HVG!AJ3>B&&0VR,;A(GU7KEO50X0O`JHT,YY\2KW7T&">-5\US MPY"Y_+O-M5>HBF?TQ%9=53-M;KUJG*KTMDW]K2.V/YO7[;'`UU-2+K_XE+*? M%XF)13@Z-9!-!\%1*M\VY/BZ;XH)1#5/+3%)JRO4D91,Q/S(&;^7.N+*?)@S M$-&G)'RM,!W04#,I["KI3&W1Z=]MD0YJL8]=:RG(<>8H_G3)>)#EG*RA"MK) MVI#@WRC@'0T!BTS>B%EATNPBWMB>M8'V-W8C$4ZE,6C>/Y`>TYR?1-%$+"7( M-5:70L^XED@B`_6J)[UKS,*?#2818,9,L0Z2TAI79R+)Z#<=,/\.BL[3?RDZ M`/JW*SIWT.XM)'0SO*SF=*)UIO6<[34,ZD*'?/9)W9C0=CJ2Q"IM9^=QZ0,D M%OXKM)WN=']P;6?07L6'8LJXVJ?1Y*QF\1:-#%V](TSB)2GF09D#6JMN%U8Z MO]Q2J=5:ISP*8Q13P3#/<0Q9C%6HQU]Z'2$/&G,^UGR]CF["BD=B9ZP)6R5. ML3'-N"72Q!-J)FEC@,]-/"2;9_<`:$2$",$LQL^6:D/E$*>"25I3.3)1F!2* MQV_?&D`!$.4VP?@--UA?OD%(B0Y?RLBSHC(%0('\[@SN"7J?Q0I./&K&6;63 MDTG[DI":[8WX*O*"&,S+*7'2*2@QKZW=5WM[M>/.O;_FKM!WBXPE,`%WHN^J M3-8DOA-ZB&R?MXW%'D@3C`3:@ALU15[[+S$5(*B6;)MEZ#>\;MDS+1T)3.*3 MK+5"O)[S?/';RG#M]JH+VG_-T0G`WT0ET0+!)J9H#&I6,'-R4*$$R4G^M6(M*EJN$\:.SH2(Y;O@P-5L.VP>6R:Z M=")E]RA[83CV;\N&T*;"L;U3R+Q7G\E\*)GE)RD*D>=H7+[J1"%Z/4+$IS:S+H[EL*54% MNN)?KE-7$J6W^W;H[::B9RPA`%*_,O9"N#B/BI5"$ZS7.D!2#!L2X]*#T."` MPR?\IL1XF\/T!,:MC:??;FT\?_8D4^9\M0:PJTLI)*$N1*O(*T1.#9:CU=(\ M0V0WO!;"-J^CTY_-]QL75@*]8)N,V=I71%E7B(8T$$>C;M[AL08+>N=T2E\) M/.E="E<.J9Y+10G-)D2+&77+GV70)(+:+.V#SIH`7?8##\Y`&V4QB00\@,W8 MA)5)-H1'A03S%&,KS\PK*CII'TO9V([C_7N(H.L<-'8;(KOU[$4^CS4NV%+F M9`"G&*@!_1NCF"S#<`2C6XF&"UO0*F]XZ3:?"ON8?:9P7!?@B-Y8!EF$22E/&M5,P3=OLXUEL/-!*^GRBQDK[,3C5(;DND MQY`8&2Q$U%J[GUZ[4"59\*=*PHAGV>P"=8CC5283%C^]J!SOAA.LM\Q_(JM8 M;P$M+WE*C#W7M=;87/-./O7Q"ENI*0#B.QBI*[("[`+(Y3=XZ_DW&UL[S_(H MO\L-7@L4@^M,GG&J>+9>QO;$^ZLR19XY4Z1^/,PF#^97&%8JV@>P<=-:.9== M8JR.R":TYHO*U@@_+>)41^[.T\?/BR=7-.DB=>A.=X[[(]]_V"@58'J.5))C M8JJFLOUD^PEOAM^Z)!+M;'/(I?I"R@%))/K7+';[22T2'LXS27^9/*R]U*UO MQY?Z/8K%_X=::H(@HAJYBI@/1FM`62X4^Q<)"T5UI/H,E[Y;0.TQSN+2/1#/ MPR4100FJ#F=T@(HE1#Y-]34(O@E=3%,I"<-UTHB]!=?P@D0E4ZT#\4CE:G+A M**FY)K#N,!D4L_W\1/T"L/.KM#DB?YI$:@!%.*AJ>(7@I'@Y[3*$K*9495L$ MT44/1VZUW+[V[K*0DVXQUSZ[K*Y@Z[F:C@K^`H39"REID5>"UDBE;OP%$5+; M?C:=;]:^I:7\FL%7$9=O$G%YP)XQB1&02#YEKX)PJ1-,(6#^UG)UC)U2J;+Y M(XK)WPG%U^-.@5:AQO`;C=2(_X1MA&:7"_)&Q)N^:\2!=-`9":#4?YP"NB,X MIW##SRD"I4@B'=@$5`\1T\D7R?(S0%3*S:2,>D)D/A8T;EB)5$#3-_BZ9U@4 MUP/<6^0S7`T_#(.E`EQ1\'!XDHN-?82*1/-[RN41JDE*.BQ'18DW77>88/U3 M-2R5H)7CXUV).;)EL7XJ57L3=8=4+2^2%U&TKN9X`U5W].SF+C4>RY^'M'-A?G>19H&* MG#0%2^`"Q92YIQLA3SDPV?I5QS;^<<;Y"/1J9R!/#J&_3KU8PN(.R8QE M8;25G5"+A!\IAC(5RY*048<=W()C7N]2"^:(KK5..L"?B^5]$VOK`D-!,<`' M9[KA&L3%(0$Q/L(XS>PJ#`[!P?3CT*>H\QQH8FP=[+Q*EB9]T*AFT),E8E3E0M!OY,XR=07@3Q!>E/):W^4%9?(I^(@ M4]D#"X:I.+8O4ZZZ,#B]PZ8`AZ:>)B262Y,)!A---!!HY'FY5UXV_@O)L$'' MF_C&2#L51EVS^2JV;C?V+B"O>Y%H9N0.A?)1TH;T_,CZ2)`W`5`6)1@_EX2V MLYA94O:]#K(9CJD)=GR21>0!//;AV+T0UA.V11VO2ZQH"IM:ER2/?Q3K!:W- M'G'V8+CEU.L*_7>XD70>G9OE(\AG;'$1[(^Z%AXNE;_0E@??AD8<4?2.A1"N M*7W"*\GX`4KS,W8[`%K-.LN00F^.3(8\2QA/[,,#W<[G/VMDC@5>1A0:Q_.H`;5WFV,X>^S9/!=('.8/VUV#U*6K/C!2:9QI[MWE-+A=N`D M^C$)&B@LW8U3@DC MLBS78!9 MJ%HN3V#G0$`NL?>KDX7%WG`;9+4F"Y])0(K\.P;4Q@2=*F4*&CH!BK0@&)LI M\]+-^?SB\>P5F8#<=QT.W3*Q4&JKJIQLK"X7=7#'PJ_WA:.3SYIX*65U@2.: M/*PES1X(T4]6(.LNH!T*J8-0-6+^]2'--C'?L4D9QIZR()M(\@W(J4ERLR:XDCL441/`^QO(`(4FV5<[5D6P2R3%J08N8W'T\^7_[#%X/W(,^R.X2P MD1IS)!0U/N6=Y#N6R\@BO&M#[@V_N%R,.2Q`9@VW M1X>H1"=$0RV&63@-`D>%+-F3 M5[(+)5;\N%X3HWK@)>U.ANOLA"AV-)9"75)B@-"RE?8DRER!(C$-E-Q;2=JG)PNYC>G]2YRVCDZK+O:Q.5QD$8( MD0QLL:N!\LE6B09L5%#(@FXIFF[T2R'.+!2.[A2L6GBM"DC"4K14"W%`4$`^ MB[[EKGP&"BG.D)K[D"O95#*!,V8-+_=>>&M2'0`E+IZ&B2SFEJ1 MOEJ_9!O6$79*F.8;`TK9L`+[*IY*&-MV8QTX&JDJW;30W)'E.1E>%_*\]E`\ M#ABP).$F60,$4B8/VJIK2!GYRXL1V-J^-8:^UX0@FGM#9CY^Y-Q8QI\1>>TY MTS40-5;9]Y0_!<$-9]?H96@)<^,A`P\WQ;05T"KG6**O3D*4W:#ZU6`W5@M[ M02[LL3#JED?+;"I3ID6"[NAL%NTSZG*XY@[L\"Q?<^!8.PTT_I_6[9;J*AVA1%P8?@J"=JM9TMJYV6 MQY`JOKB#;4:HTZ=SV%*^(U`SM1D]!0!*;SR'$6)O@&B+)1HA_2@KR]I/6]Q'0&+,_<@UR(P*JH5>,'[&%M_RI,^>O=C8(4A(8L@. M?V\_W^J`J]VR6_64\T<$B4P?;2#Q-V97BXND$?&[_%34N(U14$L(IHH%%3/KB7)5AR2$%Y1.!*!1ZID'[O\]]O`Q%?24/N`.+K\ M^VS99J@?0-/O7--W!:^VNQYCYD7:\9=/:#:V,S MU.MBFMPG(/S&N6P/&NZ]O"\HZ.\AB6"Y-ON0U1"4B"`9GFV=][Z!)B&"@_B$ M*VA-9#M"3;O6I=(@?^,_Z((?N3"+VX>L!L8MNVLZLA3.IT$>!)+>-?WAA(*1 M,ISM.\00$]4KR[0/6=C[;#K0]O8`>>IJ3L%J+5A^\[7O%B!.T>$/^>H=I3-; M`G(SKP7,'PB=)>V\9H^.!:K%@!"6(%7(T.LP:0!FD5$Y]F8'Q5XU^\DC+"-H MK[)XVEPCCVSHD&H,6Q MR#=U[JD/]OW1WNQ/`_!AS5K&J+%[/O[I`,+"6(:/;36S=:&S"6S!G.\HD>V1OW_AR+U>?)KU[.DZP#C:C48FJ. MA+(+T2=*5?L>3KU[3(!>;A$Y.7U>HZG>!DVGYF>@_SN,!U/#?G=W>67;E>YN M^0?4G63+\S"@37WZ-B7:33['X*72L9//Z2Z#+(`4HKD+&YM\7V>'T0%+S_SB M%F46N@+1RK9T(G>6;!/+,N1?MD;-]?H2A$0LF9RJI259#OK)A>GV:62X&"#+ M$HE@]S8:^HKBF['UD53?;LQ>[^V_9#L8!L0WW2%J_,7O,7PM>ZN1*WZN9NMOZ<6\EN<+&JB.A!_FV]AO>&K-`[UER*CM[6M[PAF&`PS%"Z@ MY:6H07\L5O<++#:TZ$#@W=RYOO\NYT*+K'JAD4_[KTPSM'^'!N&_MA$`F85_ MBM/%O_?;*(B#+V"E3*M+5@W=:9(E6D$A,;W^NA"#W6*K?767`ZE4HLH4PV]% M56XE*HZ)?8NI\ONXMC/9(F+_JH[V2*8+5KFM[2:G:WFMOE M%H)]H!Z>W`=$98]]0]_-JZ9'WN`J-)M+64*S1^^PQ,YV!BRX9I7-WCLQ08<4 M>^08B<)$TMV0B'6CAC5%5IR^U>L,2(CQO7B>Z#B6AM2Y;ISX->/M?J:\JQ91 MO^$21>S\/H'R,M;`*NV[KZR_#\J'#BBUAJ/%GE?%N?Z8;]`PHJE93TY;44E.\R%">&BU'4H9A)#YP98*I#TI%JZD7[/]( M/I3<"6VVC.9D40AY6P5#4`-$*V!IX4G9OY)0]=3K84Z7]=XY3;-FN%K7+ M?"JKO^>R^C_,KU`/U&D"3+0,N'=R__LOHC]B7O3][+VKE;,/&6->14UURRKG MDEKS]J=IC#U^M96:@((J6AN)#$>PG:AP][^I&O=W]Q6,AFPJ/.K!%X)L>V%T MLKXP_5W%0>MD.:$]O%A0"U:NC;3 M.@;3R>2);TE!4R!MM3#LREL4[6(44^%=I/<2&YKM*G@-_2*P'LJ0MEKQ?72V M&;;!9;-Q)!XHO=>;+6V.(NW13^2E$H14=F-TKM^VLS+7OX7G3,*T#S64*G;, M?;XXMV8Q9+^"[&_9:ZG:E&8'%Q-*=:A+P2]Y,H=@2.C[-OR,RB"3K'.>GGS?:E64T[*^E MN;V0P[MTNP_=G&,%:?EMN#.\%;]`=JWC2WKSF?87:SWRC72U!'/(\T6FDTJ> MZ'_P%3@A[TX).R=XZ63QGZZ[GYWB,LKJG3@T`=+^H.C+]P?JA];?6TL#)BG3 M!*U(L@`8DUMX270;@H]"/9?%J`LKE8?=7EK<5_\JEO?M()3U)2D:]NK\&,$$ M,OX;K\I=E&U<*1(@77K'P1Q!2OI'W-(QC,)YX/Y`E0X) M;#A3[(53`&(A`_QN$/8_1?-)]G*YZM;5$J`:;PDH"ZTNM>EPN(W3N!1_@4=P MR$J.L):$!>T-6;17Q'>0]G<6?=LF1?G."I<)T0?7\DI+<))K-JQF@IZ$#!'$ MB/LJ!+!O@2M&-#U8B=!HG]]!\?K1@,W:^B#(^L,2>G2 M%8]V'L?.U``M<>SD7&2K!YVA^\,5P["XLOLT_A+Y#/T7=\6.%_90B@9?UO6V=OSY&7M&\'!W<8BZ';CMO0-C#Y?X7B)4JXO4J1H?YY1$1'BL73/ M!?BOH7PKC52'-=5\ZG8L0X7,,Z9QH;BYA@ZU54;(\JD)$E0ZZ27+\+8;&3); M%8BQXO595MM\C`LSR,$YKAZ#"!8/<$;8S0G!Z5#:"",^N/[[C M6J"T2%WB6ZO`L^+UM9:Y>HSUEU\P8A*9D$["V]F_2TM$IX,::3OXJK4C29=) M]&.2E?QX+JL*$,[&GJ2'9"@D\:29DMI+_W47M9LVL"IAB*V+^/-B&PO"U10+4)XFBWAS+P4DVFP.N;I!ST0)-45`293/F MBT)2=W:*_O?.+-]F+8E<2DOM782<)4H[\\PSL[.SRR5Y]?VS[VF?G"AVPV"J M]]YV==3KQ\='P[?AMNG`"^68>1;R?P,7KHQ)O(L5WH:;NY6(;^QD[NYR0N3I6O^\O+]0Q!&]L(#J,\] MTU[FLMF''?&^NXS".%PG;T%<)UROW:6SBW+2F71`TO55L/4M/XFU9;@-DJEN M%(>T])OWJZD^U+74Y'FX`A!_^G4;)M_](?WSYL]OWG3_\^UW__K)6?W[YV]V MO_OY6[V3JR$RP0?5,M]V*\7"UZGD3F;!]=4Z#(@A)M"$;%T^!>'GP,+O(!C` M//S9]57\F_;)]N!(#^$M0R^,M`2\#/:Q(X'M.^DOYK;G+B(7?[:V?==[20\; M>(`%1O8[WP4WX<%.JN&\>A:()K=IC#`XF_IXA-KD@TDV'JRVR?YECTV9=T'C4[ZR0]9E:?ABZ%?U[9.'K''%RY@&M'8\QJ5S29UVOS(WWKN_$VIWS6?LI].T`B:6#&OLU M-R9S@2=?/)2>R3O/?0C20B'>;J`674;N)D%H16#(5XQV<;$G7\4^],6PM=N/ M&KNF-?@L`&*(#-?SBFJW/\!Z$(Y<7T'AG3A18,$'+7M__[*!:C"`.0+ZK9/^ MKN;7#Y']TC-83236(`X]=X4H'N:L!LW(G`]OK?DMTTN0B:(X(-2RYJ,6A-[. M)G/Y2.>3B6RAA@4OR4+?#?`E6:@%_\VE<9J-`J8LD(4\+7%QSMA].YI,)N/> M<#P>3\Q^SS09R8LLHMU@Y3P[.(V41M,N@@$@F/3'DZ$!0+KFF*DZ*X(^`!@- M!N-!;V*8\#\;=MI'()O3@:[:JP2!(J\2!(J\RJ8M'0F9/^LIL(*CN*\2!(J\ M2A`H\NI(<@8>*?E59\9AEX MHMRK!($BKQ($Y_9J/JV:W]Y:;.EEMS*35A]GNK"(;ZZ+S1IAGKH(HQ4L&^3G M97HX4TV/75]YSCJ!&6GD/CSBWR3W>43*.-67%)N4A5M:2BRGHFS"7-D=D?FP!BF$S9)JGUGY6[] M7>L*W7OC$FA$;NL-)QP&A9(L',I5OPYZ(7.?8`OF:N9IP080$WE("+:086.Y M`BYJ(VDA9B-I(&@C:2%J(W2=?9TK9W(5;N%L[&L'6]:XVTT7&T7U5`LDP/=$ MS'X0I,TNG[5-]C!:VZ:IK9!?=OK&S,`7JX[W6%K38M?.F@9[K*QI(6HC'S>Y M=SGAQ=(%IN<]2%[QS?W\.!B@*&V8XWF5!+/\A(NWZ6D0X72WW]Q:\<1JD-!L MN!*V@2C)V[RB5I;=._RVI"]Q'+A'^NB\H$%ONN MKY[79&L'[+?!O0^X(L$[9)B)TH.82G?P!/+Q,D@N<4 M_;"392^)P),P'Z?HA^6PO?J!%Z7Z(;B$]F0A@T2-' M`$Y0@0"W;V4<0'BJ0`"3R1P!!&B)`.!41,4I_:!'LAG$0*D2]+>E$G),;B6G MLD4K#Z5?T%]AI<6EWY-H)OD6`KVD&3Y4`#A)Y:$4JRK%$+=#3RLI@`\5%%@P MZLH9\F"YH8@[X*`$H(P0DG0Y0)`&JAB1%Y4DYX).449F$NL0$A28BE1#`#A* M(!!']!2-OSV*0=$(3*-!T1!,(7!C<'66D-HGJ">X$5(1!L"CI%>4^;K'C1AG MI(%`4)4A2308JE(DQ:`J1Y:N,%2E2`)!58:DGE"5(BD&53F2N$)5BB00@!$E M&9)Z0E6*I!A4YPIG3F"+]ARX]JI]AA&[F\PR<0+YY9PP(ET MO-`R<9?TR.?(WMP[SS`53<^&/:\/K_4"DGQ]XW4P\@@/8BKUPY*_KC51+IV? M$["<3D2MY6Q27[LP_RHR^,7MV@BI!8&+.ZHQ(-<9!NDA(*F+8,]531,,DLHQ M4%?!@"F6*RQ@#I-/@VR&IYT;)@^D)UL"!Y1<2<.G+D$XM5VG32X:*9=M.>TS MS1V!M`CYH8TAQ(`H$],N&`6G<2$=3I.XP*GF7BYPM;*J2^0+0HUZ;%Y_-$&( M2R-[$=8`/!@YU%NG`NISTV2X+T$E9Q9;V6(&/C" M0_14>%Q*E9^A3NY!+>-K7DQQ$=DR.JG.K:LQ^+YQU'@ID\TSP#V57BY;XIE6 M\>&G37J%TND=#@#0A9L-TZV&[DJG368GS3AHB?;$73^V7QX,C"7"H4A7V<> M9*<1%VW.Q7_9QHF[?CEA[M5R[<.WR+)0O!V2:ZJ,570"68L3IY&Y370<([S/:CX-UX$!,M)_/A3NR\(-M[![OMR+7+_)7+Q=X\ M#6\H"S?`[_Y1N]#>+5%-<0H6Y^V+K>O!?9EP\0#W32YAAAGZL_1@MM.M2E:Q M?HJ3;BH+!MRFLD!"VEL-W$M+<,&HWE16,=[WP5HB"R[K;BP+`B/%!?=5Y61! ME#3%!4TR63SW`T'NS7U^9-<$$+[`9!%<5%;I1YRE$%E@,`7S!+6Q]"//_4"0^]<9 ME8]X0S#B4RFE[^`=X0BK7Q&.4BFEU_@H[PM&>2JE]!=;E`P;'&1$8\*B4Y=:#1]B$^``M%P4WHACG?Z0%#<7\*PX(B7 M8,!'$4`_P.."X$E$&O"2#>(<0;@AN8F8HB_P].`5JDW$0.L4#1]_N+[11`RT M3L7P217K)Q$Q[X/-MO`0GTMQZ!81\<$-GIP5'SE\EC``I(BD.V>;1'81?WR7 M,@2)N<.[U!0R^!21WIT_OZ5.5G_>P4UI5E-U#] MKY[+.Q8QWA-\H!:[EU$Q'P"B5L[:WGK)??'E5"_?_Y7=/!""*?O5C^ZG,&$B MIGKY_@/>E1%Z,9S<@73S(88[_<%?;1NY4_V_M[/1Y.;6,B[&W=GXPNP[@XO) M8'9S,3#GLYL;:](UNO/_`67X]+%+>'S5"4_W8D\A@PMO>N9E[,$SP*+,V`S\ MQ_+85":_Q#YO@2'KX((54G5W9%VI-'NS.RU20Q83>*,;4K[[^><&$+LP&QZ M0[Z>O.?UL8]S6#Z\%7GPRI46LHP)'0Q)P,M49J+3[M^>[>Q)HP\J,Y;+D M,7GGFCRL/OVQ/$KUHO>;*4JF(%+M0MU MI3C+ZI>*/(R&PVE8,%$2J[!0?33D=BM2_B330\%+8T44SYD!_WHO*GU6*](^ M<@53+X?J+I5%!1(;D0OS7HN2H$@7GW>E5&R3P[C?Z)BE9^WZHB-?B%1)+;=F M`'*A-=H=\SR_U0B M^UN4'+(-\V38YE^>\]3P#&:.!#@C&RE?\-7/<&L(070-8!#]\QSF,<(H81.F M?7X.^5Q/VU<59'S+#KGY1Q[_XF*W-Q!I`FG`;"RR]R>N4Y@&B#6()JB:RAPD MX#1&@T&$>3V7T/*Z$=5IVQ)V;8:JGD,8#U"L9UQ7#UTP4H M7T\+Y`/91X1C,H.)BXF&N7E=#9?A*V0_/1%K2\!O0U"72,X$3B!X:(Q`;OH; M01B-X'RAL[6]T8X;>7&[Q*@A'".0A?Y&$(8ET1KON%&USBPQ;A$3ETA^1SC. M0*2_,X1C`J-N9F+JQEU;HNULYA))E[AX=YQ!*?1WAK#K[-Z-N[9$V]G<)9(N M<P9\^IJ;9%V8.J7 M0!>YX0V_F+TW!80];Y?*LC5@$<>;5R9)%[GA;?X1;PA[WBZRUIM%'&]>H21= MY"+BE`&%;UK_Q-6TY\ZKP/6)<>QYU9)<86[YP\VW]\12NU6WMQ#JU>'ZQ+3] M=4KB"G/+'V[2_?W9+;WM+_*K@EK&\>>7Q17FEC_UN[\#``#K#@``&0```'AL+W=OV)2<5$L?#((?8\5 MB4AYL5WX?WX_?)CZGM*T2&DF"K;P7YCR/R[?OYL?A'Q4.\:T!QX*M?!W6I>S M(%#)CN54#43)"K!LA,RIAD>Y#50I&4WMHCP+HC`9K*+#['9\(3= MBV2?LT*C$\DRJB%^M>.E.GK+DR[N!I.4\Y9&#*[DFV6?B? MR&P5C?Q@.;<%^LO9035^>VHG#E\D3[_S@D&UH4^F`VLA'@WT6VK^@L7!Q>H' MVX&?TDO9ANXS_4L=U339=S*0X>;!:@4B4U6X_,P(M)*(:RO)X0!&'6?#*+[%)`*^C" MTS(.HWGP!)5+*LP*,1/?JS$G1`#D=03`VC\"L^@\@FCB!("0B>UGDR]^"Y]9 M!)5I9!.'L4.(F&$#,ZH19QD#I)EQ>ZT->.%'MLI12(:U2]N*%9JGUCP>DMIZ M1@A[JSNA`3<(3SD@(9K'EI"08?@ZX[@/HP$W&,>U2V1$\Q`9PRN$L-&ZIVC` M#4)WYZ`9":_0&4%OC$U["PVX03=U\D-S*]U='SH#-G2GR9N>1@]+BI"JB=/I ME6U#0`BZ9VG1Y[QQZ&[7"M1A2,C;E`EEIWU0K>N%WR4(1YS:^VQDN-GHB^31 MCIT>71M68G2D\]ZRZ,;FULE>M#J_-*S$ZTIT45:<6)7=BK3=38/-JN#)! MYK79@]%1)7=DK;=;C+U$B3BJY$YM96_/L9S8;'+M M'10YDM6N%A;=X#Q5$S6ZLM_B[*50D:-0[N!6]ENW"<( M2&G]+]YU5N:N8T^WM0&N&B7=LA]4;GFAO(QM8&DXF$!T$B\K^*!%:0_/:Z'A MDF%_[N!2R>!L'PX`O!%"'Q_,=:B^IB[_`P``__\#`%!+`P04``8`"````"$` M0K7G0$X1```!60``&0```'AL+W=O9^O\,;8V.;&-LX@-G9_?M3HE626JGA&.^\ MC'M2I51+F:H6+<&7/_]^?3G[:[7=K3=OMZGT^67J;/5VOWE8OSW=IL:CRA\W MJ;/=?OGVL'S9O*UN4_^L=JD_O_[W/U]^;K;?=\^KU?Z,&=YVMZGG_?X]NKC8 MW3^O7I>[\\W[ZHU+'C?;U^6>_[M]NMB];U?+AT.EUY>+S.7EU<7K7/_XW7UMH])MJN7Y9[O?_>\?M\)V^O]1^A>E]OO/][_N-^\ MOC/%M_7+>O_/@31U]GH?U9_>-MOEMQ?N]]_IW/)>N`__`?K7]?UVL]L\[L^9 M[B*^4>QSX:)PP4Q?OSRLN0=JV,^VJ\?;%*4CFJ6O4Q=?OQQ&:+)>_=PYUV>[ MY\W/ZG;]T%J_K7BX62@EP;?-YKL*K3\HB"M?0.W*08+>]NQA];C\\;(?;'[6 M5NNGYSWKG>UTK;_"0+/\^_/VY M?M@_WZ:R5^?YZ\MLFL//OJUV^\I:4:;.[G_L]IO7:1R4UE0Q24:3\%]-DLF= M3)+3)/Q72,YSF?SUS2EWPO=\Z`[_U22Y\YM\/G=U<_WQ[EQI$OZK2=(G]Z:@ M.?BOYLB?7ZY-QY<++:>=%)79PZ,A?Q`N*P'BDO]\NO M7[:;GV>\RF.Q=N]+M69,1XI85B+QNL&L37ZU-.$UB6(A17.;8C?SJF/'"ZJ_ MOF:N\E\N_N(UT+V.*6),.AE1D@BUX%&T91^X\X&*#U1]H.8#=1]H^$#3!UH^ MT/:!C@]T?:#G`WT?&/C`T`=&/C#V@8D/3'U@Y@-S'UCX`!EY11@R8AH$Q"-0 MCT`^`OT(!"10D$!"`@T)1"10D4!&`AT)A"10DD!*`BT)Q"10DT!.`CT)!.5/ M*GKRL187/*W-W.8,^COFMJ)1(`#%B MBE14@AA0CT`^`OT(!"10D$!"`@T)1"10D4!&`AT)A"10DD!*`BT)Q"10DT!. M`CT)!"57T<1$YB7K[YC(BH;?%+@/Z>XR43(I8I`W('2`60 M*B`U0.J`-`!I`M("I`U(!Y`N(#U`^H`,`!D",@)D#,@$D"D@,T#F@"P`(4+( MRBP:$LI*J"NAL(3*$DI+J"VAN(3J$LI+J"^AP(0*$TI,J#&AR(0J$\I,J#.A MT(1*$TI-":T3R8#?,_R.9*!H>-'/?YPE^Y67#>(@]2G5!/G9P(2(D\J`W`%2 M`:0*2`V0.B`-0)J`M`!I`](!I`M(#Y`^(`-`AH",`!D#,@%D"L@,D#D@"T"( M$"HB5$((=244EE!90FD)M244EU!=0GD)]244F%!A0HD)-284F5!E0ID)=284 MFE!I0JDIH74B&_#[C40V".\@R,=T%7V8]#)9BS&B7OV8&9[)9I)IH&2"I%H9 MD#M`*H!4`:D!4@>D`4@3D!8@;4`Z@'0!Z0'2!V0`R!"0$2!C0":`3`&9`3(' M9`$($4)6:-&04%9"70F%)5264%I";0G%)5274%Y"?0D%)E284&)"C0E%)E29 M4&9"G0F%)E2:4&I*:)V8X_RN^80YKJ*3#M?O2@O`5*.D3Q_]G,>[-GD@_W.!,E#H0)(%9`: M('5`&H`T`6D!T@:D$R-IV]4N(#U3ZTA7^R9(NCH`9`C(")`Q(!-`IH#,`)D# MLH@1IZM$"!5-/;>SN:2NI/W`ZDMOR1K"0"@_H?Z$!B!T`*$%"#U`:`+2+G"[ MK6W@0MH'GIW];FMON-VVYC#=1BL0>H'0#(1N(+0#H1\(#4':$7$?$\F!]QH3 MR2'>D3N_YC7=_GE]_[VXX0G-K_P#*_TL[[S%^W&*))DS-&(G4@F0I+V`"LN/25K M`@.A[(2Z$PI/J#RA](3:$XI/6GVWRUI^%]+Z&PN#MJ3]X';9&L)T&2U`Z`%" M$Q"Z@-`&A#X@-`)I)\3]2^0(/DCP[W.$(DGFB!C)V:=&2FTRETM;RH6TISQZ?W"TSUQZ;3272]O*A;2O/'I_<+377'IM-I=+6\N% MM+<\>G]PM-]<>FVXF"N1R]+\[C&1S`(+FTS>K&P.X.C5VIZW*8?=+AJ7'^^B./]*1CGCS18^ M]&4:/#(Y^228#G.Z:,Q__![$_=+K7,;OM)D,QX=99H,[#F8"6!_S2;+X7J7! M_'7!;]'8WSJ9#Y=A%XWCCW=19H$99M#53(I?=3&9\M6)-??4Z?])^?$!-]ZK M%L\4^3FB9H67\KUA*.DH9T#+`MF!N1.H8.@K`MFHJD#6(#6!;%1=(,O5$,A& M-06R7"V!;%1;0U=V\=W!J*Y`EJLGD.7J"V3O:R"0C1H*9+E&`MFHL4"6:R*0 MC9H*9+EF`MFHN8:$+J,[G475=AR^@.Y])C>.<[G*"PG9%>K>_`>WY;*JNZ]Q?0'T^GXKW%]"? M,POR!1S`J03Y`A[@LZIQG-O?I`N2:4&=/#PA+<0'%1-I(89R5H>2^A:6RA36 M)F4-\3=V))_<"60K5@2R457DJF%472#+U1#(-$T@/<7 M4)[30ASG\@6TY[2`?`'U.2T@7T!_3@O(%W``IP7D"WB`TP+R)5V03`OJ/.() M:2$^OIA("S'$CPKWF'2#_"J+%`1^DG M$F7IIT@_PZBY0$?I%Q)EZ3D1@74X$8%W.!%I[&@+G)NPJOC.71($7,9?H?M0 M$P'K\2>9N*K;1,!IG*X^U$3`?IS!L(F`VSB#?:B)@`4YJ6$3`<=Q4OM0$P$; M2Q8H:XH620"6!W%51 M7)&_?"]1=SHJ:U],5#3D/'&KR%63BI:K+I#E:B!7$[E:4M%RM06R7!WDZB)7 M3RI:KKY`EFN`7$/D&DE%RS46R')-D&N*7#.I:+GF`EFN!7)Q,HI5C M)")=/E'?O3Z1W M^41[ET_$=_E$?9=/Y'?Y1'^73PS@\HD#7#ZQ@,LG'G#YQ`0NG[@@YDNF!GZ& M_(;4H%B\U!!#.=[(=7:TO'?K)?5C,/ZKE1A2OR3@5(0=-1V5_N6.6AS@+=:\ M!585VZ]IB-N7;%47*&XLN*-F6I-*3:1N"<_1KK4E2C8D_!VMC@XXWK4NMM\3 MYJ/M]R5*]S:PHV8ZZRKD#>T0VQ\)LQW:L4"ZL=".FFE-AG:*U#/A.=JUN429 MH?5N>J$#C@\MY\;XGMPE3E&XC]X!I\NX:EX;-[2C9CI\9'@YG^(]5(3<#C"O MY!(-AG?43(LRQ+R*0_J&4!WOHC@_+Z,=F=W6]^J!^LN[[BG&Y@^W-Z&960/;QX^)F]4$&&?W\O6"/+ M!8?C:1X5Y2**?[#/*RAR`7][+M!XG@L.ZUR_QA47'%[V>@7\<>$RXG\.:R6_ MC'=<(_Y%CV`9[[Q&AST3O`O^@0\N4WLG@3+>=HW8*<$RWG#EVPR7\69VQ!^S M@O5X4SOB7SD)EO%.=L23+UC&>]@1__))L(PWKB/^S!4L&ZBR0;B,SPM$G.*" M]?B@0,1+QV`9'QB(#GMN@3'C@P,1_QI,L!Z?%H@.>W"!>GQ.(#KLQ07*^`Q& MQ(^-(&=1E17#97P`(^)G1K`>'[V(>*D=+./S%A$_(H)E?.XB.NQ5XGTJFZF= M.2Q1)@M[3%DL[#!EL+"_^&A+I#9NL1T^TQ*I_5LL4=8*.TL9*^PK9:NPJY2I MPIY24S0\0]4$#<]/92>U@XMWK91^]QX;VHJAF>BFHB_F(?%`MO[\/[;SX85+N$#F-@. M-;B$STX&2CI`R4#+N$3BX&2"9?P84,L*1*T0\9%/Q%N%B,]J M(MXK1'S($O%1(>+3D8C/"A&?FD6\?!WQMUH0[UU'_$T@Q*EXS>,4+.EP"7^A M!.N4;R(^$8]X[R;B;Q`@3L4;;B-8TN$2/I#.=2Z,M/S[L^_+IU5[N7U:O^W. M7E:/_+B_/'PO91O_@FW\G[U>:GS;[/F79P^KCF?^J>$5?TWM\IQ?!3QN-GOY MCVK`_'CQU_\)````__\#`%!+`P04``8`"````"$`XGV9NF4'```+)@``&``` M`'AL+W=OMA%G MD>TB[0(M4!1]G!59MH58EB$IR>Z_[W!$R9RA:$J7()G,@S,ODEZS:%Y?CSOWG[^=/:]=IVO2R3\_5)=^Y/_+&_?SX\T\/ M'U7]VISRO'7`PZ79N:>VO6Z7RR8[Y67:+*IK?H'?'*JZ3%OXL3XNFVN=IWLT M*L]+?[6*EV5:7-S.P[:>XJ,Z'(HL_UIE;V5^:3LG=7Y.6UA_^MS*:X M*]/Z]>WZ*:O**[AX*F&:];_Q!ZV/]>7'*H-NR3V(&7JGH5JM_V0@3&2\WZ&7?@S]K9YX?T[=S^57W\ MEA?'4PO;'4%&(K'M_L?7O,F@HN!FX4?"4U:=80'PU2D+T1I0D?3[SO4A<+%O M3SLWB!=1L@H\4'=>\J9]+H1+U\G>FK8J_^N4/%Q4YPN7]C5MT\>'NOIP8+]! MN[FFHGN\+3CNU]1Y&%9I6B2L3CAY$EYV;N(Z$+^!RKX_>O[J8?D.U=`:-):QF6!(L0UW2>'GZR$)91!;E$DOYT@G4,/YXF&!.&*$,]587[WN# MWRYRIQ,J.M&@01($E>D)"F78'-6MY]]2ZD)W2JJ.(30TBAI:;+G]'A3(-)25=(ZN=`@VG9G/?KU"F?J4$,E%2 M",=3$!!FYR1(5@MKX80=C2HEM)<,V[6A4>\G*)1I*"E!II$.]`!>:CKW':,V M]=R+:.WB\=IYXNCSXGD;>_'0D`66&*'E2PR!9Z'$D^@(;S#I11W8U=;SQ&E7 MH*5T!8TS!)?T$`YS99H0ILE M*45Z"_H,%!;7.A_0`42C]3.,)W%O4!/!^OGK"?<)M&1)"6=:"0TCQ6?XL.2I M,P,=8)Y`9-K=LP#AZX#H1;2$AA'E,V9@";W(/AO1D%50XH,VH6&D^`P?E@KJ MR$`'N%^\@@'CP^2^L$*1E`1>1-@BX8LBN0' MR2DTS*M`G/7)L$!M%DTX`-%(3@P68I\VL'?W6R'0H=&+:$*&N14P:%BB22HH MXQX=0$+Z]`@8%41"DV[I:,C*-G:I"`T3,9C%#-1FT21&1G(:`T2RF<#80.)` M+=T8(4+#=`QF$0*U65(2&OAA!F%LR`AQOP=0F[KN182QH6'>BHFN'B%LBQ!, M+6$E#)3ZH2=8"6UTPW0,&3(LT?1+!3K`:)RP(8."R,A?A1-PA):LE@,@E+M? M:!B\(6.&)2F=%>@`%C#2%+/`(/:/78MZ$6T*P^`-1UB1)!..%1JR"HZRPC!X MPUFL0&T63;)"!WK(6&'9')T/Z``W1VT%P[0-&1]$$WI1,*4)]=L$.@-[Y%>PFB$%9/^+D5#%F6X32C5C`QC,9I%"]1FT89;!:=%-$(+ M+X;/CFT$1$,690P6D6$L1K-@@=HLFN2'/A:C6;!`;>9:\H/`(C*,PF@$%O[: MFT`+M&21QV@1&697-(L6J,VB&6D1S:(%:C/7$B"TA(9I&(W0(@XG]*#."G0% M2Z&L,`RL>!8K4)MFV8MT5L2,%?=QB]K,M00$+:!A8,4,$(A;^X<5:,;"#J10 MN6085S&#AR5)B0?ESH0.<+,U182J@#`AU`-%I"PY!*&""F7V/0DB;5BT@7QH:IDLSB!VJS M:,,%@Q^MA,'B?@E1F[F6C*`E-`RIA#$"#_*D/T?0DD66"*$E-$R5A"'$DJ=D MA'+:T`$L0*>[^!Q=903VQ0;*8HDAS%A&4D0S,LRK9!8_4)M%D_P8R6@$%MZD MCVL320:U<*.P,,RN9!8L4)LE981%,@L6J,U<2W[03C=,P_4(+`+[1PEH1L/V M(MH4AGFUGD4*U&;1C*18,U+@V8W7]HL9&K(H$AHDI\0PNN"I#3E?]X\5:K-H MP@'\UQ#?M^#_9KNG-]W[EC*OC_DO^?G<.%GU)I[5^/`P99`.3WZ>?&'/Y>'V MJ7L*M!Q^`T]QKNDQ_R.MC\6E<<[Y`7RN\+)2=X]YNA_:Z@KKA`; MCQ_6!Z4?32Z$)=!:;6@B=N45D$ MX7@\#THN*^H95GH(ATI3&8L[%>]+45E/HD7!+>1OQ M*FN@V,E"VA='2DD9KQZR2FF^*\#W,YOR^,CM7L[H2QEK951J1T`7^$3//2^# M90!,FW4BP0&6G6B11G3+5KO`=TT2D?)]87^HPQ!!S27DNE]H=MWRSUNI`H-^`-C7'W<-60'PY%T@"L5L$1W1!"<@8*.#3AK') M.G@"TW&#N?48^#UA6D0`HJTRJ`U71C`J8U4PE5L?Z,J$EV4F?1DL^O3-HA^- MXB(H;]<$F[;\/@./F78PLQ;1,PJ0X481#+WHTC)V(O;2'M3%G!`]:3`Z7!K! M3KHM__WJFXJB_01/H] M75SV@A-W\*%`<%^JB4S

MN^66?%[U,9DL\[?^Q@PO[&DVD;^?ZLATSN MQZ'[8L?0N2.&Q[U3*M>>\'J`);?RE0R20:AO:OF&J7?-#YCKKRO8A*:G+OG) M[<=C*70F/HFB,"16>YS*(0R\-MK>&%NW8U_'IZNMOTF"]@M,\IIGXAO7F:P, M*40*G./1`GJO_5W@7ZRJH00PSY6%&>X><[BS!0R]\0C`J5+V^(*W3?LO8/,7 M``#__P,`4$L#!!0`!@`(````(0"\N)%;H`0``(01```8````>&PO=V]R:W-H M965T&ULG%A=CZI($'W?9/\#X5VA&Q0QZLV%R>S>9#?9;/;C M&;%5,D`;P''FWV]U%T)W,Z+NRXQ8IZM/G:JNHEU]^RARZYU5=<;+M4VFKFVQ M,N6[K#RL[;__>ITL;*MNDG*7Y+QD:_N3U?:WS<\_K2Z\>JN/C#46>"CKM7UL MFM/2<>KTR(JDGO(3*\&RYU61-/!8'9SZ5+%D)Q<5N4-==^X425;:Z&%9/>*# M[_=9REYX>BY8V:"3BN5)`_SK8W:JK]Z*]!%W15*]G4^3E!U^RTH&:D.>1`:VG+\)Z(^= M^`H6.X/5KS(#?U36CNV3<][\R2^_LNQP;"#=,XA(!+;L1@%M;5C>OF7!I6^FY;GCQ+X)( MZPJ=T-:)!^Q;.WPUOMA!(C*NEZ1)-JN*7RPH%MBJ/B6B],@2'%X#PNV[$&]% M"*$))]^%%^D+R->0EO=-Z*^<=U`R;2$10@+;ZB!$1\17A$@`L.LH0G`F10\R M][7F5T9BDM,81I%,YCG,38,B$D4XTW>.$.(K$`,1 MCR$T:N#D<6H"O+8A[BY+@;%QA)"%S/+$"WVJ4X\U._%IV-DU6E#O*BU1>/[- MDW3-JEAD*#?OW,M2C!`")+H(C`#B,81&<:Y3'$^J`.O*A6;!(<27RA'/TXG' MFI6ZG56C!.='56V+&RV#0`]3E1NG M)=$FK]XS\FI!F,Y)8':\N+4C\0FA7E^AFF#$F`IWJ&'C5IN&9V93>H03+B7S M%F:A:>8)G??+=5ZB(3]=;`3;N,K/-S/:8I`?]0QA8\T\F2D9U_F)IOP\/VSE M*C_B&ETU(@C"U)$@Z#,G4Q]K=CH+^O4Z0]&=GV>(/5UG:/2OB"`()0SGQOR/ M6S,&X,W\7F*=H.C."L$[I3<<",0U=H[$"QHVL'94`?#A,[ZTM6)/34:R'`V$-?H8U$+NDE,'0\CQ(P)<2>CP]%`7*/8 M(S+6^MOS,`;1A3/&@W@3N3_!R%=SPDA=U(*PYOT%-02.6SL*3)270(T@-0;% M8P3E*G-@]'T5!T8+NDFPM=\C:(R+!PD.QP8A?7&W!!&$!&3PY0H MDJ[7-KZP!Y[2/UH)T0G:?7?6!X`2XF48+XT%JPXL9GE>6RD_BXLN@8G>?8N7 M\`@NX?+&ZG0&N`.?D@/[/:D.65E;.=O#4G<:0&>N\!:-#PT_R4O;EC=P^Y4? MC_!K!X,[ICL%$[SYOH@KHG=[R>;_P```/__`P!02P,$%``&``@````A`.VF MK:P!!```.`X``!@```!X;"]W;W)K\+GQ=HUW6%%E%&KS1/S'5 MOVQ__65])>T;/6'<:<#0T(U^ZKIS:)HT/^$ZHP8YXP8B!]+660>W[=&DYQ9G M!4^J*].V+,^LL[+1!4/8SN$@AT.9XYCDEQHWG2!I<95U,']Z*L_TQE;G<^CJ MK'V[G!V:&_1/B:]T\%^C)W+]K2V+ M/\H&@]M0)U:!/2%O#/JM8$.0;#YEI[P"?[5:@0_9I>K^)M??<7D\=5#N)2AB MPL+B,\8T!T>!QK"7C"DG%4P`?K6Z9$L#',D^^/5:%MUIHSN>L5Q9#@*XML>T M2TM&J6OYA7:D_E>`4$\E2.R>!*X]"2ROF;E.GPO7/M=V#>1:WD\\W^TYX'H3 M`7]G3@!D<@?@>DN>K]SKD^%ZF[UCK)`5.*N7)*8H!:]LG'79=MV2JP;;!$@G(2M<>$%N& M[$8@C@R)1R"N#$E&($L9DHY`O#O$!"/N;L"B&KHQ[0(#*RZ@.RTW*A*0%5_` MS+F=.A"K`XDZD`X&I+G"(IX_5P;>Z$#U*,=*F:N`^+RR&457P,/:4F0RC2F8Z M'I/DPF$YE#M]^#"P+#-0'AD)B*BLZ]O*JMV)<.^"[%"LI"IK)AFF*D]-QV.2 M4-8/_O0[AR4I@I5#*!(0V$G_NYD%0ECBH,"WU8,J?LF1O$2D4PC)B$`V8KKB M#*P8H.S52$#Z(QQ.875I2W$E.1X&77_I*85-AO%%X-B/$YJ_'U(I/G&$0XHQ4X7O(?TQ'MA!8".%)GY-D[R&L`:X:JB6DXNK'E>PE%['Q6-?81":"6@H5;&=RB$CN)Y/$8A-!;/XPD*H;]X M'D_APX&/F_<'0-]^SH[XSZP]E@W5*GR`J5D&ZS1;T?F+FXZ<>0^T)QUT[/SO M";[0,#0[E@'@`R'=[08>;-Z_^;;_`0``__\#`%!+`P04``8`"````"$`986D MF@0*```"2```&0```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`#`,^K98&OO(J\B)Z);!%#!-C?N549R`M-,Y,M9&:!KX7HNED9 MR9:9T<"0S5D4A=HC:^\*DV]LDL7+1+:N2QKP:6!%`P$-A#00 MY0)-UIVN?8IU(ZE/E1_DLZ[#->\ZV;J.L\!7(ZGR[IL418^T@%8D)(E>%#2) M420JV1?3$M(;RJMK"L-:ZZM']DG/MTJ,G&56(LC*S$N(G,0N$22)4T+D)(L2 M09*X)41.XA4%;?YED9!]Z$.Q@B*`(H0BJA)2:;"A4BH-?KAML_&END3X4E*) MT,"$!C0:T&G`H($I#9@B(/=;4F=6F2%[:7:#F9>9MMQE[!N,4V8Z#6989,C#Z-YA5B1F08TAP@PG+#-FG49GYVJ=2?V9G?%)_KN['7$O] MF`8F-*#1@$X#!@U,:<`4`7$MP,\J+!J8T<"E3O(X@;C9B8; M_CP:6&:!_">1XZU?9L@PM"HS)$]09DB>,#/9&D>Y@-0YV/G\'9V#:W8PS(^2 M`W($&`O#/N\ZDI(FGT"A0:%#84`QA<*$PH)B!L4<"AL*!XH%%"X4'A1+*'PH M5E`$4(101%5"*A%VI2N5R&WG`WRIQSH[Z;B6@3H@@]Q8F,'E6JS?[K;8'_GH M-,F+3JL[*`@M+TISZ'E1FL/("Z77+G[*-"^Z?79CCJRH*4!%U5M0S*"80V%# MX4"Q@,*%PH-B"84/Q0J*`(H0BJA*2)7"+G>E2JD^T^":5@@9*L;"]"X5TFOW M"OUN(D!%O]-0"AVF,*"80F%"84$Q@V(.A0V%`\4""A<*#XHE%#X4*R@"*$(H MHBHA%0B?*LG?R:LN$*YI@9#KF[$P:8$,67W0(_-$B*H*@3ETF,.`8@J%"84% MQ0R*.10V%`X4"RA<*#PHEE#X4*R@"*`(H8BJA%0B[(Z^5"*WG6WQI6BID$OX ML3"B5)3+R18YB9D(454J,(<.3*X=-H=U2.F'63;H,-R6G7F'_# MAY5715E,,-$PT3$Q,)EB8F)B83+#9(Z)C8F3DE[GB0LX)%`9#+4)>" M(9FO\A!8IJ"B$_B8K#`),`DQB2J)7#%\JNZ.BA$S>W+%D-8<\Z]SH8J!1$NS MB+&FS<_UY+O/.OX80\JAJ"6WCG$2$Q,+DQDFW-B9.2BIVP`(3%Q,/DR4F/B8K3`),0DRB2B)7#I_9 MS`\X_!9:AP7![0$Q(2H//'1RGW__%PT\D&@XBXZ)@6 MB%1L&_]/#U,O8'E??T:.^OCZ_9PJNWB%]8FK09_^\51O,-%_').WB]ODOB1 MG-F[5RX_OK%W[<3L6NTNI59,S3 MS"[2MTMVK;E(F9V3&OI?G?);A6J7]"-REZ3\^G;[E!:7&TB\Y.>\_M&(CD>7 MU`I>KT69O)SAOK\;BR1%[>8'D;_D:5E4Q;&>@-R4=Y3>\W:ZG8+2T\,AASM@ MMH_*[/@X?C:L>&Z,IT\/C4'_Y-E[U?E[5)V*=Z_,#W%^S&H/&4M':;$?BS'!VR8_)VKO\JWOTL?SW5,-Q+N"-V8];AAYU5*3@*,I/Y MDBFEQ1DZ`/^.+CE+#7`D^=X9,--3`)V!\?ZO"4IV*3V792)T\/9?$^@N4"+E[=$K;X&!93PYSF MP]IF^<^2'+*;J3PSF<IM]@-J4B9M<3HT;L,8)-'29K MZ\#1@:L#3P>^#@(=A#J(=!!WP!2,:]T#PWZ%>TR&N8?WO4,@[9QK5F$$-K%U MX.C`U8&G`U\'@0Y"'40ZB#M`L0K6*V*5"9.F?_'$O&*M8)E4\DJS8B=BNLFW MU-QJ0UJ["'$(<0GQ"/$)"0@)"8D(B;M$\0V6:^(;VW3NG*!,!N8X'#HSU%1M MVO$@<\C)-J1UDA"'$)<0CQ"?D("0D)"(D+A+%"?!-,7)X*,[3DS8 M7#H6+E0+]VT0-K,)<0AQ"?$(\0D)"`D)B0B)NT3Q![;I._QAT:H_G)C;=AG; M$V(3XA#B$N(1XA,2$!(2$A$2=XEB!LR!.\Q@T:H9G(`9W631EZ4VJ$T60AQ" M7$(\0GQ"`D)"0B)"XBY1_&'/-'K=8!H32*X[%R8FI%K'R0+VALX\6VGSK`UJ MK2/$(<0EQ"/$)R0@)"0D(B3N$L4ZR`G%NN%UB$6K_G`"_N"M[PFQ"7$(<0GQ M"/$)"0@)"8D(B;M$,8,5T(H;K`!=PAI^9QHU.JI/`FF)M-8224:AG39%#D4N M11Y%/D4!12%%$46Q@E0768':G8[#.<6>/;2D$JB;5139%#D4N11Y%/D4!12% M%$44Q0I2G6'UZ!W.\/(5ZB3,AAU[*@*SM#3:Z&G41F%#6S9$Y%#D4N11Y%,4 M4!12%%$4*T@UBU6A=YC%BU;%+(X6_)T%>X;;&P39%#D4N11Y%/D4!12%%$44 MQ0I2G6%59=<9_IP\6<.&5Y_R].NN@'4+IE7/Q#/A>5@\)?/:5#%,(-AH.[O= M5L\N$;5IT])FI3RDI,@8D,'[XMF M"\T)%P.DC(=(ROB(5D)&4PGPO%0)$4F5")'HC*%W)L:`1D8UE!7)=QC*:VK% M4([F:S14KW8-$2!SPD8DI[&#"(JM=NH9&Y*E1,O#AE++1\2G3$^6$I40FTB5 M"-%/5&(\WY.EK'R^PU1>;2NF/=8Y#,+5L@$PK8CM':CNU@%"MF8+%>DF6%*GO89E#9 MQZA%HVR2_9`*A]AD4#C"*-'EC=[E6%%6!PE&=W!R?"EN/ROW.J7(G,EHH\11 M,Y'Y)?GG1OY1YI*5K]D^.Y^K45J\L4^),(&?'EK,OW/"(XG%JGB8*^2,"6>: MP=7/K"QXV=738FW!2YX>OK'@#48/WUKP,-_#C1EH84% M+YUIAW9+"UZV`I^VCL#7X%ORFOV1E*_YM1J=LR,,\:QYBBCY]V3^HQ;I]5+4 M\!VXR;03?/?/X'EJQMZQ'8NBQA_L`NW_)'CZ#P``__\#`%!+`P04``8`"``` M`"$`[6X(U:`"``#@!@``&0```'AL+W=O/U=4-1L;2MJ"-:GF. MG[G!MXN/'^9[I3>FYMPB8&A-CFMKNXP0PVHNJ8E4QUOX4RHMJ86EKHCI-*>% MWR0;DL;QE$@J6AP8,GT)ARI+P?B]8EO)6QM(-&^H!?]-+3IS9)/L$CI)]6;; M73$E.Z!8BT;89T^*D6390]4J3=<-Q/V4C"D[9GC99+=W6"RF/O\_!)\;P;?R-1J_UF+XJMH.20;RN0* ML%9JXZ`/A3/!9G*V>^4+\$VC@I=TV]CO:O^%BZJV4.T)!.3BRHKG>VX8)!1H MHG3BF)AJP`%X(BE<9T!"Z)-_[T5AZQR/TB@9QU-`HS4W=B4<(T9L:ZR2OP,F M.3`%CO3``>\CQS2:7,>CY/\D)/CCP[NGEB[F6NT1M`Q(FHZZ!DPR('X]'@C$ M89<.G.-KC,!7`S78+9+I>$YVD#AVP-P%##Q?,#V"@&BO#&J7*SNP4W:9=:[< M!<-0)GU=9O0>&0>&T@R<3^-9SQN4`V8\P$QZQ$F``+D\0`>&&@QITR3NB8-T M``TQ;TA#4UTN[ND_NP0(Y[HN8)DGOS$F4T_=(.?"IU,&2^M,W;`_HLF$( M[L"EDTET#;[]NTG=QE.-@^6DK,D;[>+F]<7GP8%/I8)E_!)-F"CAR$FN*_Z) M-XU!3&W=M$CA$/76?I`M?3;^MH^SI1]PI/\!`Z:C%7^DNA*M00TO@3+V*=)A M1(6%51UX"7-&69@M_K.&FX3#.8HCR&>IE#TNW!#L[Z;%'P```/__`P!02P,$ M%``&``@````A`$L&ULK)A=#XI9>X^1&-XG3* MDG13),]Y>JVY2)E>XAK:7YVS6X5J>?(1N3PNGYYO7Y(BOX'$0W;)ZK=&U#3R MQ-L_7HLR?KA`O[_;XSA![>8'D<^SI"RJXE0/0,[B#:5]OK/N+%!:SH\9](#9 M;I3I:6'>VUYDCTUK.6\,^BM+7ROI?Z,Z%Z]^F1VC[)J"VS!.;`0>BN*)A>Z/ M#$&R1;)WS0C\7AK']!0_7^H_BM<@S1[/-0RW"SUB'?..;YNT2L!1D!DX+E-* MB@LT`/X:><9*`QR)OS?7U^Q8GQ?F:#)PI\.1#>'&0UK5NXQ)FD;R7-5%_C#R?LZ3UY8Y$'5Y'7'P]WFV[" M%9\S&C@SUW9_]J2)R(0K9KJ##[1P*O+@*O)`H:=',"&;%L(5GV,/9JX[GLRF M_7V[$YEPQ

EXCEL 15 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Q8V,P,3@W-5\T,#,U7S0Q9CE?.&4R-E]B9#DP M869F,V0W9#0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=OF%T:6]N7V%N9%]"=7-I;F5S M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC M:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O&5S/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-U;6UA#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7S(\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O&5S7T1E=&%I;'-?5&5X='5A;#PO M>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D5A#I.86UE/@T*("`@(#QX.E=O#I3='EL97-H965T($A2968],T0B5V]R:W-H965T&-E;"!84"!O3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\Q8V,P,3@W-5\T,#,U7S0Q9CE?.&4R-E]B9#DP869F,V0W9#0-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-C,#$X-S5?-#`S-5\T,68Y7SAE M,C9?8F0Y,&%F9C-D-V0T+U=O'0O:'1M;#L@8VAA2!);F9O'0^)SQS<&%N/CPO'0^)S$P+5$\'0^)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)S(P,30\2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S`P,#`X-C@R-S@\2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)U-M86QL97(@4F5P;W)T:6YG($-O;7!A;GD\'0^)U!24$@\ M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q8V,P,3@W-5\T M,#,U7S0Q9CE?.&4R-E]B9#DP869F,V0W9#0-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,6-C,#$X-S5?-#`S-5\T,68Y7SAE,C9?8F0Y,&%F9C-D M-V0T+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2P@<&QA;G0@86YD(&5Q=6EP;65N="P@;F5T(&]F(&%C8W5M=6QA=&5D(&1E M<')E8VEA=&EO;B!A;F0@86UOF%T:6]N(&]F("0T+#$Y-R!A;F0@)#0L M,#8T+"!R97-P96-T:79E;'D@*$YO=&4@,BD\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^)SQS<&%N/CPOF5D(#4P+#`P,"PP,#`[(&ES2`H M3F]T92`T*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S2!S=&]C:RP@870@8V]S="`U+#,S-BPP-3,@86YD(#4L,S,V M+#`U,R!S:&%R97,L(')E3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\Q8V,P,3@W-5\T,#,U7S0Q9CE?.&4R-E]B9#DP869F,V0W9#0- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-C,#$X-S5?-#`S-5\T M,68Y7SAE,C9?8F0Y,&%F9C-D-V0T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!S=&]C:RP@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E M;G-E'0^)SQS<&%N/CPO#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\Q8V,P,3@W-5\T,#,U7S0Q9CE?.&4R-E]B M9#DP869F,V0W9#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-C M,#$X-S5?-#`S-5\T,68Y7SAE,C9?8F0Y,&%F9C-D-V0T+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M)SQS<&%N/CPO2!O<&5R871I M;F<@86-T:79I=&EE6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M2!O<&5R871I;F<@86-T:79I M=&EE'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-EF5D('5N9&5R M('1H92!L87=S(&]F('1H92!3=&%T92!O9B!.979A9&$L(&ES(&$@;6%N=69A M8W1U2!B=7-I;F5S2!P2!A;F0@;&]C86P@6QE.FYO6QE.FYO2!A;F0@;W5R('!R:6YC:7!A;"!P6QE.FYOF5N M9V5S+"!P6QE.FYO M6QE/3-$9F]N="US='EL M93IN;W)M86P^)B,Q-S0[/"]S=7`^($-O;&0@4F5M961Y($]R86P@4W!R87D@ M:7,@82!L:7%U:60@9F]R;2!O9B!O=7(@>FEN8R!G;'5C;VYA=&4@9F]R;75L M871I;VX@=&AA="!I65D(&EN('1H92!M;W5T:"X@0V]L9"U%15I% M/'-U<"!S='EL93TS1&9O;G0M2!1=6EC:TUE;'1S/'-U<"!S='EL93TS1&9O;G0M6QE/3-$9F]N="US='EL93IN;W)M86P^)B,R,3`[/"]S=7`^/"]F;VYT M/B!#;VQD(%)E;65D>2!I2!F#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E65A65A2P@=&]G971H97(@=VET M:"!I=',@6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^ M/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O9B!3 M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/&)R/CPO'0^)SQD:78@#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E M2!M86YA9V5M M96YT('=I=&AO=70@875D:70@86YD('-H;W5L9"!B92!R96%D(&EN(&-O;FIU M;F-T:6]N('=I=&@@;W5R(&-O;G-O;&ED871E9"!F:6YA;F-I86P@65A M2!F;W(@82!F M86ER('!R97-E;G1A=&EO;B!O9B!T:&4@8V]N2!B92!A8VAI979E9"!O=F5R('1H92!C;W5R M65A6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M#L@1D].5#H@,3!P="!4:6UE2!A;F0@2!M86YA9V5M96YT(&%N9"!M87)K971I;F<@<')O M9W)A;7,@=&\@;W!T:6UI>F4@8V]N#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@8F]L9"!I M=&%L:6,@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E&%M<&QE2!A('5N:69O M2!B87-I6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE.FYO6QE.FYO2!L;WIE;F=E2!Z:6YC(&=L=6-O;F%T92!F;W)M=6QA=&EO;B!W:&EC:"!H87,@8F5E;B!C M;&EN:6-A;&QY('!R;W9E;B!T;R!R961U8V4@=&AE('-E=F5R:71Y(&%N9"!D M=7)A=&EO;B!O9B!C;VUM;VX@8V]L9"!S>6UP=&]M'!I2!L979E;',@870@;6%J M;W(@8W5S=&]M97)S(&%N9"!T:&ER9"UP87)T>2!C;VYS=6UP=&EO;B!D871A M+B!);B!A9&1I=&EO;B!T;R!#;VQD+45%6D4\6QE/3-$9F]N="US M='EL93IN;W)M86P^)B,Q-S0[/"]S=7`^($-O;&0@4F5M961Y(&QO>F5N9V5S M+"!W92!M87)K970@86YD(&1I6QE.FYO6QE.FYO#QS=7`@6QE.FYO6QE/3-$9F]N M="US='EL93IN;W)M86P^)B,Q-S0[/"]S=7`^('!R;V1U8W1S(&-A2X@4V%L97,@86QL;W=A;F-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#(W<'0[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B!B;VQD(&ET86QI8R`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE2!686QU871I;VX\+VD^ M/"]B/CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E2!I=&5M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG#L@1D].5#H@,3!P="!4:6UE'!E;G-E M(&ES(&-O;7!U=&5D(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@9F]L;&]W:6YG M(')A;F=E65A'1U#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M2!R97%U:7)E;65N=',@87-S;V-I871E9"!W:71H M('1H92!D979E;&]P;65N="!O9B!/5$,@86YD(&]T:&5R('!E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE.FYO#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!I;G-U6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!W92!D;R!N;W0@2!O2!A9F9E8W1E9"!B>2!C:&%N9V5S M(&EN(&5C;VYO;6EC+"!R96=U;&%T;W)Y(&]R(&]T:&5R(&-O;F1I=&EO;G,@ M=&AA="!M87D@:6UP86-T('1H92!T:6UI;F<@86YD(&-O;&QE8W1A8FEL:71Y M(&]F(&%M;W5N=',@9'5E('1O('5S+B!!="!*=6YE(#,P+"`R,#$T(&%N9"!$ M96-E;6)E6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!P6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A M;F0@,C`Q,RP@;W5R(&YE="!S86QE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6EN9R!V86QU92!O9B!O=7(@;&]N9RUL:79E9"!A2!N;W0@8F4@6EN9R!A;6]U;G1S+B!)9B!L97-S+"!A;B!I;7!A:7)M96YT M(&QO6EN9R!A;6]U;G0@;V8@2!A;F0@ M97%U:7!M96YT(&%D9&ET:6]N2!T2!O8G-E2!T;R!D979E;&]P(&ET M6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE M6%B;&4@87)E(')E9FQE8W1E9"!I;B!T:&4@0V]N9&5N M6EN9R!V86QU92!W:&EC:"!A<'!R;WAI;6%T97,@9F%I#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPGF4@:&ES=&]R:6-A M;"!R971U6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE&-E961E9"!T:&5I M2!B M92!R971U'!I2`F(S@R,C`[3W9EF5D(&1E9'5C=&EO;G,@8V]N=')A2!O9B!A;B!E>&-H M86YG92X@5V4@9&\@;F]T(&AA=F4@86YY('-I9VYI9FEC86YT('!R;V1U8W0@ M97AC:&%N9V4@:&ES=&]R>2X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2P@87,@;V8@2G5N M92`S,"P@,C`Q-"!A;F0@1&5C96UB97(@,S$L(#(P,3,L('=E(&EN8VQU9&5D M(&$@<')O=FES:6]N(&9O2!A'!E;G-E+"`H:6DI(&-O;W!E'!E;G-E'!E;G-E6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG'!E;G-E6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF4@86QL('-H87)E+6)A6UE;G1S('1O(&5M<&QO>65E'!E;G-E(&EN('1H92!F:6YA;F-I86P@ M2!C;VEN8VED97,@=VET:"!T M:&4@=F5S=&EN9R!P97)I;V0N/"]D:78^(#QD:78@#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2P@ M9F]R('-H87)E+6)A'!E;G-E(&9O"!M M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@,C`Q,RP@=V4@8VAA6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG2P@9F]R('-H87)E+6)A'!E;G-E(&9O#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E2!C;VUP86YY+"!E;G1E2!#;VUP86YY($%G2!A;F0@ M9&5P=&@@;V8@<&5N971R871I;VX@;V8@86-T:79E(&UO;&5C=6QE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!A<'!R;V%C:"!W:&EC M:"!R97%U:7)E"!C;VYS97%U96YC97,L('=E(&=E;F5R M86QL>2!C;VYS:61E2!T:6UI;F<@9&EF9F5R96YC97,@871T"!A#L@ M1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`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`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E"!A2!F;W(@=6YR96-O M9VYI>F5D('1A>"!B96YE9FET"!Y96%R65A&%M:6YA=&EO;B!B>2!T:&4@=F%R:6]U6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@1D].5#H@ M,3!P="!4:6UEF5D(%1A>"!"96YE9FET(%=H96X@82!.970@3W!E&5S+"8C.#(R,3L@=&\@69O6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E2!O9B!R979E M;G5E(&%N9"!C87-H(&9L;W=S(')E;&%T:6YG('1O(&-U2!A M9&]P=&EO;BXF(S$V,#L@5&AI65A65A M6QE M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T M86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@ M1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3X\3X\6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U) M3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2P@3F%N8WD@2F%N92!';V1F2!38VEE;F-E(&%N9"!$97-I9VXL($EN8RX@*'1O9V5T:&5R('1H92`F M(S@R,C`[1V]D9G)E>7,F(S@R,C$[*2!F;W(@:6YJ=6YC=&EV92!R96QI968@ M6QE.FYO6QE.FYO#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E7,L(&EN8VQU9&EN9R!T:&4@17-T871E(&]F($YA;F-Y($IA;F4@ M1V]D9G)E>2P@96YT97)E9"!I;G1O(&$@4V5T=&QE;65N="!!9W)E96UE;G0@ M86YD($UU='5A;"!'96YE7,@ M)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6UE;G1S(&]F("0\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG7,@87-S:6=N960L('1R86YS9F5R#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG65A M6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E"!S;VQI9#L@ M34%21TE..B`P:6X@,&EN(#!I;B`P+C(U:6X[(%=)1%1(.B`U-24[($)/4D1% M4BU#3TQ,05!313H@8V]L;&%P"!S;VQI9#L@0D]21$52+5))1TA4.B`C.65B M-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/ M3E0M4U193$4Z(&YO6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI M9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^(#QD:78^,C`Q-#PO M9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED M=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1) M3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P,#`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`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P M)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!! M1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)4 M24-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS M1#$P)3X@/&1I=CXQ,#`\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V9F M9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U35%E,13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!"04-+1U)/54Y$.B`C8V-E969F.R!&3TY4+5-)6D4Z(#$P<'0[(%9% M4E1)0T%,+4%,24=..B!B;W1T;VT[($9/3E0M5T5)1TA4.B`T,#`G('=I9'1H M/3-$,24^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@ M(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T M=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R)3X@/&1I=CXM/"]D M:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4 M+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!L969T M.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$24Y'+5))1TA4.B`U M<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E,13H@;F]R;6%L.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+1U)/54Y$.B`C9F9F M9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[ M($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U! M3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z M(&YO6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA#L@1D].5#H@,3!P="!4:6UE3PO8CX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2P@=&AE("8C.#(R,#M2:6=H=',F(S@R,C$[*2!P87EA8FQE('1O('1H M92!S=&]C:VAO;&1E2!C2!A;65N9&5D(&5F9F5C=&EV92!E86-H(&]F M("AI*2!-87D@,C,L(#(P,#@L("AI:2D@075G=7-T(#$X+"`R,#`Y(&%N9"`H M:6EI*2!*=6YE(#$X+"`R,#$T+B!4:&4@4FEG:'1S($%G2!T:&%T(&YU;6)E&5R8VES92!P2!A('-I;6EL87)L>2!C;VYS=&ET=71E9"!P87)T>2!T;R!M86ME M(&$@=&5N9&5R(&]R(&5X8VAA;F=E(&]F9F5R(')E&5R8VES92!O9B!T:&4@4FEG:'0@86YD('1H M92!A8W%U:7)E2P@82!S=&]C:VAO;&1E2!A;F0@:71S('-T;V-K:&]L M9&5R#L@1D].5#H@,3!P="!4:6UE#L@1D]. M5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2!L:6YE M(&]F(&-R961I="!A9W)E96UE;G0@*'-U8V@@87)R86YG96UE;G0L('1H92`F M(S@R,C`[,C`Q,B!%<75I='D@3&EN928C.#(R,3LI('=I=&@@1'5T8VAE2!$=71C:&5S2!,:6YE(&%S(&]F($UA>2`R M."P@,C`Q-"X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!,:6YE+B!4:&4@;6%X:6UU;2!A;6]U;G0@=&AA="!W92!W97)E M(&5N=&ET;&5D('1O('!U="!T;R!$=71C:&5S6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2!V;VQU;64@;V8@;W5R($-O;6UO;B!3=&]C:R!T2!P2!O9B!T:&4@87!P M;&EC86)L92!D2UF M:79E('!E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM M97,@3F5W(%)O;6%N)RPG2!S=6-H(&5X8V5S#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!H M96QD(&%T('1H870@=&EM92!W;W5L9"!E>&-E960@/&9O;G0@2!U;FQE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M&EM871E;'D@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG2!,:6YE('=E M6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE#L@ M1D].5#H@,3!P="!4:6UE&5C=71E9"!A M(&YE=R!E<75I='D@;&EN92!O9B!C2`R."P@,C`Q-"!W:&5R96)Y($1U=&-H97-S(&-O M;6UI='1E9"!T;R!P=7)C:&%S92P@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4:6UE2!I;B!O M=7(@9&ES8W)E=&EO;B!D2!F2!I2!,:6YE+B!792!M87D@9&5L:79E#L@1D].5#H@,3!P="!4:6UE28C M.#(Q-SMS($-O;6UO;B!3=&]C:R!D=7)I;F<@=&AE(&]N92!T2!I;6UE9&EA=&5L>2!F;VQL;W=I;F<@;W5R('!U="!N;W1I8V4N(%1H92!# M;VUP86YY(&AA2!P M;W)T:6]N(&]F(&%N>2!P=70L(&5X8V5P="!T:&%T('!O#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E2!H96QD(&%T('1H870@=&EM92!W M;W5L9"!E>&-E960@/&9O;G0@2!U;FQE6QE/3-$ M)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4 M+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P M<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@ M1D].5#H@,3!P="!4:6UE&5M<'0@9G)O;2!R96=I#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2!A M="!V87)I86)L92!P97)C96YT86=E65A"!M M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!O6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M#L@1D].5#H@,3!P="!4:6UE2!A9&1I=&EO;F%L(&]P=&EO;G,@;W(@9W)A;G1S(&EN('1H92!F M=71U2!G M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE2`U+"`R,#$P+"!O=7(@ M2!#;VUP96YS M871I;VX@4&QA;B!W:&EC:"!W87,@2!S:&%R96AO;&1E2`V+"`R,#$S("AT:&4@)B,X,C(P.S(P,3`@ M4&QA;B8C.#(R,3LI+B!4:&4@,C`Q,"!0;&%N('!R;W9I9&5S('1H870@=&AE M('1O=&%L(&YU;6)E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPGF5D M(&9O6QE/3-$)T9/3E0M1D%- M24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG"!M;VYT:',@96YD960@ M2G5N92`S,"P@,C`Q-"X@5V4@9W)A;G1E9"`\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@)U1I;65S($YE=R!2;VUA;B"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,RX@ M070@2G5N92`S,"P@,C`Q-"P@=&AE6QE/3-$)T9/ M3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!- M05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE#L@1D].5#H@,3!P="!4:6UE&5R8VES960@9F]R('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@ M,S`L(#(P,30@;W(@,C`Q,RX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB M;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE2!#;VUP96YS871I M;VX@4&QA;CPO8CX\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!& M3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P M="!4:6UE2`U+"`R,#$P+"!O=7(@2`V+"`R,#$S+B!!('!R:6UA2!# M;VUP96YS871I;VX@4&QA;B!I2!#;VUP96YS871I M;VX@4&QA;B!P2!B92!I2!#;VUP96YS871I;VX@4&QA;BX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[0TQ%05(Z(&)O=&@G/B`\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF M:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT M9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/&)R/CPO"!$:7-C;&]S=7)E(%M!8G-T6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3X\8CXF(S$V,#L\+V(^/"]D:78^(#QD M:78@2`D/&9O;G0@&EM871E;'D@)#QF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG'!I6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M&%B;&4@ M:6YC;VUE('1O(&]F9G-E="!T:&4@=&5M<&]R87)Y('1I;6EN9R!D:69F97)E M;F-E"!D M961U8W1I;VYS(&%T=')I8G5T86)L92!T;R!O<'1I;VXL('=A"!A"!B96YE9FET3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q8V,P,3@W M-5\T,#,U7S0Q9CE?.&4R-E]B9#DP869F,V0W9#0-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,6-C,#$X-S5?-#`S-5\T,68Y7SAE,C9?8F0Y,&%F M9C-D-V0T+U=O'0O:'1M;#L@8VAA6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EFEN9RP@9F]R('=O2!P871E;G1E9"!44$TN/"]D:78^(#QD:78@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'!L;VET($]40R!D2!C97)T86EN(&]F(%!322!087)E M;G0F(S@R,3<[&-L=7-I=F4L(')O>6%L='DM M9G)E92P@=V]R;&0M=VED92`H6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D]. M5#H@,3!P="!4:6UE2!F;W5N9"!T97)M#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6UE;G0@=&\@4%-)(%!A6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P M="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE"`P:6X@,&EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E2P@9&ES8VAA'!I2!E M>'1E;G-I;VYS('1H97)E;V8N($5I=&AE2!M87D@=&5R;6EN871E M('1H92!!;65N9&5D($QI8V5N2!O6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG2P@=V4@8V]N=')I8G5T960@:6X@1FES8V%L(#(P M,3`@)#QF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O M;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPGF%T M:6]N86P@97AP96YS97,@86YD(&=E;F5R86P@;6%R:V5T(&%N9"!I;FET:6%L M('!R;V1U8W0@979A;'5A=&EO;B!A;F0@86YA;'ES:7,N($%T($IU;F4@,S`L M(#(P,30L(&-A6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M2!04TD@4&%R96YT M+"!04TD@86YD('5S+CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@,3!P="!4 M:6UE2!B M96YE9FEC:6%R>2X@5V4@:&%V92!C;VYS;VQI9&%T960@=&AE($IO:6YT(%9E M;G1U6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG2`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;B6QE/3-$)T9/3E0M4TE:13H@,3!P="<^=VAI M8V@@=V4@=VEL;"!B96=I;B!A;6]R=&EZ:6YG('1H92!C;W-T(&]F(&EN=&%N M9VEB;&4@87-S970@;VYC92!P2P@8GD@=&AE M($IO:6YT(%9E;G1U6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6UE;G0@=V4@;6%D92!I;B!$96-E M;6)E'!E8W0@=&\@;6]D:69Y('1H92!* M;VEN="!696YT=7)E)B,X,C$W.W,@<')O9'5C="!D979E;&]P;65N="!P;&%N M'!E M8W0@=&AA="!T:&4@2F]I;G0@5F5N='5R92!W:6QL(&1E&5D.R<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!T:&4@=V5I9VAT960M879EF4@=&AE M('1R96%S=7)Y('-T;V-K(&UE=&AO9"!W:&EC:"!P2X\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@ M,C`Q,R!D:6QU=&EV92!E87)N:6YG2P@=&AA="!W97)E(&5X8VQU9&5D M(&9R;VT@=&AE(&5A2P@=VAI8V@@=V5R92!I;B!T:&4@ M;6]N97DL('1H870@=V5R92!E>&-L=61E9"!F6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@,"XR-6EN.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E&-E<'0@<&5R M('-H87)E(&%M;W5N=',I.CPO9&EV/B`\9&EV('-T>6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0G/B`F(S$V,#L\+V1I=CX@/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`Q,#`E M.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%, M24=..B!C96YT97([($9/3E0M4TE:13H@,3!P="<@8V]L"!-;VYT:',@16YD960\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO M='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4 M+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P M<'0G(&-O;'-P86X],T0R/B`\9&EV/DQO6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P M<'0G(&-O;'-P86X],T0R/B`\9&EV/D504SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P M="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G M(&-O;'-P86X],T0R/B`\9&EV/E-H87)E6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!72414 M2#H@,3`E.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/C,L,3,X/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24[ M($9/3E0M4TE:13H@,3!P="<^(#QD:78^*3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!72414 M2#H@,3`E.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/C`N,3D\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@ M1D].5"U325I%.B`Q,'!T)SX@/&1I=CXI/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=724142#H@,B4[($9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[ M/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!7 M24142#H@,24[($9/3E0M4TE:13H@,3!P="<^(#QD:78^*"0\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E M.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/C$L-S$Y/"]D:78^(#PO=&0^(#QT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24[($9/3E0M M4TE:13H@,3!P="<^(#QD:78^*3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E M.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/C`N,3$\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U3 M25I%.B`Q,'!T)SX@/&1I=CXI/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=7 M24142#H@,B4[($9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@ M,24[($9/3E0M4TE:13H@,3!P="<^(#QD:78^*"0\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E.R!&3TY4 M+5-)6D4Z(#$P<'0G/B`\9&EV/C,L.30R/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24[($9/3E0M4TE:13H@ M,3!P="<^(#QD:78^*3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E.R!&3TY4 M+5-)6D4Z(#$P<'0G/B`\9&EV/C`N,C0\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q M,'!T)SX@/&1I=CXI/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=724142#H@ M,B4[($9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24[($9/ M3E0M4TE:13H@,3!P="<^(#QD:78^*"0\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/C$L-#(Y/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!724142#H@,24[($9/3E0M4TE:13H@,3!P="<^ M(#QD:78^*3PO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/C`N,#D\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXI/"]D:78^(#PO=&0^(#PO='(^(#QT6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE: M13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M25I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE: M13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE: M13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL M93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U3 M25I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!& M3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD M:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE: M13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-! M3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^3W!T:6]N6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D M/B`\+W1R/B`\='(@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F M=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@ M5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S M;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58 M5"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI M9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D]. M5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U! M3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@ M5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V M,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U3 M25I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E' M3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\ M+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I% M.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@ M6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U! M3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I M=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P M="!S;VQI9#L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q M,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S M;VQI9#L@5$585"U!3$E'3CH@6QE/3-$ M)T-,14%2.F)O=&@[34%21TE.+51/4#H@,'!X.R!-05)'24XM0D]45$]-.B`P M<'@G(&%L:6=N/3-$;&5F=#Y$:6QU=&5D(&EN8V]M92AL;W-S*2!P97(@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O M=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I M=CXH)#PO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@ M1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@ M5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@ M;&5F=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXH)#PO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T M(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX@ M/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T M(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q M,'!T)SX@/&1I=CXH)#PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E' M3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T M(&1O=6)L93L@5$585"U!3$E'3CH@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E' M3CH@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58 M5"U!3$E'3CH@;&5F=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXH)#PO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U325I% M.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E' M3CH@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2!497AT($)L;V-K73PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78@3X\+V1I=CX@/&1I=B!S='EL93TS1"=# M3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE&-H86YG92!#;VUM:7-S:6]N("@F(S@R,C`[4T5#)B,X,C(Q M.RD@87!P;&EC86)L92!T;R!I;G1E'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3X\8CX\:3Y396%S;VYA;&ET>2!O9B!T:&4@0G5S M:6YE6QE/3-$)T-,14%2.F)O=&@[ M($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[ M5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!F2!O9B!E86-H(&-O;&0@2!D96-L:6YE6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U M=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R M/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!W:71H($=!05`L(')E M<75I'!E;G-E2!A;F0@97%U:7!M96YT(&%N9"!I;G1A;F=I8FQE(&%S"!V86QU871I;VYS(&%N9"!A#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE.FYO6QE/3-$9F]N="US='EL93IN M;W)M86P^)B,Q-S0[/"]S=7`^($-O;&0@4F5M961Y($]R86P@4W!R87DN(%=E M(&%L6QE/3-$9F]N="US='EL93IN;W)M86P^)B,Q-S0[/"]S=7`^($-O M;&0@4F5M961Y($]R86P@4W!R87D@86YD(%%U:6-K365L=',\6QE M/3-$9F]N="US='EL93IN;W)M86P^)B,Q-S0[/"]S=7`^('!R;V1U8W1S+"!A M;F0@3W)G86YI>#QS=7`@6QE.FYO2P@=V4@;6]N M:71O2!C=7-T;VUE2!O=&AE2!497AT($)L;V-K73PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78@2!O9B!T:&5S92!I;G9E&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M)SQD:78@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E7IE9"!T;R!D971E2!I;F-L=61E9"!R87<@ M;6%T97)I86PL('=O2P@86YD(&9I;FES:&5D(&=O M;V1S(&]F("0\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@)U1I;65S($YE M=R!2;VUA;B2X\+V1I=CX@/"]D:78^/'1A M8FQE(&)O&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\ M='(^/'1D/CPO=&0^/"]T2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)' M24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE M3X\8CX\:3Y02P@4&QA;G0@86YD($5Q=6EP M;65N=#PO:3X\+V(^/"]D:78^(#QD:78@2P@<&QA;G0@86YD(&5Q=6EP;65N="!A2UN:6YE('EE87)S.R!M86-H:6YE&5D.R<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^ M/"]T'0^)SQD:78@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-, M14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-) M6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P M="!4:6UE2!O9B!U6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG M#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE2!A;F0@ M9V5N97)A;&QY('=E(&1O(&YO="!R97%U:7)E(&-O;&QA=&5R86PN($]U2!L87)G92!N M871I;VYA;"!C:&%I;BP@2!A;F0@;&]C86P@ M2!I;7!A8W0@;W5R(&]V97)A;&P@97AP;W-U2!I;7!A8W0@=&AE('1I;6EN9R!A;F0@8V]L;&5C=&%B:6QI M='D@;V8@86UO=6YT&EM871E;'D@/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG#L@ M1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE&EM871E;'D@/&9O;G0@6QE M/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2X@02!S:6=N:69I8V%N="!P;W)T:6]N M(&]F(&]U2!P2!497AT($)L M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78@3X\+V1I=CX@/&1I=B!S M='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4+49!34E,63I4:6UE#L@1D].5#H@,3!P M="!4:6UE#L@1D].5#H@,3!P="!4:6UE6EN9R!A;6]U;G0@;V8@ M=&AE(&%S2!W M:&EC:"!T:&4@8V%R2!C M;VUP971I=&EO;CL@86YD(&=E;F5R86P@96-O;F]M:6,@86YD(&)U#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM& M3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M2!A;F0@8V]M<&%R86)I;&ET>2!I;B!F86ER('9A;'5E(&UE M87-UF5S('1H92!I;G!U=',@=7-E9"!T;R!M96%S=7)E(&9A:7(@ M=F%L=64N(%1H97-E('1I97)S(&EN8VQU9&4Z($QE=F5L(#$L(&1E9FEN960@ M87,@;V)S97)V86)L92!I;G!U=',@6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3X\8CX\:3Y&86ER(%9A;'5E(&]F($9I;F%N8VEA M;"!);G-T&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X\='(^/'1D M/CPO=&0^/"]T6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UEF5D(&%T('1H92!T:6UE(&]W;F5R#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2 M;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%2 M1TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E2!A2!F86QL&-E961E9"!D97-I9VYA=&5D(&5X<&ER871I;VX@ M9&%T97,@86YD("AI:6DI('=E('=I;&P@86-C97!T(')E='5R;G,@:6X@=&AE M(&5V96YT('1H870@=V4@9&ES8V]N=&EN=64@82!P2!F#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9 M.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO M='(^/"]T86)L93X\'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE. M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E#L@1D].5#H@ M,3!P="!4:6UE'!E;G-E9"!W:71H:6X@=&AE('!E2X@061V97)T:7-I;F<@86YD(&EN8V5N=&EV92!P2P@6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O M=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P M<'0[5$585"U)3D1%3E0Z(#`N-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3X\+V1I=CX@/&1I=B!S='EL93TS1"=#3$5!4CIB;W1H.R!&3TY4 M+49!34E,63I4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)W=I9'1H.C$P,"4[ M('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D M9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\2!497AT($)L;V-K M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78@#L@1D].5#H@,3!P="!4:6UEF4@86QL('-H87)E+6)A6UE;G1S('1O(&5M<&QO M>65E'!E;G-E(&EN('1H92!F:6YA M;F-I86P@2!C;VEN8VED97,@ M=VET:"!T:&4@=F5S=&EN9R!P97)I;V0N/"]D:78^(#QD:78@#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2P@9F]R('-H87)E+6)A'!E;G-E(&9O M"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@,C`Q,RP@=V4@ M8VAA6QE/3-$)T9/3E0M M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG2P@9F]R('-H87)E M+6)A'!E;G-E(&9O3X\8CX\:3Y687)I86)L92!);G1E6QE/3-$)T-,14%2.F)O=&@[($9/ M3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$58 M5"U)3D1%3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!C;VUP86YY+"!E;G1E2!#;VUP86YY($%G2!A;F0@9&5P=&@@;V8@<&5N971R871I;VX@;V8@86-T:79E(&UO M;&5C=6QE&5D.R<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T2!;4&]L:6-Y M(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/&1I=B!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE#L@1D].5#H@8F]L9"`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N M)RPG2X@4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O6QE/3-$)T9/3E0M1D%-24Q9.B`G5&EM97,@ M3F5W(%)O;6%N)RPG2X@4F5S96%R8V@@86YD(&1E=F5L;W!M M96YT(&-O2!R96QA=&5D('1O(&YE=R!P2!P&5D.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,#X\='(^/'1D/CPO=&0^/"]T"P@4&]L:6-Y(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\ M=&0@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S M($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N,C5I M;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E2!A<'!R;V%C:"!W:&EC:"!R97%U:7)E"!C;VYS97%U96YC97,L('=E(&=E;F5R86QL>2!C;VYS:61E M2!T:6UI;F<@9&EF9F5R96YC97,@871T"!A#L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%- M24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1% M3E0Z(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E"!P;W-I=&EO;G,N(%1H92!F:7)S="!S M=&5P(&ES('1O(&5V86QU871E('1H92!T87@@<&]S:71I;VX@9F]R(')E8V]G M;FET:6]N(&)Y(&1E=&5R;6EN:6YG(&EF('1H92!W96EG:'0@;V8@879A:6QA M8FQE(&5V:61E;F-E(&EN9&EC871E2X@5&AE('-E M8V]N9"!S=&5P(&ES('1O(&UE87-U"!B96YE9FET(&%S('1H M92!L87)G97-T(&%M;W5N="!W:&EC:"!I#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9 M.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z M(#`N,C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E"!A2!F;W(@=6YR96-O9VYI>F5D('1A>"!B M96YE9FET"!Y96%R65A M&%M:6YA=&EO M;B!B>2!T:&4@=F%R:6]U6QE/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE M9#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\ M+W1D/CPO='(^/"]T86)L93X\2!497AT($)L;V-K73PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQD:78@#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)T9/3E0M1D%-24Q9.B`G5&EM97,@3F5W(%)O;6%N)RPG#L@ M1D].5#H@,3!P="!4:6UEF5D(%1A>"!"96YE9FET(%=H96X@82!.970@3W!E M&5S+"8C.#(R,3L@=&\@6QE/3-$)T9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)RPG6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA M;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!O M9B!R979E;G5E(&%N9"!C87-H(&9L;W=S(')E;&%T:6YG('1O(&-U2!A9&]P=&EO;BXF(S$V,#L@5&AI65A65A6QE/3-$)W=I M9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C:6YG/3-$ M,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!/8FQI9V%T:6]N(%M486)L92!497AT($)L;V-K73PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)SQD:78@#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I M;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[5$585"U)3D1%3E0Z(#`N M-6EN.R!-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE3Y792!H879E(&5S M=&EM871E9"!F=71U65A6QE/3-$)T-,14%2.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE M=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E"!S;VQI9#L@34%21TE..B`P:6X@,&EN(#!I;B`P+C(U:6X[(%=)1%1( M.B`U-24[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P"!S;VQI9#L@0D]21$52 M+5))1TA4.B`C.65B-F-E(#!P>"!S;VQI9"<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!A;&EG;CTS1&QE9G0^(#QT6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=. M.B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!C96YT97([($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E"!S;VQI9#L@5$585"U!3$E'3CH@8V5N M=&5R.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE"!S;VQI9#L@1D].5"U714E'2%0Z(#0P,"<@=VED=&@],T0Q-B4^ M(#QD:78^,C`Q-#PO9&EV/B`\+W1D/B`\=&0@"!S;VQI9#L@1D].5"U714E' M2%0Z(#0P,"<@=VED=&@],T0Q)3X@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N M;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M5$]0.B`C,#`P M,#`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`Q M,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P M)R!W:61T:#TS1#$P)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U19 M3$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q% M.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I% M.B`Q,'!T.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@ M-#`P)R!W:61T:#TS1#$P)3X@/&1I=CXQ,#`\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/ M3E0M4U193$4Z(&YO6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-464Q%.B!N;W)M86P[(%!!1$1)3D#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D%# M2T=23U5.1#H@(V9F9F9F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-!3"U! M3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$P)3X@ M/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4U193$4Z(&YO#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D%#2T=23U5.1#H@(V-C965F9CL@1D].5"U325I%.B`Q,'!T.R!615)424-! M3"U!3$E'3CH@8F]T=&]M.R!&3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$R M)3X@/&1I=CXM/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4 M+4%,24=..B!L969T.R!&3TY4+5-464Q%.B!N;W)M86P[($9/3E0M1D%-24Q9 M.B!4:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U35%E,13H@;F]R;6%L.R!0041$ M24Y'+5))1TA4.B`U<'@[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-4 M64Q%.B!N;W)M86P[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($9/3E0M4U193$4Z(&YO6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F=#L@1D].5"U35%E, M13H@;F]R;6%L.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!"04-+ M1U)/54Y$.B`C9F9F9F9F.R!&3TY4+5-)6D4Z(#$P<'0[(%9%4E1)0T%,+4%, M24=..B!B;W1T;VT[($)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED.R!& M3TY4+5=%24=(5#H@-#`P)R!W:61T:#TS1#$E/B`\9&EV/B0\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O M=6)L93L@5$585"U!3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0M4U193$4Z(&YO6QE M/3-$)W=I9'1H.C$P,"4[('1A8FQE+6QA>6]U=#IF:7AE9#LG(&-E;&QS<&%C M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R/CQT9#X\+W1D/CPO='(^/"]T M86)L93X\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)T-,14%2 M.F)O=&@[($9/3E0M1D%-24Q9.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z M(#$P<'0[34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\ M=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C M96YT97([($9/3E0M4TE:13H@,3!P="<@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M4TE: M13H@,3!P="<@8V]L6QE/3-$)T9/3E0M4TE: M13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!C96YT97([($9/3E0M4TE:13H@,3!P="<@8V]L"!-;VYT:',@16YD960\+V1I=CX@/"]T9#X@/'1D M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^ M(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N M=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0Q,#X@/&1I=CY*=6YE M(#,P+"`R,#$T/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U! M3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X],T0Q,#X@ M/&1I=CY*=6YE(#,P+"`R,#$S/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C M,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI M9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P M86X],T0Q,#X@/&1I=CY*=6YE(#,P+"`R,#$T/"]D:78^(#PO=&0^(#QT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#$P<'0G M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P M<'0G(&-O;'-P86X],T0Q,#X@/&1I=CY*=6YE(#,P+"`R,#$S/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-) M6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\+W1R/B`\='(@ M6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O M;'-P86X],T0R/B`\9&EV/DQO6QE/3-$ M)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O M;'-P86X],T0R/B`\9&EV/D504SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI M9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P M86X],T0R/B`\9&EV/E-H87)E6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@ M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X] M,T0R/B`\9&EV/DQO6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@ M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X] M,T0R/B`\9&EV/D504SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)!0TM'4D]53D0M0T], M3U(Z(')G8B@R,#0L,C,X+#(U-2D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG M/B`\=&0@6QE/3-$)U=) M1%1(.B`R)3L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@ M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q M)3L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E.R!& M3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/C$V+#DT-#PO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U=)1%1(.B`R M)3L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@ M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D]. M5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E.R!&3TY4+5-) M6D4Z(#$P<'0G/B`\9&EV/C$U+#@T-3PO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U=)1%1(.B`R)3L@1D]. M5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I% M.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E.R!&3TY4+5-)6D4Z(#$P M<'0G/B`\9&EV/C$V+#6QE/3-$)U=)1%1(.B`R)3L@1D].5"U325I% M.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T M)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!724142#H@,3`E.R!&3TY4+5-)6D4Z(#$P<'0G/B`\ M9&EV/C$U+#3L@1D].5"U325I%.B`Q,'!T)SX@/&1I M=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@ M,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P M<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE: M13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I% M.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@ M,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C,X+#(U-2D[ M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@3L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CY$:6QU=&EV M97,Z/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@ M,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@ M6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV M/B`\+W1D/B`\=&0@6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P M<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE: M13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS M1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF M(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^ M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO M9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G/B`\ M9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T M.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@1D].5"U325I% M.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T9#X@/'1D('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q M-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G M/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4 M+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z(#$P<'0G/B`\9&EV/B8C,38P M.SPO9&EV/B`\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^(#QD:78^ M)B,Q-C`[/"]D:78^(#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H=#L@1D].5"U325I%.B`Q,'!T)SX@/&1I=CXF(S$V,#L\+V1I=CX@/"]T M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@ M,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO=&0^(#PO='(^(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^(#QD:78^)B,Q-C`[/"]D:78^(#PO M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5-)6D4Z M(#$P<'0G/B`\9&EV/B8C,38P.SPO9&EV/B`\+W1D/B`\=&0@6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C,X+#(U M-2D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@3L@4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U3 M25I%.B`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`^/'1R/CQT9#X\+W1D/CPO='(^/"]T86)L93X\'0O:F%V M87-C3X-"B`@("`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`@("`@(#QT9"!C;&%S'0^)S$P('EE87)S/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)S<@>65A'0^)S4@>65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@ M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^)SQS<&%N/CPO M6UE M;G1S(&9O'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO6%L=&EE M3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'1U86PI("A54T0@)"D\8G(^/"]S=')O M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO&EM=6T@06UO=6YT($5N=&ET;&5D(%1O(%!U="!4;R!);G9E3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!2:6=H="!4;R!5 M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO2!,:6YE($]F($-R961I=#PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO2!3 M:&%R92!"87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!$965M960@0V%N M8V5L;&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`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`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q8V,P M,3@W-5\T,#,U7S0Q9CE?.&4R-E]B9#DP869F,V0W9#0-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,6-C,#$X-S5?-#`S-5\T,68Y7SAE,C9?8F0Y M,&%F9C-D-V0T+U=O'0O:'1M;#L@8VAA&5S("A$971A M:6QS(%1E>'1U86PI("A54T0@)"D\8G(^26X@36EL;&EO;G,L('5N;&5S&5S(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO'0^)T9I"!!"!!3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q8V,P,3@W-5\T,#,U7S0Q M9CE?.&4R-E]B9#DP869F,V0W9#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO,6-C,#$X-S5?-#`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`S-5\T,68Y7SAE,C9?8F0Y M,&%F9C-D-V0T+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\Q8V,P,3@W-5\T,#,U7S0Q9CE?.&4R-E]B9#DP M869F,V0W9#0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,6-C,#$X M-S5?-#`S-5\T,68Y7SAE,C9?8F0Y,&%F9C-D-V0T+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC&UL/@T*+2TM+2TM/5].97AT4&%R=%\Q8V,P D,3@W-5\T,#,U7S0Q9CE?.&4R-E]B9#DP869F,V0W9#0M+0T* ` end XML 16 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies
6 Months Ended

Jun. 30, 2014

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2013. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the six months ended June 30, 2014 are not necessarily indicative of operating results that may be achieved over the course of the full year.

Seasonality of the Business

Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.

Use of Estimates

The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

Our primary product, Cold-EEZE^Ò Cold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE^® Cold Remedy lozenges, we market and distribute a variety of Cold-EEZE^® Cold Remedy QuickMelts^® and a Cold-EEZE^® Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix^®”). Each of the Cold-EEZE^® Cold Remedy Oral Spray and QuickMelts^® products, and Organix^® products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.

Cash Equivalents

We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.

Inventory Valuation

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At June 30, 2014 and December 31, 2013, inventory included raw material, work in progress and packaging amounts of $1.5 million and $1.1 million, respectively, and finished goods of $1.7 million and $1.4 million, respectively.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost. We compute depreciation using the straight-line method for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures – five years.

Concentration of Risks

Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC and other personal care products in order to compete on a national level and/or international level.

Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.

We maintain cash and cash equivalents with certain major financial institutions. As of June 30, 2014, our cash balance was $7.3 million and our bank balance was $7.6 million. Of the total bank balance, $636,000 was covered by federal depository insurance and $6.9 million was uninsured at June 30, 2014.

Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. At June 30, 2014 and December 31, 2013, our largest accounts receivable balances are with two customers representing approximately 48% and two customers representing 46%, respectively, of our total trade receivable balance. As a consequence of an evaluation of our customer’s financial condition, payment patterns, balance due us and other factors, we did not offset our account receivable with an allowance for bad debt at June 30, 2014 and December 31, 2013.

Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately 91% and 91% of total revenues for each of the six months ended June, 2014 and 2013, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three and six months ended June 30, 2014 and 2013, our net sales were principally related to domestic markets.

Long-lived Assets

We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.

Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Fair Value of Financial Instruments

Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments.

Revenue Recognition

Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.

As of June 30, 2014, accrued advertising and other allowances included (i) $1.7 million for estimated future sales returns and (ii) $1.3 million for cooperative incentive promotion costs. As of December 31, 2013, accrued advertising and other allowances included (i) $1.5 million for estimated future sales returns and (ii) $1.3 million for cooperative incentive promotion costs. Additionally, as of June 30, 2014 and December 31, 2013, we included a provision for sales allowances of $37,000 and $128,000, respectively, which are reported as a reduction to sales and account receivables.

Advertising and Incentive Promotions

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended June 30, 2014 and 2013 were $1.1 million and $527,000, respectively. Advertising and incentive promotion expenses incurred for the six months ended June 30, 2014 and 2013 were $4.5 million and $4.4 million, respectively. Included in prepaid expenses and other current assets was $180,000 and $1.3 million at June 30, 2014 and December 31, 2013, respectively, relating to prepaid advertising and promotion expenses.

Shipping and Handling

Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.

Stock Based Compensation

We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.

Stock and stock options for the purchase of our common stock, $0.0005 par value, (“Common Stock”) have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 4). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended June 30, 2014 and 2013, we charged to operations $64,000 and $40,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned. For the six months ended June 30, 2014 and 2013, we charged to operations $128,000 and $79,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.

Variable Interest Entity

On March 22, 2010, we, Phosphagenics Limited (“PSI Parent”), an Australian corporation, Phosphagenics Inc. (“PSI”), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the “Joint Venture”), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the “LLC Agreement”) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM™ technology (“TPM”). TPM facilitates the delivery and depth of penetration of active molecules in pharmaceutical, nutraceutical, and other products. Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture. The Joint Venture, of which we own a 50% membership interest, qualifies as a variable interest entity (“VIE”), we are the current primary beneficiary and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010.

Research and Development

Research and development costs are charged to operations in the period incurred. Research and development costs for the three months ended June 30, 2014 and 2013 were $273,000 and $216,000, respectively. Research and development costs for the six months ended June 30, 2014 and 2013 were $551,000 and $404,000, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.

Income Taxes

We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 5).

We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.

As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits. The tax years 2006 and forward remain open to examination by the IRS. The tax years 2004 and forward remain open to examination by the various state taxing authorities to which we are subject.

Recently Issued Accounting Standards

In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”). ASU 2013-11 amends Accounting Standards Codification 740, “Income Taxes,” to require that in certain cases, an unrecognized tax benefit, or portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date, and retrospective application is permitted. The adoption of ASU 2013-11 did not have a material impact on our consolidated financial position, results from operations or cash flows.

In May 2014, the FASB issued new accounting guidance, namely ASU No. 2014-09, “Revenue from Contracts with Customers”, on revenue recognition. The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. There is no option for early adoption. This ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2016. We are currently evaluating the impact of the new guidance on our consolidated financial statements.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 17 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified

Jun. 30, 2014

Dec. 31, 2013

ASSETS

Cash and cash equivalents (Note 2) $ 7,350 $ 1,638

Accounts receivable, net 2,343 5,319

Inventory (Note 2) 3,248 2,521

Prepaid expenses and other current assets 733 1,801

Total current assets 13,674 11,279

Property, plant and equipment, net of accumulated depreciation and amortization of $4,197 and $4,064, respectively (Note 2) 2,509 2,564

Intangible asset, licensed technology (Note 6) 3,577 3,577

Total assets 19,760 17,420

LIABILITIES:

Accounts payable 1,399 1,011

Accrued advertising and other allowances 3,078 2,847

Other current liabilities 1,475 766

Total current liabilities 5,952 4,624

Other long term obligations (Note 3) 200 200

Commitments and contingencies (Note 3) 0 0

STOCKHOLDERS' EQUITY:

Common Stock, $.0005 par value; authorized 50,000,000; issued: 24,635,266 and 21,437,059 shares, respectively (Note 4) 12 11

Additional paid-in-capital 48,560 43,607

Accumulated deficit (9,327) (5,385)

Treasury stock, at cost 5,336,053 and 5,336,053 shares, respectively (25,637) (25,637)

Total stockholders' equity 13,608 12,596

Total liabilities and stockholders' equity $ 19,760 $ 17,420

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

No definition available.

+ Details

Name: us-gaap_AccruedMarketingCostsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 18 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Cash flows from operating activities:

Net loss $ (3,942) $ (1,429)

Adjustments to reconcile net loss to net cash provided by operating activities:

Depreciation and amortization 133 120

Share-based compensation expense 128 79

Changes in operating assets and liabilities:

Accounts receivable 2,976 4,281

Inventory (727) (1,237)

Accounts payable 388 (269)

Accrued advertising and other allowances 231 (576)

Other operating assets and liabilities, net 1,777 2,572

Net cash provided by operating activities 964 3,541

Cash flows from investing activities:

Capital expenditures (78) (250)

Net cash used in investing activities (78) (250)

Cash flows from financing activities:

Proceeds from issuance of common stock 4,826 195

Net cash provided by financing activities 4,826 195

Net increase in cash and cash equivalents 5,712 3,486

Cash and cash equivalents at beginning of period 1,638 572

Cash and cash equivalents at end of period $ 7,350 $ 4,058

X

- Definition

Net change during the period in the amount of Accrued advertising and other allowances at the period end.

+ References

No definition available.

+ Details

Name: prph_IncreaseDecreaseInAccruedMarketingCosts

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other assets used in operating activities less other operating liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets and liabilities, other noncurrent assets and liabilities, or a combination of other current and noncurrent assets and liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 19 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Investment in a Joint Venture (Details Textual) (USD $)
6 Months Ended 12 Months Ended

Jun. 30, 2014

Dec. 31, 2012

Dec. 31, 2010

Dec. 31, 2013

Jun. 30, 2013

Schedule of Investments [Line Items]

Stock Issued During Period, Value, New Issues $ 4,826,000

Payments To Fund Joint Venture Investments 500,000

Maximum Amount Committed Towards Contributions In Joint Venture 2,000,000

Cash and cash equivalents 7,350,000 572,000 1,638,000 4,058,000

Acquisition of product license 3,600,000

Finite-Lived Intangible Assets, Useful Life (in years) 12 years 9 months

Ownership Percentage In Joint Venture 50.00%

Payments For Legal Settlements 2,100,000

PSI Parent [Member]

Schedule of Investments [Line Items]

Stock Issued During Period, Shares, New Issues 1,440,000

Stock Issued During Period, Value, New Issues 2,600,000

Payments To Fund Joint Venture Investments 1,000,000

Cash and cash equivalents $ 374,000

X

- Definition

Maximum amount committed towards contributions in joint venture

+ References

No definition available.

+ Details

Name: prph_MaximumAmountCommittedTowardsContributionsInJointVenture

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Ownership percentage in joint venture.

+ References

No definition available.

+ Details

Name: prph_OwnershipPercentageInJointVenture

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash outflow associated with the funding of joint venture investments.

+ References

No definition available.

+ Details

Name: prph_PaymentsToFundJointVentureInvestments

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of cash paid for the settlement of litigation or for other legal issues during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_PaymentsForLegalSettlements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ScheduleOfInvestmentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 20 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Earnings (Loss) Per Share (Details Textual)
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Earnings Loss Per Share [Line Items]

Class of Warrant or Right, Outstanding 1,632,500 1,301,500 1,632,500 1,301,500

Common Stock Equivalents [Member]

Earnings Loss Per Share [Line Items]

Weighted Average Number Diluted Shares Outstanding Adjustment, Total 559,318 359,271 571,736 401,849

X

- Details

Name: prph_EarningsLossPerShareLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 21 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 22 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Organization and Business
6 Months Ended

Jun. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1 – Organization and Business

ProPhase Labs, Inc. (“we”, “us” or the “Company”), organized under the laws of the State of Nevada, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (“OTC”) drug, natural base health products along with supplement, personal care and cosmeceutical products.

Our primary business is the manufacture, distribution, marketing and sale of OTC cold remedy products to consumers through national chain, regional, specialty and local retail stores. Our flagship brand is Cold-EEZE^Ò Cold Remedy and our principal product is Cold-EEZE^Ò Cold Remedy zinc gluconate lozenges, proven in clinical studies to reduce the duration of the common cold. In addition to Cold-EEZE^® Cold Remedy lozenges, we market and distribute non-lozenge forms of our proprietary zinc gluconate formulation, (i) Cold-EEZE^® Cold Remedy QuickMelts^® and (ii) Cold-EEZE^® Cold Remedy Oral Spray. Cold-EEZE^® Cold Remedy Oral Spray is a liquid form of our zinc gluconate formulation that is sprayed in the mouth. Cold-EEZE^® Cold Remedy QuickMelts^® are fast dissolving tablets that are taken orally. Cold-EEZE^Ò Cold Remedy is an established product in the health care and cold remedy market. For the three and six months ended June 30, 2014 and 2013, we operated in one reporting segment and our revenues have come principally from our OTC cold remedy products.

We use a December 31 year-end for financial reporting purposes. References herein to the fiscal year ended December 31, 2014 shall be the term “Fiscal 2014” and references to other “Fiscal” years shall mean the year, which ended on December 31 of the year indicated. The term “we”, “us” or the “Company” as used herein also refer, where appropriate, to the Company, together with its subsidiaries unless the context otherwise requires.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Balance Sheets [Parenthetical] (USD $)
In Thousands, except Share data, unless otherwise specified

Jun. 30, 2014

Dec. 31, 2013

Accumulated depreciation (in dollars) $ 4,197 $ 4,064

Common Stock, par value (in dollars per share) $ 0.0005 $ 0.0005

Common Stock, shares authorized 50,000,000 50,000,000

Common Stock, shares issued 24,635,266 21,437,059

Treasury stock, shares (in shares) 5,336,053 5,336,053

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 24 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Details Textual) (USD $)
3 Months Ended 6 Months Ended 12 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2010

Limited Liability Company Agreement [Member]

Jun. 30, 2014

Estimated Future Sales Return [Member]

Dec. 31, 2013

Estimated Future Sales Return [Member]

Jun. 30, 2014

Cooperative Incentive [Member]

Dec. 31, 2013

Cooperative Incentive [Member]

Jun. 30, 2014

Accounts Receivable [Member]

Two Customer [Member]

Dec. 31, 2013

Accounts Receivable [Member]

Two Customer [Member]

Jun. 30, 2014

Sales Revenue, Goods, Net [Member]

Jun. 30, 2013

Sales Revenue, Goods, Net [Member]

Jun. 30, 2014

Building and Building Improvements [Member]

Maximum [Member]

Jun. 30, 2014

Building and Building Improvements [Member]

Minimum [Member]

Jun. 30, 2014

Machinery and Equipment [Member]

Maximum [Member]

Jun. 30, 2014

Machinery and Equipment [Member]

Minimum [Member]

Jun. 30, 2014

Computer Software, Intangible Asset [Member]

Jun. 30, 2014

Furniture and Fixtures [Member]

Accounting Policies [Line Items]

Cash and Cash Equivalents, At Carrying Value $ 7,350,000 $ 4,058,000 $ 7,350,000 $ 4,058,000 $ 1,638,000 $ 572,000

Cash, FDIC Insured Amount 636,000 636,000

Cash, Uninsured Amount 6,900,000 6,900,000

Inventory, Work in Process and Raw Materials 1,500,000 1,500,000 1,100,000

Inventory, Finished Goods 1,700,000 1,700,000 1,400,000

Due from Banks 7,600,000 7,600,000

Concentration Risk, Percentage 48.00% 46.00% 91.00% 91.00%

Provision of Sales Allowance 37,000 128,000

Accrued Liabilities 1,700,000 1,500,000 1,300,000 1,300,000

Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage 50.00%

Marketing and Advertising Expense 1,100,000 527,000 4,500,000 4,400,000

Prepaid Advertising And Incentive Promotions 180,000 180,000 1,300,000

Research and development 273,000 216,000 551,000 404,000

Common Stock, par value (in dollars per share) $ 0.0005 $ 0.0005 $ 0.0005

Share-based compensation expense $ 64,000 $ 40,000 $ 128,000 $ 79,000

Property, Plant and Equipment, Useful Life 39 years 10 years 7 years 3 years 3 years 5 years

X

- Details

Name: prph_AccountingPoliciesLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of consideration paid in advance and included in prepaid expenses and other current assets for advertising and incentive promotions that provides economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

No definition available.

+ Details

Name: prph_PrepaidAdvertisingAndIncentivePromotions

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph a

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph 5

-Article 9

+ Details

Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.

+ References

No definition available.

+ Details

Name: us-gaap_CashFDICInsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.

+ References

No definition available.

+ Details

Name: us-gaap_CashUninsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

A bank's noninterest bearing demand deposits in other banks (such as correspondents).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.1)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 9

+ Details

Name: us-gaap_DueFromBanks

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3),(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryWorkInProcessAndRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The total expense recognized in the period for promotion, public relations, and brand or product advertising.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_MarketingAndAdvertisingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

No definition available.

+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate selling price reductions recognized during an accounting period including, but not limited to, the sale of defective or nonconforming goods, a strategy to increase sales (generally over the short-term), move slow-moving items, develop distribution channels, or reward valuable customers. Allowances are a deduction from gross revenue in arriving at net revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesAllowancesGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 5A

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6759159-111685

+ Details

Name: us-gaap_VariableInterestEntityOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 25 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document And Entity Information
6 Months Ended

Jun. 30, 2014

Aug. 12, 2014

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2014

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q2

Entity Registrant Name ProPhase Labs, Inc.

Entity Central Index Key 0000868278

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Trading Symbol PRPH

Entity Common Stock, Shares Outstanding 19,299,213

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 26 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies (Details) (USD $)
In Thousands, unless otherwise specified

Jun. 30, 2014

Commitments And Contingencies [Line Items]

2014 $ 641

2015 1,140

2016 100

2017 0

2018 0

Total 1,881

Employment Contracts [Member]

Commitments And Contingencies [Line Items]

2014 541

2015 1,040

2016 0

2017 0

2018 0

Total 1,581

Settlement Agreement [Member]

Commitments And Contingencies [Line Items]

2014 100

2015 100

2016 100

2017 0

2018 0

Total $ 300

X

- Details

Name: prph_CommitmentsAndContingenciesLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the fifth fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInFifthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the fourth fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInFourthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the next fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the second fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInSecondYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the third fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInThirdYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 27 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Net sales (Note 2) $ 1,797 $ 1,939 $ 7,968 $ 9,481

Cost of sales (Note 2) 1,005 1,011 3,196 3,214

Gross profit 792 928 4,772 6,267

Operating expenses:

Sales and marketing 852 709 3,849 4,072

Administration 2,804 1,721 4,311 3,216

Research and development 273 216 551 404

Total operating expense 3,929 2,646 8,711 7,692

Loss from operations (3,137) (1,718) (3,939) (1,425)

Interest income 1 1 1 1

Interest expense (2) (2) (4) (5)

Loss before income tax (3,138) (1,719) (3,942) (1,429)

Income tax (Note 5) 0 0 0 0

Net loss $ (3,138) $ (1,719) $ (3,942) $ (1,429)

Basic and diluted loss per share:

Net loss (in dollors per share) $ (0.19) $ (0.11) $ (0.24) $ (0.09)

Weighted average common shares outstanding:

Basic and diluted (in shares) 16,944 15,845 16,709 15,799

X

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a),(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35710027&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.

+ References

No definition available.

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).

+ References

No definition available.

+ Details

Name: us-gaap_InterestAndOtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total amount of expenses directly related to the marketing or selling of products or services.

+ References

No definition available.

+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 28 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Investment in a Joint Venture
6 Months Ended

Jun. 30, 2014

Investments in and Advances to Affiliates, Schedule of Investments [Abstract]

Investments in and Advances to Affiliates, Schedule of Investments [Text Block]

Note 6 – Investment in a Joint Venture

On March 22, 2010, we, PSI Parent, PSI and the Joint Venture entered into the LLC Agreement of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM.

In connection with the LLC Agreement, PSI Parent granted to us, pursuant to the terms of a License Agreement, dated March 22, 2010 (the “Original License Agreement”), (i) an exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit OTC drugs and certain other products that embody certain of PSI Parent’s TPM-related patents and related know-how (collectively, the “PSI Technology”) and (ii) a non-exclusive, royalty-free, world-wide (subject to certain limitations), paid-up license to exploit certain compounds that embody the PSI Technology for use in a product combining one or more of such compounds with an OTC drug or in a product that is part of a regimen that includes the application of an OTC drug.

The Joint Venture is managed by a four-person Board of Managers, with two managers appointed by each member. The LLC Agreement contains other normally found terms in such arrangements, including provisions relating to governance of the Joint Venture, indemnification obligations of the Joint Venture, allocation of profits and losses, the distribution of funds to the members and restrictions on transfer of a member’s interest.

Pursuant to the Original License Agreement, we issued 1,440,000 shares of our Common Stock having an aggregate value of approximately $2.6 million to PSI Parent (such shares, the “PSI Shares”), and made a one-time payment to PSI Parent of $1.0 million.

In accordance with a Contribution Agreement, dated March 22, 2010 (the “Contribution Agreement”), by and among us, PSI Parent, PSI, and the Joint Venture, we transferred, conveyed and assigned to the Joint Venture all of our rights, title and interest in, to and under the Original License Agreement, and the Joint Venture assumed, and undertook to pay, discharge and perform when due, all of our liabilities and obligations under and arising pursuant to the Original License Agreement (such actions, collectively, the “Assignment and Assumption”).

Pursuant to the Contribution Agreement and in order to reflect the Assignment and Assumption, we, PSI Parent and the Joint Venture entered into an Amended and Restated License Agreement, dated March 22, 2010 (the “Amended License Agreement”), which amends and restates the Original License Agreement to reflect that the Joint Venture is the licensee thereunder and which otherwise contains substantially the same terms as the Original License Agreement. The Joint Venture has the right to grant one or more sub-licenses of the rights granted under the Amended License Agreement to one or more third parties for reasonable consideration in any part of the applicable territory. The Amended License Agreement provides that PSI Parent shall not, directly or through third parties, exploit the covered intellectual property during the term thereof, subject to certain limitations. The Amended License Agreement will remain in effect until the expiration of the last to expire of the patents included within the PSI Technology or any extensions thereof. Either party may terminate the Amended License Agreement upon written notice to the other party in the event of certain events involving bankruptcy or insolvency. The Amended License Agreement also contains, among other things, provisions concerning the treatment of confidential information, the ownership of intellectual property and indemnification obligations.

Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture. PSI Parent will conduct and oversee much of the product development, formulation, testing and other research and development needed by the Joint Venture, and we will oversee much of the production, distribution, sales and marketing. The LLC Agreement provides that each member may be required, from time to time and subject to certain limitations, to make capital contributions to the Joint Venture to fund its operations, in accordance with agreed upon budgets for products to be developed. Specifically, we contributed in Fiscal 2010 $500,000 in cash as initial capital and we are committed to fund up to $2.0 million, subject to agreed upon budgets (which have not been established to date), toward the initial development and marketing costs of new products for the Joint Venture. The Joint Venture has not engaged in any financial transactions, other than organizational expenses and general market and initial product evaluation and analysis. At June 30, 2014, cash and cash equivalents includes $374,000 which is expected to be used by the Joint Venture to fund future product development initiatives currently under consideration by PSI Parent, PSI and us.

Our determination is that the Joint Venture qualifies as a VIE and that we are the primary beneficiary. We have consolidated the Joint Venture financial statements beginning with the quarter ended March 31, 2010. In Fiscal 2010, we recorded the $3.6 million payment noted above representing the estimated fair value to acquire the product license as an intangible asset. We currently estimate the expected remaining useful life of the product license to be approximately 12.75 years which we will begin amortizing the cost of intangible asset once product development and commercialization begins. Thus far, the Joint Venture has not generated any revenues and its expenses, including organizational, marketing analysis and preliminary formulations have been absorbed by the respective Joint Venture members. Furthermore, the liabilities and other obligations incurred, if any, by the Joint Venture is without recourse to us and do not create a claim on our general assets.

Due to multiple factors affecting our capital position, including (i) the $2.1 million payment we made in December 2012 under the Settlement Agreement (see Note 3) and (ii) some of the product market research performed, we expect to modify the Joint Venture’s product development plans to stagger and/or defer into future periods certain product development initiatives due to the pre-commercialization investments required. As of June 30, 2014, we have not established a formal commercialization program timeline pending the results from additional clinical studies. We do not project that any such OTC products will be available for shipment within the next twelve months. We do not expect that the Joint Venture will derive any meaningful revenues until its commercialization efforts are completed which is not expected to occur until Fiscal 2015 at the earliest.

X

- Details

Name: us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the information summarizing investments in and advances to majority-owned subsidiaries, other controlled companies, and other affiliates. It reflects specified information about ownership, financial results from, and financial position in such entities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 6

-Subparagraph (SX 210.12-14)

-URI http://asc.fasb.org/extlink&oid=34726532&loc=d3e611322-123010

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 14

-Article 12

+ Details

Name: us-gaap_InvestmentsInAndAdvancesToAffiliatesScheduleOfInvestmentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes
6 Months Ended

Jun. 30, 2014

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

Note 5 – Income Taxes

As of December 31, 2013, we have net operating loss carry-forwards of approximately $34.7 million for federal purposes that will expire beginning in Fiscal 2020 through Fiscal 2032. Additionally, there are net operating loss carry-forwards of approximately $20.4 million for state purposes that will expire beginning in Fiscal 2018 through Fiscal 2032. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock are assured, a valuation allowance equaling the total deferred tax asset is being provided. Management believes that this allowance is required due to the uncertainty of realizing these tax benefits in the future. The uncertainty arises largely due to substantial marketing and research and development costs.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Earnings (Loss) Per Share (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Earnings Loss Per Share [Line Items]

Basic earnings (loss) per share $ (3,138) $ (1,719) $ (3,942) $ (1,429)

Basic earnings (loss) per share - Shares (in shares) 16,944 15,845 16,709 15,799

Basic earnings (loss) per share - EPS (in dollars per share) $ (0.19) $ (0.11) $ (0.24) $ (0.09)

Dilutives:

Options 0 0 0 0

Options - Shares (in shares) 0 0 0 0

Options - EPS (in dollars per share) $ 0 $ 0 $ 0 $ 0

Diluted income (loss) per share $ (3,138) $ (1,719) $ (3,942) $ (1,429)

Diluted income (loss) per share - Shares (in shares) 16,944 15,845 16,709 15,799

Diluted income (loss) per share - EPS (in dollars per share) $ (0.19) $ (0.11) $ (0.24) $ (0.09)

X

- Definition

The amount of diluted options earnings per share during the period.

+ References

No definition available.

+ Details

Name: prph_DilutiveSecuritiesOptionsEarningsPerShare

Namespace Prefix: prph_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the amount of loss attributable to dilutive warrants and options

+ References

No definition available.

+ Details

Name: prph_DilutiveSecuritiesOptionsEarningsPerShareValue

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Represents the number of shares attributable to dilutive warrants

+ References

No definition available.

+ Details

Name: prph_DilutiveSecuritiesOptionsEarningsShare

Namespace Prefix: prph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: prph_EarningsLossPerShareLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies (Details Textual) (USD $)
1 Months Ended 12 Months Ended

Dec. 20, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Commitments And Contingencies [Line Items]

Payments for Legal Settlements $ 2,100,000

Settlement benefit (Note 3) 100,000

Additional Royalties and Commissions, Accrual Interest Percentage 3.25%

Additional Royalties and Commissions Payable, Installment Amount 100,000 100,000

Additional Annual Installment Includes In Other Current Liability 100,000

Additional Annual Installment Includes In Other Long Term Obligation 200,000

Litigation Settlement Interest $ 13,000

X

- Definition

It defines the portion of additional annual installment includes in other current Liability.

+ References

No definition available.

+ Details

Name: prph_AdditionalAnnualInstallmentIncludesInOtherCurrentLiability

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

It defines the portion of additional annual installment includes In other long term obligation.

+ References

No definition available.

+ Details

Name: prph_AdditionalAnnualInstallmentIncludesInOtherLongTermObligation

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Represents the interest rate percentage computed on royalty installment amount due.

+ References

No definition available.

+ Details

Name: prph_AdditionalRoyaltiesAndCommissionsAccrualInterestPercentage

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents additional royalties and commissions installment amount.

+ References

No definition available.

+ Details

Name: prph_AdditionalRoyaltiesAndCommissionsPayableInstallmentAmount

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: prph_CommitmentsAndContingenciesLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the amount of realized benefit as a consequence of a reduction of the previously recorded accrued royalties and commission obligation.

+ References

No definition available.

+ Details

Name: prph_SettlementBenefit

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Interest expense (income) directly attributable to an award in settlement of litigation.

+ References

No definition available.

+ Details

Name: us-gaap_LitigationSettlementInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid for the settlement of litigation or for other legal issues during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_PaymentsForLegalSettlements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 32 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies (Tables)
6 Months Ended

Jun. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Schedule Of Future Contingency Obligation [Table Text Block]

We have estimated future minimum obligations over the next five years, including the remainder of Fiscal 2014, as follows (in thousands):

Fiscal Year

Employment Contracts

Settlement Agreement

Total

2014

541

100

641

2015

1,040

100

1,140

2016

-

100

100

2017

-

-

-

2018

-

-

-

Total

$

1,581

$

300

$

1,881

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet and the combined aggregate amount of maturities of known contractual obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-K (SK)

-Number 229

-Section 303

-Paragraph a

-Subparagraph 5

+ Details

Name: us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Earnings (Loss) Per Share
6 Months Ended

Jun. 30, 2014

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

Note 7 – Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of our Common Stock outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised or converted into Common Stock or resulted in the issuance of Common Stock that shared in the earnings of the entity. Diluted earnings per share also utilize the treasury stock method which prescribes a theoretical buy-back of shares from the theoretical proceeds of all options and warrants outstanding during the period. Options and warrants outstanding to acquire shares of our Common Stock at June 30, 2014 and 2013 were 1,632,500 and 1,301,500, respectively.

For the three and six months ended June 30, 2014 and 2013 dilutive earnings per share is the same as basic earnings per share due to (i) the inclusion of Common Stock, in the form of stock options and warrants (“Common Stock Equivalents”), would have an anti-dilutive effect on the loss per share or (ii) there were no Common Stock Equivalents for the respective period. For the three months ended June 30, 2014 and 2013, there were 559,318 and 359,271 Common Stock Equivalents, respectively, which were in the money, that were excluded from the earnings per share computation. For the six months ended June 30, 2014 and 2013, there were 571,736 and 401,849 Common Stock Equivalents, respectively, which were in the money, that were excluded from the earnings per share computation.

A reconciliation of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing operations, is as follows (in thousands, except per share amounts):

Three Months Ended

Three Months Ended

Six Months Ended

Six Months Ended

June 30, 2014

June 30, 2013

June 30, 2014

June 30, 2013

Loss

Shares

EPS

Loss

Shares

EPS

Loss

Shares

EPS

Loss

Shares

EPS

Basic earnings
(loss) per share

($

3,138

)

16,944

($

0.19

)

($

1,719

)

15,845

($

0.11

)

($

3,942

)

16,709

($

0.24

)

($

1,429

)

15,799

($

0.09

)

Dilutives:

Options

-

-

-

-

-

-

-

-

-

-

-

-

Diluted income(loss) per share

($

3,138

)

16,944

($

0.19

)

($

1,719

)

15,845

($

0.11

)

($

3,942

)

16,709

($

0.24

)

($

1,429

)

15,799

($

0.09

)

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Policies)
6 Months Ended

Jun. 30, 2014

Accounting Policies [Abstract]

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Policy Text Block]

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and within the rules of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements and therefore do not include all disclosures that might normally be required for financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying unaudited condensed consolidated financial statements have been prepared by management without audit and should be read in conjunction with our consolidated financial statements, including the notes thereto, appearing in our Annual Report on Form 10-K for the year ended December 31, 2013. In the opinion of management, all adjustments necessary for a fair presentation of the consolidated financial position, consolidated results of operations and consolidated cash flows, for the periods indicated, have been made. The results of operations for the six months ended June 30, 2014 are not necessarily indicative of operating results that may be achieved over the course of the full year.

Nature Of Operations [Policy Text Block]

Seasonality of the Business

Our net sales are derived principally from our OTC cold remedy products. Currently, our sales are influenced by and subject to fluctuations in the timing of purchase and the ultimate level of demand for our products which are a function of the timing, length and severity of each cold season. Generally, a cold season is defined as the period of September to March when the incidence of the common cold rises as a consequence of the change in weather and other factors. We generally experience in the third and fourth quarter higher levels of net sales along with a corresponding increase in marketing and advertising expenditures designed to promote our products during the cold season. Revenues and related marketing costs are generally at their lowest levels in the second quarter when consumer demand generally declines. We track health and wellness trends and develop retail promotional strategies to align our production scheduling, inventory management and marketing programs to optimize consumer purchases.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.

Our primary product, Cold-EEZE^Ò Cold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE^® Cold Remedy lozenges, we market and distribute a variety of Cold-EEZE^® Cold Remedy QuickMelts^® and a Cold-EEZE^® Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix^®”). Each of the Cold-EEZE^® Cold Remedy Oral Spray and QuickMelts^® products, and Organix^® products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash Equivalents

We consider all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Cash equivalents include cash on hand and monies invested in money market funds. The carrying amount approximates the fair market value due to the short-term maturity of these investments.

Inventory, Policy [Policy Text Block]

Inventory Valuation

Inventory is valued at the lower of cost, determined on a first-in, first-out basis (FIFO), or market. Inventory items are analyzed to determine cost and the market value and appropriate valuation adjustments are established. At June 30, 2014 and December 31, 2013, inventory included raw material, work in progress and packaging amounts of $1.5 million and $1.1 million, respectively, and finished goods of $1.7 million and $1.4 million, respectively.

Property, Plant and Equipment, Policy [Policy Text Block]

Property, Plant and Equipment

Property, plant and equipment are recorded at cost. We compute depreciation using the straight-line method for financial reporting purposes. Depreciation expense is computed in accordance with the following ranges of estimated asset lives: building and improvements - ten to thirty-nine years; machinery and equipment - three to seven years; computer software - three years; and furniture and fixtures – five years.

Concentration Risk Disclosure [Policy Text Block]

Concentration of Risks

Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC and other personal care products in order to compete on a national level and/or international level.

Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.

We maintain cash and cash equivalents with certain major financial institutions. As of June 30, 2014, our cash balance was $7.3 million and our bank balance was $7.6 million. Of the total bank balance, $636,000 was covered by federal depository insurance and $6.9 million was uninsured at June 30, 2014.

Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. At June 30, 2014 and December 31, 2013, our largest accounts receivable balances are with two customers representing approximately 48% and two customers representing 46%, respectively, of our total trade receivable balance. As a consequence of an evaluation of our customer’s financial condition, payment patterns, balance due us and other factors, we did not offset our account receivable with an allowance for bad debt at June 30, 2014 and December 31, 2013.

Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately 91% and 91% of total revenues for each of the six months ended June, 2014 and 2013, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three and six months ended June 30, 2014 and 2013, our net sales were principally related to domestic markets.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Long-lived Assets

We review our carrying value of our long-lived assets with definite lives whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. When indicators of impairment exist, we determine whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The determination of fair value is based on quoted market prices in active markets, if available, or independent appraisals; sales price negotiations; or projected future cash flows discounted at a rate determined by management to be commensurate with our business risk. The estimation of fair value utilizing discounted forecasted cash flows includes significant judgments regarding assumptions of revenue, operating and marketing costs; selling and administrative expenses; interest rates; property and equipment additions and retirements; industry competition; and general economic and business conditions, among other factors.

Fair value is based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a three-tier fair value hierarchy prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Cash and cash equivalents, accounts receivable and accounts payable are reflected in the Condensed Consolidated Financial Statements at carrying value which approximates fair value because of the short-term maturity of these instruments.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Sales are recognized at the time ownership is transferred to the customer. Revenue is reduced for trade promotions, estimated sales returns, cash discounts and other allowances in the same period as the related sales are recorded. We make estimates of potential future product returns and other allowances related to current period revenue. We analyze historical returns, current trends, and changes in customer and consumer demand when evaluating the adequacy of the sales returns and other allowances.

Our return policy accommodates returns for (i) discontinued products, (ii) store closings and (iii) products that have reached or exceeded their designated expiration date. We do not impose a period of time within which product may be returned. All requests for product returns must be submitted to us for pre-approval. The main components of our returns policy are: (i) we will accept returns that are due to damaged product that is un-saleable and such return request activity falls within an acceptable range, (ii) we will accept returns for products that have reached or exceeded designated expiration dates and (iii) we will accept returns in the event that we discontinue a product provided that the customer will have the right to return only such items that it purchased directly from us. We will not accept return requests pertaining to customer inventory “Overstocking” or “Resets”. We will only accept return requests for product in its intended package configuration. We reserve the right to terminate shipment of product to customers who have made unauthorized deductions contrary to our return policy or pursue other methods of reimbursement. We compensate the customer for authorized returns by means of a credit applied to amounts owed or to be owed and in the case of discontinued product only, also by way of an exchange. We do not have any significant product exchange history.

As of June 30, 2014, accrued advertising and other allowances included (i) $1.7 million for estimated future sales returns and (ii) $1.3 million for cooperative incentive promotion costs. As of December 31, 2013, accrued advertising and other allowances included (i) $1.5 million for estimated future sales returns and (ii) $1.3 million for cooperative incentive promotion costs. Additionally, as of June 30, 2014 and December 31, 2013, we included a provision for sales allowances of $37,000 and $128,000, respectively, which are reported as a reduction to sales and account receivables.

Advertising and Incentive Promotions [Policy Text Block]

Advertising and Incentive Promotions

Advertising and incentive promotion costs are expensed within the period in which they are utilized. Advertising and incentive promotion expense is comprised of (i) media advertising, presented as part of sales and marketing expense, (ii) cooperative incentive promotions and coupon program expenses, which are accounted for as part of net sales, and (iii) free product, which is accounted for as part of cost of sales. Advertising and incentive promotion expenses incurred for the three months ended June 30, 2014 and 2013 were $1.1 million and $527,000, respectively. Advertising and incentive promotion expenses incurred for the six months ended June 30, 2014 and 2013 were $4.5 million and $4.4 million, respectively. Included in prepaid expenses and other current assets was $180,000 and $1.3 million at June 30, 2014 and December 31, 2013, respectively, relating to prepaid advertising and promotion expenses.

Shipping and Handling Cost, Policy [Policy Text Block]

Shipping and Handling

Product sales carry shipping and handling charges to the purchaser, included as part of the invoiced price, which is classified as revenue. In all cases, costs related to this revenue are recorded in cost of sales.

Compensation Related Costs, Policy [Policy Text Block]

Stock Based Compensation

We recognize all share-based payments to employees and directors, including grants of stock options, as compensation expense in the financial statements based on their fair values. Fair values of stock options are determined through the use of the Black-Scholes option pricing model. The compensation cost is recognized as an expense over the requisite service period of the award, which usually coincides with the vesting period.

Stock and stock options for the purchase of our common stock, $0.0005 par value, (“Common Stock”) have been granted to both employees and non-employees pursuant to the terms of certain agreements and stock option plans (see Note 4). Stock options are exercisable during a period determined by us, but in no event later than ten years from the date granted. For the three months ended June 30, 2014 and 2013, we charged to operations $64,000 and $40,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned. For the six months ended June 30, 2014 and 2013, we charged to operations $128,000 and $79,000, respectively, for share-based compensation expense for the aggregate fair value of stock grants issued and vested stock options earned.

Consolidation, Variable Interest Entity, Policy [Policy Text Block]

Variable Interest Entity

On March 22, 2010, we, Phosphagenics Limited (“PSI Parent”), an Australian corporation, Phosphagenics Inc. (“PSI”), a Delaware corporation and subsidiary of PSI Parent, and Phusion Laboratories, LLC (the “Joint Venture”), a Delaware limited liability company, entered into a Limited Liability Company Agreement (the “LLC Agreement”) of the Joint Venture and additional related agreements for the purpose of developing and commercializing, for worldwide distribution and sale, a wide range of non-prescription remedies using PSI Parent’s proprietary patented TPM™ technology (“TPM”). TPM facilitates the delivery and depth of penetration of active molecules in pharmaceutical, nutraceutical, and other products. Pursuant to the LLC Agreement, we and PSI each own a 50% membership interest in the Joint Venture. The Joint Venture, of which we own a 50% membership interest, qualifies as a variable interest entity (“VIE”), we are the current primary beneficiary and we have consolidated the Joint Venture beginning with the quarter ended March 31, 2010.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development costs are charged to operations in the period incurred. Research and development costs for the three months ended June 30, 2014 and 2013 were $273,000 and $216,000, respectively. Research and development costs for the six months ended June 30, 2014 and 2013 were $551,000 and $404,000, respectively. Research and development costs are principally related to new product development initiatives and costs associated with our OTC cold remedy products.

Income Tax, Policy [Policy Text Block]

Income Taxes

We utilize the asset and liability approach which requires the recognition of deferred tax assets and liabilities for the future tax consequences of events that have been recognized in our financial statements or tax returns. In estimating future tax consequences, we generally consider all expected future events other than enactments of changes in the tax law or rates. Until sufficient taxable income to offset the temporary timing differences attributable to operations and the tax deductions attributable to option, warrant and stock activities are assured, a valuation allowance equaling the total deferred tax asset is being provided (see Note 5).

We utilize a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than fifty percent likely of being realized upon ultimate settlement. Any interest or penalties related to uncertain tax positions will be recorded as interest or administrative expense, respectively.

As a result of our continuing tax losses, we have recorded a full valuation allowance against a net deferred tax asset. Additionally, we have not recorded a liability for unrecognized tax benefits. The tax years 2006 and forward remain open to examination by the IRS. The tax years 2004 and forward remain open to examination by the various state taxing authorities to which we are subject.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Standards

In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists” (“ASU 2013-11”). ASU 2013-11 amends Accounting Standards Codification 740, “Income Taxes,” to require that in certain cases, an unrecognized tax benefit, or portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date, and retrospective application is permitted. The adoption of ASU 2013-11 did not have a material impact on our consolidated financial position, results from operations or cash flows.

In May 2014, the FASB issued new accounting guidance, namely ASU No. 2014-09, “Revenue from Contracts with Customers”, on revenue recognition. The new standard provides for a single five-step model to be applied to all revenue contracts with customers as well as requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a retrospective approach or cumulative effect adjustment approach to implement the standard. There is no option for early adoption. This ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2016. We are currently evaluating the impact of the new guidance on our consolidated financial statements.

X

- Definition

Disclosure of accounting policy for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

No definition available.

+ Details

Name: prph_NatureOfOperationsPolicyTextBlock

Namespace Prefix: prph_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=32704220&loc=d3e8275-108329

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 20

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6387522&loc=d3e8384-108330

+ Details

Name: us-gaap_AdvertisingCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f(1))

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_CompensationRelatedCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for credit risk.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61082-112788

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6480020&loc=d3e61044-112788

+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 5A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6759159-111685

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 4

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=28200181&loc=d3e5728-111685

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 2AA

-Subparagraph a

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6759068-111685

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 2A

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6225816-111685

+ Details

Name: us-gaap_ConsolidationVariableInterestEntityPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for determining the fair value of financial instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section CC

-Subsection 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 05

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6390181&loc=d3e202-110218

+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4556-108314

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 206

-Paragraph b

-Subparagraph i, ii

-Chapter 2

+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.

+ References

No definition available.

+ Details

Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 45

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6408196&loc=d3e61069-111654

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Handling Costs

-URI http://asc.fasb.org/extlink&oid=6514758

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 45

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=21915142&loc=d3e60635-111653

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 45

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6408413&loc=d3e221937-122793

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Shipping Costs

-URI http://asc.fasb.org/extlink&oid=6525344

+ Details

Name: us-gaap_ShippingAndHandlingCostPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Earnings (Loss) Per Share (Tables)
6 Months Ended

Jun. 30, 2014

Earnings Per Share [Abstract]

Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block]

A reconciliation of the applicable numerators and denominators of the income statement periods presented, as reflected in the results of continuing operations, is as follows (in thousands, except per share amounts):

Three Months Ended

Three Months Ended

Six Months Ended

Six Months Ended

June 30, 2014

June 30, 2013

June 30, 2014

June 30, 2013

Loss

Shares

EPS

Loss

Shares

EPS

Loss

Shares

EPS

Loss

Shares

EPS

Basic earnings
(loss) per share

($

3,138

)

16,944

($

0.19

)

($

1,719

)

15,845

($

0.11

)

($

3,942

)

16,709

($

0.24

)

($

1,429

)

15,799

($

0.09

)

Dilutives:

Options

-

-

-

-

-

-

-

-

-

-

-

-

Diluted income(loss) per share

($

3,138

)

16,944

($

0.19

)

($

1,719

)

15,845

($

0.11

)

($

3,942

)

16,709

($

0.24

)

($

1,429

)

15,799

($

0.09

)

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes (Details Textual) (USD $)
In Millions, unless otherwise specified
12 Months Ended

Dec. 31, 2013

State and Local Jurisdiction [Member]

Income Taxes [Line Items]

Operating Loss Carry forwards Expiration Dates Description Fiscal 2018 through Fiscal 2032

Deferred Tax Assets, Operating Loss Carryforwards, State and Local $ 20.4

Domestic Tax Authority [Member]

Income Taxes [Line Items]

Deferred Tax Assets, Operating Loss Carryforwards, Domestic $ 34.7

Operating Loss Carry forwards Expiration Dates Description Fiscal 2020 through Fiscal 2032

X

- Details

Name: prph_IncomeTaxesLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The expiration date of each operating loss carry forward included in total operating loss carry forwards, or the applicable range of such expiration dates.

+ References

No definition available.

+ Details

Name: prph_OperatingLossCarryForwardsExpirationDatesDescription

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 25

-Paragraph 20

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314

+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 25

-Paragraph 20

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314

+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 37 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Consolidated Statements of Stockholders' Equity (USD $)
In Thousands, except Share data

Total

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings (Deficit) [Member]

Treasury Stock [Member]

Balance at Dec. 31, 2013 $ 12,596 $ 11 $ 43,607 $ (5,385) $ (25,637)

Balance (in shares) at Dec. 31, 2013 16,101,006

Net loss (3,942) 0 0 (3,942) 0

Share-based compensation expense (Note 4) 128 0 128 0 0

Common shares issued (Note 4) 4,826 1 4,825 0 0

Common shares issued (Note 4) (in shares) 3,198,207

Balance at Jun. 30, 2014 $ 13,608 $ 12 $ 48,560 $ (9,327) $ (25,637)

Balance (in shares) at Jun. 30, 2014 19,299,213

X

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11149-113907

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11178-113907

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 38 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Transactions Affecting Stockholders' Equity
6 Months Ended

Jun. 30, 2014

Stockholders Equity Note [Abstract]

Transactions Affecting Stock Holders Equity [Text Block]

Note 4 – Transactions Affecting Stockholders’ Equity

Stockholder Rights Plan

On September 8, 1998, our Board of Directors declared a dividend distribution of Common Stock Purchase Rights (each individually, a “Right” and collectively, the “Rights”) payable to the stockholders of record on September 25, 1998, thereby creating a Stockholder Rights Plan (the “Rights Agreement”). The Plan was subsequently amended effective each of (i) May 23, 2008, (ii) August 18, 2009 and (iii) June 18, 2014. The Rights Agreement, as amended, provides that each Right entitles the stockholder of record to purchase from the Company that number of common shares having a combined market value equal to two times the Rights exercise price of $45. The Rights are not exercisable until the distribution date, which will be the earlier of a public announcement that a person or group of affiliated or associated persons has acquired 15% or more of the outstanding common shares, or the announcement of an intention by a similarly constituted party to make a tender or exchange offer resulting in the ownership of 15% or more of the outstanding common shares. The Rights Agreement allows for an exemption for Ted Karkus, the Company’s Chairman and Chief Executive Officer, to acquire up to 20% of our Common Stock without our Board of Directors declaring a dividend distribution. The dividend has the effect of giving the stockholder a 50% discount on the share’s current market value for exercising such right. In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one common share of the Company. The Rights Agreement, as amended, includes a provision pursuant to which our Board of Directors may exempt from the provisions of the Rights Agreement an offer for all outstanding shares of our Common Stock that the directors determine to be fair and not inadequate and to otherwise be in the best interests of the Company and its stockholders, after receiving advice from one or more investment banking firms. The expiration date of the Rights Agreement, as amended, is June 18, 2024.

2012 Equity Line of Credit

On November 21, 2012, we entered into the equity line of credit agreement (such arrangement, the “2012 Equity Line”) with Dutchess Opportunity Fund II, LP (“Dutchess”) whereby Dutchess committed to purchase, subject to certain restrictions and conditions, up to 2,500,000 shares of our Common Stock, over a period of 36 months from the first trading day following the effectiveness of the registration statement registering the resale of shares purchased by Dutchess pursuant to the 2012 Equity Line. On November 26, 2012, we filed a registration statement with Securities and Exchange Commission (“SEC”) to register for sale for up to 2,500,000 shares of our Common Stock and the registration statement was deemed effective by the SEC on December 12, 2012. We amended this registration statement effective May 29, 2014 to withdraw and remove from registration all unissued and unsold shares. We also agreed with Dutchess to terminate the 2012 Equity Line as of May 28, 2014.

We drew on the facility from time to time, as and when we determine appropriate in accordance with the terms and conditions of the 2012 Equity Line. The maximum amount that we were entitled to put to Dutchess in any one draw down notice is the greater of (i) 500% of the average daily volume of our Common Stock traded on the NASDAQ Global Market for the one (1) trading day prior to the date of delivery of the applicable draw down notice, multiplied by the closing price for such trading day, or (ii) $250,000.

The purchase price under the 2012 Equity Line is set at ninety-five percent (95%) of the lowest daily volume weighted average price (“VWAP”) of our Common Stock during the five (5) consecutive trading day period beginning on the date of delivery of the applicable draw down notice. In the event Dutchess received more than a five percent (5%) return on the net sales for a specific put, Dutchess remitted such excess proceeds to us; however, in the event Dutchess received less than a five percent (5%) return on the net sales for a specific put Dutchess had the right to use any such excess proceeds to off-set against the aggregated deficit proceeds.

There were put restrictions applied on days between the draw down notice date and the closing date with respect to that particular put. During such time, we are not allowed to deliver another draw down notice. In addition, Dutchess is not obligated to purchase shares if its total number of shares beneficially held at that time would exceed 9.99% of the number of shares of our Common Stock as determined in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended. In addition, we are not permitted to draw on the facility unless there is an effective registration statement to cover the resale of the shares.

During the period January 1, 2014 through May 23, 2014, we sold an aggregate of 698,207 shares of Common Stock to Dutchess under and pursuant to the 2012 Equity Line and we derived approximately $1.2 million in net proceeds. The sales of the shares under the 2012 Equity Line were deemed to be exempt from registration under the Securities Act of 1933, as amended in reliance upon Section 4(2) (or Regulation D promulgated thereunder).

2014 Equity Line of Credit

The Company and Dutchess executed a new equity line of credit agreement (such arrangement, the “2014 Equity Line”) each dated May 28, 2014 whereby Dutchess committed to purchase, subject to certain restrictions and conditions, up to 3,000,000 shares of the Company’s Common Stock, over a period of 36 months from the effectiveness of the registration statement registering the resale of shares purchased by the Investor pursuant to the Investment Agreement. On May 29, 2014, we filed a registration statement with the SEC to register for sale up to 3,000,000 shares of our Common Stock and the registration statement was declared effective by the SEC on June 4, 2014.

We may in our discretion draw on the facility from time to time, as and when we determine appropriate in accordance with the terms and conditions of the 2014 Equity Line. The maximum number of shares that the Company is entitled to put to Dutchess in any one draw down notice shall not exceed shares with a purchase price of $500,000, calculated in accordance with the 2014 Equity Line. We may deliver a notice for a subsequent put from time to time, following the one day pricing period for the prior put.

The purchase price shall be set at ninety-five percent (95%) of the volume weighted average price (VWAP) of the Company’s Common Stock during the one trading day immediately following our put notice. The Company has the right to withdraw all or any portion of any put, except that portion of the put that has already been sold to a third party, including any portion of a put that is below the minimum acceptable price set forth on the put notice, before the closing. In the event Dutchess receives more than a five percent (5%) return on the net sales for a specific put, Dutchess must remit such excess proceeds to the Company; however, in the Dutchess receives less than a five percent (5%) return on the net sales for a specific put, Dutchess will have the right to deduct from the proceeds of the put amount on the applicable closing date so Dutchess’s return will equal five percent (5%).

There are put restrictions applied on days between the draw down notice date and the closing date with respect to that particular put. During such time, the Company shall not be entitled to deliver another draw down notice. In addition, the Investor will not be obligated to purchase shares if Dutchess’s total number of shares beneficially held at that time would exceed 4.99% of the number of shares of our Common Stock as determined in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended. In addition, we are not permitted to draw on the facility unless there is an effective registration statement to cover the resale of the shares.

During the period June 13, 2014 through June 30, 2014, we sold an aggregate of 2,500,000 shares of our Common Stock to Dutchess under and pursuant to the 2014 Equity Line and we derived approximately $3.6 million in net proceeds. The sales of the shares under the 2014 Equity Line were deemed to be exempt from registration under the Securities Act of 1933, as amended in reliance upon Section 4(2) (or Regulation D promulgated thereunder). At June 30, 2014, we have 500,000 shares of our Common Stock available for sale, at our discretion, under the terms of the 2014 Equity Line and covered pursuant to a registration statement.

The 1997 Option Plan

On December 2, 1997, our Board of Directors approved a Stock Option Plan (the “1997 Plan”), which was amended in 2005, and provided for the granting of up to 4.5 million shares of Common Stock. Under the 1997 Plan, we were permitted to grant options to employees, officers or directors of the Company at variable percentages of the market value of stock at the date of grant. No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998. No options were granted under this Plan for the six months ended June 30, 2014 or 2013.

We are precluded from issuing any additional options or grants in the future under the 1997 Plan pursuant to the terms of the plan document. Options previously granted continue to be available for exercise at any time prior to such options’ respective expiration dates, but in no event later than ten years from the date granted. At June 30, 2014, there are 67,000 options outstanding under the 1997 Plan with various expiration dates ranging from October 2014 through December 2015, depending upon the date of grant.

The 2010 Equity Compensation Plan

On May 5, 2010, our shareholders approved the 2010 Equity Compensation Plan which was subsequently amended, restated and approved by shareholders on April 24, 2011 and further amended and approved by shareholders on May 6, 2013 (the “2010 Plan”). The 2010 Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Plan is equal to 1.6 million shares plus up to 900,000 shares that are authorized for issuance but unissued under the 1997 Plan for an aggregate of 2.5 million shares. The 1997 Plan expired on December 2, 2007 and no additional awards may be made. As of June 30, 2014, 1,481,750 of the options issued under the 1997 Plan prior to December 2007 expired unexercised or were terminated. As a consequence, these shares are deemed and remain unissued which up to a maximum of 900,000 shares became available for issuance under the 2010 Plan and the remaining 581,750 options are deemed cancelled. No options were granted under the 2010 Plan for the six months ended June 30, 2014. We granted 15,000 options under the 2010 Plan for the three and six months ended June 30, 2013. At June 30, 2014, there are 267,159 shares of Common Stock that may be issued pursuant to the terms of the 2010 Equity Compensation Plan.

There were no stock options exercised for the six months ended June 30, 2014 or 2013.

The 2010 Directors’ Equity Compensation Plan

On May 5, 2010, our shareholders approved the 2010 Directors’ Equity Compensation Plan which was subsequently amended and approved by shareholders on May 6, 2013. A primary purpose of the 2010 Directors’ Equity Compensation Plan is to provide us with the ability to pay all or a portion of the fees of directors in restricted stock instead of cash. The 2010 Directors’ Equity Compensation Plan provides that the total number of shares of Common Stock that may be issued under the 2010 Directors’ Equity Compensation Plan is equal to 425,000. For the three and six months ended June 30, 2014 and 2013, no shares were granted to directors. At June 30, 2014, there are 176,135 shares of Common Stock that may be issued pursuant to the terms of the 2010 Directors’ Equity Compensation Plan.

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 64 162 1 false 29 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.prophaselabs.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 102 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.prophaselabs.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets false false R3.htm 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] Sheet http://www.prophaselabs.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets [Parenthetical] false false R4.htm 104 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.prophaselabs.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations false false R5.htm 105 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.prophaselabs.com/role/CondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity false false R6.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.prophaselabs.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows false false R7.htm 107 - Disclosure - Organization and Business Sheet http://www.prophaselabs.com/role/OrganizationAndBusiness Organization and Business false false R8.htm 108 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.prophaselabs.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R9.htm 109 - Disclosure - Commitments and Contingencies Sheet http://www.prophaselabs.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R10.htm 110 - Disclosure - Transactions Affecting Stockholders' Equity Sheet http://www.prophaselabs.com/role/TransactionsAffectingStockholdersEquity Transactions Affecting Stockholders' Equity false false R11.htm 111 - Disclosure - Income Taxes Sheet http://www.prophaselabs.com/role/IncomeTaxes Income Taxes false false R12.htm 112 - Disclosure - Investment in a Joint Venture Sheet http://www.prophaselabs.com/role/InvestmentInJointVenture Investment in a Joint Venture false false R13.htm 113 - Disclosure - Earnings (Loss) Per Share Sheet http://www.prophaselabs.com/role/EarningsLossPerShare Earnings (Loss) Per Share false false R14.htm 114 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R15.htm 115 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.prophaselabs.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) false false R16.htm 116 - Disclosure - Earnings (Loss) Per Share (Tables) Sheet http://www.prophaselabs.com/role/EarningsLossPerShareTables Earnings (Loss) Per Share (Tables) false false R17.htm 117 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.prophaselabs.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) false false R18.htm 118 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.prophaselabs.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) false false R19.htm 119 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.prophaselabs.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) false false R20.htm 120 - Disclosure - Transactions Affecting Stockholders' Equity (Details Textual) Sheet http://www.prophaselabs.com/role/TransactionsAffectingStockholdersEquityDetailsTextual Transactions Affecting Stockholders' Equity (Details Textual) false false R21.htm 121 - Disclosure - Income Taxes (Details Textual) Sheet http://www.prophaselabs.com/role/IncomeTaxesDetailsTextual Income Taxes (Details Textual) false false R22.htm 122 - Disclosure - Investment in a Joint Venture (Details Textual) Sheet http://www.prophaselabs.com/role/InvestmentInJointVentureDetailsTextual Investment in a Joint Venture (Details Textual) false false R23.htm 123 - Disclosure - Earnings (Loss) Per Share (Details) Sheet http://www.prophaselabs.com/role/EarningsLossPerShareDetails Earnings (Loss) Per Share (Details) false false R24.htm 124 - Disclosure - Earnings (Loss) Per Share (Details Textual) Sheet http://www.prophaselabs.com/role/EarningsLossPerShareDetailsTextual Earnings (Loss) Per Share (Details Textual) false false All Reports Book All Reports Element prph_PaymentsToFundJointVentureInvestments had a mix of decimals attribute values: -5 0. Element prph_PrepaidAdvertisingAndIncentivePromotions had a mix of decimals attribute values: -5 0. Element us-gaap_CashAndCashEquivalentsAtCarryingValue had a mix of decimals attribute values: -3 0. Element us-gaap_MarketingAndAdvertisingExpense had a mix of decimals attribute values: -5 0. Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -5 -3. Element us-gaap_StockIssuedDuringPeriodValueNewIssues had a mix of decimals attribute values: -5 -3. 'Monetary' elements on report '119 - Disclosure - Commitments and Contingencies (Details Textual)' had a mix of different decimal attribute values. 'Monetary' elements on report '122 - Disclosure - Investment in a Joint Venture (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Jun. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 103 - Statement - Condensed Consolidated Balance Sheets [Parenthetical] Process Flow-Through: 104 - Statement - Condensed Consolidated Statements of Operations Process Flow-Through: 106 - Statement - Condensed Consolidated Statements of Cash Flows prph-20140630.xml prph-20140630.xsd prph-20140630_cal.xml prph-20140630_def.xml prph-20140630_lab.xml prph-20140630_pre.xml true true ZIP 40 0001144204-14-048848-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-14-048848-xbrl.zip M4$L#!!0````(`'=X#$4H+;FDKIP```&!!0`1`!P`<')P:"TR,#$T,#8S,"YX M;6Q55`D``Q%EZE,19>I3=7@+``$$)0X```0Y`0``[%W[<^.V=OZ],_T?<-TF MV9V19+WL]2.;.UX_,L[=5VVG2=OI>"`2DI"E2`4@9:N=_N\]YX`/D*+D1V1; ME'7G)I%)``0.OO/Z`)`__OUVY+&)4%H&_ONM5J.YQ83O!*[T!^^W?KTZJ^]M ML;__],__]./?ZG7VL_"%XJ%P66_*3GC(KQ1WONFD/FLU6HU=!C^:>_6C:%!O M-UM=]E_-W8-N^Z#][K_9_W[]]'_L]/**U=G-S4W#A19":J'A!"-6KR?/^<`U M/`/:^?W#Q4?6;K3B>[<]Y#;OOZ8*S&P_=;PS`<'VQO8Y-C%8R'4-OC M/6IT&[O0W.W`L$P-3_K?OB=NQQGX>!FI[!WTE#3A#Y MH9KFQ::%TQ@$D^WX)LY,I]YLU3NMM%JD%(!O7KWX+DUIOJ(K9'D=N%%27-PZ MP_+R>*>D@O0G0H?E5#A6<\K#G9(* MD:X/.!^G=?I<]VAFXQLE0[_U%N#G]X\6J*-0+8`-W-T"%6;L1U2$`TT0OQ!] M1HIQ$$['XOV6EJ.QA_BE:T,E^N^W4,7KB18W;K6[Q;:A(6,IC@,_%+ MET(QZK;(#3,1^?'Y/[9^:L+_]G;WVN_V?MPN5DX>M5UX5JX'8Z%DX!9[`'JM M0K"WXB?L-$Y0LY6TD]U+FK*&XV:56FV8U>SA;ES%[I+U\.12+,.X[86";5N" M;5=1L.W'"+;]](+M7`7-W>M.DWY74;"=QP@6*NW6.\TG%FR*V-*@NT^1K#=IT-L=XU,07>53$%WC1#[<,$^'6*/]!>_?+Z,?MTL=EX]\NZ^?KR%FOCQQB M4T%RCI`3WO/$0X!U?743'$=*PIJ`LK]AT?%[Y+8 M\\'L^8B9#"_'03#&;2!R(L[)$,"/#5+*D3)?5FN($2LQV=B4M;`IS\0O=38V MI;HVY>DP8N_9:7:2/3O7'^5(@IY\E+PG/>CQ<3`:"%PMU'[E!J=IZ50O@02<\UNI;\/!^-53`A`6H[ M>?NJ4./"Z53<>"\KY/TI>C:&17N^#^0%03>4EJ=8^1 M9]G>O22ZW-3/$G&:#=H3L4GXGE$#^.T::D`9PNR!+A?/SZEO&PT`R#I#Z0LU MM46]L?P/1N(".6[L_9JA?6/EG]?*/TJW-FB_QI0H"H6Z#/KA#5>0*T->.I`] M3QQI+1Z*^^I"^T%@NY?0-K!;`+NS2/D2&3P0]9F\Q5\/C:1?"=;F2VH#L+)E MNM'8"Z8X7CSUIKB31/A("!78XR\]3PYH>;::>"ICQ(MC2F`T5RYKN,)B[X`1 M8>A1HE<@_5XI'*C,7*&L&19:]J%+^&%^X]Z3JV$0:>Z[5S?"FPBTO^'T(X2/ M7_K'2K@R%_9<#@,57@DU.A&]L/K.9\YPDIT@]Y/,"[F>=KWUJ+.GK7K[&2ES M2XIG0:1"(?P-PF81=I=L-N'-XK1M%/B78>!\RR$IA,>B-(Q0,4\)?&0YB90X MB4(`B=;SEOY>J661>5-@;K)BF%B)/3.Y:^_OO M2"6<,%#Z5DE.8:OV23`2.I3.L7F/HPV+<]^!FU?\]B@*(?VJ[+[;!"#SQI/<+Q7% MB\07S[`).W_R?(."54%!)4YOY\%##-&1[WX,'.[]$BFI74DOUWC-,+I#*!M` ME?BB#9!6&4C/?D@H>['O]50DT;(*-U0LVG@\'.]?MOLB5*`)A1/Y9_!1WCXHDS27W[$=@:W/:__7R9$[C4@?==NO=`91X?-O7 M,.#K2^Q@X2FNG`#VBK.`53]'(_PB1Z"*P+MWUVR!%ULL>>")\(.1]!<_\BY1 M%Y\YVVARUQKY/60XCF9$E^\2%KC7_.`7>$_-"]V*W]_-XD,(^(:!YPJEC4I^ M#D)Q(K7C!=CP%>#T@P=E6`S:"]&?2^5M4?_/.#S)O6YM_?2]%Q["V)D.IQ[8 MJ$]'%S^??SY@S7$(_]P>LK,OGZ\.6`O_O@*#HMEG<<,N@A'W:^9"#;JM9)]M M?3\(#UFAN>./IT<7![T@')J6ZF='G\X__L=!H:E#NG=Y_I^GYE&'C^[&%N.> M'(#)^R/28$&GU"OL5`]_H-Q8EWW/1^/#?VGM-`_9E>*^YB1VS8[Z?9P!?\!L MD9O2>X#L0V;$C^UM]Y*6MV&\JSUV23_,H'>;IM/RJ;I_=?K[5?W\\\DI=KHI M_4/VUP?DB7Z8G\ET6-9,L0LY&(::X0GGPAB?;++RHVVT=Y8\X"_X5>YQ:#SZ M7HVU]O?AW^"?V8>`*Y<%?9:^!(2YPO'`$KJ,,V/.?!=^Z%#)7H0(Q]*&=30` M9U\CY0RY%HGDW@CN#)GTJ7;$/6]:@[82!6@W#ZE<^G?KD$&T`%;'\U!O)@++ MAT,Q4T-;5=ZR,9_B=S)9&%!A;>D:]A!&$^#([)&W=Y*AXS>C1&_*',B&254Y MFP,!]J:T*RQ];Z;=J0:[@L)4[89KIJ.>%G]&4,B;,FY>J\"$,0\3P4A,T-4W M\BW[Q*>LW:FQ-@1Q-;@"EXZB`6@@:^W1U7T2$MR`.[]$OHBOM[KFF<5>@<1U M\L@:PV]=P$1J&#-RO!#K(F9MI%&='=(C[$Y_#,G1.@\ M\X,PZ0*A+`)!>=2_G"JX$`76V,U0@D1OI.>QGJ!"@H-[-C+A(+X>Q+.^!&LS[*WD<(C.@]*'3A"GKZ#X!PI&NV%EBN7;/C M(9<*9$WJ>CR4HL].;X43D<9_@;EUA*KA2.,I9##K\%>[^1WV&$URSK;>R!#2 MJ7"QK39:5FJLS2C36X@=PB<9(6QK($E)B_K/EXNLG68!6=!'^N(Q&FAZ-LY) M3I!.I/!@7MYF]`D1I);8:QV!WBF`U,_=$!Z(BCV0IB8S<'CZ:CJ#.9KTB;T3F9 MY93.C]6;U`[,J*VUL3V$ MPLQ8P`*,!&YP/J%L;%)Z0H=DMN"QH2X(E"I*N&P''"#"?DC6"3_?3>KH3M!M MD1!PBA*K)/T)-$J#[G'_&Q;M@[V(K9&X'4OSM7#R+//D59@Q;0<$[6YC-=.) MDN@[GTNL<"JT('/`UTO'"1U#CHNB8V*YUBAY^(R?2J,(ND5!9QMB'H'!HT#S M!JIB8G!AQ.#%8G!(#(RG:OZ&[#57"NV8`7(AN"Y*,Q?QHR]DR0MYV9?Q.%`A M,B!3=A:!4IZ?U]C'K^R-U5Q2.-],'/NG+:'YE"&&(5:L6\/H_0]TDG`1?#8N MH&+T`9XUSO--TN*;Y780GW'D2W6;[=I.LUEK-O/>Y)`($U1?!1/;(24&&!<8:R33A8;X\M" M)76A8]RCZ8][F0C49;;,;8^"U8H3WV`YV.U:L(/PF)+3.1TBE%Q"Q*5@8H29 MIM/$=Z*LI":?9N/D\O0X!Q'H5#(N!X_`;F<7\3:0)93@$#S#G*5G3E&#NFY21W#B(R57\ MAOJIQ`A$;0"2:PE],:B8UA&*'$I&O@:7EX;0V`U/!T;'W8*&XM22+T975C;) MZ,9`=-2U))M]!@NY;`/Y[`[MJ2T^S*JKH'`Y0]].C@T(5*6IA?^:0`1@ M`3;51]W,HB\^AK@/<>["- M&G?KL<0*$)6U5.JFO3/K$BMI-O+6HF(V`M4QY04-!B+B M;$H-/2B9!HPB60A_AM-Z'WT2!"D.Q87+A,=^@<1ZF^`;`AQ,['*Z=B,PM4+? M%FNB&8D=&_S[;T=?<\%!F7ZZ41H`T[+PE?BLA?G+*:$*S'OA9'W?C)5K] M"+ULL!Q3D=H[DX.`9Y5(<^,Z#^I1Q M/$?4"W5'D%>9U]V@WZ\3Z`<<]Z28N1R`GQD0G>L2"12F558^;:^ZN5)QH("S MFD_DQL:Q$>LRU:"9X8T0L5(6PP4W)8\L'T@7*:Z!AL=QTDC1"1+;THD\KO"Y M#8"32HE+$T%!_)(L.!#W;"*8V`C`DXBA*M=\'N_UMI0(#"VV%)B/ON53VB1; MD7TBL,(@A.@A6[R)[V;T))C)H8!@G\>1%D5^-T$$EQ#NRUY]V&_L[Y>'23-] M+,VW+.[/+0LY+R*PH*V.6V^]^2-U"E:BF":)1X89;^UWNC;35A"Y-6]C?&I" M(-!,%2/GR(\-$@)0:EI:2%.S.;D;\@Z4S>?3ZI0MWUB,)[48)YE+CSWV+]R/ M./CE5I)%#U40#8;6VFVK2[B@%!E=3V+M<=Z6JBN[^WNU=O/=/%HHGSM8B9`) MT=!\W47`8*%L`BFU4^19*;&[I2],@H%8:F3?:K3S(QI)ST.E`&U&)YVZ2DH& MCZ$BIX-9*Y9YR*Q"Q[8*C&A!3Y*=B<:TWX#\"NN^ M:;]E;R"BN!`#<`!T[03'`+E4;)O1'-##WJZ\+L\0WW-W`E66Q^^N-X]_55C$ M2HV"H/5IXE1]:&PI+'YW+HM/NT]EE<_KR,=LXH6JC/ M<=LSR4ZZR2$QWI`_/);LAB8]+][<1AE<_`P:`2\2>LO>=%>VF%EC#O4[^"0D3A^>]]HP&:0$8XV82Q'D+-(DV]EP$7SANA.^"`[O$NV M^:5<9;;:BYNK%!D(W#X1;^>F/Y&,1:LPCND>ZSYI011?IZUMGA+KW#`$S4^EVBV\#5+D,^.?EG4N-5)VOH\Y!.1 M1QVDQY&3WPEH.FU!*E[*C9]GK77DN%6=^;><"L6]I>>;_>0S(]H8[9?AVOGJ M4>UV$)5%0KW\WH$',N^Y;(=P&+=Y%P5?BN=5X^2[&TY^!3CYC;5Y&$]/NZ$[ M!9:>KG::STK3/WC_YOW)^NY+D_6=1I%A^DMD?;=*9#T["DOP1`'0LC>./0@] M?,*E1]%30G[5T%/DF9":)3)#6,QA*&(B8T*;O&T(SN/B-HL8+SPMS/,Z8;H-IWC?3?W"#.9/;)_L6)8\I@YT$L"(TE9RQ3IH;0;>R4F]OR5=\&^S55\G2`M72S;"XZHIZS8&Q" M=+@`EM8+IH+.=9H3BQI)@^R05?%(%![/4])D[";UXH/,W.=.\&'`:&Q5F-OU M1IU8[BF^SP%R$!C;3^+#C?$@P:AAP&R\2GK$-V,%0LA(IH(CD.A8UTP_41J4 M:"XN14M:=#T[#(]G_G3A64FZ&LO+)`'IH>E)0+`:0V)O#A1#CN%X7&LC86VF MVW[71(;_W/0C@,_`#4#C>`J^<#00I)5`@"!"0Q!NZBQD?!X^P;N6M\FBDE&/ MG$-$">';]#?Q\`LL@%#J#;J*!SE=$S+A$8Z$BN/I*T+3&:<#Z##?.J&-^E$8 M*7M+;X:B8C":BR'&6,(-G(CB@=CN(ETE)C*(-`2A":[P+3/2CY)SFOG0)3UE MBZ?D\3T#F.:FN]@II8^[;K]7)68$Z-T*^9.4(*Y>%%)H&L2TH,>-TN;T/:6J M2)'CKI:%>V'*<2QW7\^[V7@OG2/K3&S9O%!"C788Y#PS?H:K]73:%$?X!C[7-HGZ+ MBOU00.RIQB[,Q$H#2*8@1J\N;T5N$=+EF<4$;$S1Z2Q]52/.%N M3O+E,N^X?5Q53M[(LE2;UII'%"2;1SRP5T\0,>\O2)[-ZU?0@IM/P_]/',BC M?(@<0&^1'GPLL[;Q"T*>D#M:'/`;>&3](8-OF'4[38*$Y5W\^@/;[_,;R)ET M@HH1=P4X.8).P<\M%PFU[EZK]FZGZ.#B-[7$?FZ!T-,(P/)5,+YD[-#U.&Z@ M=^=0&)N>0'5IA-PEVC65/^R+4 M]H0#YJ80*J60+5/J;#\3C@6=^7+YJ=+IC.?1$J>#'?0\G(.[T@R[]_=+-6@W M2-+,,H>W7.SOS$QKN=@6"0)"-6%HN84BZ3QCQ-J&D+6ULU^*UWMXHH7)Q$+O MOLDL7_`,%7@3FU#)7HODK@(_4.4LXAX(I/_6XWM+&%H:9Z8$ZNS+2N/P%R.@^SE8X_HER2&-TXF6*2S79:\9];%\38\ M/=DI5MP'UA?&LF=LL+4#'W>4DEW`$Z^"$RV/KTZSDIF'=?<)LYX'R^UITJ-N M>S8R:+"SAWG\+A5!M-3(-L>[>O^_O3=M;MS($D6_3\3\!]RZX]MV!"ESU5+5 M=H1*BUL]JI)&DEVOYTL%1"1)N$"`C442_>O?63*!!`@2X"I2A8[N+I$$,D^> MS#S[H@M8&`:A5KQ%^:!Y=%AKMKN;DP\6VL:#=._U//_D3I\%/?_]YX4+JJNJ[>O'*[7DC M\6"^K*/H>NM[++K>U8NN,SH-P*<(=MVRF[NDMU(NB@U'L4FFS?G1[20F!L.! MO#&V:4`+!)S\`(0"WY_405=@0Q2Z-3<8JM0YR*1**UL:*BM]`3<9&+N4K:2H MP2'%9%C22K6`J+-.P*0WMM5H-6(W3/Q=NY61"9+6?K)"NN37KXW>5N.@,QN] M9&)_5>0VCTL@]W(.NP ML$@PQE3$E?J\9[(#DIBJ0B)96K8$`(<64IP7(P=DY@77[^)`E@/0.5R3,WHQ M*<,63XG8C>&Q\014;E"6-K:BN`(_UOVF?-QPPN7C`8J_)!P!+YGCF+->9E8. M]-=-W\:SXIC^`$^KG`05*6SMA)63.::$/=IHJ@V$Z6-6,I:_!L`=;TSKZ'E! MF!.3NS_"QCR985J^4+FUP95[ZEJGUA/N5_#@G:J:\L%];PC'SA$W?>WIY:60 M]OG""C3_@,VS5JYN**E$EQ^R#A*+54I:?9U$S;N^O MC%O3IUH&^+EJC5YX]W[&>T8:3:DA!G(+C?@WZU9?-$PS7<^MC()0]W^8@ M.!]=,Q@L'5%B38*#5$8*YSR+D*Q/)K9R`/`?;C]5YO=MG]TKC%MT71FP'IOM M4H=0/\JZY0<[5LPTI9C&M=T3+IP];1Q5H4._+%.!"S>^#<(;G.NI`=*QM%A1 ME7S4/0<.VQ.<3M^;F`ZF[<+S-3[,=3JO/^;4]W!`Q@I9@H+!QJ9MU:,Q?,MS M8L#JR]CQ[-"X>3@S+#\:R!Q\^3KG<<%!1GE+]<`9/7K6)'FD/^O\PU&OJUO+ MYS^0(@=_]\WUGNM#[]GX<6X#(QS]0?2&KN=X@XF.'=77YR?*8G?K&T>2>J&' M'8(CUTIC!.%.`\N%KP,N>J#0*,-3N7RET)NN4'!>,C97%G#CK<%'4P.I/&!, MW^/3B,D%(TH*Q%]4/PHM/31)6XZ'K?(E]+C@@OT]U@D9D4F`%(/Z+LR#X> M.TG;X)QE:Q4%>EZZUIF$KC,I*YXQP)07EU2=/)Z.(UABY&(>M#R*G.JI5_O( MO('*4W)N85[2@O#FH[HN9#^A;)>U/M].)M>,"D5\M)Q:#,[$_H-]U6^*GTQ1 M,=7-I+HFV[XFMQFN.YMEDKU,NCW6'7;562R/3'5NT^/;XO2-35J29H4*`O(T MP88KD*G68SF>(R;['[`^Y[$1$41!`$LCL7\'/T3O?A\PZDL!]X7+'7`;:PD5X`_N"6= MJSO)YU&J?`49#9,C,DRJ@4+/^R8#"FJ4@CI$DQXGT`D?!,L1%]JR(F:2"E;' MYF@$U5VT49-*5DB" M4`/VA0F*#)=/>'FS`4A'.FE',*Y44Y,! M/(!;LAFR2RL%:2W6\JEFCLS=1SI/=`[CE]"@)[#;JE9Q#'>(=]GKYU98U8P+ M1>L@WYZ,G;=5216M?ZZ6F:8:(/5.;F6`^/"9N,/]9?%T*)T1ZK9RZ"DMVRUUPVI2>&`($!V#H*:KL?`@0.#& M^XI-C91Q&G[K8Q=8\I_9+C)?,ZEAE&I%FG]@F*+.5'TK3OC:G#!C"GYF00LO M"[<:?W8WWM=76BGP'&G2Y32/.=`I')$,K)B*]D`2]X!N(>,91=PAG>B!M!=J M[EWRA(QDN18XQC"9\IGP#9GI%W:%L))JQ5EC#?(XP5#-@83FU$TV-5GEAC5- MZ9_.LUWEM&-GO*G@1^5>KTW7+F4/SUP*78L;:??,LOG]D(8S# MJZC@'+`I%`"!'@=#&>X+7.XG/`P8!&1P&0I>KGX54J>5`R;(70@KB#=4^2@S M5SA?7D-PA#L@.["4C?HVFE-Q9M)C8_5+\3'L_^P/3-?^RY2.4I`%6*)#\`;" MI0@M64B$^1"O1%$%H47"H&8(8TP".S?0F?<>_4/X!]XT>%<7-8(U1Y\==:;/ M(&^?38GZHA?&9:ZB8`99BD^AK,R00PXE4D*J\BG;ISL3*?VF95:8(<_G'55, M?/LA"5B<2RBQE!0*+=LA?08HLJM/1A%,9?WCZD(JJ-P'TY359E2V2%PV$K6/ M+S(8$P^"Y]B6*FJ6F2*YJG%9KT"+T8O=S@"*CP4T6&YEE59&?C:H*J-&TXGD M@^:"NCC/N9U*=,J\"Q0)E?-'CPH[8A"$X%)-)+J#T#`B9%"K>#9S(]7M$0]. MR1[*FTHUXE'`P:(:J.513!WA.+EW:F"E]?`U3S)QX:KW(P?&[(NLC*-Y;1]% MQN"^7M=`Z^`HDYO!A5!R9\F\+5.DDO# ML@$ODE[AX$$F9/-A&`%K,OU:SC%6C(A9!]=XF`#R0>>*)%=!24>Q&=TKF.9$ MM52H(7,560!,H,SEXD73Q-"`;QGQ8_,Q\/S'A*!K]6G2T$JI^<"XY*H2:(*H M21M,QA!*'%,WAP+@$9N%;2KD7X2>133&*O9+.[>?'.*MQ;&=,XV277FIJ"T7ON,"MK(\O))JQUX@"^0F MIQQ#(:A(](=8HP?40>CX,NV%C`3>*,I MTBEEQ%CSDVX&O!_/B@P3ZCS+[N=;G, MZ`#>P#=9VZ3F3ZK^DR1=<-9D@2PMH+$'3Z)>!]B(,)B0>*"D)C#@G[&5.>Z4 MBA$[L6(A.4>V<.G0'L>]?6Q5B?X%1GH6SI.0:9#Z5&I?\\4FFH5+XA(<(V$B M!T;N&W,$-E`B3YC&C.AC]X%`J85PX<*X'HALN*F+\5X/*+(<,)&"N@GMD4#" M`77LW*",?8I/7S7F/!O%?F&2_3*X%3ZY\9'FED`I#X;B(?6/ M-P\/-Y_H[3GD.DB((ADK1\5%D51C*IA,6`(Z2JE@V=RB'@?Z M!'J]4"DQJDXV==7)IE21?[TN81S,3JSOP#BW'8)Q]DJD*Y+=?&,OE/X)"U^D MR!\DZ5ROE>DJ7,8@*?0-\[%(3!9%4UH?*8HJ#27EPJ?*0U$4A1\J-VYZ3;[D M>&S#(MN9JK.4F[5.BXF?C9"!_+SP)*!Z8C8=Q-$H%QPXM=( M@/"NF(Z,XW]$I0`?]K"R-_*9QVA2?S1Q`?&6Q24M]>?T3BP4=J%J-J']DY/. MT@4GK6R5_:2VY\QW-"5Z7LWR<$8E`]ZR9NVP367TZ?MFK=UH4E%]39ER)ANL M(E,1K=(K6KIFA;SM3R+O8LA@!(HD`*7^,4T9D^>D]*ST&M)T`NEE3O?=5,F' M&'T4EZ/.O0$_IB*\M$-[D5B-,U$91*E(]*;R:Z%=3Q;'KG!93)6(E7B%*U,<,&LC63O9#FEZY_HBSEJUH[:A_1C!PC'<>?D M51=3D:D=(%.G9`!S>Z2=:&$H6M`.R#UH-?1DN+TE7(^L\UKM>REE):V!E+8O MS=%`0`2Q`WZ-+F!^J<% M/[W?P/9(I6?V"6"A4D[RY>K\X1_X(FJD'V_NSB_NZFGM_M>09MA;:"S,37C`S&`3TPS+Y!FOM92*MSL$V[N@=-6F-D] MS$A3W.Z0O-O3\_.KS[_%[+:IQ(^USB)9B9KDT4']%J8RR(TM1895=C4E2.[4 MTM\@@ML[M?0WB.#J!'\')WA55J`C1!9\J3:?-K\U!1!Z2G9JP6\#K3)'=Y>6 M_#80>W%[OU/K?1M8K:A`107V";$5%:BHP-Z@M:("%178(ZQ65*"B`ON$V-V@ M`ODVBX^G9__]V]W-[Y_/T5EX<_?>\`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`S=<><>%'XOF^_".O#.Z,G'.RPW;/=`;V'G\>F M9E_OI9_]-/_E1`_OWG**@/3'/\_D(VG;X5/K5#?Q`OX4?'ZWW[ M]3__XS__PS#^KAZ\\0>F:_]E8OF&,\\EGPQ]P.;5P4W_UA>!<$/^*@IL5P3! MN0AZODT5'TY=Z[37\R(WA-ENX>6>+8)X,J/GN2%\N!-]N"6-YE?X;ZO1[#QX MC<.O[0;]_79J]T+:^=M_]*O=)H9.="^A5"-G;@)O+^VH\V",1&)_% MLW'GC4RWQE_4C'OAVWVCR(_!Q^3R]-/5];_>9X;ZD#E"'Y8&(W:%R*R)>']3 MYV\G(7Q4?]CX!YT'P^L;^HF@A=CQDAXWM3BZ^E>?SR\^D^.*_5:KKSAV3ST, MA1&Y9F39Z*2"4VL)-^"_Y(V`#WW;-=V>;3JP&OAB!$@(C*'Y!%1`"-<8^V(, M-PU]7(8)=\*WX&EA/-OAT!@(5_BFXTSP%S'&T>D/3'0CCS!N-[""`_3)^ M9*9SW&HU/MQ?G,6?FA]^,LSQ&.XOD;70*X8"9O0%P"N`_!NN%Z)OSXDL`HX71'!6X$$S-$;(#N`Q?T1H>`30Q;\C&_&%:\Z=91Y&\]&7@V>)J-]= MVMI[')T0=CJ"Y?7,%$9^.SV]U5%R8.#!P*E&8].=X&1K.R6/$P,.ICF@)VA- MP"0,&IS0&\!GQV)$F;0,F.;/R.WAO6,<>)%?/'=-[@L"CXB`G:(]@"`>[$V/-#`Z:ZA#V#2U7_;]HH'&(";Q@"5F\9YZ(G1H_" M-]K-F@'DO'U@7#'"O;'M(J2`ZF2=-3H$T]UC.#H=%WO&=`DUH=/&Y[ M5@#XL.!\P%,U;?M&IB7X5.3/H`8)[!=C!,QO&$A$_3-RA=%N$)(Z!IP`NC)J M]3:<6#F?#5,E8\*^J(GX&IET=\S>T!9/,*SW)'R)GL@/A$)6/P(TXS8=3(LZ M>R/#;%0T47+0V!\/WW\V0Z!4-_V;>"/I^$F#?5F M8$Z+._?"##P7'@TGZE*I,_96A)X;H/:N"(W`1-:))`G(@(U417)48J1]WQL1 M8[AY.(-KX"!M'0EK`@]Y5M0+@P/C+/)]N(C.I$8/)N/9;M^)!/!L8G?$U:+' M/T4O1`$#?NJ%D:2;DDN']@A)'B!\'/D@O0!%DZ*&`330'@$Y!M7O23CXB"5& M^".27)Q6P8-A5;TAS0_L1#%,N8<\00T&<05%!K3_!\9O M2J(`UJ7_8H`P;`G@0RC*!1KCP&'N4?0@M@CK_&3"2@`HP4M$S%J(DX2QC8!3 M2-3:`:(NH+E`MOAWE'J2Q3G`U;,PD8,3_![]U0>ZX_FP&5^$)@6)%P2*QE`8 M'MJ^93#>(A]0\._(]$'2,X8@H,$_A%WB:MK1<#S8%!:[`"[8[&`,P@\+#3T0 M3P(:?F3ZWP2Q+!S>M`"MH1W@9P0#G@])'+1$`.<0T`:X@3T;@3R2WC\K\I6P MDMJ*.P#-C:1PZPN'.'@R:<\+0CYVFA08XC`@40"+%T&H5B=Q$0B4X6(,T!8A MVB,0#=7I2L:R1,_!^T\H#GVT?@R%Z&*#WE!8D4/'U79AZ;"_*9D1ITB6#V\.?'-$ MXWEC/.=_B60UZCH%^R@0E./16T9Q[3;!MW%'=A( M<1E=,"ILN>W3$XN_2Z'50)Y?C"?3B3255]]LQ3>1Z_1Z?B12G!IXVY",%(`2 MXN]*GS7'"(QOX\:E$%-+887T:3P4O&.L;TM5]HED'U@`_A7S0LFV4W8I&O\T M'E:WR-2`T9*A"I!B1*Z-ER!6Z^T@1/R,1#CT6"Z$DT^B`:S/1".2A@C\6=X) M>7@"[2P$I.0'\ZX-2AJ/)MI_8!5#F-M#>Y*CR5R`#Y:,=:$@):XII3Z^K8_" M0<6>N#B9?D!B,7'/0R6^BCFWQA>Q?>D`Y,YX5+@VMG@.8L*B#&=2*:[IZZIE MEOQG9`UX>%BFJ80E-.&A%GY@G*(0[\16BAY9K2P;R(G/N@-LAH[':0%DYWCB M%/&>XZG;`]9S0W(E8-^/E;::<09\N'YQ\;\7N(@^$&ZU"AWR^\D(^'4LO071 M6#V%;]3I[_=LT]7PU&I*/,'SL3B'+\1(*QY(>QTA!=F?=$['^PL4-UQK%`)/ M^0O/J,&4"61L6-]?0&*,`6B6(&4#J4+R$#G,<5DM!"&8+7DHS.-]=0@I3ZB= M>7"*`3M"*@=2+20^%R5L6]?7@@G<&F\$U^!27FBB0R`]L^4Y36!F4]$,>Y%D MUP[4?L4,RT82@?0,$F%9M M]]"X"3_!;U(3H\]//Z&9FP0":9X'E1_H)\X;#(73KSMV7TBU%]7\`"24&`B@ M?[;$%O%Y7-J/,"0@#8&1(R;\4^ID1`?_A%]Z$9!2T%F4+`3Z:AU(&NP$:S-C M-;1)MF94,N@;V+[4H2YY6IM'G=1Q,_+/&[`=UK64W!/Z]F.$RP-NBZ>/[`=K M!^!_(KOW[9,`RKK*B'2ZU@_<#2C&QOW8-R>D$YM.@+*F&R%S`Y&P-@MC<(W( MM-M#;C$`@0$NA83Q#U`-1G!QS@R8$$0U8E^Z<,!&X9<5EI!V\%R@Q4>*HAM$ M$"UO/9NI["0U&G-U?"2&EY[IPWW4;GCF*C-=8CJ*8MA@X(L!T;((OG&!'RD: M(#=>,S_A?26`HS%+_[&A<`8)U*00<[ZTRZ!,R_(2*@-V M'P^:)"HTBX(2S3DQ^<'9<0`8CT4Z$_]+OC!-N".AIR;U$Q2JA)6(1"`,26+$ M!D.D&4ST8D%0FH18H'JX[VP$;6.,"AJ]YT\:[08X3X;VD;OH]C^1<3")'G-T4`/8IL#$I]MD?RD M?.C2,C]""VGLK_*%4!YH#\WZ09!2(G47"^N:I+N+!&<'C$7MFU@*I4=1ZV42 M91&9([/*$Y-/]`9XKI@HJM:/7(M5:F8RY"0@LP[+Q"^2A)-JBQ$`\CTT9`#O MB`A&(NA#SP_K0&U'F>4*\D'$.-EG2E:*5F4)W)62IU>E:2=[0=/VSNZ]"$AI M3W2\L\8?RJSW5CS0R=)`A:2['DMNZ+#S6=T.PAK(37CGR=M*9JB^[0=AW889 M^"^,G2+9S/CQ\NKRYJ>:X2DB@EIB/$TH1BPHFB"C3?YB0V@\.$T6F^!3-(@H MG::^QR;65#03C@PD".ZT#6*T!0)AF(W\<7."IG1SLJ2Q(%^:STCC`'.F`[*D MYW]#LDIN/B+F*,B"L&L.$F)*%N?_FF?1,?Z6V:*_U?X6X.;\+3]LNGG039MO M1K;CT*IA^C7/U,R=J:;9],D+[U+X%^'7&'@8J;7^11]M;=&=$HO>9V8VBR]E M^=>M]'7<.J8;`O>[4.Z.5?E9L_%],+2W$F>N#D+-H*/`DCY0:,'\T/D2F1A0P,N6M`L`2I[SV;^$P7*O(Q!)1AF72?#AN8&2[Q% MFE,T\L<>!H0`.])&DTY59,ARMMSP:Q+4/;3"4(@JQB41'5;6&(O=DNP'!1TN MLAU+10;9(S*X,\>L&R&;WM'0&T[J+H*.D:L!$$,,,L2U"E+ MB4=.6C;[W=G!MS-?6':(?RU.>YL5[=TGVIO:>[S.N.MO)M[U,J)KKV)(:AQZ M0)97D*&E51=(4]\FFXKCR("62%E(TN&L:,'FR)8)!]E@3(9,HDB\($3TGDS; M48]2L(*)MY_>&PBR[L;Y'.D@RMAK0I$2\%8J^H8#7@;HX$3-04;_2$TD"#RD MZ<)*"+9F?,;-Q8#>)"(!B`4%/*.!1B0^`5P0$CA<(OL/!6M@KBE#&3D>%P;Z M6>4NI7_:B,._V!.VJ3R)J6RS*N)EZY0^EG>! MKH=^Q"21O&9C#V/$;(K[4$L)_P)%6GXA4<*C&3IKUB5ISQ<1"W5`&#')'2 M3QTG4!Y"CA`\I9.1LN]Q!@P-^F@ZK"\!`5FKT>CHH#W;/(73/YKNMTU.?Y@[ M/7`#F6/CA>0I3X"HK1>"P_9AK=%HI*'`=?8P'9*E,\7\0%7&#%&VK`:13SA9 MNQWO\.`D?TL0JLBEF5F73YV6O:0!L=:0)@9[JQ8\S*+05@NVQZ/*0Z/LX-$ MH*6"J\`YLA6!GBZ0OC&DF!2D/R(CEZ,Q![J(Q)VA:AY]"#1"&(>I M,!'E23A.AE6<)&_J.2X0(!44E!8Q"!U^9@GRT?=,BXU(Q$=C(*4OA/(9)B"] M^O!`K%P`;FPRE`_HAV M%R]C3G!(MAV%@)HA;-:;*`&=(BH]S*<,4 M.?Z!1;'9H*QW\C1__"'KP9):%+-)E@^G44C2Q13MF+JJ^MDJNJI3Y`9HHI(2 M\"Q$.0D*%,1FV1;=7Z_?1YLN&3YX\W7`.0K%36+S4ODT4[PO_XA5''$'."+2 MY"33BJQ!B:+#A)T,!IS=P:'LRJ"4ER$N0T;C&R>L3=[]DV;.W=_L#,@SZ3;' M6*/L(BVT.+<>B'81F+RFG+[&:4HE);]-<"?>70[?D$R"XTU9@(DM3+,K"5S* M)]AK0R:H@D(J,>Z\5#6#9Y$YMEK>FP7$$M2XGK2U[K679XZW9BI"+,XMO/'/ M[0#D%M.YZ5][[N`:BSZ<4AKARM[VUJYZ?"KO#FYUW:$"'[S9;\6Q\T7(8'QI M?)$!IARX)>FEDRQ>YB:3O$(E/&PTC5/"+I:`P+PO`^EX2!J7)I+W;+\7C8*0 M15Q5'XH%\#`GM%72?CD?BN@H13VR;(Q_0RDL MCE(#*$E&HZ#_V.$>N2KQ5F"=E5%2"XK<7DFI*_R!,C8D8,!!*#P8UN'*-5?2<$U?A.T()1:0>H%[8;9T@Q,Z1")EYX0 M5B"!T7*Z*3:8]E5&$RND)$GU\1,(5IR?^^_(2ZJ%<.I;P'$--*[D!`PM>^O0 MUD\.+4M@\1(A0Y5-&\AF\$&R&1H(E3XOE-SU`[X$#.U/F3PWA7QMDS#MWD!9 M2@]O3->%DZ'9W@@^H?4J%(F^'XL`J(\R.E2^X10N.%T2,:[-C\7[`+)T(;1$ MZ=:ECR0+&%-^?([ET)*AD]S\FB9O3<#[II(M:PZ;2#7:<#O63-.F'^#$N0&F MJ)MQ?8H)T0/I[@:)D1XQN1;/HPB?N?P?TP^0?FV4+,G+P\1_!-)WQ*>/DN4H M.35VG<=UDN(Z!3T9"H!5/GP-`NW2:D/B862IN![:=!KCIX;P&4M,44:OA_4_ M_Y*9%+8[C@#`*&!DR.&T=Y5!#(>,+_Y[XYH\^LV:7N#*>P25B!5].:PDV(JT MSJ*I'^1PK=1P<@Q/\C'3+1I&5BG!^&JVNUEPU7LA6]V0>ZI/,9Q\V7GR=FKR MR)U>39+9"!L1HC[K8U*SW'#*7B16'-2TPJ=LT&1B9J`IB4-!5-TGC"/QGE-E M)_99UUA&@<@J(7B9,8U!W/1C)^U5XJ/EMQ?7.MIO3^O8P025L_E.R= MN.*U;7XKBL?9+"]R+=6*?QBT=!AJ'8,C4_HR[>LWVF7*6H3I94R7*#=ZS9(/5>V3C2 M>7MD:O>-(S$4:3(EM]?0]O>MD*7[N`"KII:GDG^?00-"5S)*U$H4]EE*U)V_ M<JMB#WJ9B2D`-.NPJM0@X9!:+1S$[,7%AZ=K960746FFK^,GPQWA4FH3 MKMHX\KA8BMHLO#!8KHDN`0>46UH5%RK-1`$*!M92Q*XM7#-)U65B'QKI/U2( MWD?'$BK!OC24"4M:RKBT+IWD3.D6.K^J3\,($W^P<%9X?XL5@YE#$-ECDR!PF6^7<;-;\Z7J18 M&B,=5FZA7!3KG2@%]>%N!0HKIBOGI'0\A^QLYQYH,-WU[(.O`T;#H[O2S&%/F M:$&A6EHE3SZ'>@3*\]!CE&-3"6HL$H(L3LS:$K(*--%D_5.6(2I=+4S[I&'O6C3:EQX3#T#Y@3%>0B6]?H9(M0A7%@ M*:]X7'1.%D>7,6B;9X;KJJKS1GAA;BQT3H7960*@+'J`-'X[N?Q:_=?$3S,M M91&)7S-$,\*W$:)2U7)5Y'E.@-Y.8'Q&R8C]QGBJLILY?=IGA4P^BP379J;8 M=)`M9K?N2A;MH^E`^?47L6@=3\V2C7E,>G(D9;TQOM%7C(Z\-8R.Q$JF&<_V MVOY4:$K*VIY.D^M[AN=O9="(IZ9^TMFD@Q!&.-4TS[&.P M9%S9FT>Q@]F#4)4KM9Z%T$=R0^2K(LY)J&:)$$V.R=Q*S:CU\[AN:YJ33L7K MKH3'DH&N&\!B9VLUOCKERETA162!R98-,VVMVTF8_.XL0WQ M:68Z9\FDG+2DQ15_V:2B<)?5!J;/XSY+5P7"4E:VNIN]0]`AB-?6UG$ MJEH^[HC85;+!H\JDQ`NA#L);$;MNI5F,)195UUU;\%`N&'U4F*FA/'_*HNO7 M-*TUD1PXJNS)P\X1'*JER1L]!PBQW;?YE=AQ=D4I860'5#5W='\;M;F0#Z/;@SCH\GA/!,A5"\Y="%1SFE2O@D]#MW=G\L/7;8]M/)!$F4\?1LLC=N'*(/*@_U+:&VM$DDU4?' M['VKW_>&V`Y.ODM$$AU%*ELKN>6T^^(:>ER0DN9$6`N\5UEE2KOH$OM&:0.JJH9FI@_!@(87S&[L&= MGPX8L-2%%2_"[]D!B06R0V0<\I#.MXDP$3XBUZ_K24\Z%:B0*5&JPFB2\4PM M;.1ZLUFKI;)5GX64O"SNUZMZVJZY+$UG"_IK9UI)SNJDY.O0F$`NY8Y;3<9M MA;2@U9@D2X9@!T$D_[NS-[+,N7 ME,IS"NO*2&YX[P],QX>1KV2>VP4ECRR;_K`??8@JTX-4`-3F&VKW#=[^MZ(` MW+C&)\Q(,UHMHJ\-)*LUXW;H!>,A%NFT>X%Q+=M4ZD+&[?V5<6NB33?=\Q>8 M\"DF<\)$)HK,_MACLIP=],KM'61'S`QEG,.5I>+@VC@R&/`QL"T;8ZV`J"6P ML*OE=AB1W_[:?,27/)\*C5Y?GQD_(FW4YOPGR-RA\0>\&?EBYNRJ36>2?B@; M?M@_8L1FRZ^[A]I,JZ]X&AB%Z0]=SO,$D M=4+BAU1'2/@"DWT1TW%/*M#=@&'*TF:6&(=4V`6X@-"*9:N$15#_>A%W&3?& M7!U6P+)[6)G%C;!#8?Q1*[\,-S4CINR9<)):E5X1/PE#R5<`L_$H[+_'%*FY`^Y" MG$3KJ+T%=;/5G"[+F_7LET36ZP5#=+O-K=A,IBTS"Z(J6Y=/F?RR=[#%K*\&AIIMJ@E`K'LR751UNK9UM0O:6M?$9 M_C?>50.V5;R9.,LO<3QD4G*,RR#'2B/EW:'&H*IQ4C%FE68;1R:S9J?R@D[T+B)DB7"D-JD^NLP^%A3)D90&$$JKH5 M".(S9B7I/ZE)F>J?'+='E^^J$F])"1KAPFT=J31$+7N7^#=,!:H[PD4UJ0Z, MWT$9SVC+_&DL1@-;6R/]*NYA&M?L%:2# MR21D+FHZ?1JH$),@)Z)**4R\,=V?*I_B*UY_$^M'^"E:&*VH;_>!0,.=[Y'KD=<*\/$=\X5) M@>YI.TF,))@3"J3,H2NOB84S-CK&7-)R,D@-EE^DKZA% M;77E-YYP:1?W-@8LT?[.^&9<^F M*'\V$4Z-[5)[AWC\1.I`JA"Y&L_7+HBD,?@-^]=;C<:A+#/M8S0+JA\FEZNF M!#'Q8L:U/A\G=+FN[NYS1NDL.(IJ+<8=Q6`H(I.<$DW7"%Z+C9A:E[)]UH=F M*3=9)0A.Y"EGDL#TM[[G>DA(M,))*RM'.]LE=,U-`G9',YK3PT!I26OU**0, M'7<"V1QPN"L.%4A.%Y8UG]QY0OSYZ-0./W,04IZ>^?WO^>>OVS=T#@U)O-FNX\O.7DM\2QY8*N MHY%PH!G&1RGC4/5J$Q`2&C=QW=]KK`I]AE'GD@2CMG'/'6_H;7R`RBN;])&+ MUJ?>,"ZHVJ9>ZB.S%`5ZVGNG_0`"%]9BRD?/F6=1#0E:XU&GD4*`;B&HZ2"0 M(,U-C%A"=>.`-1G?#KB:Q>YHP5H;A[F/!D-5SS9)19P7VSJ=36WF*6Z4"4B\ M/:G23#6\>YG=DOV)8D%"[A8IW+)]DKY;5,)*JQ!#M5)3=;TD4_T3E(X`I'RN MHO)`A<)AEW@1]#R6Z>&S2U%\U!V):G]3)[X`JVX1GZ_))#L05.V1-,L'2>8H M.JGE9+"`)]E6]$U`&$FF7T`L2U$S!AD\'(T$J*LE" M<&TU5;`Z&59U&:7]LZDZ#M=/DM!9,OH13HY^R%5S'BZ/@C4<`1/8JE"VLG*5 M:)AX.),#I)2`6KH/B&9^\'RM-OC!.IE"BB=L=.!U,PU^CX)'FT_T]K8UKRG@E=TA2%/$UGVAI@[\&K%G]$? M8R9,:!#!/:2NF"Z0'*`F>)TE+^[4&R>U=$4KSHRB>WE&M:!ZJGG%F2HEI;&H MFD$Q,_R29HXY2'!.Y`1A"B0W5%:\0+('#+1QD,\\"38D4?*"K.^D%X!RXHY' MLDQ5#%I2Y.?AG-GLMR5T+F>NA/O479NHR+@?@RU2]5$R+ M;85X1M5E*6!DB22T"4M4/IW='U5_414^)W29;D%D.C>/CK2/7M)A^1<<@D^R M;O2][$GZ@!"L8`_8V1Y2^QG.O'FHOT@KX%1U+S0F)F9Y]DFBU0^\=E9$GRB3+RB&C_?7Y_#>!DA2(\$U^NSA_^@8\W?DAN#1,V.?G'F[OSB[M8$OJ_ M)^+Q$$@S8,4@HOS!D$]<7UP^Y/X>(Q/V+?Z?E,CD_-WN#_$X9S?7UZ>W][`( MZAD\#L0'X^:/B[O+ZYLO[PVLI$:-/N33)/'-!NKNZK=_Y$%52(2G]I$QXRNT M_.."1VZVQB_:[]8LM#7H/T8S@5#;':-'X=]*M7GXUS6LWO7\D>FD=SQ[^$`N MN;F^N8O'GU*./AB`N8>KL]-K-14<(Q!SY(-?Y"HZ#5@Q\:U?WC4/?T@14/R; MKV)R>)$#3/-&YDT91*QGF6M8UO2JYJ@D^6O9XTV%Y>-]@A,/A[HUA8H+RM(D MF3-6.*H-WJ<-;L_?X/O8]F!Z6RLR`37L^Z/YZ> M_?=O=S>_?SZ'`]/K"="?%T!&2DZ9/FX+L6$4A9?8$OVTM?&1;%@IH&[W' M>[VS:UX_U:'/7_[MZ?GYU>??E!C<5:K,SJ&D,8V3;J=9G?7JK+^]L]Z:QDE3 MYH549[TZZV_JK.?0]<0Y3J.[^5U4G]#D_J;HEZU5FMSNIBHM[W?59W1M#;N%WO MZ'N6YW=A>6^()&U6^WPU0:\ZJ=5)74C0JTYJ=5)W\*16-'5'A;R-6_..OV=9 M?MEXX3>HF2Z&@'W572N+8'7:W^AIWR5ALSKMU6FO:/M^":QSMGUGC)++YD*] M&;VD\$ZWX4Y;7D29TZ^O9*\QPOJ_-H.7'=+.UQE[W:QUCU\M^KJZ*-5%V4ED MY8C([2K&LKHFU34IYB?'WS<_T>7KI`J7&FBC)0HW. M4ZJ'Z6)GU[BT-35+XKJ[>&'<:"2HN6\@NZZY'K4*P"_DT[*Y3U*M4M5&C.LT MU[C69=_A=D.R"+(JL(N=A9(^#4FEW1J68YQ5V:QFB)>>&--DW*]=UKG<3,TS M>3IGD[U453"M;MC(']$U]K*15N]@DW]_9+A9D=Q$R^X?8529Y24Q2[;2JA8ZVS M9-2J1\<$J0VF*J[.57)74TUE=VKI;Q#![9U:^AM$<'6"OX,3O"HKT!$B*SA7 MFS^CJB(V*=JI!;\-M))IID+L^A%[<7N_4^M]&UBMJ$!%!?8)L145J*C`WJ"U MH@(5%=@CK%94H*("^X38W:`"^3:+)'RC+CM@^(/''UN-3JW5/JZUNMV?9H6M MY-DUGH=V*.KH,Q3O7>_9-\>S8Y%F+X@"!K!S'H41X`^/_L_TT(_8`_>GQ/U: M$JW2-=KZ80.'9WIYRA%;8K8?R\8VY00NQ?[>$O.T:\WV\NF#"RSHIWW?D74D M$"^R,\W#VDEG^0X2FUS9SN[1MFY-XZ!Y4EV:'=J09NVHVI'=)&/=VG%G^>KB M%1G;+!E;/B#X>[HTVY/&3CJM:D=VD8P=UHX:6^$P%1E;G(RUMB(G[_VEV9XT MUFE5TMA.DK%N[>BD(F,[>6L:!]MA,/,O35EC(!GT%K$`;B>R:0M'9QMW>A^7 ML8\P5ZBO4%^AOD)]A?H*]7NRC'V$N4)]A?H*]17J*]17J-^39>PCS'N-^FU$ MH2UE@Z+J-/:3"*8K>51'9\>6L8\P5ZBO4%^AOD)]A?H*]7NRC'V$N4)]A?H* M]17J*]17J-^39>PCS'N-^JT$/Y6#^&9,56>KDZ+/L6I[H.IN5ABO,%YAO,)X MA?$*XQ7&*XQ7&*\P7F&\PGB%\0KC%<;COU\I%.E[K9VVH;.W"`C;LU56FUQM M_77VN/]S*4V M,ANYPKKU_N?0A(4E']7.(5SXB_'H^9;P?WG7>!?;Z&TK'+YO-K"'#CU3=\R) M%X7O^_:+L#Z\,WK"P0[;/=L=T'OX>6Q:EOPY(9&SW-#>.-.]/'L!S=NX_!KN_&U MU6AVWAFV]#ISH:GW@6`3AJ-*8@RDV7AN7*?A!MZ_N2+YW^["`/![ M9SY_,D/AVS!\>0@/YT/8[&8@+#7]FF!NMKZVFPAS.PWS40',S;7"?&F[=@"' M^S?/LQ9`['$!D$>S@$S-MRQ4LU!W4@!59RFHSB-QZ7NCCZ;[K3R&VHWYL!P= M9F#19YFZI9Z+ODC?Q*HP=W;P#:@/?F$.1#,-4:/YM<&8>?!BR-I?[TU'!'<" M5AL)6N-G$7X2HT?A1P'.,#7!Q\E'X?:&(]/_=OIB!^FE-;6EC>$NZVMKO?NU M<7#2U"[]'-C7L\[D-'P][?60JL!2>\)^0EJ\R"J_/CQ[9U$0>B/AZ^]],O_T M?/5#,(V/5A$^.H=;PT='V_?.FO>]O4/[GE[GZ^Q[IW#?CY?#!VW;J>-XSR:\ M%.10P?SSGP9O#GL&<:'9.D[1G[PY5X`KM3]IN.8P98"K?;0P6+#[?B2L:]M\ MM!T[M$5P%OD^X!:8X&=`.W^81[J_7@0A@``"W&44PD[*>P-_NGP@QOYX**O,8[-[7^13)(505\-!1O8_TZ!$+2F_?_#!!D7:/X5AFN)(+P`V,/) MS;,+5'MHCQ-".X-6-8!6M24>&E^O[9$=)C!,SKS1V'0GIP-?B!&,PSBQA'TM M!J;#T$U671K^[,(_`0,3(>^%MC,7+V/A!K-6FY(,TT"WYF]7 M)RL_SY]_+=#.YB.==@&TV9NU06@[Q;B=K[QW6T?;AG4.9@L4^RD5M!RT2$;> MW_IB;-H9.A+3&U!>1QZ5OBRM:'7FBQ/-8P9UH_O#="*A;%?E<9SAXU^!47RE(738.TC6`/"N+O06 M`C$E8TJKFK"0\,+Y(8%Y<5HVA^_"L3@Z24N9N9.N!-KLZ]6=PQ7S!//UP59, MIKK-N;!U&IL&;0[:YG`G-']VE@`-K@\_B MTM_2RDMO^B&L_&@W5HX4)@+1_=[KA\]`=D".!YAMD.A/@T`LBH/T,H]V9X,O M01NV43N&,2[M%_QKT4N=7MLQK*V[VMK./#2I]<+(=&X>'7M`5/X\@BWX#,MY M>!8.*+'PS+"\0-F=I[&WD=$TTUZMTB!L!OBO%Z.QXTT03VK`(-';,X:-9)ZI M[3B(/+CNK+*SB77?"UBH]2]A^J6/Z>$\ M91W!;G;*PIW,OFZ(UW8VY^GZM$>[L-AU'<@YIH+%#N0R:WT8VOZ")W&>N6`A M>..YUPSNVH[AO'@"6.GK+G)=QV^>>6+3VWGI17XX7.SXS7,RE-V49-YUP[JV MLU<@EKSV,M=T^HX*I)#-+=/N+WCPC@H$AW*@JFG7#.FZCMU1@9CQNHMCACZ+\*PX5"(-:@%?;K4[[:R/>^:LJT$X`YG'18I]NWFR-(1Q""4\4AIG MQP6@K80[/9RG@B"W9NAH%T MHP7TO77<.5H:0N*,TZ&0Y=%79,CK''53P,V8<&FX M9B&M@+P?'1XN`]8JF"H@YMV3;BL%TGJ@F8$?N&_SP>D*PD0DKGIIM&7AFXJ=(K6AU3PX7A$?CP,`\5L)6$8>84D2+ MYEX=UIF8+&(B4]KKHK"")D<<^=+S*:4I<8W,2NYL:4FGK0RX!^[4%LB0_,\1>L=O^IH`?1J%0\^W_Q(6$.^K((@P"_CF M2?CMP[SPW:;./N`/_AN++SP,O2@P78N#9YE+78-P";/Y`M"M1YG?PY3A@U2Z M<^/*FZG"1-01(=!Q1U@/WFT4/GCH00Q"&,2] M<<6Y;SZ?>\_N9R^T>R*AQC?]4Q@;_C@W;6?RA^=$(W'C/O@F9M.O`]FOA<(YDU%`'T=EGNBW3H10EN1M MY/>&9@#_PH1!Z-L]2BB>>O.F'Y3!Z"Q@/^-XV!5SMOO@G([I'#"^L\\H'=P"2V9_';O[N@ M/]^/`>:^W8LC!LMF!RIA(H4U3(7'01@LS"'T7#*,8Q[D>13VAG"-9Q4;V<0> MM8JEIL.3XU;C2.W3X@@K@W"RC;UQ5!>4+FFF-(Z%\%0N^?[4]S&KEI,SDT>D M+>;TV?2MFS%=N)LH!/W&1?&+I>.Y4;48@-,\.3E*I87"=Y_-41X:.B5.7*8< MV+J7LS9\*=V!CW^B-A3B"XL.E<37?+V&3DZVK.3:U_.Z"#NW?=$#ZAXLB+G# MXI/6:76W@[F$R:UPD,_QNEMGJ(TZSGI/V5$QKKK'S:-N0^?7ZUO*NBG8;_!@ M".R?J6:I%5&VJE-<>XR^W M!L^")RY55^\U3]Q:[G]Z:$V&4Y*D3;+/&DEWM,046EG*_"2` M?5BLU."H.54![P0\Z9.!DJP`P<4+_&8'Z#0@,9R^74B2SJ"KL,!Q4YDC-@7T MNJ_H'P"9L#!4_`4D:"S<[^%7&A!KEW93]0IG7=J.9*S;7F?.R4/])M;"_925 M]M6,.:DJBODEJ-,G<[)R\^_7*-<*A,+!E0&AX?<,T>C"'`W,80DZ"7^,S-)4! MM(X^F3UBZ+X!E$=]L`QZ,1R:KM%M_&`\4BA-SS8=PU,B@1I-EEFNP8Q!$K)D MC,P)3`SD#+!F>*Z:M>_Y]*E'HA2WO<^,="#IXCP81(\0`[\Z)A!(`+\2`L[,/2H-,,<4Y5(/D?('`R\B@"%<6D'/1@< MOCL^6$$4S]VEJ38OHB]\'ULXO7#^UPV70W<'UUX04"(YG#J\H<&Y-P(ARN[- MK:>N'CI#'ZX_T2G-E0OH$C@1&X=R"H@WYU5B106EWAO8MR8&P)7J*]#LEHAM:G:R=9I+@5MR MD>1WVNP:"]JVM::<'&4@31=UEU''#]YEY%K_]&PW_`,^1UB\55DM2JTM`_G\ M&)^43:D4")L!>N$-*>KCTEAM8:EP)\X1(U,%740JF6,_1F3/N'+U\9;8H()V M+*W42I:%:^T%?1;=L'FU7*G'4CI_=*GJ.1Y<+>P#'OK7R>?RE12F*YFS/QZVDBZZFE/E4V=U86FW.191'X6 M(;-H9)RQDOK@:;9M*=Y3A]2%^SPH(@;69%=LSWU?,RSD\:NS"'EC-G M=X[FNU7E[IQT.FM:3FXO[L7O2+;$:7YW(V#Q=0Q336#/G7X5&.>AMET>QE9G M`S"6.NPO`6':O28*B!O`@[=V+'JB@5":$7;#95W.$_5*G MM+CV^!)PK'\)\Y!?P%Q?>PEESGAQL?&=6,*\72@N)+[Q)=![B]^!XQ+\LC3X M!,/ZP)Z#\>,2?'';8)"^QYV"X19[-)L/.[*Y8ZWJ48:&.)*[K6 M%OBHK6KF(1FK&J&4JQ?'I*-U[\5IV4 MX.SEK$*S8-K,DN9M4YGHVE*6H>TLJ5\XZM-TES=NE,M[K4A:BLDO* M\K"E.5&VU.^R5J(9=WXQ..>AN!3[+[84K01GF=-=JJ=XL;5H+7#.P^?)>BQ& MB]#Z68?[U/HS8O]YJ30VC>%H;MW2F=$I/+0:)73O3@-TF"(*6[RXS>)H9LKX M&G!40M'O'C6/VH<[BJ/\Y+3UXJB$[-'NGK2.FCN.HTV>HQ+"3+=[TFX>KQU' MJ3*N8Q_FY$!!,78$!=JZUNG(\T/[+_I^9N>-TE7E6D7EHSO`TK(U]-<"XO:6 M/J-B6ZNH4G6GD6ETLJFE:Z?WUO1O?#JK'#^7;XB8NZI2DA)7?6DT-.FU!!1S M`)?Y$J7J"&0`+I/QWFAD8H_F3+T2E#/16L*5OUXHKPKS;C,0EO#.MSJ'[6[K M\'`.A%>I7-B%H9N%OV8)`:;5[+2/&GHZ5$GH4M6=^<'R>&N6$1O:[<-&MSVC MGC3/N!10,]%5@D\O`]0]<,;@#O.+,#:WE"";`:R@U/5))]-!,C/C<@#-UA!: M1;6NCTX.C]<'4+%JU2HN;]T^63]`\S!46,,ZP^(+`,*N.3?]WSS/H@K7PG^R M>R*X]YS%]?K6W(+5U(NPF0F6G3GYRF#.0V&!(;S=S-13WP"898Y>@65[JIW4 M!L&<@\UYQ:=EC_/NDF#^YGM4?7%NA?)9Z)M7-QKA.FQEZF%ILRT.R#P$%?0W MZ!P=M58'I,2!FE>:F:A]ZWA]<,Q#2"&1+XV/>^$XJ(.Y21LPV0YSB0-3J$%D M]FGVY"N#.0][16V2CSLGFP:SS&$K:I7!Z&BSKG'#6ZJ3"&P:VKG3KP/6 M>:@MX%'=;G,[L)8YMP6,*TL8-@[K/+P6=?D\:B\/:YR!+'^?E38W#Y=%;.LP M(YQ,S;DL4/.05L2ECC*4=&6@RIRZ`G[4.NP<;@:H.9CJ%#5I/LF$.)4'*HE# M6?Q4=8H"7YK9BJDYTRX/V3R$%;"0>CMKX%@+9"7.5Z>`6V`(U/'F()N'LZ)T MRG8ST["N!&2J7PP0.NIXPT\N<=2*#%8IP/)G70FV>8@KLEUM"K8RQZVHP_.F M89N'MP+ZOPIL2TMSG:)&S[E`S>#;N%I46 MF`J]?M.8FG>FBDH63(5S;QU3,(2D8X6=3F>>A^),RX(Y5P-MW@849U!N!+0R MMZ@X,W*CH,W!VKR"/LN!ELI26/R$S2W54YR8LPPT\]!3K!'.2ZA9!)H2Y^BP MA!:X)MR4.3HE-+\Y"2R+4_-;X5-Z/)J_M/C#)<[8`LGZ>LC]TB!N>JWS=FF! M]`(];'_GUEKF?BR0HJ"'_N_L6N?MZR)I#ILXPXOUGO^:M#>^-6WKRCTSQW9H M.DL&,A\6<-1.^["1B?PI;%>_X(+N1&AB86*5C['D2HZ*DAN[[>/N9E>2"JY; M=AE%;!L$Y/:&=T0+J5QV%07L/N-9*+&"^:EMZU]`J6S%9@/6H47*%B:[+2Q% MK6,I!>+%QB3`-9.J;&6@[:UC712J4+-=FPP\H^'+.NA3><5U+O1)@@O6!LT_ M*'2='K.5Y*DQ46"'0@;Y<2GA.]'S!BZ-LESQHU91Y:!F)I!MTRO818RM@QR5 MU^&_2PROEV@>%\715H=Z;?3]N$!T^][1O`[VIQC^'+1T7V*HZ MQZW#:6&Z;*W]M0._!@Z1K;(UWS']RLM=,[DNBA8_SO9`?MW5KXMR%I?.W)$% MKX6&E1>AU[E:5DZW?IE+),6VFR?'K<;16MJA%%@YUKNVHERJU@;L-!NC/475 MP3K'W<.&_-1QO)ZIW!A3 M'?Z6COG+%NZ:SMQ+JZBEP%@K\/,07Q3AF56PEX+^RNTA01'G@O^]QY M%(!6(NPG:CBY..*+:G=V6L?9*-!B.-8(^SR\%U7HA)TYW`#LV"'+#3W?7B(/ MI-THM,9DZ/G<^=7AGSV+E',?)RP(07U9:JKM+/%FW*DPJ.IF-N2T*Q]'?/VH:B14_/HJ(C` ME%T'?(6M\VY][\FVA/5Q\GN`3=_B-T\!I"?9(JDK7>U4RT&2]9]*[.1S0*&3=:X>>T.2Q=X6WD5<_:G6<3) MC]>TB!D;RUU%-W#/FL4:X6ABF)X1%X6YH M@#/=GKCI:Q:")?:O2-\^25N["T%8%\SS-J'81'^X&M`SMNW2=N'53=RBH@3* MS"ZL!M]65CMO_PKDCJG]6^]R\SOYLGT[*^`LL95%@D?G.%.$;`%P-K"4>?M4 ME`EZE#&OKW\IA?V?XY##5AKVHNIE60E]J?;.J_:LSAR=HLIFG4;W>'6@;_R! MZ4K[(ER7P'-LRY2VQUM?!-C9&#_>].7],IW8V!R?']X;3?S\8(]$ M8'P6S\:=-S+=&G]1,^[A7/6-=_]O$'XP,L.=75^\%3?6`PZ@\WMP1*>3`^&/+5CS?Z.UWANG8`_>7=X[H MAP0F0OF(?WSV0F$TC?]GCL8?_F^SV_A@Z+MBF*YE?(P"VQ5!@._\_*C>_AD6 MN?X%+X'W!.T,&Z_DL/%AL_`^7/Q_#_6KS^<7"&7CH-6U787Z918QM4/`8FZ' M2"ROS4=X"HC6@?$C+^ZXU6I\>!;QA^:'FJ']$@7:+X;G&Z`8Z[^CB=ET)]I# M/]7@,=IU8<&]MP2_XYC/@>'UZ6^Z>/CALW@R+;-FV(%A&K".J`]W"6ZA7X-/ M:`>!E_'46%CZR7Z,0@``7C/ABR?A!W;?ACE\TQW0:$-O)+RQ&0[M'KTU%*83 M#HVQ[UE1+PQ@:C,T,)7#Z_>%#V^&'H$SX#)3QCAZ=&S`S!=!3P&!\@SA#LP! M/&J[]*@OZ_LP5$F%'YQ^#*!5#AJ8`-QW/'1C/-GP71..Q0T2K9H`H$*"/UN@1N"Y6PPQ&HB>BT.[A M>N3[!ULXLNL^L9F;MV?W[2;R`?O`X_R)\2@I'AYR/$+:,:\E!QOHHSKSZ#K% MS0R`[^&Y@@,#&^O`08=]MR;:>?:02071",X!#.U[T6"(!\GF0S$T;1C3%P/Z M7#.",?KEG'!"HZ.SR(%?0]-V`)T>G.P#`^'N.^8@&-ICX]''YP#J,YB\?G'Q MOQ>(_3ZP185^'>7WD]&CY\3\`,ZI>@K?J-/?[UW/![ZO;7"K*3<8GH^)*[X0 M[W;Q0-KK"*EQQVA"X#W>!^#VX^0^O.J2=`C_`L",@1/!)B(]=+R_@-K@J0)` MGX2+-*?GV"[=Y2",+'2VP)X#Y8IZ@LZ2%;$RH`AKCW0_.BT'0.4-4\9QX&NI M)9=<2_.HDUI+"OP$WFQS M0#?B1_NG]0/^/Y&-40=.&*PR(B[U1WL3\-T@([@?^^;D8).#,]=U;!"Q+<*Z MVIS9&\(L%-X+<("$+8Z\*!QN`-@U[11PQ[X9A'@R02]X0@(;HDM+EPE"\QM< M.0^PXV31_EKT`??'-42`L-K!$-`=4S!&NY03-/:?<`F^D`?&I939@#\(?BJP M7V##W'`8@'1CP:C_C%QAM!LU`W4:>@25.+K6'ID;>*,]%^6?,89Q``(#,2#! M1Y%9GTNV!\;0?")")!+*ZTR,ON^-Z+E9W*P24K8MI("8&X&P:1KG(#)B");1 M;AH3$&_K<"SPUAM]I2EK^SZ._+$7H+``FC%(T6X/]QS^L%TE3_=!FX9W<"AY MPK09Y"D+AG`LC$=F8R`BCW2EXI('P`=U[0./FI],"K-YZ*:;?E-_":$(Y'0C M8?+%P2_A?(.B,)00`FW3T2#Y*2W!=BV;`FL.C(<<8->I.QEF@'MB*822"D)+ M1F@%7O,QLTZ`IZ;P+;/+(Y-Q#]0'_)K)I/'H^J'7825B=\6?;"H?OFXW&#Q^8M-8=^BLXN`(C""&67J`WE4L1^W=MARM;D@ARU!+MPS=1R-2C^"F:6@U M$KP:"K&[:BI2!!63@>S^9`L<89VL*S9QP1^V^F.6I&/\+3/\WVI_"W#@O\D% M)$`F&Q\+-5BK@B1__0[2$_'$^VM:0Y80N29H9[+'J(5AEO27I#_P(6&D04QO M6%!Z%"!UCH&]FCY+629<`-]"5QY3<6F<`A$*?A%C',U,[H@4L8"N$\.VT=ID MC_+G0_:)0RI35H1O*8M'KMXZ0W)JH;.1!":4?37;5CW%VD;%G`EN*O$ M&X`G%4*!3(<*IQF6!SHBRK,])[+0Y.:@D"[IL)3.1]C=T&`Y&M#P&/.JK)"B MS3(/H_GHR\&S1-3O+FTM<0I"V.D(EMP.:%7@TW'<0C_!&5`QCPU'4C&.".9$64J"Y1J6PVZO]-&Q4+5/DR89LL M%OB0-[9=:=1(UEFCPV$FJ9>&"P,$`?(0'-T$%<]&PT)"8A*K2.Y"08RUV@`&B$#A)&4X\0:S>J4]UC.#H=%WO&=`DUK=F%R"02(QUK3M&YF6X%.1/X,: MI$@]\VDCXM7;<&+E?/:3T,:$?5$3\34RZ>Z8O:$-JII%1FJ)GL@/A$)6/W)8 M=)\6!-?%'::-?)6JIP._;M"WR.KOA4DN"2N",D\']!U M!%W(?B+KS"+V#N,L\D&3#1U0W/#!9#S;[3L1ZKA$ZHFB1X]_BEZ(S!5^ZH61 MI!F20X7V"*\[^J`BOT>./LEF#;C_]HBLR^BLPDQ-8&V83$E` M!"2SD'O($]1@$'<0LO,K@/%\NQ^X(9T%S`5_\=I9YD409P M]2Q,4H_)9D5_H2/&\P/R^242@'A!H&@,A>&A[5L&XRWR`07_CDP?/7M#$$[@ M'$N473M:"1>.X0+-CL8>YP99\NH$1P^[?0Q+4!K:`?X&<&`YT,2A2P1P#ED MIR7LV0@5JM3^693/*G&C;<6=,LRQ^80Z"&N3]BC8';==DX!"'`:X*;`W++4K M5R=Q$0B47V(,T!8I/Y0Z7TNO8S-\\'<6J"X"IK[!/C(Z M%%59YXBEZ7D:75K9R>@*K(.@)PE9!M%$U)AJL=E1OZ%P%4?F-X&>#\8>4\8` M[N28^1Y[;?I]Y(ELFD9^,J)T)0H0"0(A(7-L\]%V$M4V42_QP1X%5@Z(+LQX M)V1/JXQ88?OV#"SD@>+KY%>H3D$:L4:V('HDO&M6=M8D#D`3ARN&W$2IR,0R M,6*4E'+DXH\FTLQ'T)"8[P#&(U^J+$""O6=4?0.=&GJ/H,>(H(<1HQM1162(_#0\$[QGJ>5*&> M2.[`H)XGD?`AR3)3]A`:_S0>-AT.]4S`(%_%.$CRM"IUT@XP9L@8"=#A62:# MDT]L&=9GHO%"0P3^+.^$/#R!=A8"4BZ#>=<&N3S5)$+E?&ACU`<%%R3R#N"# MI5*=(:=$):5,QK?U43BH4!(')9,#2`MHR947!V`1#A,>A0"2IH.D)#Y(%QB@*T$VO'/;*66#8& MA;'<#INAX[%R3;YF_)24[6I[&H:41,E$(?"4O_",E@Q_D2H9"*!L05+!0,Y$ M10BEHX%BE8SXG!8:I.M*P01NC3>":W`I+S31(4M(:VF:P,RFHAGV(LFN'6@Q M"LRP;"01.!S&\A`%!/4L?HI$`0?$;K:+CL8@EB-4-8ZM4=\``:95VSTTJL%/ M$O4@NCSTT]H7B6!0)J%0=T&^DF1"D/A].N.W1=2Y405.P`))08"Z)\ML45\ MGD)[8$A`&@(C1TSXI]2'B`[^";_T(B"E%(7'LA#HBG4@:5S)19$I'-KF`7WKS984EI!T+%VAMD:+H)L/#<'GKV4QEHZC1F*OC(S%Z]#`E1+_A MF:O,=(GI*(IA@X$O!D3+(OC&!7ZD:(#<>,WT@_>5`([&+/W'1KH9)%"30LCE M!,0'8\GNI34H[SE?VD10IF5YB:)T^WC0)%&A6124:$J)R0_.C@/`>"S2F?A? M\L%HPAT)/36IGZ!0):Q$)`)A*"[UA<8ZI!E,]&)!4(MR#]`>J>"*[PI:@VQ- M='CQ&3WGR6-*2>ALN%K%-%#N18EG<1X$;J&-B3$N[6)2;!X3&/3;, MM(XP%V=OA+Z],\)@`IFA99#MHR3\1<3R&3E`T=X,DI",VK4IX9JOIC0TCS"1 M)':_8,RG="9Z:*4.@I1>IGL,6'TC=5@D.#LPSC+?Q((=/8J*)-]ZBR@'62J> MF"*A<=MSA8I%1:^"Q5HJTVVR>9.EA,7,%TD525M$9ZY\[XGR#:U(J("W8.CY M89T"\=++%612CW&RS\3A[5IM=]V'>17+^7\HH]1;\5TF2P,%B*Y5+'>@J\=G M93$`9=O"W+L1^>G(B-*W_2"L8T(1_X41)R19&#]>7EW>4-)?''.N38,=$-FI M"!+&Y"\VX\6#TV2Q`3EUW8FH:,IG;"!,Q8#@R%J`/(@S84XX^U2HB6X,E>0, M\PB?D9P`YC!;ZMGSOR$%(P<1T4T4PT!4,P<)W2)[Z7^M\R@V#[IIVC*R'4"9C@!8>!A?,OZ%WVTM45W2BRZXANO+E7N.I-0E8MJ M!M4NXJA)Y>]X*^PB6>0X7J3FU/'1VH^*+G,1I.5D54&C'5I-+*T4K!$%RJ2( M3GP,Z:R3,JNY/N:GF^B%994C#=F8G"TWU),D20\U;PJ'PS@0HEY*`[?8%<6^ M+U!E(MNQ5"2&/2(C*_.9.FC9,K_%!H34702=4DN`A&!(G2O\K-.K+N5O>`LM MLZYZ7@+L&X'7#Y\1B^I)^0!1W,AW*?)#TM\7C@+1`NC[J"/3&Q6Y*J`":0*V MA8NYIT3MS"-O9^(XN+.#;V\F<.\RHOND'/(U]N.2&0M$.FDB@SO?MTF;!F6; MHP,BI1NGX_+0',AA`A..6$`'MXR$3DS*1$V>3-M1CY+GU\1,*'I/3]CB-_5H M,+T\`+V5"F7@Z($!>HM0D)6A%%(P#@(/B:6P$DJ8J5>!D8F)>S==3"(VL.*" M?(M#\M@9(U@AB.L,<&`A#/2S2D!(_[01[^G>B#?;\)3J%2;T2%%A45D3BM:D MBBM4@X4-P0/I8X3/EC=63C,MJ9@K4/2EER@*T+N5)._+$-:;G`#74G9]0S?G M)W5.?*$O0(<2+APZK;PH4.NJR44EQ2S,`5Q.6TSE+5R"TL)ZH!\-C%-KA-J, MHG*ZI^;R_#2=UN):-0HKC=-;:C3@/[1",[=#$U;5\\:>L$WEEDFEC%3A`UNG M]+$@"70]]",FB>2"B(OT.)/XJ$44NQ)H68@]G1'2N>_Y`M-K?&"(*G`G%>^- MCZ`]5+?($HWV32N.8$'GABH(7YV*5S"EQTR:]HI9<<:Z3=Q215^Q>[^?.DX@ ME8<<;G5*)R-E;N)0?AKTT718$0$"LE8;QM%!>[:U!*=_--UOFYS^,'=ZX`8R M6<`+R>V8`%%;+P2'[<-:H]%(0X'K[&%.$TMGBOF!#HII7FSH"R*?<+)VL]+A MP4G^EB!4D4LSLY*<.BU[20.V[478>)CS+`H]AU=(;I!A$QP[")/50Z]._K59 M*2DJGV;,!;'AWQ#E9HXV4!D[L6?NR7,B7!*0(BS,-::@)DYS$(&6SZFBD,@( M(UY"+.,A(<7L!OT1&08:C3EJ0"36=94T(Y]4\E#SZ$.@$<+8Y\]$E"?AH`-6 M<9($D."TA M3-8$?!UPCC]PDT"G5'+" M%._+/V(51]P!CGBCE_-B:U"BZ#!A)X,!A\J+XD*5''\7WSAA;?+NGS1S[OYF M9T">2;^NK/;+3(*#]UB`B2U, MLU.B5RA6YZ72LI]%YMAJ2406$$M0XWK2UKIO[I/*5;(+KI)KSQW4'4K[/Z5L MMK?B)?DB9)BPM&3(.#T.RI'$QTD6+[,FB?E38K^-=F9*)<3$<,Q(,9`HAJ2^ M:/)MS_9[T0B[L/9$4C&%I=DP)T)0$E(Y'\J[*)(\L@L:976TJ7$NH!S,8XNU MEJ`H7FR,;4*1)HY``BA)X*%PY-@M'+DJ)5!@]8514AV%?$A)\1?\@6+))6!` MCF61/2XU:/O9E0"9N^K30^AQTL%S/*;GN*(!UT^7*??\)J@4*`*""`FJ`M/X M&9C2(1(OU"1&`J-EFU*()>VK#,I42$G2?>,G$*PX<_#?D9?4$."DG("][S2N M)*L,+;N^T'!.WB%+8$D#(2,^31NH=?!!TFP:"#4H+Y2LBHHF`G?X4Z;U3"%? MVR1,"#90,-%#U]*5DF2$JS>"3V@*"D6B/,?\%)4[1H?*A)K"!2=R(<:U^;&< M%4"6+@V4:+`Z*T_R$S$9P>>(`RU-,\D:KFF<.EVW@'R7@#GA.$GIB,2Q\23B M7.,/[)1#;HQ+#C[,3-*U]#!^T)R5,Q%'L$#)\"=)/I;G?M#U_%A=I2]C9"9J M:@U/)]8H297=V$=I?Z]MX)?Y-YJ3RNTX4>,Y*2"&^AW+37C62,&CD!F\F:;- M/11\TPTP>=:,,^4-A?[H>/J*7$&=4_ZU;'^@*]!H%U:;4@\C"QBUD.;3F/\U!`^8^$9 MRC7TL"+>7S(@W7;'42BKLZ*[GX?3WE76)1PROOCOC6MRCS=K>MD;[Q$$#=:: MY;"28"O2.HNF?I##M5+#R3$\R<=,MVB8I.JU-&)9<-5[(9NPD'NJ3S&2LY1IO2890WX]EWVD. M\NP[+(%) M?<>TH`K/GK[ELNB9<<>JU%O*X;F/ZP1J>F(JJ>\91'+JX(,=AZ1LIK6[4OZ" MN#0W`6IE MOK3<"$N:;K@"))WD3)4#.K^JE/8(\R6PQDQ<5Y.H@JS\S!%..S%VP$1YW\U]'C"&1[OE61>E;4B:T_H6?_8:Z0V7)> MC-8@QJL/>A+B\%EPW#57X(X?B[45Z;&VS!'UY%.PJ:9$D5O'BQ0+,Z14R2V4 MBV)%"(6(/MRM0&'%=.6<]"Y%(LBMFP&2AIJBS9N];?I)F#&/I)UD096JN="/ M&M<2(BR,91MAS82JR!*-3``2U:5ZZA1?2ZCQ7(IOZ0UEMB:C,XSC3ZQ$/20O M4<0!)C0HGK@4R,GI&7,,'9&\Q/&N)5[J)5*PFR-VK(:G,SU3M*?N!!G:D]\3 M.&@-,P#1CS'@TZ:H]I"]29S029:$OCV0)9-H6'1F^5F,*?NHH$`@=GT,] MON!YZ#'*L>XWU7X/090E9FT)6:R4FTS[6`5*!NBD"8Y'%4@#5%6('7"NE#00 MVJ-'K-N-0,195R"4LQ%=VWPJCIY,KDX6FD:%R=9&4T6V4*"S++6G$ER?^3RS M\90^<34_:7MF43V/^M&FU+C&#AJLS8D*89#=!72R1:C"*)^4SS.NSR1K^,H( MH\TSPSTKS;%I7I@;Z9I3C'&6`"@SK)'&;R=Q6"N5F#@.IJ4L(O%KAFA&<"Y" M5*JPI(HKS@F_V@F,S\A/WV^,IXH@F=.G?59`W+-(<&UFZK(&V;I/ZTZ;;Q]- MAT&O/V.^=3PU2S:B+2D=GU3`Q>@U7S$Z1K^J()@%N M)0+;.))M*X5?UL\[NJUI#C45Y;@2'DN&!VX`BYVM%>KIE*M9@Q21!1%;]@JS MM8+SB9BH;)DJ/H][)K7L MM;EW3\66>Y6PA2?H'_!_&*[U5N246VF?81:O:O%J"Q[*!:.S!`/"E0M*F1;] MFJ8^):R6XVV>/*SVS4$L&H/N.4"Y[+[-K\0>G"O*/"&#E"KMH3M^J#2Y?#A= MN!,A5!L==`E0AEA2;`,D<^GE(6,^-=3BV,\@,4^G]`IW=FL0/3C1]M/1 MRDD8X_1LLB5?'`,,HC:5;*=N>$E@R4?'['VKW_>&'K7!Y1+]2&MP(2//$M*% ME8*;"$4Z0AL-'QVWN M@J1F#U:32!H"55[@K4=;T-'B$CKZ(8OKD:LD;96,R:TVZ.$UESUH'(!8G5$Z M@&/R/:BE"MF<,10$?*JB3=*.ENXJ\T;$>N9ZNYY;3[XA)Y3)$?2DO<+=XJHH MJDO1`-39I.B)CBHJ'1@8/P:@[W[&IH6=GPX8L-2%%2_"[]D!^5]E[NS/[)1+O-4/;4S'Y#\PO1N)]I9*-+BB$_ZV( MR3>N[$C<:A$5:B#QJ1FW0R\8#['PG-T+C&O9QTIGQ;?W5\:MB1:W=%-`8%6G MF%,%$YDH6/ICCXE7=M`KMW>0'3$SE'$.BBY5DM7&D2%0CX%MV1AA`E<_@84- MX;?#B+R5U^8CON3Y5#SO^OK,^!$IB#;G/T$R#8T_X,W(%S-G5WV\DBP@V1&T MA@D=LL,8QI;$F+J.GSSC)XU3)4I,P8!PQ;^FI!HI4Z>`E"EQRJ\;VP(T4463 MX2AFCIIC4[9)4CQE-$*YQ.1\/Z;`SY[O6,\@IJ?+6]8Q5/+HH\?42HA(?>)&YLANQ8>;C]I&H`MS^`L-,;NI[C#2:I M$Q(_I%I&P1>88CCML@(8#;$66Z['$.*1B!5 MJ4[Z_OUQ=3'=0=17<5TR@EFV1WR$#>N#UFK*G81'2X-91>PO*3:LY7;(QZ[\LB:S7<_EVN\VM M:.C3=H`%496MV:3Y05R1M#S47\3"'3:%8*APBR"GBKB74^\YYO)O@D7L#7?8 M=87PBGN[/Y@OXLW$97V)XZ>26C1<;#)68RC_!6585?.,2EZJ=+H_V)"!9?`Y+;NC"PS9&V-7D\S M<-5.`>?7TC.FWV`-';1=7S7$88.9S"NR91XC5BGPL36UJ3I/8D5O?M3Y0MZQ>MO8C71>A"*<7+C*:.*;UUJA."G MR%6^$MQ?+AI+1<0?R/_I8ZT\',UF7RL?&A&?2?6";&V>T)''2>P>P6ELMH0\ M"\I8\K0"3#`F'"$\?*K65I+I!9../++??,-RC'1-72],,LGBZ2G9BM+_`ER, M[`X867:H^X&!X'E.I.A<;'D9CX7I<"-2&&U@2I>K!W>3@C:XNA6C),""0I:. M$U5Q1:&$%=]0Y1+'96FY"%8<+D(+HQ7U[3X0:+CS/7(9\5H!/KYCOC`I,)9K M(L=%F.$>AHY,LCIU)XG:CKE90,H_YYZ_;-W0.#4F\V:[KNYY6HD!/.T^T'T"ZP`(@^>@Y\RQ*7*8U'G4:*03HZG!- M!X&D1NZ+P.*8&T?5R%A6P-4LVDX+UBI#SWTT&*JJ?DF>SKP`O.D4/C-/2Z$T M&6)D2:U*JF3:R^R6;'D0@[]C?CL4J@1-5R@"JC4W"?`4B_$U&HR`P5[0(^D-3=( MTJK01RB?2]PG9A]])G&"0;,K"]EG`4FPKY+L0?)-1#M"+X@+,[DXGPY&@I3* MDX7@VFJJ;&LL>7&GWCBII"7 M--O#08)S(B<(4R"YH3)9!9(]8)R#(ZAG,5M-*,):%A71JXXX<1,%61LE!BTI MK6)B?7^LE1,D]E4MTB.'F5%]$H?Z^*@*MZB.@_Z.EA%N;DFZNX5U:)0QT#79 MVZ^J;X=)5YU8R^=RA'%BB9NJ_JQGE<7U6.)EZ?CCZ!?4@60A%!4]2]65XCJM MYC1]9]L3TM1H1-TRGQ1C`)S\&7$OPI21"LBX(PMB4S=NWK',;OJ4].LJDZ=L M:$']BB372+\`#^.9@W]FL]>2W+60N1[J4W]AIB[#(@"^3*DUQ;38,(9G5%V6 M`D:62$+3^J?Z@'^SP\]C/,?\.1[?C_^R8N*L_^DG?^(T^.GO/T=!?6": MX_?W23F=1&B]Q?)"<-@>Q$OXT?%ZWW[]S__XS_\PC+^KMS!^W&8C_:EKG9'% M0S97/8]O4OPV'6GX<"?ZO[R[;32_PG^1\#QXC<.O[0;]_#!:":WOK9; MG7>_9DCSTAJ2\6ZW%&"\`G,MRW]1[N&I[ING?NOQM$TN_CRW*6C3C*R)A[08*$%P^>T],L=%*R&'Z MU'6A1['FABP$K\R@__2&KG%V8/SF67U?3&K&9Q,KNO_3=$7R'5X/^<&X1T^@ M[.-Y3N7U:C),-FZHGHD=E6\&*6-%GZJ=_PF\G-@5<&M;]+6>##A&4DQ5T';6]3G6I[SHX[<6&YXG9Q^*K6*=3%8(U-@4MPNN5N1HZ&>S45U M),(B3*?#(A5^SS'MD4RZP2RW$$-C.&24JR0JIANODB-&X#U?=8W'52<0L,K&.,=)N/N9M5ZL5/;WFRIV&$*C^<.%UA]N4_-'A/=RG1=NJXJ+WC=)RJ%.Q:+= M:,0MBP">M3I'VD`GTO'N>J"!1`V>8[@7JHKIYA$R=J(@KF&8^+[7/75./.LS M%9>PK>RQ;V-\D27%A?P[FKJ;6'EBX&)>B@,EL[PFNYR&\8TLUT'1DM$E>VW,)I77\, M=,XL>1F>240XN]39YC1U914-KD2FK7M@-^59^"+C/*;JJ&)HT"A*WX2XU`3S M/Q39I7,J+:?Q(;*8;UZR.4X6\$7KK$.6RA_9!!<%<.J#G][O06B!IB.G#],6 ME.?3ZZO?/K^_!G"RG@`\:5^NSA_^@8\W?DA,4VPEE)-_O+D[O[B+S?__]T0\ M'H(ZB]8'LD1^,.03UQ>7#[F_Q\B$?8O_)T^ZG+_;_2$>Y^SF^OKT]AX6@>W@ MS7$@/A@W?US<75[??'EO8,U:ZO$EGR8WQVR@[JY^^T<>5(46S:E]9,SX"BW_ MN."1FZWQB_:[-0MM#?J/T4P@U';'Z)$*HF[=P[^N8?7,#-,[GCU\'PS`ULU= M//[4O?U@`.8>KLY.K]54<(Q";R0?_")7T6G`BLD(_,N[YN$/*2LE_LU7,3F\ M_X++.VUH9D-O!A'K6>8:EC6]JCF4/7\M>[RIL'R\3W#BX5"WIE!Q0?53B%?' M7K9J@_=I@]OS-WBF);?:X$UL\.9O[`-F8GPW.R@]APLRX?6L^^/IV7__=G?S M^^=S.#"]GA#]_@+(2,DIT\=M(3:,HO`26^Z0\+>MA8]LRT(!;:/W>*]W=LWK M)Y--_O)O3\_/KS[_IL3@KE)E=@XEC6F<=#O-ZJQ79_WMG?76-$Z:TM16G?7J MK+^ILYY#UP^_;[J^,Y)LG_ZS*8L1B*K=U]KFTBO;.DG;[O*VHE%OAV*M<C0%7I[4ZK?LB+%9GM3JK"U+6YO=-67=&W%M8YE]4W#O\GJ7Z75C> M&R)*:UQS#E&J[_Q65B?U.SRINR7J56>U.JN+B7K?]UG=&4%OXW:]H^]9GM^% MY;TADK19[?/5!+WJI%8G=2%!KSJIU4G=P9-:T=0=%?(V;LT[_IYE^67CA=^@ M9KH8`O95=ZTL@M5I?Z.G?9>$S>JT5Z>]HNW[);#.V?:=,4HNFPOU9O22PCO= MACMM>1%E3K^^DKW&".O_V@Q>=D@[7V?L=;/6/7ZUZ.OJHE0792>1E2,BMZL8 MR^J:5->DF)\ODY+6:J`5"_CD]S?84G.I_2D;OE@!\*GRX8X9!#?] M+]PE\\:_PYMZ\2+\GAV(6]_NB?C'0/X:---5Q$^#&W=F]?#N.R-R;7[R]_OS MKV/A?[T?FKYXAZ5M;3CT`:+BUTY76]$R,*F%6<)^?^[U(D3(PV0LEJAX?OCN MUV:C_C]__SD[EC['J>H7<^F8@R4F.7KW:Q\6+WB6U&AY2[FE&OP7KG6.12@7 MG^[XW:_<8.*PWFZD5Y8:.F]N+G^$18\NX9M@B=E/>/;TO)EA9\_,`"XY=QL. MU_^T\F;6AM7GOH`+%$Y4;4.CO6I,T/KT(_PQ^&F#=Z\5G[KS[]1Y("PQBW`EJNN4.9... MB8Z'U#PZ&%CD$]ZYGXP>/6<)`+JP^W>W_^"Y4H/E[#,0<,^]Q][$1!F#FRBD M5A]4]7B*TAY_;;;RICS4*&U`X^@D]NKS)5"UD];)2:O93AV%.;/G]9I(/2M[ M^$T#V?W:.B8@OSX\>P^R6N&E%_FA$.[%OR.8^-IV@8YS\[=/5'4T"G"6^R'L MUX/P1^?BD:CNZ8L=9-9Z5+S6-LMV:3Z9`_SR:XSW?C-K/"Y>8ZN[V!K'_GCX M/JY_A?-GCG97.]H;WD)@";?MPT]__WD:J!2XMY'?0R)*?/\/TXG$UK>BTT@+ M,1G116W"#'"S!^P6NR@+*[CTO1%N#_:W`<"2G2M#;C:SSN;L==:!HK4/,\>M M<"ES+M>9.;9#T^%C>B=`.G\2L!3_DLJHJM&VO]>MXFLWY]:56U46+5^H![BP M3I^$;P[$YPA!ONG3*!HY_F@&=@]D_'/;B<(L28K/25L[)^W,XMHE>$3WZ.0D M6=MRH&UT@7/X;J=38H&'1XW=7&"GQ`YVR^S@L:Y-[>`"Y^U@&3'F\*336=<" MF6ISIWEX^Z:/2C-V'KAQE>%W[&_E_W@IL? MP33UNEJ-8[O?WO?A$1<>`4;SS7BAKWP/34+#,!R___GGY^?G@Y='WSGP_,'/ MK4:C_3/^_#,^^$X^'P+[^>4=+!<4?V&]^Y4&_WEJ=/C^[S_C4/9[_'^"XO\' M4$L#!!0````(`'=X#$5I)N9"SP<```1D```5`!P`<')P:"TR,#$T,#8S,%]C M86PN>&UL550)``,19>I3$67J4W5X"P`!!"4.```$.0$``.U=;6\B-Q#^7JG_ M8VET"K_O>.#20L+%Y#PF&X M?@HA,_;,/#/C&=N[.?TX[$?>`+B@+#XK50\J)0_B@(4T[IZ5/K>N_?Y\@!DXDA%Y[Y%T225JQD"0.GKG4,'E\U0\?/I3U7Y%4T!.A^6]80*0V5:%-XI9Q$\0,?3`IS(40)G)4'[2:0$U]_U.'3.2@E/>MK,E>.C MBN)_4T?T^M`B0Q`E3PWS^:&>D3;A+.GAQ!%I:[N7%5$YPU9&(5XHQ@7K]ZGL M0RQ%+0XO6"S1H]"S*(A+D(1&*TEG,]JK"!V'$`M0,P@6T5#Y^CF)E,,T>P!R M1:&+1]N4T$V,+-#VNN_<)RIHT6E?+OVR8;^%&A=$]*XC]OBZ6LR,NEFO?R5W MGQ$S(%&01AJ"&Q0J(RX,):#FX51@->SKQ)G.3SA[Q(+,C)'*C(QG+3294*>_ M#A%MG0-3X7<)2GR'(+4>(1K`+=+TQ*H:+1ED1LT9#ZGQK,:$!]/Y M\..">V07K`E%6:3]OA[-IQA`4_X.9WTK`";SL_5U2P6*R1)%0:*2QW@('*L6 M+%H>@79[$C^[AW,3`LQ"OP/A:R$\R[X_V,YJE8_JH=NHMGJ4KP_J#/?^8#JC M5#ZD1VY#>LU2+GMK8SK+OC^@SFJ5C^I;QU&EG9>`^LR]1Y@^*Y4/Z<^+D*+6 MY;F*+0.PF5>.$/Z[^2NF`1+J5DA>$\Q&V4K^2*`53'K+C=P:Q.5];R$!VZC@, M:"T(6(HR/T``*'\[@CN0%A%F9-L5^,Q:.%RUU^,!BLCX".4UH)0EVQ54LE([ M7&@W."2$AE?#1*WDF`?N90^X[2)EQ;TKF%DIXW!UW<`B#;@<-;``DRB^RN:) MVB8T!YB9S1GPEJ-F$M_A_'=-8]3[A@X@K,>2Q%V*N7NLJQFP(D;G(2M2P#I= M_M_N)%]N*&G3B$H*ZC2@*5GPM<+W^J1^(;%70F\?PEM>`S$<9EC<'ME!4(UZ.1RX*Q7.!:7RKF&61^GP/H=R M,19KH0NWZA=('8!IM6#*BN]RA1F&="Q7@U!L["](0B6)9G0PU9D6S#L%G8U" M#B]J#^HB80SA%>$Q)G"!Q7/:5Q:'\!(Z-*"F^L6&>:?`M%'(X;6MQ8&(E(^L M4F8>\4Z!E:=`\6KFN[.EN.3^]A;V%N]`CA\YN&'"5,S.T6WK/'$JP35ZS[CR M3#%:GTUX#AW&8>8ABJNAY`2=@<:$C^IH=*%Z#G4CAT4H7[<>8R\"PGP\N<%9 M'8B[7!=8/.W29PF&@/W&4L,%9QUCW M9*@<`-;@GO.`9$1W&(@FB4`\P`#B%,RGI`N4#@"2XT8+O?B\V`Z#H7;0[SN? M&`OU?@/P`0U`-+%(,[;DRYEV`R*3!L4MG;_]U6IRP\5JK7JF=0"<%1):C@(N M8],$O6ZB/SV=3TT$-Z4X`Y-+:,W[VT+.,^CAWM:9-QO2FYGA1 M,/;J^0P.P+6%'FR9-1P.UZG(Q0&Z0/E]8[Q".&^O!GK2>R+M.2XLYH9[*8<# M:*^P<9:C@'VMZMB&]?.K.K;Q#HK<1YD:P"D+T=3J8``N8?S3U**N-,QV@D4] MY(/R8:BS4+>IGY;]6H`UV/C:5$ZB,>_EOVA@!T)O'3>8C\R7FL'A MON7EISI;S*FOX/0Y4._(-O0E)!P".GY&')((-`+8>/49E_3OS(/F.8#:L>\M MSG;J.US^UB(]."ZX/<+AG.AEN*\*!RU[<55L.\#>NH"M`9SN>K,+6#U>?`+8 M7#);L.^M`]BI;W]=Q`7\I\\:FR\<%_!]1XAG]"Y^M8I+4,\]>+16G#_Q?D>0 M+^B>#_OQRQ+\XJLFU3?YXBP^BI0#YFKL>X?G:NKG0_K.S35;[[@^F65R.;CH M11CV@^R=*ZQCA'R'>.]$:E]B';4TB4ULWU@/[(#G;'#[QMH,#G>!N(;IO=86 MJP5H'@Y+WX!A<)-5!G'`)5XG7!9>';*"$8IWA9Q+)MI3=7@+``$$)0X```0Y`0``Y7UK M4^2XDO;W-V+_`]O[F88"FLO$]&X4T,QR%AH"Z#F[L?&&PY15E$^[;(YL`W4V M]K]ORJZ+JTJIBRV55#-?IAF0Y'SRD2UE*C/UZ[]]C).=-T+S.$N_?NI]WO^T M0])!%L7IR]=//YZN=D\_[?S;O_[3__OUGW=W=WXC*:%A0:*=Y\G.95B$3S0< M_,QG_7=ZGWN?CW?@A_W3W7[YLGNPWSO:^>_]XU^.#GXY./G_._]S?_N_.]\> MGW9V=][?WS]',$)1C?!YD(UW=G?9:__Q M3)//&7W9.]C?/]R;-?Q4M_SE(X^76K\?SMKV]O[S]N9Q,"+C<#=.\R),!XM> M;!A>O][9V=E>]5=HFL>_Y%7_FVP0%I6JI'+MH"W8_^W.FNVR7^WV#G8/>Y\_ M\F@N%[2)BOECF@-\V:O_^`G4M;/S*\T2\D"&.Y6LOQ235_+U4QZ/7Q.&L?K= MB)+AUT^O]'54,;)_?+C/'O4OC^5X'-+)W?`Q?DGC83P(TZ(_&&1E6@#]]UD2 M#V*27Y(BC)/\B7P499A\VF'/^_%PO:2!5YJ]C@!,$CY77.ZQ1GOMQM\#6!V! M763C<5R,25KD_32ZR*KGP;1>/$T'ALIH1H1.(Y+FA#TA!]U$[$4[#Q,V6Q]' MA!2:0LM'VXBF6\P;C4$-0(!O6)J'`_96Y_WAD`S8TQZ+;/!SE"41?-F^_;V, MBTE[."T?8`#:-7S)Q^0I_.C"AF`0(R*^D;SB^CK]2Q:GQ>_P8TE)%WG51C0@ M_+>0IL!E?I/E^3VACZ-P_A@=B87#V!6SA7Y51MO(Y_`>'IP6(U+`PJ+Y?=$< MVA:<1]C_D.H[=S>\>V5;*_:-Z`P%&W83,-:_:T;A$;?!*R+,!]=)=F[67(: MHQH`<9D-2C8PK)G?8,DL)M?I,*/CBGT=L<7CS`4-Z6`FZ_3'YO#S#2M\@/>B M>+PW;;,7)LDG*3ADZSS;^;(]\Y<*S.56!06.[H745.LZ)O M]%V:#3@7#&9LG,;LM;^!X98>!`L]@8];-'L4D\B615B9N2!.D@V69$B8+9Y1 MV6>1_298?PA`(M?P)6$_+/Z>9+#*?AR9I%';#>P0F(K5CJRVX#/Y_?PC$OL+:YL\GS\B;5)Z(7>N`3 M?F1NV8S>""WB'&0#N:[!YMI2J#Q$<[]NDEK=' M[D!KX[WCK;^:L/E,?M%GLJF&89@_5[HH\]V7,'S=8PSOD:3(9[^I.-_=[TW/ M1?YE^NL`Y`0M%)/[)*Q-U+^7\2O;!)Q/GN#9R`*LT3LX[FW9LJL+CL_HL7>, M,J'1C[5&[^#XP.D"K,N/)KLK0/GLGOR1V?5C^=TDS;*%MH5]:H;N\S).HGII MF?UX/7ZEV5OM\T179*W^P?&AN^58]WWDTZR.DT_PF2N";\/!"$Q\.FE"EM(J MZ!4<'VT[F3)TB%MCWQ6';*=8%H0^9L/B/:3D.BW"]"6&W44_SXF<3:7^P?&7 M;>=5'2?"<,\5PU=2`@XAL(4'RM0K6AEF M]=GM0YS_/)^5"GE0$0H;>%-V@9*_;)F['(KLV-ZSOQ,TZ]3_D`&)'YC'R;I M^HEU"8ZM'@"HK9Y*+QJ?1R$NA#=GWJ3',"$@Z1M)2_);ED7Y=X4-+=XI.''H M^37`G009PIXS;]%5&-/?PZ0DYY/YC_\>$PH*&TUN`$8BV?RH#1"<;*N/5P,? MPJTSU]!07^4.ZEP'L%)Q[XA?5?5`G/"$Z$S18N)SPRC98D M6CXOKLZA^TF2O;-H^5P4[Z3:/SBQZ0"V%N>D!0\ARUR`DXHTXL`7]1&"$ZN> M7;6`)BWUMZ2O`1!R7F!N\1G-CTJF^& M%0DZA(\6KAY1%.>R_+!$6G;E\^N\A MC11"]Y;:!2\[#*6QRS`-.PUBL-TY?:FCF?+-K< MAY,J69#!6F!+(W9*^STD`F5O.?$!_C+GE MQ^;9DTDFVU$?.O,O?1N_)MF$D"II_*Z22^I=0OL$IS:/#!1]2]:^$_P9(U8& M0K>SF*?;\&\9O2CS(AL3BGFF\,;!JZ&2\)*/^!H MG^#4JJM7>85'=,\G2HP&XGSU?;`6OMPQ. M/0BS%K\`'.L6P8%HVIQGZ.D]4U/T6L/@U(.P9VT]\V$@:C;G\'F"ORK.:$[3 MX-2#J&1]52-`$&6W\,M@7X^LI(I?C[66P:E#[V;[KPQ&)ZS46?EA=6N%7P0UY"9.ZL!*R1^6T"DZWK18$!@)1?D>/A*KR:V'0;D&3(GKJEZ3&DG`[VB,V].S'[O#U@J75CXP%Y=Q$X_C@D0W@0;K8(S/X))E]4J4'U#;$3YSG)HVBC?CS6B/0O21<)9MLMM M^!&/R[%"'G>C77#F0;CEZCS'7*2K<>>#4461@36Z$ M`6>!",T*T#?3>QXD2S36)3BSZ02RN6(+$2&,N2LVPA%6ZJ+&.P5G5OU)RLN[ MD`-UVAJ@$.*7L<`_K.[&6YA4U[,4%R&E$UA? MJDP5`<5*_8,SAXG2+>H9ZX-#:'579H3=0'!Y?7&=LE2EJ#]FZ"4TKK4/>ONN MRV.VYPU!@Q#EKHH(B/HCC35H6FD-L!P&,'4DB8L%H!@W#ES(UR69(KP'P>IC]%##6;`1"'7I0.O*R#0-AP MYE)9*UQR3RC[1?A">J+E2]`-@#H,L.FRCDE!(>RY2P1A67F+/"395X_7'(!Y MD*S8@BT<#,*2,U_*-(5L=@H*^&8V91I]ASE7_X^`-[4!`+P'"8XMF-2!AU1& M=^9=^3V$;=%SP@J/$DKRHCX5OWM/"OB"R*@5WD,4($'Z9`M&-9$B)#L M,&]AFJX)$[*1R#GU%`D/XT0=`>QV>E-48"$KWM M\IVT0(>0Y2[N@^0$%,1<=I>LJDY651&6OV_"?@!U._TK"J@0`AW67QV/L[3* M2KL/Z1VM[E2-*B_K[$9BH74A[0VPM]/+HHP-H=29CX6?V2BR-K@=`-QV^EA$ M#FKK!]P[^::5G4- M_Q23M=`.(*]K;T,+&E0P>78YZ6R>E&'20,B* M,G^'WR"VT&4EN9%(NV3@OM/^?5ED"P+"PW!$P> M%*'46R!X"(SY8[[08X/@-J#VX M,%V=,65(GOE+52E;07+DP8WH&I^X=>%]\VNB48/BCYRH&P#UX+H2G5=(AL4W M?R7+A2[(3?Q&HNNT"-.7&%;/&K"8-G%'`.LP\ER?.!4T8K^EJ^^>](,'PGM0 MWU#W2U=+C:C<6BJ;T>CS.9_61PX"(=B3(B5P"AW#FS)#2V6N*`\\#!I$H3!0+AQYJ1HR%G-J:=1F-YDZ4M! MZ/B2/!=*)4[4!P$E>.![:L^E$CSD*-=A8!<:,R.,`$)[!;TO'CBI-%F4XD%H M<^8":67&"?;5O2\>^*Q,6`$RC`B1[JK`+JH&2,\P5YH"(`_\53*%XR_<.A:$ M'&>NDWX4Q;4P]V$<7:<7X6M)$=(.T,H#WP$;GX-Q4X[+A`517H+V!['H`RKO#*`]<*>THU05'4*I,W_*$R5A7M*) MTD=TO3&`\L"/THXR#`U"D3-7RCHZK6T*@/+`;=*.(@P-0I$SGXEL\]7A>``` M>^!%:4>?&C:$S%,?:\H\P<@E2+D=I65.S*6`VRLM0)=MGS5'N8^I,7DB89I#J\\X,G/)\V_R&X$51X$%.?'G:%J#&-[03VX5C(4 MS%`NO=QJO3%@LFI9J]\VJDF#G,PF0"O)#DY)\R,=8A/L66G>.V!DG]N$JTS4(NQ64LNT"9`4DI,Z0]2.OV:E"I)I44 MWP1C+*E@`ZKW8T4US8%L]6QQY"[D8JGD5G[)/IW?L[?J>W@*?7KB%4!G#$#G MNHZ&>/*C3.G@,Y=&H$M;OWPI\Z)W=K"_?]:2M?4A`)3KVAGF2,/@F\@Z>X2,C=\#J-XKS(H>Q:]/F:1D0LN10!U6PV&4_3\" MLA3950'J6U*#4][]V/!N<@+(-L/N,B4N1C$9WL%7,60?N+OA,!X0*BV@+.@% M<#T(F6KUDO+IEF+U+:FB$OC;!QF4[+HJ+4KYO0"F!ZY&TY2*L)K+ML`.2GF3 MBFTTV.^OXC2$G4:8R+AK.Q2`],#!:8#0;@KP+5'C/JQ,@OPJHU6IIT4M<=$^ M6M`+8&Y'/=?U`W1E=.8R.J1E[<])"OKC12_R&X*`KAU%G>(7$$#F\BL0C2\" M7Q^R29A,`X,J*#G;T^55NER8S&Y$%5X4VW%$@.S:;]2)PZ[(S65EM"5[FL=Z MG>9%F"25SV3,$EQ;7XSH=)&5$\NNT MRO":INS-`@-Y@9$=1PQZIZXO>C'$=3ODYM)`.I/-4OF>"!T+ZV)W'A-@N[Y2 M9D.$8]A]2Q.Y`3RU?(M]QFP5$FQW1=T`J$/?@Y']KAR>.#=DDX'0S8"K_G!( M!@SK>ORVA:#H]8?(,/P1 MPIOGY8YJ=.P.XRP51#PI]0/UV#3.U8^ZA/3QOU(*P#P+5UX15'JLP6T/R*P: M],J'5@KZYQ,G@.59J+(QPOPZ;3+/G+?EW1N)RO+3A]6V@,R#JC."UP4Y6>#C M\*S4.ZM#^CT<$\GRU6P&.&PZ1ZRN5NLX/*O5/A-0^I%;;ACTSJPZ,927HW4% MBXEHBN]9"?8.5/BUT+3G1+:@F+.5V+-[9V>_I5G`]"%@6[?YZELEPYM=X`Q8,XB+9T"""9BPW69J?7B9W>,A0/JL9T M9F<=DKD@8%5V+LF04$JB?AK]2-EM'NQ"(V;6P&ZBH3:QDG0!83VH%Z,(C-2'.:":K&\E[D?8,:]VC9`U@_$ M]\#+H4B#&AC?HF$-I:6<;:WW0P#(MZ+B[K(2#O;]\*0(R%)D5P6H;X&O3GGW MRVVSB0D@S49Q5@[=?.H"/,C]`MOJ)44.&&18K4?G.DY=.-CWP%-E@-!N"O"M M6+KY-+*#?0\\9:9?7!%6W\JF]]]#&CW!4R0;YJ5V`,6F1\WJ1ID#Q+=JZ8^C MD)+S,"=1TPSK4QJF+W52S/EDT6::.U/A6H!+(^4S+AN/`\5:]>HI;[4Y=//G MA3TM^!:2^P>97G[MZ)W/,]EVWUU9^0>2%S0>%"12BQ+BM@>('CB9[7TD^)-% MH`K?*M,_,!7(:O_.V@`$FXYIJQN(%1"^E9^OQ)._8XM6`,.J=UJ]1N^R8@7: M;PHNKAB_)?KW:RUK0X1T^7'F;;H%)8[+L922I78`R8,K]-8F.Y\*CN1(F+>S MV_%NPP\U$IKM@H.>P_1-71+6)4=(,%VHKV-QWH.>'U7V-99B*1Q$\^8B8XQ5 MACWH675T=BK*6ZE22?--,(CNS<6]F-2]'PNO:1)DB_&AN8"5C9?E/>@Y]!@K M3'^4*AU\"&T&0UTV6Y;WH.]B,3UUAI^6-U1PZ^"JD96?22%;/@XK4#PK?-CE;%%H'0)]L"RVU*/, M;0\0/0@8E;Q"2K0U\2!4.3OXKU-YKM.(?)#H*;O.\W*^*DPOCA8O=FH#`'B; M/E2K:Y\.0H1>9R?^(MF5OJ]J`P!XJQX_Y452ARM]ME>T!FA^7N;:Q-'%`2.TN9P$3:Z(JQ-ER>P1'5CT#&C8FKGQ%MIJ`$+[< M>7),\N77`FB2.-D"]\5_8TRLH\3*.G=Y*\D46AV[OA!251C!N/>@,$ M1W;=.*JQR8+7A>,?U82'\&4NK*,ASU56TH*0M`-CLB$`E`\>@/:_M>LF>"!(O*F/VR`'3Q/PB(2MGF*DP'Y.Z-T,/CVRPM1FB<6H^;XL8..]94H[)7?I$PRA.7RY#]/(/ZP\&!;J^OJG# ME+&M%V1BF0MJ:8G#\'0!L*[O?]K@)*C1(M2:N_UP)L%#_#("@7[DY-O'@.3Y M/N_DR0ZG\Q0L7E9#U&-EU]SMB[8#-BLKHUI=SK%A M!2%SSN!]C$P)E4LNNBPI+$D@?IQ%M5P_4GC/_E``TO4] M4JVO:&F#%*F4;B[.")'L]S`I25GY7%GD!%BZ`KRTBH1/-\+-`I:Y#U36GC655(+/+70!66Y@SZ[K^&BX,:QNS M"WL6J-1UN/RF9Y=8%I;`BMK5%OR3-ZYB;^P^Q\(M*3544+E8LJ_ M?<#?XIR%35368?5;J1EFZWF@KFWTVME5!S)[G(4!=GUU?@?]5)1N6)^6$8I?"B_J`V)OF4=&$1+"A+GB4VTF4KV^P*H2TZJUD#9C#P"%_%F\ M*0+\R(1PYLB]2,(\OQO^-62`BKMZ]SN;S]5Z-O]C/OUKWA-\ZEN-%QRYO&B@ MRW>\`UQD)CC+S5TSH*\QWX:D1W!D-1/0)ILB0`A?!F^=F]F<['.!?8Z7&H%@ MKLMPM?FD!]W]\_O]+LE7W\@9+\\R`;[U7* MN$[A1_(4?I#\DA1AG.1/,%()4OVKD5#C^>AS_>'1Q.MM@P.#*3&-!U09J0J" MU)FK!T9&#$?OU44+8]'-T58L,N+;N`1 MR5]*&N=1G5\@K\`E[@FH'3IMU-XGY"A%!1B2*>&*1D!%\B(>7+!=(YU(R>.V M!V0>7-O9AC(!'.2TU!E19$@H)1'#E^>DR.>WBMYD>7X14CH99I0=S.4S4"(: M]4<#K;CV7ZAN3#NC1.PD8R;!NAQ74SD61S6L!#G81OF`QI4@F-G09BQ`Z=H[ MH65DM,?(9])9V2R-&;FTFIAYE9>&!/VX#@"V^#YSH/*G@A/?QRPJ\#K]2P:* M^QU^+"GIX@@QM*D;C$A4UI=?SV04>E#4.@8'78.,9N7AXVIT!NAP^C.#* MM4L5CJU::.WNKSA>V^3SY;;B"[&H:3^\&QU4;L&%@1T1Y?%]2$55P'G-0$:' MUBM_DO*.>7A2&_,F8!H=93GL8%Y(&@\DEX)PFH*,#L,5U#6+2>Z9"^`BHZ\9 M['=)<],H]=@(>@%*AR:]"C_*((Q9[*8\W%-5DIOXC437:1&F+S%L"FJ[Y7QR M&_XMHU7,GO1026LDT(;S6[W4MT.=0'IFVDLP+!!\#\?R:K`M1@.MN+U6K!.; MK28&K@:AL?\GG1Q^["3]F26RC6G/6;7ONV)$Z!H,V4HOZ`5P'29F=WZ;^;1+ M\2*TNJN$)*K']9V\5W\2NMF4!@@.3GRH/ZWMS6J#$J'873DB0;VN#@PO]P?H M/A2K-DTP#R3"K[F"0--$J?PINRK3J&E>-%"A-J]*9P#B04"#/ENZ"!&JC-<6 MK\O;LC#EN*ART:L#GXLL+6C\7%8)Z\OG*AA[;<<#N!Z$.[0DM!MHA&-GX2LL M[[6?1NP?%B[]%B9,"_VB.@N$#PN67Z/5'Z![<#U1^\^M!DB$7W<9.?//3W]0 M54M9W>X)N)7V!<@.W5_=>54$B'#JS#=VA5H`/W(R+).;>"AZ956Z`W"'\2W= MF57'B)!K+NV&4[A(;765=@0`#@-0.BZCBN@0>ISYH6:?C*N,5J=YCZ0HZ@`` ME2\IIQ?`],"QT/T;BD)##N;W-Q\V]"VD*:S6.8MU@EE7F\SZG;&Y=1+:XK>UWN[8KW.?7DMN,.*OD[*>J(8_;JS@N6/66- MC/=IZO5YF`O3)S1'`JVX3IW07GHZ0?4LR>FOA*7`DVAZP]ERY;K&/04IZ`EK7U%9BP""C&YJH?&;^21#$H*>H-WORX(O"J=L(R5WBB` MS&$1%BWU_@X,R#D`-KK#4PF@L5ZOK2=7[?`)`' M80367[4:IF^Q0.K[ZJE"C)@CT[%`)1Z$)+1@OB-BWZ*%D'WV5.:U[;:^:8*- M!.KP((2APP1HA==<,)'5G:_^CA?@>1"AT(%.(2YQ8)$G1S`FR]=9.(DYW#=7 MZ=WD2,,#\. MC^PQM[E<\H8ET0B:%*=`B_K`HN*#AP1_)3CKG1R/9P<]W$LPU`PH6=?@Z-#U M[6_:FQ8];)Z=X'`M/,R^ZT=_*^NP+UT;63XB:-;UW1:MF>\$67A.M$FSZR*# M3FEU\5&:9TD(AF7"4`!;%2UW MN&_UU+E5M%REQ75EK\N]5=%R(+$?!D\'E7L;+=UB5"W95,!@,KY(-F:E'!(<]#VPKO47) M+';?[+"%X0@[LSM:J:;.[Q:<7FOT!M0>'%WK,:X,RS-#;.TNPFE]]7_H7'XYG077F[M`\['EP4MR1K"84S\J&/5$2YB6=-*05D,1I#:@\ M./O5(PB%X4V-;J[+80XROQM.2X_#7[?2W7#@K+95:W=#;^-'Q3(%JKD;>EX= M#5MV-_2<'_2*:%!P-_1L'>=:,X)[;H]I42W*;-^>K7-8BYKVV-V@IG)OW0V/ M8<+NF'TC*:L!)O(:K+2$3[&GIJ!@B>!!\,Z&SXN[X6]9%N7]-'HD]"T>D/PQ M2\1&!-8),'IJ].$TR=!X9JC_1MGQ(,V&L>CU:;0"%)[:=C@G:^)[9GC/KR3Z M]O'*#(A<(8\-[0,(/;7M<((D8#PSOQ])DK"C[S2Z#>E/TI!;M`*AG0"C!R7% M)!0@:Y($E&<5M7\C*8!,F)L\&H.*&4"6#B1G3](3T'I0.ZP5A4K(?*MU_4!R M`LIA%0HO84>49-6QAIQ&83^`ZD%ML58D*N#R+9=M#:?.6@>0/*@@UHHJ!(MO M669S,1I."]HS>04$\3L$AR[C M4]MQ)$)BKIJT69KD"]-*2X"S=?X)+@3?:C\O7NPK@,M*5\=I"2_\XF3FG`PS M5A5W?LOLMP_XIH/@<1K22:6%[UG*?.^@RJ3Z5M2XA>Q:>RJH>>M<)-;5X5M% MZCF0Z;MQ#GMNL<,%Z0'PML[Y(H3B6YWII1H!`GZ6V@&4K?.X<`"8*PMML1P7 MLW!:UWI"1@B.?##\]/C3@N9;16GY`@"P5A#)`@!;CPF3WP/?C1:?;9=5H0;$ M1:L]>?VK+?]EG+/8AI(J.+L\<"NUX),_,;HH`9DA[LH3<+^/;;<`"^5YI$TIK59-ZVN%+"5L:U?'%[PV3*V]U/ M;*MO98\.CVPN29VB88_P.``YI#]DN:/#(ZNFHZ%R1Y7^D=4(A_6'+'<$R/P( MQ[7'G+?1NHT,*^FUY&MM`9D'6SW!Z\)G"<'A6=AN/XKB6I;[,(ZNTXOP-2[" M1,J2L!\@]<&8UF5,`9-G(;P/K)AH2J*992&EC=\!L'G@^M+F2P3&LS#?I0Q& M*4N0YLB%(EO<;WKIJQH%[_:&#!Y>A0OLLWX*#P+W-6I:KY>Q_OP MBZ>'Y@)>^"!\B\-M>5S^Q=/C:EJPJWHV]6A0N*=^>GS&;$8GOH4-5^M) M73GCLJ3PW:J%KR3^3MZKOXA]8PK]`;H')_8M%EHU8+X%&R.BUTM4!U)7!@#P M'ECX1ECE(O/G1@KIFUWN[2I3_`!QB-;4>]I]A;#:GT^^0$?O.MTGFW6'Q3Q6W4;(2]H4R%,QLP#0(>> M;JOQ!$\'<4*6Y'[*%+6D M\`FP\3C0JP/8GDSW=>78`I5(T6C#'5+H#;@].$>TQRI]!ZIKQ[,BKGU2# M3Q-!SE==D?+$9;4!@L,3#PXN-STK='3CV8$;:(0=VI)+4O_;T,'4=ZVP)JD/ M`CKP(-_=_DJCJQ'?SOO6Y>\/!ED)+Q2\3B1^D[B]5+H#<`].T76)4J4;P^O; M8>*ZY-?I&WPX,QH+7?W"?@#5@X-X6]2N`?7M;`Z?C??AI/6;.^T+D#TXU+?] MVBZ!-7=.AUPGRI6#EF11;(\5&T4O]U;L#F`\.%SOQIP^7O]*!:WA9QF?JTH0 M5SE6'P24X(&OS];K*D;M6TVB;MM.:VYA4-:?Q97864N^%1Q",+$M2F[SQ$'S M`:`\#QR,1DX<6B'WK?H1;&]F`6N#OYM M)A2`&A`2506N6&PEN\S];MA(LA2M2[*^`-D#SZ-)^I#E2$T1OM6(ZJ88:Y\* M4)8'3DW[L\:$EGPK*L4`P?:+_<.V8&]APK9I=0SWJE=!,(%TA@%%>.`GU5M1 M]/'Y5H&*CZ`/,YK2"4Q468*34G^`[H$CU02U7&#BFE0.@NW+U]![X`C3#-37@88P^V7SF2F7V:!D0C.;N(KN;OR&E#OF5B4)X5%FL**2U2M=X8,+G->5'4.K*= M0/!X5DO,`$=^9,M8(,MR%HWNDO8$PTJ6,=8$)'=XGMUU$5L@L)*#HJKS/L@2 M,7FNDI!7866M#FU0?TNC2WB9)7-^J2U@<'B,VG7R M,JS@=A\E\DI%?P&YD!L-(:<#@\VNQ*"1>,E*Q;&_2I%-M8X`;PNM<55I3=7@+``$$)0X```0Y`0`` M[7UMD^2VD>;WB[C_@),O-J2(:LV,1I8]LKT;_39RKWNF>J=;\CD4&PXVB>JB MQ2++)*M[RA?WWP\)\!W$&UD%H';]P59/=R:(3#R92`")Q.__[?,F0<\X+^(L M_<,7;[Y^_07":9A% M]^@J*(.'/`A_*6I^].;K-U]_A\@/KW][=KY[.OOF]9MOT<^OO_O^VV^^_^8W M_XG^[]V'_X>N[Q_0&7IY>?DZ(BV4M(6OPVR#SL[@.TF<_O(8%!B1CJ7%'[Y8 ME^7V^U>O@/[S8YY\G>5/K[YY_?KMJYKP"T;Y_>O:)_):1%_'U!^6^S,"BIJI3]0D(*^-=9378& MOSI[\\W9VS=??RZB+X@.$/I]GB7X$UXAVH'OR_T6_^&+(MYL$^@X_=TZQZOQ M7B1Y_@KX7Z7X"08+OO`.OO#F._C"KZI?WP:/./D"`>6/GVZ$`KWKM54QO2*] MM-7/.YS'672=3NOPD-M^S^_+("]G]+W+;[/W#UD9))/ZW>6TV>./>)J>6SZK M^B5.$T_3;X?ST#TN^=X:*Y739@+_OB5]Z/4.?RYQ&N&H[A]P2_PJ;9SZ8^HB MH=DL[#68@'/.\E%Y:5NKH'BD#>Z*LZ<@V+Z"">H53LJB_@V=LLY>OZF\\:^J M7__UOLS"7]99$A'57_]]%Y?[CUF)SQ\+F+_*^HM43MJ/O^HRUCJJM=03*,=% MMLM#;*0AIOM^AX)'[0Z1:9&PP>R/T[,?[[_XURX#8AP(6-#/-=-__IY]=2#* M>=X?GB`/ZWZ1'Q6R5!2OPHQ,UMORK"?6*L\V9FJN^I&9Z:([.*ZQ=A4789(5 MNQP_$,.Y(-__Q1AVHVUX@L!Q^;3!V+*CGZ$!1%L0('.VB"3@?]9FD,3)EQ$I/E4@$[/]$N MP&"L4I"M((UJR^351'`@R MO'T<%"\G8$1Z4]/\QD_'C.3S0FL0-P,[>A#8T7)@1Q[-B4?6T%1/X]DT>RC+ M.IBS<3YE7P=Y2E:RQ1W.[]>!ULI)S&+=,TAZ/T1S38H(+:+$7LV#JG$8(DYO M$-SA2&,";M%SZ$#ZVDSA5L:(LW&UJ:!]2KLZY!/%20>M^MDRT59:C1;NP))XO1P7.GV/8MXE+\G.2 MT%\2@NIV&\#1+20OX++DESY!?)#M)/:<-)E6])O6FY)F-< M4WZ-;E:4A'4+951\3#>.-AGI=+DF?)$5&R*,XI(SPUQPGY'O/ M&,6;;9;33%'X,O0U:Q%`/H&#<-VT3.4!]D?J^&OM1;C$^29.*1?Z$GZ-/P>0 MDK5`05%0<7/\C-,=[&C!7ZNUQ%=?NW/U9LZL]M53/)F]^/7'@O3JNBCC#0RT M).`<$EJ/$+F>#BV7$(`[:D@6J/)&WCA;(U&R6:+8#'W&,32,560`LH?WRZ!8 MD[`'_@/Y,\]!`CN_ZGC$D-^Z=>C*-40:,%`?37_HL/IK/1Z(:M.ZC!`[-+H) M<+5[N)J2MO?ZYB=F<7(0*NC]V.$=)?77J.Q(8_N`48:NL6-#-;3L6<==#F%U MN;\CRB^)#8/];F')HV\M^DU8MQX#Z8;XJUD)_("9NO2&W5\+\T=BFU9HBN*A M54Z#L,5X$M20EFQ1]RDN?KG,<127\),LBI1QV8\=I3)P8527&@'1`C&&ZA^^ M&N!<,7LIJS[:F@86N?A0%X@6H\+--HAS,/%E3C2^S8H@6:YNL_3I-G[&T3G= M'3*(&"V.=CS!.])3W\*DAU>KM[':9"&<9#LJ,/KKU$?0.CL8$+;M%XC%`_-=0*$[=GG)W9`\PF'V5,: M0P2A/RUK\%JW2QUYAO"L>%"'R5\;=":@37O31N70U@PA:3%M,2+C6\9%G#Y= M9H5)\*ODM)_`J)2%RV)L.1!E\=>^Y@D'NSHW=#D&I^QW!-B985:%U>1-/5!R M&9PFB+186&(=;[>D3^=I]$A(5(\5ES4HMT%\# M]$)8JP4EC'#+59.8`%J;6ZN;+4X+MC4%R4/";Y)2TPP5%[3I$/EYHQ!&RX. M1+3E&SDWZ.:[U]RH9D>,WV=C]5!XR\.529`FV;&S<%)DJ!S*`KLNA- M,GJB>OT9?`Y66JX6MX/-&QV9^-T-QD7CO@X?JAC]-5-?Y+6[M:.-6WYSQQ"T M#@I;F:3!B5C<%;3221RKJS_Y:U:6Q'%2T$H[$4X'7/;LXR-^Z=Q2R[.4_!CB MSOF'OMV8-V7=GB9(RUW-PB^]>Y.]1OPU/?\DMVFE4U$^M-YY$+>ZN[.)JR)? M*5G=TO[B%&Z@&I4.-6S'Q4Z/D9PC.R`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`XU[HE"Z*;A*3F(OHE-=A%C M]C4GUFLS7LDWFP3?)K^7)O9\P)M'G`OC/Y,F+,>$1M)-2']FV5[H9]:&4S=P M.%G/9;*Z-KD)@.V'S5/1ZD%MC8O]`_FV(-@VXO:GHD9/)L/2$L`IC:2]J"7! MCYIV&0G1D'F`1>B8,&HTXO8'BSV9)F%1&@YZ@49^W+31*!HT>VB\V,5)Q#QW M_>/-!HJ3LB-D89QBR&\=D;IR#3%9$U,P-O_HLBI"$YN0-!J\(2@GC)P]6'X@ MBZ:8A.G[KK4HP2CEL@Y!N0Q#X#74?3?H$=HTQF2(,>T!L7O+:%?B_#Y;E2]D M87U#%@'I4TS6U;06AA)CFOQ.;ACIR#5VXP;X4,VX0"TK*Y?B$0:-1F_LEHWA MT%DL?K++TQA.^(FIO(\_PT_JV5?&9+_,B4P"KLQ'34S=74WN$=+4X\'5[M`< M#(?%ZB[V%S@-UU`W7K'F5;.Z+UO'2Z-1U*UA\6:9JSM*REINTB%RB;JZ5\K5 MK9K5`]1QTIBASIL%K>XXJ7$G&R3KK[T5GW"(XVD&U1 MH);6HXE3-0R"-]X48V`Q5P^.QZK:0#]D651\U%@5R)CL9]S)).`2R>AI8$6] M0)1^@3YZ%?6KAX1+^-(<#P?%#2_VS8]_C'$.EQ3WMW!%41&1Z3;@KKRA2C)Q MJ;\%:AB\"I-M=65`#>JO>'I%QN0/CJ`PRY\@8%HBRH+<>S9)D+_"672'+L-7GMYZ1K2O7R*(!6-$P!8>EZ+7L M'N31'EC*\Q$IG>?<&`)TF*<^`9U'-B=YOJM)"_Z9E#`^T#D9AAK09IG"95;GPS[A)(Y4;@8S#+ORE?>=/"!KB3EZP#X"?+X9K MB*M!U`.W+H+F7AOJ3RD?Z,O=K&)+5?9;#G2S-AQ<%=*7;_R2T#"$:EKH54;W MP$(.+NVY0%K7AC0%MOPEG$F8M7AH^!+DD<8=@`&=_>/!03^Y^!S^[E?Z_JAJ MN=,_L5YMO@;`*@%`U>6V$/-YGA,-L_W0BWU+TYVWWTPBRN^'2GW+7 M_#B?<_#2P%&TQL73?]]!S1\&<'_VWH^)&;YN_[$!8\_6KC?;)-MC?%]FX2_+ M+0BBW,>7\%A'O:S_''0K6D2)$:/V:/=>.19#(&H.A,U[`G_+\LM=468;G(NV M]&7$#FX%C/286UA5?_=F+A?KF4_YERO98AU9XNN6JUY_E%.SA,=^95A)_\6` M\6:"5*J?JV2JI_L9"_'W9&U?-RU?;H]1VEU4C_:5.R2&G9=V[)U/+`HM]U:' M*A7/&.>'ETQOF$<([8[R6$^'@TQHO!MCH89[0ZQ0[YP1)G_5-.514LNC/-I; M;IR!2G>D9W=84;'P6/VVAU`Q0OH85<%CSGQ#1D5SOAFAM#S?C/65FV\(D7JSA9M\3+C1X$JL#/>@=MV%1C:_S181(D]WA M%:MQALN^C3=QB:/;.'B,$](\;+@%Z?[\BQL=6AL?\.6Z=_W.MC\#?GLX50D]R;8>-J MM#S6RMWP'I6;\19ZC&K$G<\?$HV.CKKK7>S/\6:WT:AOTZ-SL'?=[R=?PX;^ MW8,Y0:I9?LM:J%:+&(A3/0STZ>QC8-!/#@/L[SYA8$RS'`;$:K58C"U((,/X M?HUQ>0N?@5->^=0O9K%?Z[*&B-%E!;5Q-Y$"JIQX$JI:0V"6QPIC[YD M3%Y@2;AJ%:')FRA$/1XZB'*;MW&7XVT0US6TB_I:Q.4NSR'9!`IHJ>M5F33B MH(BI@81\+5/*7!>V+SK7@*H&6"TUGTI]"F=VSC%-R7>R&YS MBEE+M:J"`IX(A_]`GN%SD-#G)\O+ M(,_WI*/THK+$H6GRVZ]:I2D7ET="&-BSH_!#AW6!@A+5W/6]](>L#))CY>(W M3W[^L(LCF`SMBGL^%-?QRY)S)0SA!]RRHB\_9B5&WWQU)+E*G#N0ZDC";'$> M9]%]&>2E_8$BAO>(G^(4WJV#]UM89XXJZ74:.9$3D]\K)+09(!G-#ER9//.I MP>Z\]_[JYO(F!0\;G6]@8E;,P9PM`[?*/@#N?PB^`) MOY$M"J1L[M\FZ$NA?I=@@5H.Q\N%XXMB=?V@@2_ENPI"<%DNAM^6OE.%,^/D M;@K@\[T>+WW?TBUD$8`M0]#L.XE[G^,"P)^MT$`0]_"7P6:T5+\4,U:?$('R MCW4J>(R+^B@[C3X2T=D_)`:@VX"+YT7T)!,5_NQPNC60XTMBM4B2$>)&WDXQ MAIL]:_HI((OQQP3>V<,$$"6[L+-\27%>K.-M.[U)#,J@#>LV92+?$(PU+ZJ9 MJ[MU"_0?NX`,)2NJN,SAG_"'NLCB*LLW-$!8H.9#W@1QQU=(=AB%V+1P8RL8 M&OE$$[!Y?:$JZD>\3J?<7Y45)C%N%:.#"PX*2?@;#W7=1MAG[59UK'B\V%8^ MO%CNS4H/=/Q5#WW$S4A2K/(B^[4OF_*R;>W+$=LPY+>;OF@@ERA!=ECYM"U_ MW+*[+.\Z0T1V^`<+,H+A(HYPM3U!Y8Y3%$3/-$\=;"I.PV078?K[;:4:W,T= MSFCNQSD,-62+J`4YM<$5462R3?#?9@0MQ:O4)*E M3SAW7:;6U-9Z*:G3#,WBC5!@+ZNJ95<%G_]:H0@[N'FE% M3Q'>X?!J6ITE5-1RN,S`/*X,5J_ZZI@*=_E7WTYL'DYL-EE*:VS>!?DROR_A M\06:+TB"?5KH57I&H<'MX*A"1R9^FQ^X6/G4!;ICLQ)CK9[E(\R(P,R,"N`7)&K;/=70!B9_N&&(2M?5OV6G'`(&3RIP MCYUT`.'9(U"B+JD7T^@D*<(.:1TXNS<0.93TRGJ[N^`),7ZYAS+AL'\,2>MT M-ORQP*M=#*YTZ,HV33,;F<"_D+1^3^$E6&T.'R>G;>)P$RC?D6@X/WF<]H#2N M-X^TH"5[#$^&JV-`7O[,JI+-$]B+"U#*@._!&ZJ'E8@Q>6L#DG=2C8!F^W$9 M&$68CO(@U*A)(N%Q]+C,>/_''Y>AFZ(-L4?%191#,?ZVC'(<9CC5>UR6"2WI MJ5G.5<)@UY'*>LZMDAM:_ZJT*D>@YV0TU7^<9V1'79D,S8BR>FU%,N'(Z'_GLQ%Q8-.W(0'2?#`A>+2H7$^VH2Z[ M1T;4D\K0BABOUV8D%8]`X#<^VQ&/.'U#$L'-"TN*5W,,J>7VR8XZ,IF:$;#Z M;442XI]G`9I&`?)75;$]!3WL:`=E0!>C]U^,J">5-QQ0[O_?WUP[U[V(Y#@*MK(AE_J]6`X$)O\0F'.'Z& M:>$C+B]U:@!)V%Q4_I%)(7ASID`M_0(1CD7]CI$7=T:F"I5WA$JQ![<6=3`V M4O5'$V`.*M^2KDALHT_FKLHMZZ6D*"Q%O`=`U^VQXCD7)_5K.U`05JWE<.#J M1;OZ[3(V]:B]O!:WXS?L1#(I'J_KO%W'.!O?[_*F^CS1E+4UW-N-`1[E[_!I M@-%VS*\1-3FV'!60!I;@P7ZQJL>T@]ZA7`O/7B!7>#]2'N+(V?RY`CL>4"CN MOOH2%DV6:MM(A5NIR$H`2A\%8;C;[!)Z62?"6[)6B-D]'2`/-EE>QO]@OR#$ M__O;Q9MWOZ%_(C^^_N[;!5E<%%L<0N&@Q*=X3`?'VG>#'<9K\,!!B6^)>J.; MM"3#&Y.5#_,4O(0B>H!4KB$&*8 M")4X7*=9DCW5MO2=![:DA\&A-9D`T'9DI@S)G,5BDB#,D]A+&'3Y%6S)HRQ7 M\.L4K283#*T,M,Z2B"P%8;(I]QK'!/I-6(>P@71#"'58F_"KW'MSU#!'LIOS MBYO;FX>;ZWMT_O$*W3\L+__TQ^7MU?6G^W_YU=MWOT/7__'CS<-?W!N.*3B' MIC4-F?:/-NZ"/>P?ZQ]J#!F<'6=P/1?N^5>4Q][$,CRYT.__EE&Z-PHY:$2G M%#+$6'_9HZG_?)D56KM24C97KWB(I!"]>-&6\Z8,_EC"%&&&]8_99F[0/"#C MA9THL29XR4,#:/9LAFXB\V^+2,Q%R&'=4L1]'^**'71T2#TQ#U,)ZHW>Q*?G M;100&EJ!%GZ<+%'4V/<"]EIX&<.Z!VMJK;[W#S6\PKH^S+U$.+6]AW60WF;I M4XGSS15^++4>/3-IQ*5%J"646@ISLR7A1]#`&;2`H(D%:AOQ8AMVELQ,3'C; M`5$)L^:^1E%MQ+[U8"/6'+@2(S1"K=TZ\(*B-1)KE'(YJ?LNED%6B"@8%B)R M?5%QCB!AKZ*2/V:D`;&Q2NY:^'*SE6RV:^S'!K'>7K"/&\!:>[W?N\>Y!"&R MK5O'N[2=1Q/H2PD*K]\G=?G$1]U;^8,7E&J!;HIBAR/WWMVH[__[Z]>O7_^Z M?;/C=RC8E>LLC_^!(_3KUPOR5_C?[U!,I?L>??/MXKNWOUY\\]UW=$+XYLWB MV[>_6;S^]3OVNDZ)]OOU6"VO^NK(Q&W7=HP(>""F@\5WP)UH>QX#WBF:)#U>A:G9R'C\S4#6J(Z?>N\+//X M<5?2-^[+#!XS]./814LB=NQ2=$A9OA:F#$9D-NG/ZFEFIN#XZS>I9(JM@W;%%(/G,T$69CK2082F;DBGU)' M=?8=U[/F0 M_RG(?]F)7_4:I;+["`_7Q^$(?\@1HU`\RS2[FUI/VNET]Q=*X?JANO'![[WS M(QOY6;"[W$51O-ZK<#<@LPV\82]'AK(B\01Z^AUV#[Y1"`S0)QG_.:^!TJ?Q M,&Z>02ND+]\*J"V__2GJ\_@[AABWK]45SL,H#:WWG\/44/E!QU_Q#*R0WC4& MQ,^DCJ'`>>RCI7T%$@X<`;7/9'8^`>'6Q^R9>IW?$IXW\GG*K`T7F-&63_(J M:@=)M`%4MX!^NT#0B!=SX$QY/T&=DK2@4N+:AH*JI8*6._'"?,P`.V)24]!Z M##,[WSWMBO+-.SB*FFAE8TUX8F2CTIG8&&L`O7D')O;ZG=\FIB5M3BV,F5?6 MMZ^2&9CKT'0"5O4,3`748]O7.?EU!']Z<[[-XV3&Q*;9JH=6*-/!',-LVD5O M$&WY!*;$J7KYU#'A40L^!0-6&H.Y36M:@L7$F+A,\')UDT;Q(^@W=Y8%=%`]KJ5TOM;5TCV70J)6O$/4_#DNUW03&@XLUO'V(;M.RUCC ME,"X)?=(4\HZ>KY0$4,B"B/W8+$]ZPM%O,.Z&*H>)_EM_@I2.YQ2<(#^BN),Y1R MV2_E+96!JWE=42-"CB@]ZC`X+M\]39*5OB16"VRKL<75U]8%U@RGWK9Y@5.\ M&KVE)2*TZY#'>LKEU#L.YEB@H4`#%+0K\]QTFQD++Z!.R:!?6A?*A!=+<01U_*IZ?GFV#Y(FKS>$ZA)%07F;PC.N-]B%EM2;#15F-,.2VZNAGVIET=(; MM:H*6CTP2&[2$I.!*^\P00[!P=/8O;+9+=KU#;-DE]P<;EI#Y[303-,>JAI$ M=8NH;=*ARSF^'H*^'A8.%*'EP0ZJB8&KBVM124A+W%;#"7YINX-S%.*8F,?: M$^*B#)*$NOC*1T8[[-I9S7<6/:]V*$]Q3/=7E1B^:1 M?)+OJ]I#G081:]%GUS=7"\&X%A;VU'`8QV>@AX[?"UJ5B&*Q8L37>>_G5%[! MS,WIN82#>+GS-*4.M?G231HFNP@7-RFM5%C5#*TOC(U=9YS=HBL_-T%VB8FS MUGIF7+<'!7%8JKJXUE&<#AX-;;[FCQNS[#B"*%@; M54[$9BF,LNI!NSU9+]4E!U]R-@7^P$AG4/CR$+HC M,N?(B*LZ\0"+'N'!D8C<\O&1L->RPDS5@W/5XWJ4P_6YO$+]_=,&'=W;K.05 ME!23K"]DX;S-4BR^J:K)YZ"^EUP.+N6>X:>E\R:?5VM$^!I.VL-A#UN#OBBS M>`7TUK$DZK<*0Q[EXDI5/P2/AMZ=U$Y7YSSRM"ZKIXM3SCIUFSW()5.J6E(B MW'$V&%'KQV"#%9-3G\Q^OE>_EUQ:%/D7@K][,^6,J97+?!+JU/[P*V>2(:$S M"`CGC@X(O)DTQM4K`L*!ZR-`LV_>O?N-/$MY2&5WP<+U<714@<(#+R_1:F]! M(E/IS/$DOWVM'L\NE?WQ[/5Q=#R!PJ?QY+7*C:=(I3/&\RK.<4B("[V!%9+; M'6%QKX=#W5`B[P9=H?K>Z&OI_9`P>!\780!7D%]?9*FJP)\NMV.0B&32P0SC M93]3;B^NYD\6<<7$V>,@1U'5B`]7[\UP*#<1#1`>Q6+>S+*8-UY:S)LY%O/F M)"Q&(2*5X_3,9@R,FF8C1N(AS>8*KW">X^@\C7Y,X?VHRZ!8PZ853@LZDH:& MI-V>8]/2EUO'V.K6:*(@:P]!@ZC;HI\&.%T1E9PAR!EV&'PS1D.(R\US$K[G MI/]`41H<+;?0MMYJ7LIB.7E'VGLN'X51(T:.=)?]=@QGFBC90!3G62!J./63 M/'2Q-*?X67-04MN0WF)8S6>Y@)E:#LE95S-+Z"Z49PNCDX$[02;:=:%@/V^\ M6/SK8JY?1?=89]4]?Q+$$J] MSPGM=V6XQH5JY3N@LAR&#_O(!=<5@0=#+%%J/T24:-1BQM'ND=TZ+Z^?R?\] MD.^IG/@JQ@#+KM(9P"<(DAY(BSA\0%%PG-B M`8Z\.3-6CH4&EMPF'`TZI(Q)!/2N4229DO^!QO=IN/.YC%EZM.AO'YKB1?AFIE M[[,VV.M(=8<6JY0+^&\;9*6 ME*P;1=`J>OL=8NTZW+K][Z,-O=<5CZ*.E*DC6]'R,$0=]"5N%+3J@"J=<:V. M#-11KF-XR[:(/Z,-;=_UH=`!O$;_X<=#N8SYGI!5I;F&RO8)3-QWNY+,WNDS M)N.4WZ3+%%_EPG3 M52`L,V/APTZ\ZE$U*3(O]E%4?Q4]9(A\%_Y3?YE6)T@Q@H\C^#IBGU]TRO.! MMZJZ@&@?$.L$8415-\CO71:Z^:>.[FE+E$S^$]=*AJ(Z M1,D1*#D"):>5DCMU%Z$61:7DB"KYF2F93#QEI>0H<%Z$QYKO'9MU;#E>^W/3 M@6><$YE'CN*Y3L_5GY(:CNF-C^)C3]1A'M(-'LRYU=_X%#^MR2=_+/#UYQ`7 MQ5V>A1A'1=4_=5'N"0W9=6A3).5J3M7(I(V`S9)F$&L'U0VA&N%>E-X^I-A[ MJ=P+>X)KN:Q#2/ZPQJ@@$E5/`=0%%.,TS$@<5P:?$?X,Z64DILO;=P72B%)' M=9JYG)P$C&40IQ`-$N=''%`9ISOX5\8>IX$*MH]XE>708N=M@N<@V;%4O2!) MLA=8F[OVC).]2<\GSG0EL4\!@#+BO+E?+EQ3G\!K? M'W$27>SK?H/[9DW0]HJ;E)T\W,8I8;HDB)`\9V*Q!Y8+7=G4+7\D08A1S4H# MKN[W1SP7K)";/B#H!+K8MR$:C=JJUEA/(&JK#GFA,W3/E7;'Y5,O_]2Y@T=J MW"M]6ZL)(NJ\J_1-I?3^+D76*'T-2G_NU_4SI'KGELRD9Z.1U>[G,0Q6'S$+=P MXIK2E(-2B\;2CI9A9.D3$6+M(-90[91H4ZANJWW-WN5$\%]3=#U_?!#9KZ#6 M,*V@B[YG>HB9'B*FARW30^4B=U0/1:V'H'G&WKF/G&[Q?`7/.>9^>*_U$UD/ MX;G^2M2(%YY***&!H=(V3L(YG:"T<_R1MKB#PN?!$Z%]@A>_GJFP)!PK1OQ3 M4'LH3SV0W'IU?(^.Z=I,\B.>\(*$<5'W!N)YGI.A9.\L[EN2ZD75\Y<@KR[O M%LM=691!"H=9+#-#FB!X\&\Y2"X\O+Y&%T=GC]!"_ZYKYS.P^.G259]"]%N+ MZK)[07YHO[>HTJP6Z`(_Q2G=R;L($MB0<_M2L0V=5J0H:VG1614.^I#L>20K MY!-%CVJ")^"WZOPQ-O1MZM@Q_);X6Z?CMR3Z&O=;%W*_=5'[K8LQO]4F@E8K MM?:#)^JCC/4WR^]_;#)'-?5W$EY.9;,'\W)Z!COWY&:&_[V":#&ZA#D[24:= MUG$^X^`,YJ!:&M]_UG15:-15-2$6^QIJ/N?Z(.6?BIMZ&G)\S55>NUO8#`5] M[UYTZ+:5Y@*FN:S67,0T%]:?<[Y8/HY;X\\MCN733B!PK<3X@1"6Q4W*-A.. MN-H>?NAT0E:1IHZYSF8?@S-']CD2BN$2XK#W6;["<;DC&EJ@AZP,DA,-9'W5 MZ@G'M5*3/O3276;/#B/:?KMK]>`!7FV]M?'> MU,;;O]O9G,2RGIQPT/Q/75N,L^-1E0;5K4)T@LR^E]8YK]6UQ_)G^+ M"W@=E&85T-\J#_>/]ST7-6J/HC=!;5OV+=1^K).0V4G4K+]'RP>P+Z+.)ZL\ M('9;P(<4@W\J\E#SC'U-;I@FXU:3;;IJ)XTUKS4))1QRIDGB`?HTP/7G+88ZOP\9_*HC[-$S+_2[<'*[1`;: M/<)Y9[/3P;I![V35'8&+!/#K1=?3UD=\I[V)-%OIA]E>&E-Z::ST4]IJ,O4E MA]Z$FN9(9H?TMW':7GG(>_49Y+&YE-%%D"V71!":`-.B<\4)^/RX]GMR0AD$ MGV92W<`-J"WI$H:]!/3+)QPY:"+R6#E8>S&`XK^#X%.'PX$^CJPI=>0JT(9P.-RPC24Y0H781YOZPH3 M]*W`!$3#M6CDM]7>"M3W=7Z=30=KO8E-'VB6CVY9'$^B]YC5_)":RP$_X/_Q MJT@SASSTJ^JCMQ]Q;[K'5-7`SMGY6O7X(3S0"V5J:D5X8><'MZC9QVD:YC2K M+!=4#'H(/N/B`29ID2/@Z6P7U>+ZR1>/HL6/*`WZF5*Y?B9,I-U!%2*9:NVM M>)I^5%GSRE=51`S65QO"GHLA@AI2;]X+D.M_&)WK*-\E=I1OGXA9/,"/\'V3 M<01Y\YJ):AS4*'+\8@D)5?!Y&MV23R3_OLOC(F*%;=0/A:DX[>^!*&7AZPO` M[7HXS*`\J,ODTT-B>H/$[2>8C)`]R!'`XZ*,PTLHC)KOE4`3T%N'EZC?7`A> MT0U]EC=PD@[`$$0:VC],-`Q;TCCGG/AH)2SO^]%<]A@H!!DSY'`D/I#S`? M#A;()Q,5N%*%IQ'"J%W,"!,D1F'J%PHFNPZ.AV1KAX5\1W`3S$(=P5&B>S M&^3QO1P.+*%`C$2Q[W-LWZG;W_L;2_W5"B1-.NPZ)A-`MA=N2?$ZQUS66;%= M!T\XC<-"83)CI);-9K2WW,AVJ?Q`HWF_G8-2#(P^,%6HL!?F7V;Y-B/Q!O[W M+$[+G\B@['*L/!R0BJIY6^_)B19?FW7Z$OX_I/7WG@48RLD$\'-3=!YQZ& M/OTTP\$,^7WQ+YQ<)I9'F;WW+B@@UW- M*QZR][LTZFXM=J(DX=&''K/EPQ!-B;ACAHH/2ET!YV#ON,/L\L#Q5(73.P^: M*!WDM=&+]]FN7"79"PJ*(@OC`(K3O,3EFA6>V;&7ULC2YF]4^.=*^+9*HOO3 M)1-K[)\WF9OB#*]1O!$PNS6M8XA7].2C6X5['.0^ M[!2:8'1H>.8`G7,_C*]1KA>+:S!:OOFE(0EWXCOV<(!',?2IR:1W2VV64)UW M"881KNMEN;8M]:^"F1G2G,+209[&Z5,!UTG(Q^C!@[0&EH3!`!P8$]P9N0XN!$?D;K!Q*TE>$.+CUH?D!?U! M40)%,"+V`O6/N&1U+*!7357J;/\YJ]K?+W&]W)4%69G`08G*=`W;L6ZXIG(.85OSHZH! MOK9ZIQ$K%JMUI#Y7;(6UHK-:>F4"CRT/=1B)O:,ZOJEC M&Y77$=!;]RZB?@N#TB8>]<=5Z,J@=@G7=_?4@*(L28*\:/_F@2U)$3:T&0UX MN;.-JSC9@3T_%F4>A++W5Y2:RHS]F'K@[W&XR^,R)E,P>X9NV`&:Z"?: MH#%MQ>Z.C;&,(NM`;0O-L_*\/V"YK"[LZ##25N0NM^QGR_"I_TYJ\CJL?WA3YT3YB@[%,FTX.UO;EI!MK;K)MCG<=T+?2;DUU*Q>V9 M*ZEEFN1"[L4;3SXX#I%LM1P6U^"'\2(B@0;>(VUV6*K,?J7_\-UG]"S/S%>, MF)V-\&-VY.&=I^A(-B_>\-=A2$1L?8;I(MT3WR&1[:$7<435$J4*)]H-BW:G MHO,.K1]/S1J;Y;1XP_^#PFK9=9"CPJ8MCP\+6WD/<5Q8M>;!GN(A-*#8:W"_ MU3`9UM./#$93.#M4F:KFZ:&>G3H_(S$_&_'G3,3L+,2#.5]?#K63.*631,7DK@6T.8_& MMT'"]=]W\7.0P$:*O%BQG,?RH_'R_@MJ/K#:%AT&+RH9'T@6U\M1'4CUWX;7 MQI/%>L=09G&Y^C/;(ESF]+5ZO>!4S6J_\K%:&@Y=M-8F"38K)GB-A[(MNG&G M>W^J.U!<)62C49KA82\"HM<0WZ\Q+@M69WZ-RS@,$DD.AC:G76^K)0N?^4.9 M$.-"/;;C)V%H>=Z#R^7:!^N#KN>)31%GSQ^?AV08=PE48[F"\QXHS`*O8.%M M@N&'\S0ZWV1Y&?^#_OXNA[?%ROT=D:ZS M'4IT\<]V:$++H8VP:H,F]E%SN+>-IN\Z=K&HBF)Z9A2:,O3*77IH#'T8*0UA M#$/VC.`AQT&QR_>=#DD,8)3:.OC'^\QE1514?>B[A;QASXL>X+TZ7I'@9HAX M)6AL/G$#&^[T=5&(SC2ND`@Y'#Q5(^H[_S8&/59H2)5;%'8?FY$.`?^@C(;^ M+581#Q)7S3ND?H0QVZ<4M>W67(2VH`*JJSO4W M'OA"`2BXBM8R1-@,>XMRN?HARZ*"K%3O" MID527'F>)@:NB#VX)ZS$$?=$G1Z(+,;B."%M/I&I MXT.0_X([79.%Y1(F^Q&Z3`+N-1M&3$.8AKPV#"_"&#-Q:/@"PFQJ8O=&H884 M%]1KXLEB#(-38J@)G%!%FSB-P4CA=HS:-I2<]F,=I2Q<2,$XV(%NC\Y-11-F7`1E@C&'495)-.5#%*45/7FP(-#I..TDRH91DWO,"U&BC)6< MX[J]7Z6#["ZU.VSW^BQ&=^^6H$\0E_:?5N<%B-5`=UKZ0P,O0HR+P&+S6*?$ M9#@A\Z9Z2!MZ)#W5&6=P<*@CZ/G(>^>4D`8V]4/N0.M%.&,N!KOZXA[P$TG@4;,XW9'I9-E,AQ=XE<&S3$#W$'S&Q?5GLEK(\BA.@WQ/2[]_ M))J!Y]`RN@JO)5.>YQ_IJXYR`HZE0T%>056.@<8N[2=1^TWT2#]:!V;TLPO4 M^S![AV"!^M]&]<<]B.+LJI9&@Y7:JENA9?#9!Y=R=",=S_BP8*&V71WI:N5R M+W"*Y4>,0@Y'+F:L[P+W0$CK*1Q]65$?J\2!UKUL8PF(Y57GZK_VX%Q=`9YQ M\U$@QU'I(PG@!W1N2Q:-0&.D'-&@*!^[;.;!S*4C"E0<\*8^DOT^3GGTQ;B7 MSDHQB5R#Q,8R40LF_;["'2_Q_=Z[_IRMC+590II@62? M"Z@K`*KU=((*G3ZMNDG'!WT6%40]0)L>KIC%\D]=#R^H5?/F?,QJJMH;MX=3 M1ST;-E>%,\\*%\W&OOE250OXCB=?NI-]%1_I/!TTBC2]>-=U:G!]7W"YZE8/AK(9(CES_5#`EF"/#E%5[%85Q^Y9%-R)$T-`8=&#FJ;*(T M@5%JMY5-A-CI5S;Q""X2E4N+@K@%BLFS#3X\S*!3DK^N\]1_FQT_Q2E8)JJJ M9![)5[(WA4@DEI9 M\`X4W-5:V&FP3DRNHKIM&CWOT);1.YLJO4'OOL?W"0I"'[\M! MR=%T1?6THM;?O4H)53*:)CTX6#FL%8VD]1W]UD7MM6X$7NOX[DDK%=F!*LDR*&]4 MF=9I4^2W\',(6MQV?+^G3NV8ABN-WX]BM?8ORO>$FVE0!55MA[JW-#)79%+;/K.C23Q&ODR!5RN#4R,0#5YJ5"GTO#NDF?R5HURV-I(4D%GP>F MU)=#QX:(N^\P'6G9-M>$5&*QO^Y]M)@19*E-10@K'R:?NV`_>>9I>#VP%5X> M37MI?'7%Z<5>QQ3Y&D&VC,1'^Q&@3G^Z&8721F;1LS8 M[3ZSKB^5?F`&[)W*][0!-T8R4\1:EB`BWRGCHJ[JG]&KI0%9X[]`YN"QA--Z M3WZZ='`T%-+%'XIV.1ZP?J#0VW M]TK])*MUNI$#PS%P55`<,[/3^`.^^`]SS1CZD>8#IY_9.5]7P\S.N%&.5TE0 MA[4B3<\RRX3L>9B[8%_?N`C_OHMS3.0@G2OW=V2DX0D%*,JP!1*)%S%IQ+JG M,))PB/":F5Z*8NRHYE\@VL*"QM--(UZL&F;)7)]PTW2,*"ZAOI)[(S8'ZM!0 MIZ+T5*;[HTWS)S>]'W5:]W=Y,$\[='FP8PH9G[,B M/I"04?,V`0VJZ]4PL=*F*0^6OX9HY8HA38&J/5MD[$M-IW6Q[PY_(BD6\E'?Y3IV5PX]J:97M+@>VUGT(_ MP\<0_9KC"=DWY8DP^49P^W1%I MPA@7.AY+MP'[`;RN9%QHVS*BEA/5K!YY"XT3`&IQQRO;;&)6 M1PQ6^W0O[@FGT#>SR,&T(?N[7J:2;0-L^ZO;A)_3N4\R6]T`FX1J;@ML M!J1GW'^]JFXC0I(<^62YU]O2,N"U>_-54QZN2%S%ALXAXY,R&NUA6;OV:#)> MO3N/YH-E.B\4./SZ*7M^%>&830GDA^%,0'[5]*33@0=!"0(YN35D*7HM!%,/ M093:(7QT5%\C1E_O#HKM7R9!453O"YY_CF4GYQ(>=V7V1_K/S81``NO1ZHDI M(/-@IE,.@;"FOES_%B-0UH\_!WE.0N1E_@G>7+[^C/,P+O!='D,J2?7'HOIK M\486B$YKSWX\.E%N(3`K8I3EB%(O4-T:HLUU:(J&R(?3RCD`X&*V^:-O<9*] MC5-\0\QQS&&J65Q/MMW>ZTVXP($HBW^S+C<6BIE7,!#6'2=UX%?9)HAE1;+' MB%VYO'Z/51,M(_1@JA7K6^"$A,H^MH=Y(,TJ/`HC<>)!JMX)/0;\W0_OT-7C MF#?@E7BLD3TGGXO@D^^38.PUSA$:JV,[[!]7X*G^.P("MZ,[JLON\$H4>6S+ MO:O?V[PB4;K"A`>T3FQYV%^A45>9@802`:D?]CVJ[3%#EZCZV(AX'Q=AD/P% M!_E[\AM5H,A1.T$%WV(D'Z_ M51BI7(AW*!G1OA@G0M4?"REL9_D3?HIA0SDM/P8;T<0R3FH5'X+>#J%1'0>T M=`@(W8)"IN@N'M1:/BX4+@D6\R"Y22/\^4]X+\4"1^L`#'Q_!6BH"!&E1(34 M!SP(M,T#0JKJ8R'B1''Z M=+_?/&:<\BL9!C16!W[8O^&05W]'C,#M6(_JLCO*$D4>.39HKVS3][2*Y:XL MRB"%WL@#!2FCBZA!+HDHA.C4&5BP)^$*U.'TP4?HC-%(>*$]0#;3!TAOUED2 MX;R`.X;E7N?&GH3)00*!1`(NZ;5#C!@U.B_+/'[*9'&ITGHP6Q&GA__B5O) M<;":Q6Y6G[SW,NQ7V&`&X,>1L.YX]-+WM`?#HD==9WGY@//-%7ZDIU/*[@DSV#R\X M><8M6)>KRQQ'X2XW2&2:F;<&94&M))S:KF M/PG#FB`L0.-D3$L7JB+C,L/I#/,Z?\HQS5"&.5%D0`,BNR8R["&7[5+_'0&! MRT?+5#U]6,<%PJRL",KQEMT<9B^2-4)`I.7Z;;%14/2@*D'$###>D6%9!U7J M\$]!LAL[&Q%2VH7E:%^Y8I0549433LE<(E2KT^,P+=C[=[5`6RK0,S3A&JUB MU/0@JX*,W6O`U?9@]2(!VR7\1!2=/V/B_//W.WB#)R%][';P#)C;L^T_8[CE M@J-S`I#@"7_<0;2V7-'>=DX!+H(B#L_3Z"I.=H1:8N!3&[1NY9,E'^*];@A5 M+2'6%+VEP!T2+1!MD-Z7KYIT:_$'4T,K5\1HT)=QB@JJ@:_);3LKL&U/Z*@C-,2\8976M*&/(U>1+TRWN*.1'#[H M/!(V@7$_.#;'L.,YM7(!W/GZ>?2W75$JGG6;W*(?LZJ6[+K3:M78R-R*VO:D M%:6=3SOZ6-":=W2!0.1G^K@E39-_DW^1'Q[)&I,JZ/\#4$L#!!0````(`'=X M#$7]@Q6(WR\``.ST`@`5`!P`<')P:"TR,#$T,#8S,%]P&UL550)``,1 M9>I3$67J4W5X"P`!!"4.```$.0$``.5]6U/CRK+F^T3,?V#Z//=JC(&&%7N= M$P::M=F';@B@UYX3$Q,*M5T&[98E;UT`[Q/SWR=+\D6V*^LBE5PIKZ>FH:I4 M7WY9MZRLS+_\Q_LD/'AE21K$T6\?>K\!='S;Q^^/UU_//MP\!__ M_C__QU_^U\>/![^SB"5^QD8'/V8'5W[F/R7^\&>ZJ'_0^Z7WR^D!_'!X]G&0 M/W\\.NP='_R?P]-?CX]^/?K\?P_^^_[K_SOX\OAT\/'@[>WMEQ&TD!4M_#*, M)P?L@/H6)3^]N$ERZ:_?OK$R[__2,)?XN3YT]'A8?_3HN"' MLN2O[VFP5OJMORC;^_2_O]X^#E_8Q/\81&GF1\-5+=Z,J%[O_/S\4_%7*)H& MOZ9%_=MXZ&>%J)3].D!+\/]]7!3[R'_UL7?TL=_[Y3T=?0`9'!S\)8E#]L#& M!T4'?LUF4_;;AS283$/>\>)W+PD;__9AFDQ?"C$?GO8/>?U_NXJ'^81%V2`: M?8FR()O=1.,XF12]_G#`V_W^<+/6_6D23U^@)Z'_HR#B$R_T2=[.)^AFPXZ" M[D2I/^3MI8/QF,%/T?-C%@]_OL3A"#3JRS]S^*Q)G[6;M-#]&Q@E$_;DO[/4 MI(MKU:QTXY6E&2?J)OI;'$39'_!CGC"S/F%M6.C@%S^)@(7T-D[3>Y8\OOAF MG1/7M]"QQWPR\9/9W?@Q>(Z"<3#T0=F'PSB/N-;DRZ8M6P!S M&4\F04%A"@/V,BZ^!!,YM/_D_PC-^J_16$N*8=Y762L[4Y(KEOE!F#ZQ]RSW M0_NJLME^NPHS_YHEC5FVMI-.UZ#`H%$K$*(1BU+&/Y0"O2.^G;KP0[XG>7QA M+#.4N[JUW2W5]3FH^0&[RWC][DL::7&);])?O19;FN5K3##29MKM9@WYZK2V MD[GD'CX<92\L@X7%<%(T;+HM.(]P1&3%Y'PWOIORTR>?(QI#P9K=!8QF9YQ: MS>\"UJ6?OER'\9M=4^[KM<_/U_)2+>S<[D4)JJ4#7]YCE\_ MC5CPB?>?_U``^7C8FQNH_@U^M>Q-I1/%H4O0>UEQ[_CP<*W#55H'R7KG_62X M:!Y^W.)TW<0V+_%I6JQ2'X_V61Y M_FMO.1=?AGZZ6%T&[T$JH%I9!\32=\FWFK)UBC4!B7D^ZA3/5617\<0/(@G! MVX5!$,\=]YR>+>WPN05(S.@Y84;+0_4# M>P[X63K*OOD3;(H5%078%/>@2AYQ+(A9X)`\AY<@@L0/;Z(1>_]/-I.2N%$6 MD!]UET4A&(1&%^8=71HO\R196RKD.QZL.."G:,91DBG'@_#IPHQC-BRO@Y`E MEX#C.4[D@W*M)*!V:K)I-B0%4!`"*=MKGA*?>]H^SB8_XA"A;JT,(#WI(FD" M$`A=E.TP\]4@GDSBJ+`6%C?[Z5V><:=B#E"^)DHJ@DPZ:;/118:PW<24`T+Z MM'D/V.;]H*YWL=%5H:U;FLU>?(LS)KE3U*OH]1K>)]I&=`5+=QBG><*X'\T% M?/^G,3A!&]Z1TZ.B`1G8_90)4$O7DJ\L^1&G[-;=@*SZTCL8=,O/KP2M,>(D MM;RC(U?#3=`KG1$FJ^8=.3TDZ,I;/**4P/9H$"&//YR,J$5?TAON7#48O7*' MP_0IAO4V"`/8[J?\'=&_#TAF=K7[7ZSN]2]$D7#S&VQ=,:_.$!0_P;S[?6E>?G!089C*5 MTJOH]4FP^],NG1*#HT\+#4IM^W2:\OE.' MX4;J8(31DC\Q!?6`K>ZP<"+B8!Z"].HG.:-7WCDG<@-=2$GV` MEIRG*6C%`X-]5V#!^C@*.2'\64=;UCIVZ7#?2!CUPMGRP*:C"8`2]R((4 MY'09IR;+B:*F=]Q=.Z,.-%L>W!24X/$EF$X!+.RI_^I'HW".6U\7]!KPCKMG M9JR!T)8O.`7-N(PG4Q:EY6:;A3S`CN$TH=F"=]Q="Z4)1%M^YC24HW(%\X>? M!/QI_4V4,>`N*WU[E1M,[3:\XP[;,(U`VO)MIZ`B#T`2")A;<*]@;Q7&A;WF MRSL?+TRI'!JUO>/NFC=UX=ER?Z>@$$O?2!/+MKB*=]Q=4Z84$\)W)VV7W]A; M14!)',&/0U8Y6^OK@6E3WG%WK9RUL")Z8\'VN6LO)W40<0>.3;)8SR9._$;M M>">'#K=W11=R/[S[$0;/!<.K]Z]?N>\%[%P6GJL%,7HG@@;M>B+(Q`7$M*V5CO>B=-3BY(L`;>U(+J- M>VN!=#30;FU81_ERCMG?J]`AL MN$*8`J,3M;<%%>!(E0'2-6I[IR2<*W0Y-=2(#9QT(@/7UXB+'`19SH*+'V\F M<-9Z+6VZZ/)A5-\[)>%?H'O!*WBD)_XAF&J"`1R@FLL5'/A>S"Q8- M7R9^HDJ9I*KJG3HU&M8\,&BA(A1'V2;U"YSJ9$J*JMXI"1$+2YUU4"`D%#X MY<:7%^D#&[+@E8\.Y;R/5?%.23S;TN).3+L4&:%@S0WN9OV0I?,')[_'\2C] MIK'KPRMYGTD\PFI`N0(;H9#/%M[C7^S4^M@'><"(V@(N[NR##9@5^Y-H-^"]]FIQ<^0 MOHA8-KK.N;UJOKF%'R.YKX"JGO?9J4&O#D$"BK50(BY"N[+K(<1>QG'I&O'* ME@X-0 M:F/$"/D=L\R]^:U)0)$'[ME M!_PRF8;QC+$B^=)=`49YB$?K>&3B0+2D6P;"K_X_XN0R3[-X MPA+,`(`7]LZ9,MU72.R/Q,M5\ MIA,C07ARX5BFFV#ZECW[X91M,@@R^'/@_@K!,0C[UH]G@&:9MZ1L,@]K> MN5.+C9`-P0QH``;ALENVEP=NCU`E*M=Q]AK5NVD`*2TD96*>6= MDW!T6J="0E>EUPAAW;)U?/7?@TD^T7C,5BGGG9.P:6P2@EFJ-GN.$->Q-XE! MI$=A)XG["I'RPBKZ0+7XW+ M/.%"+?,7*6=I_4:\H@W&AJ71 M,F#O[WDPXG./2]6XOKJYO(EX;T:#"9>?0A6VRGN]0_37,SS%O\]3G[>1/=)/&0IWY0\^&]?_8PE M@1_*3F5:]4%L%-U[=)3``!^B%IW,A;&$?1U$0?K"1L4K9QT]6*L`@G%J)+-! MO``0PG0G,_=>Y>P:Y'7A1S]E_%:+@1`HOLW3874;!L)E)U/H;D4TN&<)_X7_ MS'JR95M2#81$T;RFM7XK82'<=S)1;O$N;?4V1C5?BXJ#4$@\V*O!-0X'"=+: MS0RXY:.HQ?4WR&9A-8I&WT#;R_](6-=K``1'XJU?#3TP`8AH1B?3XHHS-=Z] M12Q)7X+I:N:3*(=V&R`^BO8Z'?TPQ(BH2"?SXRX?/$0J#R+G-NAI;?>LHH@ MJ*[:[W2`(1JPXR2XB!5^?I6@"EV/FN1UZWN]7M?L=#7P(51WS&-,EJA5YHTD MJP?RZ:H13P,7PGLGS7D\V5\<%>\,[_WD+GG,>.2*XB)BD0M,>A!4U@:1==64 MIXT.48A.&O+$+UUE!T-A!1!,5PUY,D`(TYTTY*%QJ[^G;)R'M\%8-O0U:H/( MNFKVTT:'*$03Y[I=)T"4Y7LMLQ[^>3(2]WKVLB*J$CUCFVQ5/>@D"6>F&I(5 M;+GUT)),H[@1Z&N5Y%@6SE!:"<"Z-Y3H,2*@4@,:RSN' M!B4F1%:1N4UH:#-4#5?U1;)RM=,I6L?K';DW>FA1)][S*("YS5^(#-U'EF5A M\9)/\W4C6@%`NC=9U&!/!Y7;O(/FVZ-;E6NP3EV`[M[P4'LMU4>X#RD$%Q-. M[H<5G>>!KK_!H>;IC86O["N4>5&D"M)L!`3GWCBASS#JK6`$UU)*00J6"QSZ M(QO&T>B_F"]/+Z>N#C)S;[MH3T4V@5K*.DA;.9Y>@J2^;BQK@\3<>SBUIQH; M."WE':2M&3Q03O926S56U4%F[CVBVM.-3:"VLA,2UXY@W$0Y%K5!9.Z]I%K4 MC76EWQ-+O/1*'B9J0A9*P:`:$3`,F%$@(#D M/<@BU\/RYD::#5%<&N"1-DFAJYH2D]O;#6W*%)X"2'F`Z-Y:)).^%EE5+)8N M&=J@:^UV-+WB$\FW^+68'T./G">46!.$EBX-=D3V('_. MTZQW#A\^K\GU=A,@"/=&'7M48P`M70(X8'H`OQ[Q/_4&TR0(&PQTK59!7`2< MOEK1!P5F6U>22\!&]^5 M*8"CY[OQ.!A*\L=HU`+9D#!&U:(4N112H44TH5N^P@7*+^]LF/.WP$::(*X% MLB%AY[*M"3*TB"8XMHH)%9@OF_SWUT'DP[KIARK*ZS8%DB%A7;.@!\U$@"C' MWOLI?^ZP[4X?(<)NMQR5YYE]T^LX*5)&K1SO9<<$22V0C7L3H#Z)XFE?B0_A M?L?.Q\HW)!_M=(`YIB1U1EQP["=54%9JXRNE>: M^6%86,"PF-7-&@1AN3<,MJLH$F&H;YB*4W437K MQC*AH%I13%OT>F>DS8LQ2QQ[FM^")$IDJYW98N65'#!DU4!$I-_!:ITPU``1'6AB8]R] MYSE4BHJX4U$:A\&(7\%54T8Y"<131#WC\KY;&6_NX[08LAJ>YCK5O5[_T-6( M6_8/\SX7%X0ND[C*T1>O>&")4-%Q*V\W/7RO3^(F1D3!.EEHY^DX=[>5&K[7 M=WI'@DI^FZ#M;N]#A)RE11%?$)7(#K0_+DFLY!668!SE-']B0 M`6:8XKZQ[%(GNP=:#61$(LJD/O5J-'L4`F>9;0PP2ABN%@,9.+VK,&=TN_=[ M%*?F?BVM\R*K#J7F[ M^[;\Q3?#11"*HRZ?FF750$0DK$LF0U>%9I\"PO`4GQF[#5[9Z`98B9X#V&V4 MPI*3+J\(@B)AD=*G70>/+3]P"L27T)03-0`GX=IK.D.7_;;EKNU^:JZD]8,Y MJMH M?3W0`DC#[;KUX*>RBTZ\EM<[(6%(-=0!)2(:#M2V'%!J'-HEIZ#>"0G+JHU3 MFPJE+;=H"FI0R<6K]&S8*`K"(&%55=&%#_9M-+:\G2E0N_+_O_>#T4UTZ4\# MV(Q4@,O.;H1C>!"" M]8UVYR7!$7OFRD-LDV>TN0.!D##0U2,8PX,0;&R=(W6T%VYV&UR_@:A(6.OJ M4:^'#E$$8^N=Z\PJU9CW@_&8#?FY=1NT^RPKVWWZ%FV;'Y$,2B MEFQ]2IH^!2D.72*Z-&X+;GT(J5'1><9FX?E-B0ZV_=,X8GB,>*UZ(![W,8>D MU&$+I1(4G0=Q#9*2KZ-3!B$5E@=Q$%D7E9R)R9:@VH=W=94#O#J&Y&99$`.) M.RP)1TIC5A7)/KRMXXZOW_P)4TS,U6(`WGU,H!KS\#8&MXE5[!*HG&_7"WJ] MT=[Y^6=YO-7U4@"'Q.V.2,B"[:NH\R0SJ/".PF\/ MU5RL2@$<$MJ0@Q0$@B5L137:D*$AF)]GJ\760 M#GV>-N/P(HY4&?'T:@-\$C<9=4F4@'*<3L28U%XC4GOK^$F89!J3N@W*0K"F1NC@W(ND'/8S,\&'2.J`#J6( MY5V%UM9;,+N+N^/,3$>')$Q8%O2@F0ALO1]S/TU83>5W=$C"AF9[FI"AM?7> MS*DF#-[\9/0$7U'L&-?*`7ZGQK:Z.T4!"%N/PMRZQKR`N"[\(ESZZM`S2!(_ M>BYS3UW,5F7F*:H*8:PD$HVT;_W:^!RP0<+4)U`1L2ZU)P1;3]:MQ5RWE'/1)F.UWNMOO>^#U7.[L7/61)4Q2 M&O"Y3U%FL)@IH=AZF=4V5>BA1EH>,+I/&"83OQ9;52RV'E"UP5>Q:U[UFC_% M_!:_%O/"&7>B4%QB&K0!LG!JKM(@"F76!"'"MF-_,!3'('_.TZQW#A\^KTGV M=A,@"??&*GM<8P"1ER".O<2T8!3>%OQ/O<$T"<(&0UVK59"74U-3BPJAP(SH MR/ZELSOJ=>I5'PH!(6R?LMH=N8T5C8I^FZ'M;B/T./8"N\JSX0M+51ZX:Z4` MCU,[C5B^@FE0U&V$AFZ9:1[S'RG[9\Z?A_),/QI7`R`Q$IY6)OR::\@F7D1#NN5KM3CS%Z.I1*]<%]`Z(!<2#QY-6!3K M@0(B$A&C:QY:<9(]S0.3Z^SM1>5!'NX-5W5V]C@8A-QN^3IMX=/PH!/6\([= M'MTT"--DN(H'X=CQ^\:GM_CI) M,9&3FHPD@:G%$"!"\X[C<*O9OH[S)&,L:L"WJ@D0"(US6WW&]2`BG._X#27" M^?9*=;O(`XAQ+*D"0G-J(:WEN:'$@Q"X*[L:PMS<)>A;SC4-]&X5*FV09Z#3 MP;\8*&C"]YI^-&1WH#[]TZ]QE+V@S#9H$A8^BK=)&TP*V&^,&=&.'2?#DRO) M8,)S^15W!R$_@-SG&9Q"HE>60D,WT5W$KA+_[2I^B[[%63!D]RP984(; M0,?@ARL_"&=_Q&$^87?14^*/@NCYRA>%8M[-AT'X%#V>M16N;#'E0>%#KQ5L?_CYU"\_= M^.XM`H&]!-._LG!T,5M(A(^(LHFBO?1&L%%'-[D[ZX%WU'=Z\JVM>+L6$1(T M=L>I"67GJ,*N.[K*$UB(`7H0CTI,WR/HZN.4#8-Q,%QZIDG/5V9-@8`H>LQK MZ%!=K(@R[#AEH9DR%,EXFJJ!N!$0"L4+T-H*($.)4-_)-(7*1[/8F]GR"BB] MR[,T\R.^\R]/L%)[NN5O`1WNG<8-E:YE82"ZV!2 M3S'_546,K9^S=;O@'1UWSG#L1D:(@M.XZUA);6E+3];N>^6SI*0B@.^F45`3 M&9*&;,<7`K2,+:]^$'+UAP6@V'_LP.:R^4D@Y\]G%M22":*PCO/9\+0KMRQ= M;!78W;B\2F8)[@,HJP-8.V=ZTP2%$.C82[N.TI;K**R>05*4EK)M[0,@Q3^/ MO4PB`42/NA7G\C+TT_1N_'>?2R&[*X\6B[%3+-C+/Z;SOZ8]R7I4JSWOV&W( M_2:+30/`B`)U*YK#EDGD!K-7*6IXQR2?_^HI@0P20K-CS_.E^8#/:-B:L58( MT+@/)5=GWA>@0#AQG?VX>E`JO"&_>0UR6KX^ MJ+Y/D,R3RKH@I\[MT0W!(4K0K7@)%527_C3(_+!<)!Z`K>2UL/->YUF>L(4@ M]!9/O;9`CIW;K3<$BRB-XUB@53?:JR`=QBG,)@&/](L\8?^$.1]7+0"1+A!91R$@P&,18D!5>GUL$ELKE3FS)NE+B"=W3B M_LI,S))X&9/!0.)6=YQ795@0K`H(A40\`1EENB17$2%1G3I%\R.PP+,[W<(G MPK_E29".RH="ZI!_\IH@(A(9-^44(G=-.M"09WJ=8A]$P=(L&%[RS5DR4W(N M+`_B(!'2K0[3$D"(:X+;\T9EA5KNP#7V3ZO=^M&)>X.2SC*K0("$<(R.V+D[DD$G" MTV@;P_4X+R/*0IQO%`)!3.X58P**; M,U&_+9F;6CF^W+_$*6POGED4#!5YFP1%`9]3FX0^+UC?W9J*;/DS)-,8]L"L MNA%4&@0EM4`T3JT+.K1JP]@'>Q-/02ZF'WU M_Q$GA>NK\@K/J"40H5/K@OXFI1%`2P8FRCJR@OW-GZCS!-1H#43IU)S02`-J M*1,NA7VP5-UE+RS9@JQ:5B2U0#1.@Q8T9E6L)$K$K1F='-PYBP[ZLNLLO8H@ M)Z?^0>;+C`X>Q)#1L?Q!LF"2W]A;\2$>?25B[='C%/`_T<2*:L>-` MFZTJ2/%RH(%^K-<'L9'P0[*N'B*8B';L.!8G9C`HWV&F3_%U'HVJAZZ*1%`3 M@DYE$`()]R-SKDTQ(D332%RT%@^?>_X'61$2I+A:NXRC+`E^Y$7W0DIG*3U\&T8C_PQ\BO/IA<4N4%7>V,"%B#^R, MZH/82"2GK+]0&,!$M,/8>IFQQ+%NK";-P;`(MK5YGI+HA;(N",NI.;.Y3FA" M1/1AQX$9[6C$-7I`_YZR<1[>!F/99*%3'83FU+C97"_T42*J0<2';COFGMZ> M0ED1P).P2=;I&)%$]V"Z6N!&#=OZXR&D^ZF/;AL>,WEI7O!#C.91S0I[@2D&0>XN+" M3Z5OK0Q;`A&Z?V>E0;)XXU@+K"6/.`IGB;\S'JB$C>:I?=?#R5:23:F4QJ@= MD*+[!UFU5:8&5$L.=NZ-D)M;495:",N#3-P_JJI-OP22)1\Y>C1?!6'.-=[\ MB+=1$^3D/BF+->J%X"SYM;5B12PZ'+RR1S;,DR`+8+XJ\QIL(I-&7Y*\AKSG(2#AUQL9M>8Y[A+1Z>L]D7\'>ZF4,:=YDE^XJAP M9I2_4976`_'0-+)4R!//@QJPZ%R%-IASUM$I7YH*RX,X2-A5-#A#%CT<%F-@IUBT"'^RQD MM16F$6C[44-V?6J]C*%25"3@C-(X#$:PVQE=^"$/\/?XPEB6EM&L7E@6#$V/ ML,ABA33IR?=K"#K+@@=-F]NXBN9!4'FPH@.N?7=MUP^XFT0E7#EE9Q*\,`B"EBT`'6,J#/O@ MBCL8#O-)'O*-PA6#?@^#,F`[FX:L("0:#29QD@7_*GY_#_L.EF2S>UA@,O@; M/U9/%3M16Y_P^CT2-@A,'<3*8Q?]'GGS5HPSL$6Y2PJQE@%4),X>!K5!8B0\ M/C$@$HE36J*\=E[[?H^$ MS"E()Q8+2(!$2#A-F]*)`]B9AB=#4M!12>C>> MYW&!O[K+N[OLCW;.W:T:0%L-/PG')J@>"2.&5*)ZIJ<>*=>)EDU//1IQ+004 M:)B>>J3<'5HS/?6\-OY)!X'LJ%;*042('M2QQG=`F#KX72<^:%3`I>9 M-K^\3_E13B=C(UH'9$/VG(Z3JX"S1X:81Q:&W.=S$D0!%PY_/:KF7E$3)$4BV&HM!=#"9NNU M-`4U>`!N0*X\$/45[$##N+A25"N!M!Z(B82=J98*:"#;GZ?36Q(R6>%!&"0, M4[5H1M!8>]1,9Q.W>MNM0^ZJ-`B$ECN.V<9M$XBU-\?.F;V)8.)@*7<"F:OS*L.Q3$HT%3O52O%$21-%!&Y@01..T%^0 MCOE<3$?7("J>#R:(A%VP<\X0/O-R3_\[2+^^PB@'H(/*362'!;S'\ M-7K7P5*.J@&:YU@=A*S4%AF9F+8#XF+^!L)#?I(35`,!TT M[TG!V,JRX?X$L!;\1\+M6CD00@=M>@((MA)JN!^MPH">_`Q;.^@ETH)W3.-P M;\:]$3A;:39H["-5"QZ(9$,:*A?KVFW"H"-A&S32AKH;":D,$(^83MH0A=(L M#F=703H,XS1/M*Z0C-H!,7;0.E$#(J(IG4PA+`LZOAES?#5L)"I3KT$8UR0, MES6T0:Q63<2`Z->.DQ"WN0FJN_59"9[$C::-#<\:)(3Y'6,?^,:U5M4*:@EX<#IUW#J[#.O:/21ST-3A#%E`O9%M<`01"PI1F3+,,SAZ]IUA[,Z[D6%#: MZY^0\/0Q)AC%8C\B8P>?+)[0\O/1WT!O8+#TF&+*DB`>?8G<^OD(;`TR5C<+ M@T3(>M6E3C)P""I7^X1?VX@EW[2KX>F`P;Z5!QN9/<^\+ MS7Q@P_@Y*EK!DHGNZM-`%2V#F9:V[48JMEYM4-CM%VMI&?3K*D]@QBV!%VB_ ML;?B+_*=HD9]$!LM^YS^-D,/VOYDF$-`EPMS`X78:`#$1L*H9T4CA-C:RD#7 MQ3,&";.>A3,&_F+/V))'Y/C8\(A!PI#7_(B!O]"7GH7#IIR_78?SF M)"1BY>)[V0\S?X2M:E[_M.?S0B)I[1, M*Q4*ULE".T_'^;CBE97Y`QY@*PSY<]W]C M&5\<[I/X-8#MR,7L.VPN;J)E\(/!,`M>@RQ@J>AEBL;B;N<#('"R9H93U/?' M)O8]"N-8TT9^2L*L8)-3+;OZ*6IQZ*0/PIH=EQMAHV$0LC7,3[&FA#6FGS8^ M!YR0,'NTKXKM2<]6B$OG)C2=C$L2_=2I#A(C88UI3QO$VJ'+M6J=,I+-'03I!FMP#CEVQ\M^*_.9WIWKY2S0; M`?F1<"EK?X4TE4X+T51@4AT$ M0<*NW(QW<\3[%:MT2W8\B,FF`.6I?/0;`0&2L"JW-57(<>]34-1F&_W6KB]` MT'\>HW5C.>U/Q%-$&GQ3E[9YJV;X`1`["4.VE5NU6MAMA5^EL'C"AG#A'C_\ M9QXD#"0$L+/9?>A'/,PY=W8LNQ("1K:>JNB`N$A9NF^0CRZB>*/8I3&TSH;8V38&@ M21C/V]K)10';5?X/W[*^^B'?UI8OW3:M1Q+E,VD&1$C"&F^V M$IHCM!4"EZJ2#&`<)WP[ M6H$G:^CJ$]-\.@T+.?GAXH79332.DTE)F,;+/[T60'@DS.AF>F$$#M$,"R[> MNWZB>I<\^]'<.Q.&Q46>@K!2)^]1JUU9/9@M^W5?@7XWGF\(_7#UEE8G5;V- M]KW^^:&K$=P(P"JUQ!.HRD4H/PC;_A2(C82)Q:(.B*>1=@1GZ4&O^^GF,9], M_&1V-WX,GJ-@'`RY2;YTD>%1/$!:0^YFYF#VV>Z%SGL5M!+PYBX@OTRV.J-? MKP&`2.*PJ"(!6>\-,.[-\./FNZ#TW^=[X,*(\LPB5V-.TIW55*@Q#(W:`4I/ MG9W+=#JJ,T+-&@+()';D-7A"#G$UX.]Z$/_E$^\ZCV]7R/W_`U!+`P04```` M"`!W>`Q%?26"M(H-``!EAP``$0`<`'!R<&@M,C`Q-#`V,S`N>'-D550)``,1 M9>I3$67J4W5X"P`!!"4.```$.0$``.U=;6_C-A+^7J#_0><##ML/CN-D-]WD M-BV2.-G+7;(.$F]1H"@*1J)M8F52):G$[N'^^\U0DE]%6I*=C7KG+[NRQ!D^ MPX<[+??>K_L'YV\ M/3@Y^/Y7[]]WM__Q+A]Z7M-[?G[>"T"#-AKV?#'RFDVL1_E#.B*>)G)`]2K0/HE#?=KX M/28AZS,:-#PPEJN32$;#H@J-Q$+AY\,](0=09+_=^OGVYL'@S52'C']9*#U^ ME&%6_K"%CQ^AHJPX/@WT5&"^\+M6\G!:-'3H_?D&%,\K98["C"M-N#\#L0(Z M-;%]?'S<,D^SHK%J#@B)IH7[1#V:HND#TW#-_7;SL)V)^"+F6DX6;534WQN( MIU;Z$,4.E\1B*:$CVN32ISGU!93ER\"#G.)T[`_SR^.3'`'&GZC2^2+)LQQK M.&&^RIA)1E4N->9)CB]*1M%0"3W)J"6@DJ8\> MP-J_CEM$^E*$%!#XNDG'44@XT4).KN#WM$$$Y_$H7TF@90L1MZ!0$TI1R?RI MW'JA5`!\B>=]()P+<#+@G,QOO!-%C/=%^A-N8/\^0<`]$/?PXO/]M=L]&/,Z MPH_1UYSQX))KIB?7H%:.3&4-CT$+.4M,`600`MIGG!FH[?TVN,A,?/X25'F) M+F].V8?6LH9OOUE6'RL:=/D/YAI(5*#-R*+G2.73(F[9625E)7T2^G%HK305 M:RWP,:>R,E$7@@>40S5PH43(`NR_YR1$'_@PI%2KA*X"Y=RD'0!3#]"J-&5M MJM";U^BE*KU$YXZ[S;B[(S`3Z"'5##`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`WK:Q$,@+(6+8V9[=J5C+?Y MC=GP:W[CMKD%9@FI/9Y[),1VPB$Y37(C?*/*(8*_FIE<$V\UVP?-P_;>6`6S MUB\#8F9C.1"97`40^>='"E:?"6"][XK6Z#P`8JG85)HKV**A5MF=YDQ5*?L= MAS%<@'+$TNOF3$4E('F'7(H@F9?+?FR,)>_@3"$P\X+37YMRM'+&I@B4J9"Y MVA3"ZOF;(AAF4LEE+%Q_'S&3# MZ0`W:A;S7*&4"U+HOH[1;;:/-H91T'G.0=!;J=Y]@JHHI'DMES,E%1`ZS]$5 MZ2F9#%Y4&+#NDUZ%&F19:E.>\@^IE4,B^*?*8-S'^ZK/O$:7G:+T?*T!=-KX M1'#=9?ZTA7DC-<%\\#P4_I>&E\2DR7&_$YW=O]9TA&E5PX,D%X\`Z]-&GX3F M8"R>7CT!A4P$/2,0D4CC`*O M8O3X#R2DZI["):]-7UX/T6+;A1#)T'^BTQ%0&ZM)'L6R*_4#.392.[ M/CZH'%R+S5?0+!>QT@+"OMI8E@?*@K_W+&H'/P>3#?U0TOHU?RXJ6_\1L:R= M`7F@+/AOV`B$@QM&'EG(]`3#%<(G9P-H`BQ6&YN*`BV<-MPP;@+WKQ]?Y,VS M=G`6@^XDC0@+U@5B2]:-(!351$Y*I7O)(KQ>M2\I^IA\9P$:@CXR7=SJXA98 MYU_W7NLZY83KL18+H+J/(1LDIWIK%AJO`5K6O-H$P6L16BQ[H%HG-^KG3!W8 MRH^U&CG28B@M)M[*?T'X&-`G\61H?8^OEVK3Y\K!+6OS63R`>+I]C*\% MZF]R'MI-+#Z#VP$^:I]%DH5_#MX+&F";[X:,]JOL@=G>1L)[,2$A M;GXRH0($#DJ9\PJXZ$G":ZZII$K?03B/._T&TW0"R8V2N]M)HXHONE>'7K4U M[L@$H5XC]C`TPVR$N6J=.\,&1JUMIC,8V]C"4TE(6,,XH.J:F_7("[,/1T^7 M*;YB^EV]F6S;^N'(>JW:*%%:)M30K:MWU\ M_'UMYL-E0`[<$!/LUPKW/"`+[@Z3U-="JMH98$56U)(KIGR"@=K^N>`URLF+ M`BUM9_O/8F>[DIT=VJ&+IM4L3D@P;= M",O6SD4ZT=F21C,7S#=![1S0>HBVGAMK?TA5C4;B$B#;*B`9LU$\^A1CJ6X? MHUW!S01^%NNAD.P/&EP)>:U4C$%0]XG*PZ-;P?5P><$-3Y*IK[P?<"/T[A9) M0OM+_$1_2(.>N(MU3R3'5D$A[W+:D>2Y(Y[Y)Z$A+YYE3=W^&=0#%QW"PLE/ M(HQ'M,M[DN#?8NF0R:8)X=::[25-W&[CUCEMK&R2I8DRF7LV&(**SXI>CGT8 MR'=2^)0&*JUO>PL,F_>G"I!MV0UZD;M8^GAP%IKPGF(JDWRL845+M]]]YI!C M#%GT#QH&YY,,![9^HN(A\4H\\>OX,@>\1$KP:[?:U[35E4RB=Z1!)\:4\+S=4TA#7^#LGYAONLQCH M3$K"!\DZZ616Y(XD"^C/1*:!H.J@?HATP80PQ),_&W:6C1<_MV[0"S7<1RBH M8?`FK,T%,EFO9H;:/W^#%C;4F43<4@CO@ME71*;.<>8Q[RF4E";^,_.2NAS# M,Z;0:.,DS-V5L?UZ\\'+6>9L2IPHIK.07`CSZM(F3HBV-W&0;=]`#)*V#%IU,,NPNQQ%+(->E`;9HBS60GGYJJG9+Y*O8UAM1HPU3 M^:ALYP.R%\OXV9D+(N4$'!?."&K&)+YZA[E6^9)%JV]U7J6#5H-M>U6@6/)W MQ&JS/K2"R(9\*%0T!$_+F5^?U:U<5#8+$N>A>N(JYL'\-\QFL^PV]CN_6&A? MT(`B2R[)3D>-"Q2F*^->1\D>#02U_/'^K]`5S?)YJ)6@ZS\QGB]2*@` M1%N89_M,=9TF1`?($F;5:(I<`\_Z`BR,\1C#`_4AB<2)SKVZFSK`ZC@6D:3]F>$\DQ"FL-M&%&Y[% M)OO?I3U+(;^^4RJ"T9Z(2`JY6(KX*^#U MH;@8RL*;RVHTHSK!V<\Y]X8B5H0'O6<:/M'5ER.U\3HEL*ZW%L_R:DIS7@;5 MT=[U:&V;9+)%3EP*6NRB&<"O/#DN(;+EI/.KF=N*Y5[JP&T.5IM9<^\K\=O# MF)]U^=(:Y^OG4@5AHI$?6LDGN(R]_P502P$"'@,4````"`!W>`Q%*"VYI*Z< M```!@04`$0`8```````!````I($`````<')P:"TR,#$T,#8S,"YX;6Q55`4` M`Q%EZE-U>`L``00E#@``!#D!``!02P$"'@,4````"`!W>`Q%:2;F0L\'```$ M9```%0`8```````!````I('YG```<')P:"TR,#$T,#8S,%]C86PN>&UL550% M``,19>I3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`=W@,1:OS[CL?*P`` M;H0"`!4`&````````0```*2!%Z4``'!R<&@M,C`Q-#`V,S!?9&5F+GAM;%54 M!0`#$67J4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`'=X#$4VOT->RT8` M`-O*`P`5`!@```````$```"D@870``!P`L``00E#@``!#D!``!02P$"'@,4````"`!W>`Q%_8,5B-\O M``#L]`(`%0`8```````!````I(&?%P$`<')P:"TR,#$T,#8S,%]P&UL M550%``,19>I3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`=W@,17TE@K2* M#0``98<``!$`&````````0```*2!S4'-D550% K``,19>I3=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``*)5`0`````` ` end XML 41 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Transactions Affecting Stockholders' Equity (Details Textual) (USD $)
6 Months Ended 1 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Nov. 21, 2012

2012 Equity Line of Credit [Member]

May 28, 2014

2014 Equity Line of Credit [Member]

Jun. 30, 2014

2014 Equity Line of Credit [Member]

Jun. 30, 2014

Plan 1997 [Member]

Jun. 30, 2013

Plan 2010 [Member]

Jun. 30, 2013

Plan 2010 [Member]

Jun. 30, 2014

Plan 2010 [Member]

Jun. 30, 2014

Directors Plan 2010 [Member]

Jun. 30, 2014

Amended Option Plan 1997 [Member]

Jun. 30, 2014

Common Stock [Member]

Dutchess [Member]

2012 Equity Line of Credit [Member]

Stockholders' Equity [Line Items]

Maximum Number Of Common Stock Authorized For Issuance Over 36 Months 2,500,000

Maximum Amount Entitled To Put To Investor In One Draw Down Notice, Percentage Of Average Daily Volume On Trading Day 500.00%

Maximum Amount Entitled To Put To Investor In One Draw Down Notice $ 250,000

Investory Right To Use Excess Proceeds, Maximum Percentage 5.00% 5.00%

Share Purchase Put Restrictions Maximum Percentage Of Ownership Held By Investor To Purchase Shares In Equity Line Of Credit 9.99% 4.99%

Stock Issued During Period Shares Under Specific Agreement 698,207

Stock Issued During Period Value Specific Agreement 1,200,000

Options outstanding - Shares 67,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 1,600,000 425,000

Share Based Compensation Arrangement By Share Based Payment Award, Options, Deemed Cancelled 581,750

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 15,000 15,000 4,500,000

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Common Stock Shares Unissued 2,500,000

Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement 15.00%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number 1,481,750

Equity Line, Purchase Price Percentage 95.00% 95.00%

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant 900,000 267,159 176,135

Cash Less Exercise Of Right Terms In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one common share of the Company.

Share Based Compensation Arrangement By Share Based Payment Option Expiration Terms No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998.

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 45

Common Stock, Shares, Issued 24,635,266 21,437,059 3,000,000 2,500,000

Agreement Term 36 months

Purchase Price Value 500,000

Proceeds From Issuance Of Common Stock $ 4,826,000 $ 195,000 $ 3,600,000

Common Stock, Capital Shares Reserved for Future Issuance 500,000

Percentage of Discount on Exercise of Right 50.00%

X

- Definition

This element represent the agreement term.

+ References

No definition available.

+ Details

Name: prph_AgreementTerm

Namespace Prefix: prph_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of cash less exercise of rights terms.

+ References

No definition available.

+ Details

Name: prph_CashLessExerciseOfRightTerms

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

It represents the lowest daily volume weighted average price of our Common Stock during the five consecutive trading day period.

+ References

No definition available.

+ Details

Name: prph_EquityLinePurchasePricePercentage

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Equity method investment ownership percentage required for rights exercisable under right agreement.

+ References

No definition available.

+ Details

Name: prph_EquityMethodInvestmentOwnershipPercentageRequiredForRightsExercisableUnderRightAgreement

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations before deduction of valuation allowance.

+ References

No definition available.

+ Details

Name: prph_InvestorRightToUseExcessProceedsMaximumPercentage

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Maximum amount entitled to put to investor in one draw down notice.

+ References

No definition available.

+ Details

Name: prph_MaximumAmountEntitledToPutToInvestorInOneDrawDownNotice

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Maximum amount entitled to put to investor in one draw down notice, percentage of average daily volume on trading day.

+ References

No definition available.

+ Details

Name: prph_MaximumAmountEntitledToPutToInvestorInOneDrawDownNoticePercentageOfAverageDailyVolumeOnTradingDay

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Maximum number of common stock authorized for issuance over thirty six months.

+ References

No definition available.

+ Details

Name: prph_MaximumNumberOfCommonStockAuthorizedForIssuanceOver36Months

Namespace Prefix: prph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

This elemen represent percentage of discount on the current market price for exercise of right.

+ References

No definition available.

+ Details

Name: prph_PercentageOfDiscountOnExerciseOfRight

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents the purchase price value.

+ References

No definition available.

+ Details

Name: prph_PurchasePriceValue

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Share-based compensation arrangement by share-based payment award, options, deemed cancelled.

+ References

No definition available.

+ Details

Name: prph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDeemedCancelled

Namespace Prefix: prph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Share based compensation arrangement by share based payment award options grants in period common stock shares unissued.

+ References

No definition available.

+ Details

Name: prph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodCommonStockSharesUnissued

Namespace Prefix: prph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Description of stock option plan expiration terms.

+ References

No definition available.

+ Details

Name: prph_ShareBasedCompensationArrangementByShareBasedPaymentOptionExpirationTerms

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Share purchase put restrictions maximum percentage of ownership held by investor to purchase shares in equity line of credit.

+ References

No definition available.

+ Details

Name: prph_SharePurchasePutRestrictionsMaximumPercentageOfOwnershipHeldByInvestorToPurchaseSharesInEquityLineOfCredit

Namespace Prefix: prph_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: prph_StockholdersEquityLineItems

Namespace Prefix: prph_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Definition :Stock issued during period shares under specific agreements.

+ References

No definition available.

+ Details

Name: prph_StockIssuedDuringPeriodSharesUnderSpecificAgreement

Namespace Prefix: prph_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

It defines the aggregate value of stock issued during a period .

+ References

No definition available.

+ Details

Name: prph_StockIssuedDuringPeriodValueSpecificAgreement

Namespace Prefix: prph_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
ASSETS
Cash and cash equivalents (Note 2)	$ 7,350	$ 1,638
Accounts receivable, net	2,343	5,319
Inventory (Note 2)	3,248	2,521
Prepaid expenses and other current assets	733	1,801
Total current assets	13,674	11,279
Property, plant and equipment, net of accumulated depreciation and amortization of $4,197 and $4,064, respectively (Note 2)	2,509	2,564
Intangible asset, licensed technology (Note 6)	3,577	3,577
Total assets	19,760	17,420
LIABILITIES:
Accounts payable	1,399	1,011
Accrued advertising and other allowances	3,078	2,847
Other current liabilities	1,475	766
Total current liabilities	5,952	4,624
Other long term obligations (Note 3)	200	200
Commitments and contingencies (Note 3)	0	0
STOCKHOLDERS' EQUITY:
Common Stock, $.0005 par value; authorized 50,000,000; issued: 24,635,266 and 21,437,059 shares, respectively (Note 4)	12	11
Additional paid-in-capital	48,560	43,607
Accumulated deficit	(9,327)	(5,385)
Treasury stock, at cost 5,336,053 and 5,336,053 shares, respectively	(25,637)	(25,637)
Total stockholders' equity	13,608	12,596
Total liabilities and stockholders' equity	$ 19,760	$ 17,420

Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:
Net loss	$ (3,942)	$ (1,429)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	133	120
Share-based compensation expense	128	79
Changes in operating assets and liabilities:
Accounts receivable	2,976	4,281
Inventory	(727)	(1,237)
Accounts payable	388	(269)
Accrued advertising and other allowances	231	(576)
Other operating assets and liabilities, net	1,777	2,572
Net cash provided by operating activities	964	3,541
Cash flows from investing activities:
Capital expenditures	(78)	(250)
Net cash used in investing activities	(78)	(250)
Cash flows from financing activities:
Proceeds from issuance of common stock	4,826	195
Net cash provided by financing activities	4,826	195
Net increase in cash and cash equivalents	5,712	3,486
Cash and cash equivalents at beginning of period	1,638	572
Cash and cash equivalents at end of period	$ 7,350	$ 4,058

Investment in a Joint Venture (Details Textual) (USD $)	6 Months Ended	12 Months Ended
Investment in a Joint Venture (Details Textual) (USD $)	Jun. 30, 2014	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2013	Jun. 30, 2013
Schedule of Investments [Line Items]
Stock Issued During Period, Value, New Issues	$ 4,826,000
Payments To Fund Joint Venture Investments			500,000
Maximum Amount Committed Towards Contributions In Joint Venture			2,000,000
Cash and cash equivalents	7,350,000	572,000		1,638,000	4,058,000
Acquisition of product license			3,600,000
Finite-Lived Intangible Assets, Useful Life (in years)			12 years 9 months
Ownership Percentage In Joint Venture			50.00%
Payments For Legal Settlements		2,100,000
PSI Parent [Member]
Schedule of Investments [Line Items]
Stock Issued During Period, Shares, New Issues			1,440,000
Stock Issued During Period, Value, New Issues			2,600,000
Payments To Fund Joint Venture Investments			1,000,000
Cash and cash equivalents	$ 374,000

Earnings (Loss) Per Share (Details Textual)	3 Months Ended		6 Months Ended
Earnings (Loss) Per Share (Details Textual)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Loss Per Share [Line Items]
Class of Warrant or Right, Outstanding	1,632,500	1,301,500	1,632,500	1,301,500
Common Stock Equivalents [Member]
Earnings Loss Per Share [Line Items]
Weighted Average Number Diluted Shares Outstanding Adjustment, Total	559,318	359,271	571,736	401,849

Condensed Consolidated Balance Sheets [Parenthetical] (USD $) In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Accumulated depreciation (in dollars)	$ 4,197	$ 4,064
Common Stock, par value (in dollars per share)	$ 0.0005	$ 0.0005
Common Stock, shares authorized	50,000,000	50,000,000
Common Stock, shares issued	24,635,266	21,437,059
Treasury stock, shares (in shares)	5,336,053	5,336,053

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2014	Aug. 12, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Entity Registrant Name	ProPhase Labs, Inc.
Entity Central Index Key	0000868278
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	PRPH
Entity Common Stock, Shares Outstanding		19,299,213

Commitments and Contingencies (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2014
Commitments And Contingencies [Line Items]
2014	$ 641
2015	1,140
2016	100
2017	0
2018	0
Total	1,881
Employment Contracts [Member]
Commitments And Contingencies [Line Items]
2014	541
2015	1,040
2016	0
2017	0
2018	0
Total	1,581
Settlement Agreement [Member]
Commitments And Contingencies [Line Items]
2014	100
2015	100
2016	100
2017	0
2018	0
Total	$ 300

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended	12 Months Ended
Commitments and Contingencies (Details Textual) (USD $)	Dec. 20, 2012	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2014
Commitments And Contingencies [Line Items]
Payments for Legal Settlements			$ 2,100,000
Settlement benefit (Note 3)		100,000
Additional Royalties and Commissions, Accrual Interest Percentage		3.25%
Additional Royalties and Commissions Payable, Installment Amount	100,000	100,000
Additional Annual Installment Includes In Other Current Liability				100,000
Additional Annual Installment Includes In Other Long Term Obligation		200,000
Litigation Settlement Interest		$ 13,000

Income Taxes (Details Textual) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2013
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Operating Loss Carry forwards Expiration Dates Description	Fiscal 2018 through Fiscal 2032
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	$ 20.4
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$ 34.7
Operating Loss Carry forwards Expiration Dates Description	Fiscal 2020 through Fiscal 2032

Condensed Consolidated Statements of Stockholders' Equity (USD $) In Thousands, except Share data	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings (Deficit) [Member]	Treasury Stock [Member]
Balance at Dec. 31, 2013	$ 12,596	$ 11	$ 43,607	$ (5,385)	$ (25,637)
Balance (in shares) at Dec. 31, 2013		16,101,006
Net loss	(3,942)	0	0	(3,942)	0
Share-based compensation expense (Note 4)	128	0	128	0	0
Common shares issued (Note 4)	4,826	1	4,825	0	0
Common shares issued (Note 4) (in shares)		3,198,207
Balance at Jun. 30, 2014	$ 13,608	$ 12	$ 48,560	$ (9,327)	$ (25,637)
Balance (in shares) at Jun. 30, 2014		19,299,213